Document:

EX-10.26

 Exhibit 10.26 
 Portions of this exhibit marked [*] are requested to be treated confidentially. 
  

 
  

CONFIDENTIAL 
 LICENSE AND ASSET TRANSFER AGREEMENT 
 BY AND BETWEEN 

ALZA CORPORATION AND JANSSEN PHARMACEUTICA, NV 
 AND 
 FURIEX PHARMACEUTICALS, INC., AND GENUPRO, INC. 

(A WHOLLY-OWNED SUBSIDIARY OF FURIEX PHARMACEUTICALS, INC.) 

 
  

 

 Table of Contents 

 

							
	 	 	 	  	Page	 
	 SECTION 1 DEFINITIONS
	  	 	2	  
	     1.1
	 	Definitions	  	 	2	  
	     1.2
	 	Miscellaneous Interpretation Aids	  	 	13	  
		
	 SECTION 2 EFFECTIVE DATE
	  	 	14	  
		
	 SECTION 3 TERMINATION OF LICENSE
AGREEMENT
	  	 	16	  
	     3.1
	 	Termination of Rights and Obligations	  	 	16	  
	     3.2
	 	Final Accounting	  	 	16	  
	     3.3
	 	Release and Covenant Not to Sue	  	 	17	  
	     3.4
	 	Interpretation of the License Agreement Under the New Lilly License	  	 	18	  
		
	 SECTON 4 TRANSFER OF CERTAIN
INTELLECTUAL PROPERTY
	  	 	18	  
	     4.1
	 	License of Alza Intellectual Property to Genupro	  	 	18	  
	     4.2
	 	Assignment of Trademarks, Domain Names	  	 	20	  
	     4.3
	 	Rights Retained by Alza	  	 	21	  
		
	 SECTION 5 TRANSFER OF PRODUCT RIGHTS
IN THE TERRITORY
	  	 	21	  
	     5.1
	 	Completion of Transfer of Product Rights	  	 	22	  
	     5.2
	 	Country Designation as a Group A Market, Group B Market, Group C Market, or Group E Market	  	 	23	  
	     5.3
	 	Rights and Obligations of the Parties Based on Country Designation	  	 	25	  
	     5.4
	 	Designated Sub-distributors	  	 	32	  
	     5.5
	 	Delays in Transfer of ALZA Marketing Authorizations, ALZA Regulatory Submissions, and Product Rights	  	 	32	  
	     5.6
	 	Reporting During Transition Period	  	 	33	  
	     5.7
	 	Disposition of Product Contracts	  	 	33	  
	     5.8
	 	Responsibility for Transitional Development	  	 	34	  
		
	 SECTION 6 DILIGENCE AND COORDINATION OF
EFFORTS
	  	 	36	  
	     6.1
	 	Diligence and Cooperation	  	 	36	  
	     6.2
	 	Transition Manager	  	 	40	  
	     6.3
	 	Transition Team	  	 	41	  
	     6.4
	 	Regulatory Transition Plan	  	 	41	  
	     6.5
	 	Pharmacovigilance Responsibilities and Product Inquiries	  	 	43	  
	     6.6
	 	Other External Communications Related to Agreement Product	  	 	44	  
	     6.7
	 	No Warranties	  	 	44	  
		
	 SECTION 7 PAYMENT AND FINANCIAL
MATTERS
	  	 	44	  
	     7.1
	 	Document Transfer Payments	  	 	44	  

  
 i 

							
	     7.2
	 	Transition Services Payments	  	 	44	  
	     7.3
	 	Service Fees	  	 	45	  
	     7.4
	 	Taxes	  	 	45	  
	     7.5
	 	Regulatory Fees and Other Costs and Expenses	  	 	46	  
	     7.6
	 	Accounts Receivable on Pre-Transfer Sales	  	 	46	  
		
	 SECTION 8 MANUFACTURING AND SUPPLY
MATTERS
	  	 	47	  
	     8.1
	 	Manufacturing and Supply Agreement(s)	  	 	47	  
		
	 SECTION 9 ANCILLARY AGREEMENTS
	  	 	47	  
		
	 SECTION 10 CERTAIN PROVISIONS REGARDING
DISTRIBUTION, SALE AND SUPPLIES OF AGREEMENT PRODUCT
	  	 	48	  
	     10.1
	 	Orders for Agreement Product	  	 	48	  
	     10.2
	 	Labelling and Packaging	  	 	48	  
	     10.3
	 	Recalls	  	 	49	  
		
	 SECTION 11 REPRESENTATIONS AND
WARRANTIES
	  	 	50	  
	     11.1
	 	Mutual Representations	  	 	50	  
	     11.2
	 	By Alza	  	 	50	  
	     11.3
	 	Alza Covenants	  	 	60	  
		
	 SECTION 12 LIABILITY AND
INDEMNIFICATION
	  	 	63	  
	     12.1
	 	By Genupro	  	 	63	  
	     12.2
	 	By Alza	  	 	64	  
	     12.3
	 	Procedures	  	 	65	  
	     12.4
	 	Settlements	  	 	65	  
	     12.5
	 	No Consequential Damages	  	 	66	  
	     12.6
	 	Insurance	  	 	66	  
		
	 SECTION 13 CONFIDENTIALITY
	  	 	66	  
	     13.1
	 	Confidential Information	  	 	66	  
	     13.2
	 	Non-Disclosure and Non-Use	  	 	67	  
	     13.3
	 	Permitted Disclosures	  	 	67	  
	     13.4
	 	Disclosure of Financial and Other Terms	  	 	68	  
	     13.5
	 	No Use of Name	  	 	69	  
	     13.6
	 	Publicity	  	 	69	  
		
	 SECTION 14 FAILURE OF EFFECTIVE DATE
UNDER SECTION 2.1 TO OCCUR
	  	 	69	  
		
	 SECTION 15 TERMINATION AND
SURVIVAL
	  	 	70	  
		
	 SECTION 16 GENERAL
	  	 	70	  
	     16.1
	 	Entire Agreement/Integration	  	 	70	  
	     16.2
	 	Notice	  	 	71	  

  
 ii 

							
	     16.3
	 	No Third Party Beneficiaries	  	 	71	  
	     16.4
	 	Assignment	  	 	72	  
	     16.5
	 	Compliance	  	 	72	  
	     16.6
	 	Governing Law and Dispute Resolution	  	 	72	  
	     16.7
	 	Execution in Counterparts; Facsimile Signatures	  	 	73	  
	     16.8
	 	Schedules	  	 	73	  

 Schedules 
  

			
	 Schedule 4.2A
	  	Domain Names
	 Schedule 4.2B1
	  	Trademarks to be Assigned to GENUPRO
	 Schedule 4.2B2
	  	Trademarks to be Assigned to Menarini
	 Schedule 5.1.1
	  	Third Party MAHs
	 Schedule 5.2A
	  	Group A Markets
	 Schedule 5.2B
	  	Group B Markets
	 Schedule 5.2C
	  	Group C Markets
	 Schedule 5.4
	  	Distribution Agreements
	 Schedule 5.7
	  	Product Contracts
	 Schedule 5.8.1
	  	Ongoing Clinical Studies
	 Schedule 5.8.2A
	  	ALZA Universal Calendar
	 Schedule 5.8.2B
	  	Example Invoice
	 Schedule 5.8.7
	  	Post-marketing clinical study reporting obligations
	 Schedule 6.1.1
	  	Documents to be Included in Development Records
	 Schedule 6.1.1.1
	  	Listing of Record Categories in Index of Transferred Development Records
	 Schedule 6.1.2
	  	Third Party Software
	 Schedule 6.1.5
	  	Additional Information to be Included in Electronic Media and Provided to GENUPRO
	 Schedule 6.2
	  	Initial Transition Managers
	 Schedule 11
	  	Exceptions to Representations and Warranties
	 Schedule 11.2.15.1A
	  	ALZA Marketing Authorizations
	 Schedule 11.2.15.1B
	  	ALZA Regulatory Submissions
	 Schedule 11.2.15.1C
	  	Pricing Approvals
	 Schedule 11.2.18
	  	ALZA Sublicenses
	 Schedule 11.3.11
	  	Required Consents

  
 iii

 LICENSE AND ASSET TRANSFER AGREEMENT 

This License and Asset Transfer Agreement (the “Agreement”), by and between ALZA CORPORATION, a company
incorporated in the State of Delaware and having offices at 700 Eubanks Drive, Vacaville, California 95688 and JANSSEN PHARMACEUTICA NV, a corporation organised under the laws of the Kingdom of Belgium and having its principal place of
business at Turnhoutseweg 30, B-2340 Beerse, Belgium (“JANSSEN”) (collectively “ALZA”), and FURIEX PHARMACEUTICALS, INC., a company incorporated in the State of Delaware and having its registered office at
3900 Paramount Parkway, Suite 150, Morrisville, NC 27560 (“FURIEX”) and GenuPro, Inc. (“GENUPRO”), a wholly-owned subsidiary of FURIEX organized under the laws of the State of North Carolina and having its
registered office at 3900 Paramount Parkway, Suite 150, Morrisville, NC 27560, is entered into as of the date of signature by the last Party to sign below and is effective upon the satisfaction of the conditions set forth in Section 2
below (the “Effective Date”). ALZA, FURIEX and GENUPRO are each referred to from time to time herein either individually as a “Party” or collectively as the “Parties”. 

WHEREAS, ALZA, FURIEX, as successor-in-interest to Pharmaceutical Product Development, Inc. (“PPD”), and
GENUPRO, entered into a License Agreement having an effective date of January 2, 2001, and which was amended on December 26, 2003 by Amendment No. 1 to License Agreement, and which was further amended on October 16,
2009 by Amendment No. 2 to License Agreement (such License Agreement between FURIEX, GENUPRO, and ALZA, hereinafter referred to as the “License Agreement”), and which the Parties have further taken in context with the
Termination and License Agreement, having an effective date of December 18, 2003, amongst Eli Lilly and Company (“Lilly”) and PPD, GENUPRO and APBI Holdings, LLC, a wholly-owned subsidiary of PPD (such Termination
and License Agreement between Lilly, PPD, GENUPRO, and APBI Holdings, LLC, the “New Lilly License”) relating to the licensing by GENUPRO to ALZA of certain rights pertaining to the development and commercialization of Dapoxetine;
and 
 WHEREAS, FURIEX, GENUPRO and ALZA desire to terminate the License Agreement, at which time ALZA’s rights and
responsibilities thereunder will terminate and revert to GENUPRO, subject to the survival of certain rights and obligations as described therein and in this Agreement; and 
 WHEREAS, ALZA desires to transfer ownership of Product Rights (as defined below) to GENUPRO and achieve an orderly and efficient transition of manufacturing and marketing capabilities to GENUPRO or
its designee; and 
 WHEREAS, the Parties therefore desire to state their respective rights and responsibilities in
connection with the termination of the License Agreement and the reversion and transfer of rights and responsibilities for Dapoxetine-based products to GENUPRO, all on the terms and conditions set forth in this Agreement. 

  
 1 

 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth
herein and intending to be legally bound, the Parties hereby agree as follows: 
 Section 1 Definitions 

1.1 Definitions. The capitalized terms used in this Agreement shall have the defined meanings set forth below or elsewhere in this
Agreement. Capitalized singular, plural, and other variant forms of the defined terms shall have the corresponding meanings. 

“Affiliate” means a person or entity that directly or indirectly through one or more intermediates, controls, is
controlled by, or is under common control with the person or entity specified. For the purpose of this definition, “control” shall mean with respect to an entity, (a) the direct or indirect ownership of: (x) at least fifty
percent (50%) or more of the capital stock or share capital entitled to vote for the election of directors of the entity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction);
or (y) at least fifty percent (50%) of equity or voting interest of the entity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) or (b) the power to direct or
cause the direction of the management and policies of the corporation or other entity. 
 “Agreement Product”
means a drug product in its final dosage form(s) containing Dapoxetine described in any ALZA Regulatory Submissions made by or on behalf of ALZA or any Affiliate thereof prior to the Effective Date or in ALZA Marketing Authorizations of ALZA or any
Affiliate thereof. 
 “ALZA Derivative” means a Derivative of Dapoxetine that (a) is not a Product-Related
Improvement (as defined in the License Agreement), (b) is not incorporated in any Agreement Product, and (c) was first developed or conceived by or on behalf of ALZA, or any Affiliate thereof, independently of ALZA’s, its Affiliates,
or their sublicensees’ (i) exercise of any rights granted under the License Agreement or (ii) access to, or knowledge or use of, any Confidential Information (as defined under the Licensed Agreement or this Agreement) disclosed by or
on behalf of GENUPRO. 
 “ALZA Distribution Termination Date” shall have the meaning set forth in
Section 5.3.1.2.1 of this Agreement. 
 “ALZA Know-How” means the Know-How disclosed in the documents and
Electronic Media identified in the Index, Controlled by ALZA as of the Effective Date, or coming under the Control of ALZA prior to the Final Transfer Date, that specifically relates to Agreement Product and was used or generated in ALZA’s and
its Affiliates’ and Sublicensees’ development, use, manufacture, importation, sale, offering for sale, distribution, or commercialization of, Dapoxetine or the Agreement Product, including any Know-How resulting from any On-Going Clinical
Studies, but excluding any Know-How to the extent specifically relating to any ALZA Derivative. 

  
 2 

 “ALZA Marketing Authorizations” means all health registrations, marketing
authorizations, centralized registrations, labelling approvals, Regulatory Approvals, any other technical, medical and scientific licenses, authorizations or approvals in the Territory for any Agreement Product (together with any amendments or
supplements to any of the foregoing) filed with or granted by any Regulatory Authority, that, in each case, are Controlled by ALZA or any Affiliate thereof (and which shall include those held or controlled by a Third Party MAH on behalf of ALZA or
an Affiliate thereof pursuant to a Distribution Agreement), as of the Effective Date, or come under the Control of ALZA or any Affiliate thereof (or any Third Party MAH) prior to the end of the Transition Completion Date. 

“ALZA Patents” means all Patents (if any) Controlled by ALZA (directly or through any Affiliate) thereof as of the
Effective Date, or coming under the Control of ALZA (directly or through any Affiliate thereof) through issuance after the Effective Date and prior to the end of the Transition Completion Date, including any claim Covering Dapoxetine or the
Agreement Product. 
 “ALZA Permitted Liens” means a Permitted Lien arising, directly or indirectly, from the
acts or omissions of ALZA, any Affiliate thereof, or any Third Party contractor or licensee of either of the foregoing with respect to Agreement Product, any Product Rights, or any Distribution Agreement or Product Contract. 

“ALZA Regulatory Submissions” means all Regulatory Submissions, together with any amendments or supplements thereto,
that, in each case, are Controlled by ALZA or an Affiliate thereof as of the Effective Date, or come under the Control of ALZA or an Affiliate thereof prior to the Transition Completion Date (and which shall include those held or controlled by a
Third Party MAH on behalf of ALZA or an Affiliate thereof pursuant to a Distribution Agreement). 
 “Ancillary
Agreements” means the following: 
 (a) In the event of a Section 2.1 Closing: Non-Group E Markets Manufacturing
Agreement, Group E Markets Manufacturing Agreement, Non-Group E Markets Quality Agreement, Group E Markets Quality Agreement, GENUPRO Trademark Assignment Agreement, Menarini Trademark Assignment Agreement, Domain Name Assignment Agreement, PV
Agreement, Delegations of Authority (if any), Transition Services Agreement, and Sales Service Agreement; or 
 (b) In the event
of a Section 2.2 Closing: GENUPRO Manufacturing Agreement, GENUPRO Quality Agreement, GENUPRO Trademark Assignment Agreement, Domain Name Assignment Agreement, GENUPRO PV Agreement, Delegations of Authority (if any), Transition Services
Agreement, and Sales Service Agreement. 
 “Calendar Quarter” shall mean a calendar quarter based on the ALZA
Universal Calendar for that year, a copy of which, for 2012 is attached as Schedule 5.8.2A, and which shall be updated by ALZA for each Calendar Year of the Term consistent with the ALZA Universal Calendar used for ALZA’s internal
business purposes; provided, however that the first calendar quarter for the first Calendar Year shall extend from the Effective Date to the end of the then-current Calendar Quarter and the last Quarter shall extend from the first day of such
Calendar Quarter until the effective date of the termination or expiration of the Agreement. 

  
 3 

 “Calendar Year” means a calendar year during the term of this Agreement
based on the ALZA Universal Calendar for that year. 
 “Clinical Trial Application” means an application
submitted to a Regulatory Authority to obtain the right to perform human clinical trials, including an IND. 

“Commercially Reasonable Efforts” means the carrying out by a Party of obligations or activities as specified
herein exerting overall a level of effort no less than consistent with the level of effort that such Party customarily devotes to corresponding activities, with respect to a pharmaceutical product or products of similar market potential, profit
potential or strategic value, based on conditions then prevailing. Without limiting the foregoing, Commercially Reasonable Efforts requires that a Party: (i) timely assign responsibility for such activities to specific employees, contractors,
agents, Affiliates or Sublicensees, as applicable, who are held accountable for progress with respect to such activities, (ii) monitor such progress on an on-going basis, (iii) set and seek to achieve objectives and timelines for carrying
out such activities, and (iv) allocate resources reasonably designed to advance progress with respect to such objectives and timelines.  
 “Copyrights” means any and all copyrights or other rights in any works of authorship specifically relating to any Agreement Product, Controlled by ALZA (directly or through any Affiliate
thereof) as of the Effective Date or coming under the Control of ALZA at any time prior to the Final Transition Date, including any such rights in works for any websites, package inserts, package layups, pill photographs, templates, artwork,
development, advertising, marketing, promotional, or sales-related materials developed or used by or on behalf of ALZA for any Agreement Product but excluding for the avoidance of doubt any rights or interests in any trademarks, logos or trade dress
owned or licensed by ALZA not specifically relating to Agreement Product that may be incorporated in such materials (including the corporate names and logos representing ALZA and its Affiliates). 

“Confidential Information” shall have the meaning set forth in Section 13.1 of this Agreement. 

“Control” means possession of the right to grant a license or sublicense or other rights as provided for herein by the
applicable Party, whether through ownership or license from any Affiliate or Third Party, without violating the terms of any agreement with any Third Party. 
 “Cover” means, with respect to a claim of any Patent in reference to specified subject matter (such as a composition of matter or method of use or manufacture), reading on or literally
encompassing such subject matter, whether generically or specifically. 
 “Country Transfer Date” means, on a
country-by-country basis, the date on which all of the Product Rights (other than any ALZA Regulatory Submissions and Governmental Permits that cannot be transferred by such date, as contemplated by Section 5.5) in a country are to be
transferred, assigned, and delivered to GENUPRO, directly or to GENUPRO’s designated Affiliate or Sublicensee, in accordance with the terms of Section 5 of this Agreement pursuant to the Transition Plan. 

  
 4 

 “Country Transfer Transition Period” shall have the meaning set forth in
Section 5.3.6.1 of this Agreement. 
 “Damages” means any and all damages, liabilities, claims,
costs, charges, judgments, injuries, awards, fines, penalties, fees and expenses (including, without limitation, reasonable attorneys’ fees) suffered or incurred. 
 “Dapoxetine” means (a) (+/-)-N,N-dimethyl-l -phenyl-3-(1-naphthalenyloxy)-propanamine, (b) (S)-(+)-N,N-dimethyl-l-phenyl-3-(1-naphthalenyloxy)-propanamine,
(c) (R)-(-)-N,N-dimethyl-l-phenyl-3-(1-naphthalenyloxy)-propanamine, (d) (+/-)-N,N-dimethyl-a-[2-(1-naphthalenyloxy) ethyl-benzenemethanamine, (e) (S)-(+)-N,N-dimethyl-a-[2-(1-naphthalenyloxy) ethyl-benzenemethanamine, (f) (R)-(-)-N,N-dimethyl-a-[2-(1-naphthalenyloxy) ethyl-benzenemethanamine, (g) any pharmaceutically
acceptable salt of any of the foregoing, or (h) any active metabolite of any of the foregoing, including without limitation mono-desmethyl dapoxetine and di-desmethyl dapoxetine. 

“Data Room” means that certain electronic data room created by or on behalf of ALZA to which GENUPRO was provided access
by ALZA in connection with GENUPRO’s due diligence activities related to the transactions contemplated by this Agreement. 

“Delegation of Authority” means a written agreement between ALZA or its Affiliate and GENUPRO and/or its Affiliate
and/or Sublicensee delegating authority from ALZA or its Affiliate to GENUPRO and/or its Affiliate and/or Sublicensee to distribute Agreement Product in a country or countries under ALZA Market Authorization(s) in such country/countries, such
authority terminating country-by-country on the Regulatory Transfer Date in the applicable country. 

“Derivative” means, with respect to any referenced chemical compound, any analog, isomer, tautomer, enantiomer,
diastereomer, prodrug, metabolite, ester, salt, hydrate, solvate, racemate, or polymorph thereof. 
 “Development
Costs” shall mean FTE Costs and Out-of-Pocket Costs incurred by the Parties and their Affiliates in accordance with this Agreement in support of Ongoing Clinical Studies, including but not limited to: 

(a) all Out-of-Pocket Costs and FTE Costs incurred for activities in the Ongoing Clinical Studies; 

(b) the FTE Costs of scientific, medical, technical and other personnel directly engaged in performing clinical study
activities; and 
 (c) the Out-of-Pocket Costs and FTE Costs of clinical supplies for the Ongoing Clinical
Studies, including (i) the supply cost of clinical supply of the Agreement Product; (ii) costs and expenses incurred to purchase or package Third Party comparator or Third Party combination drugs or devices; and (iii) costs and
expenses of disposal of clinical samples. 

  
 5 

 “Development Records” means all regulatory filings, records, and other
documents (whether in hardcopy or electronic form) in the Control of ALZA (directly or through any Affiliate thereof) at any time prior to the Transition Completion Date, material to the development of the Agreement Product, including any
Governmental Permits, ALZA Regulatory Submissions, or Manufacturing Records anywhere in the Territory, including such portions of any documents bearing ALZA Know-How relating to Dapoxetine or the Agreement Product and any Governmental Permits or
ALZA Regulatory Submissions for the Agreement Product and all material written communications with Regulatory Authorities with respect thereto. For the avoidance of doubt, Development Records include such records used to obtain and maintain
Governmental Permits or ALZA Regulatory Submissions, and such records needed to support clinical development. 

“Distribution Agreements” means all agreements between ALZA (and/or its Affiliates) and any Third Party, including Third
Party MAHs (as defined in Section 5.1.1), granting such Third Party rights to market, promote, distribute and commercialize Agreement Product. 
 “DMF” means a drug master file, as provided for in 21 CFR § 314.420, device master file, as defined in 21 CFR § 814.3, or similar submission to or file maintained with the FDA
or any other Regulatory Authority or governmental agency (including any supranational agency) that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging,
and storing of one or more Agreement Products. 
 “Domain Names” mean all registrations for, and pending
applications for registration of, the domain names associated with Agreement Product or the marketing and sale thereof in any countries of the Territory, as set forth in Schedule 4.2A. 

“Electronic Media” means those encrypted hard drives, identified by serial number in the Index, provided by ALZA to
GENUPRO in connection with the transactions contemplated by this Agreement. 
 “EMA” means European Medicines
Agency, or any successor agency. 
 “Execution Date” means the date on which this Agreement has been executed
by the last Party to sign this Agreement. 
 “FDA” means the United States Food and Drug Administration, or any
successor agency. 
 “Field” means the development, manufacture, distribution, marketing, advertising,
promotion, and commercialization of Dapoxetine, Agreement Product, and any Related Products for any and all uses or applications. 
 “Final Transfer Date” means, for a particular country, the later of the [*] or [*]. 
 “FTE” means a full time equivalent person year of professional scientific and/or technical work or managerial work to the extent working on or directly involved in Ongoing Clinical
Studies. 
 [*] Confidential treatment requested. 

  
 6 

 “FTE Cost” means [*] ($[*]) per FTE, which amount shall be adjusted [*], as
published by the [*], upon each [*] of the Effective Date during the Term. 
 “GENUPRO Know-How” means all
Know-How Controlled by GENUPRO as of the Effective Date, or coming under the Control of GENUPRO prior to the Transition Completion Date, that, in either case, specifically relates to Agreement Product and was used or generated by GENUPRO’s and
its Affiliates’ and Sublicensees’ development, use, manufacture, sale, import, sale, offering for sale, distribution, or commercialization of, Dapoxetine or Agreement Product. 

“GENUPRO Patents” mean any and all Patents Controlled by GENUPRO that include any claim that Covers Dapoxetine or the
Agreement Product or any process or material for making or method of using Dapoxetine or Agreement Product, including any Lilly Patents (as defined in the License Agreement) and GenuPro Patents (as defined in the License Agreement) only, in each
case, to the extent licensed by GENUPRO to ALZA under Article 2 of the License Agreement. 
 “GENUPRO PV
Agreement” shall have the meaning set forth in Section 6.5 of this Agreement. 
 “Good Clinical
Practice” or “GCP” means the then current standards for clinical trials for pharmaceuticals, as set forth in the ICH guidelines and applicable regulations promulgated thereunder, as amended from time to time, and such
standards of good clinical practice as are required by the European Union and other organizations and governmental agencies in countries in which a Agreement Product is intended to be sold to the extent such standards are not less stringent than the
ICH guidelines. 
 “Good Laboratory Practices” or “GLP” means, with respect to the United
States, the then-current requirements for non-clinical (animal or laboratory) trials that will be submitted to a Regulatory Authority to support a marketing application, specified in 21 C.F.R. § 58, as may be amended, and, with respect to any
other country or jurisdiction, the equivalent regulations in such other country or jurisdiction, including any such standards or guidelines set forth by ICH. 
 “Good Manufacturing Practice” or “GMP” means: 1) the regulatory requirements for current good manufacturing practices promulgated by the FDA under the U.S. Food, Drug and
Cosmetic Act (as set forth at 21 C.F.R. § 210 et seq.) and under the Public Health Service Act, Biological Products (as set forth at 21 C.F.R. §§ 600-610), as the same may be amended from time to time; and 2) such standards of good
manufacturing practice as are required by the European Union and other organizations and governmental agencies in countries in which a Agreement Product is intended to be manufactured or sold, to the extent such standards are not less stringent than
the FDA regulatory requirements stated above. 
 “Governmental Permits” means (i) the ALZA Marketing
Authorizations and (ii) any and all pricing or pricing reimbursement approvals for any Agreement Product granted, in either case, by any Regulatory Authorities anywhere in the Territory. 

“Group A Market” shall have the meaning set forth in Section 5.2.1 of this Agreement. 

[*] Confidential treatment requested. 

  
 7 

 “Group B Market” shall have the meaning set forth in
Section 5.2.2 of this Agreement. 
 “Group C Market” shall have the meaning set forth in
Section 5.2.3 of this Agreement. 
 “Group E Market” shall have the meaning set forth in
Section 5.2.4 of this Agreement. 
 “ICH” means the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceutical for Human Use. 
 “Identified ALZA Patents” shall
have the meaning set forth in Section 4.1.5. 
 “Implementation Date” shall have the meaning set
forth in Section 10.2 of this Agreement. 
 “IND” means an Investigational New Drug Application
filed with the FDA as more fully defined in 21 C.F.R. §312.3 necessary to commence human clinical trials of a drug in conformance with applicable laws and regulations or any foreign equivalent thereof. 

“Index” shall have the meaning set forth in Section 6.1.1.1. 

“Indirect Taxes” shall have the meaning set forth in Section 7.4.3 of this Agreement. 

“Know-How” means all proprietary information (including data and results, and information relating to practices,
protocols, devices, technology, trade secrets, inventions, compositions, designs, formulae, know-how, show-how, processes and analytical methodologies used in research, development, testing, analysis and manufacture, and medical, pre-clinical,
clinical and toxicological testing, including such information resulting from clinical trials), specifically related to Dapoxetine or Agreement Product. 
 “Legal Requirements” mean any applicable federal, state, local or foreign constitution, law, statute, rule or regulation, including, as applicable, GCP, GLP, and GMP. 

“License Agreement” shall have the meaning set forth for such term in the introductory clauses above. 

“Licensed Product” shall mean any “Licensed Product” as defined in Section 1.22 of the License Agreement.

 “Lien” means any lien, pledge, claim, charge, mortgage, encumbrance or other security interest of any kind,
including any restriction on the use, voting, transfer, receipt of income or other exercise of any attributes of ownership, whether arising by contract or by operation of law. 
 “MA Delegate” means an entity to which ALZA (directly or through an Affiliate thereof) delegates authority under a Delegation of Authority to distribute Agreement Product in a country
under the ALZA Market Authorization in such country. 
 “Maintain” shall have the meaning assigned to such term
based on its applicable context as set forth in Section 5.2.5. 

  
 8 

 “Manufacturing Agreements” means collectively in the event of a
Section 2.1 Closing (a) the supply agreement upon execution by ALZA and Menarini for the manufacture by ALZA of bulk Dapoxetine and finished Agreement Product for supply to Menarini for use or commercial sale in the Group A Markets,
Group B Markets and Group C Markets (the “Non-Group E Markets Manufacturing Agreement”) and (b) the supply agreement upon execution by ALZA and GENUPRO for the manufacture by ALZA of bulk Dapoxetine and finished Agreement
Product for supply to GENUPRO or its designated Affiliates and/or Sublicensees for use or commercial sale in the Group E Markets (the “Group E Markets Manufacturing Agreement”). In the event of a Section 2.2 Closing,
“Manufacturing Agreements” shall mean the supply agreement upon execution by ALZA and GENUPRO for the manufacture by ALZA of bulk Dapoxetine and finished Agreement Product for supply to GENUPRO or its designated Affiliates and/or
Sublicensees for use or commercial sale in the Group A Markets, Group B Markets, Group C Markets and Group E Market countries (the “GENUPRO Manufacturing Agreement”). 

“Manufacturing Records” means all filings, records, and other documents (whether in hardcopy or electronic form)
Controlled by ALZA (directly or through its Affiliates) pertaining to the manufacture of Dapoxetine or any Agreement Product, including the portions of any such documents bearing Know-How relating to the manufacture of Dapoxetine or any Agreement
Product, the CMC portion of all ALZA Regulatory Submissions and ALZA Marketing Authorizations for Dapoxetine or any Agreement Product, all DMFs for Dapoxetine or any Agreement Product, together with all amendments and supplements, in support
thereof, records used to obtain and maintain ALZA Marketing Authorizations or ALZA Regulatory Submissions, and records needed to support clinical development of Dapoxetine or any Agreement Product. 

“Marketing Applications” means all applications for Regulatory Approval. 

“Material Product Contract” shall have the meaning set forth in Section 5.7. 

“Menarini” means Berlin Chemie AG (Menarini Group). 

“Menarini Priligy License Agreement” shall mean a written agreement between GENUPRO and Menarini licensing to Menarini
any Product Rights anywhere in the Territory or sublicensing any rights granted to GENUPRO by ALZA under Section 4.1, such as without limitation wherein Menarini would become a Sublicensee of GENUPRO under this Agreement. 

“Menarini Trademark Assignment Agreement” means the agreement between ALZA or an Affiliate thereof and Menarini that
assigns all Trademarks outside the Group E Markets from ALZA or any Affiliate thereof to Menarini, as contemplated by Section 4.2.1. 
 “NDA” means any new drug application filed with the FDA pursuant to 21 U.S.C. Section 505(b)(1), as amended from time to time, which is necessary for approval to use, market, import,
sell and offer for sale Agreement Products in the US. 
 “Ongoing Clinical Studies” shall have the meaning set
forth in Section 5.8.1. 

  
 9 

 “Out of Pocket Expenses” means all Third Party invoiced expenses
incurred by ALZA or its Affiliates for their conduct of Ongoing Clinical Studies or activities under Section 6.1.1, respectively, to the extent reimburseable under Section 5.8.2 or 7.1, respectively. 

“Patents” means, with respect to a given invention: (i) any and all original (priority-establishing) patents and
patent applications claiming the invention filed anywhere in the world, including provisional and nonprovisional applications, (ii) all patent applications related to the foregoing thereafter filed including a common priority right, including
any continuations, continuations-in-part, divisional and substitute applications, (iii) any patents issued or granted from any of the patent applications referenced in (i) and (ii) above, (iv) any reissues, renewals,
reexaminations, limitations, extensions (including by virtue of any Supplementary Protection Certificates and Patent Term Extensions) of any of the patents referenced in (i) or (iii) above, (v) any confirmation patents,
inventor’s certificates or registration patents or patents of addition based on any such patents, and (vi) all foreign counterparts or equivalents in any country or jurisdiction of any of the foregoing. 

“Permitted Liens” means the following: (i) statutory Liens for Taxes not yet due or payable and (ii) Liens for
assessments and other governmental charges or Liens of landlords, carriers, warehousemen, mechanics and repairmen incurred in the ordinary course of business, in each case for sums not yet due and payable or due but not delinquent or being contested
in good faith by appropriate proceedings. 
 “Proceedings” means any action, suit, litigation, claim,
administrative action or proceeding by a Regulatory Authority or any other person or entity or investigation, audit, or inspection by a Regulatory Authority or other governmental authority. 

“Product Contract(s)” means any contract(s) between ALZA, or any Affiliate thereof, and any Third Party(ies) related to
the development, manufacture, distribution, marketing, promotion, or sale of Agreement Product in the Territory, but not including the Distribution Agreements. Product Contracts include, but are not limited to, agreements with local distributors,
carriers, wholesalers, purchasers, clinical study agreements and consulting agreements. 
 “Product Rights”
means all rights, title and interest of, or controlled by, ALZA or its Affiliates, including such right, title, and interest held on behalf of ALZA or its Affiliates by a Third Party MAH with respect to any Governmental Permits or ALZA Regulatory
Submissions under, and subject to, a Distribution Agreement, in and to the Trademarks, Domain Names, Governmental Permits, ALZA Regulatory Submissions, Development Records, and Manufacturing Records, including all rights to package, distribute,
offer for sale, advertise, market, promote, import, export and sell the Agreement Product in a country, but not including the rights licensed to ALZA under the License Agreement (which shall revert to GENUPRO upon termination thereof except as
otherwise provided in this Agreement) 
 “PV Agreement” shall have the meaning set forth in Section 6.5
of this Agreement. 

  
 10 

 “Quality Agreement(s)” means an agreement appended to a
Manufacturing Agreement setting forth quality standards for manufacture of Agreement Product. The Non-Group E Markets Quality Agreement shall be appended to the Non-Group E Markets Manufacturing Agreement and the Group E Markets Quality Agreement
shall be appended to the Group E Market Manufacturing Agreement. In the event of a Section 2.2 Closing, “Quality Agreement(s)” shall mean an agreement (“the GENUPRO Quality Agreement”) appended to the GENUPRO Manufacturing
Agreement setting forth quality standards for manufacture of Agreement Product. 
 “Regulatory Approval”
means, for any Agreement Product, all permissions, approvals, licenses, registrations, authorizations, or clearances of any Regulatory Authority that are necessary for the sale of such Agreement Product as a human pharmaceutical in any country in
the Territory (excluding pricing and reimbursement approvals) 
 “Regulatory Authority” means any regulatory
agency, ministry, department, commission, council or other governmental body having authority in any country to authorize or control development, manufacture, marketing and sale of human pharmaceutical products, and including among others the FDA
and the EMA. 
 “Regulatory Proceeding” means any action, administrative action or proceeding by or before a
Regulatory Authority or other governmental authority occurring in the ordinary and due course of a Party’s (i) filing or maintaining a Regulatory Submission, (ii) maintaining or obtaining a Regulatory Approval, or (iii) filing or
maintaining an application for, or obtaining approval of and maintaining, any other Governmental Permits. 
 “Regulatory
Submissions” means, with respect to the Territory, all applications, filings, dossiers and other documents submitted to a Regulatory Authority for the purpose of seeking or obtaining Regulatory Approval (or engaging in clinical trials with
respect to any human pharmaceutical) for Agreement Product or pricing and reimbursement approval from that Regulatory Authority for Agreement Product, including, without limitation, Clinical Trial Applications (including INDs), and Marketing
Applications (including ANDAs, NDAs, and sNDAs), and any equivalents of any of the foregoing. 
 “Regulatory Transfer
Date” means the date on which the assignment and transfer to GENUPRO or its designated Affiliates or Sublicensees of all ALZA Regulatory Submissions and Governmental Permits in a given country are effective, except with respect to any
Governmental Permits or ALZA Regulatory Submissions that cannot be transferred and assigned under this Agreement due to limitations imposed by Legal Requirements, as contemplated by Section 5.1.2, which limitations shall be addressed as
described in Section 5.1.2, in which event the Regulatory Transfer Date in such country shall be the date on which a substitute action taken by ALZA (directly or through its Affiliates), or caused by ALZA to be taken by a Third Party
MAH, as set forth in Section 5.1.2 becomes effective. 
 “Regulatory Transfer Transition Period”
shall have the meaning set forth in Section 5.3.6.2 of this Agreement. 
 “Regulatory Transition
Plan” shall have the meaning set forth in Section 6.4 of this Agreement. 

  
 11 

 “Related Product” means a drug product, other than Agreement Product, in
final dosage form incorporating as its active ingredient Dapoxetine or another compound that was Covered by a claim of U.S. Patent No. 5,135,947 during its patent term, for use in treatment of humans for therapeutic indications within the
urogenital area including premature ejaculation, primary urinary incontinence, urge, stress and mixed incontinence, urinary urgency, interstitial cystitis, neurogenic bladder, bladder sphincter dyssynergia and irritative symptoms of benign prostate
hypertrophy (“BPH”), hypoactive sexual desire, impotence, retarded ejaculation, delayed orgasm, and anorgasmia, but not including diseases of the kidney. 
 “Responsible Party” shall have the meaning set forth in Section 10.4.1 of this Agreement. 
 “Safety Database” shall have the meaning set forth in the PV Agreement attached hereto. 
 “Sales Services Agreement” shall have the meaning set forth in Section 5.3.1.2. 
 “Split Lot” shall have the meaning set forth in Section 10.3.1 of this Agreement. 
 “Sublicensees” means, with respect to GENUPRO, Menarini or any Affiliate of either, a Third Party granted a sublicense to any of the rights granted to GENUPRO under
Section 4.1 or a license under any GENUPRO Patents or Product Rights transferred to GENUPRO under this Agreement (each such Third Party, a “GENUPRO Sublicensee”), and, with respect to ALZA, any Affiliate or Third Party granted
a sublicense to: (i) any of the rights granted to ALZA under the License Agreement; or (ii) any of the Transitional Rights granted to ALZA under this Agreement.  

“Taxes” means all taxes of any kind, and all charges, fees, customs, levies, duties, imposts, required deposits or other
assessments, including all federal, state, local or foreign net income, capital gains, gross income, gross receipt, property, franchise, sales, use, excise, withholding, payroll, employment, social security, worker’s compensation, unemployment,
occupation, capital stock, transfer, gains, windfall profits, net worth, asset, transaction, and other taxes, and any interest, penalties or additions to tax with respect thereto, imposed upon any person by any taxing authority or other Regulatory
Authority under applicable law. 
 “Territory” shall mean all the countries of the world. 

“Third Party” shall mean any individual, corporation or entity, or any government, or any agency or political
subdivisions thereof, other than ALZA, GENUPRO or their respective Affiliates. 
 “Third Party MAH” shall have
the meaning set forth in Section 5.1.1. 
 “Trade Dress” means any product packaging, pill
design, graphics, color, color combinations, or any other designs used to create a visual impression used to identify the Agreement Product (and not any other product of ALZA or any Affiliate thereof). 

  
 12 

 “Trademarks” shall mean all rights, title and interest Controlled by ALZA
to any trademarks, trade names, and logos used or held for use by ALZA or any Affiliate thereof that are specific to the Agreement Product, including the trademarks listed on Schedule 4.2B1 and on Schedule 4.2B2, including
registrations for, and pending applications for registration, of any of the foregoing, and the goodwill related to any of the foregoing. Schedule 4.2B1 lists the Trademarks to be assigned to GENUPRO in the event of a Section 2.1 Closing;
Schedule 4.2B2 lists the Trademarks to be assigned to Menarini in the event of a Section 2.1 Closing; and, in the event of a Section 2.2 Closing, all Trademarks listed in Schedules 4.2B1 and 4.2B2 shall be assigned to
GENUPRO. 
 “Transition Completion Date” means the later of: (i) the date of [*] or (ii) the date [*]

 “Transition Period” means, on a country-by-country basis, the Country Transfer Transition Period and/or
Regulatory Transfer Transition Period, if applicable. 
 “Transitional Rights” means, on a country-by-country
basis, the rights retained by ALZA under Section 4.3 to develop, have developed, manufacture, have manufactured, distribute, have distributed, sell, offer for sale, import and export Agreement Product during the Country Transfer
Transition Period, and if applicable, the Regulatory Transfer Transition Period in such country. 
 “Transition Services
Agreement” means a written agreement between ALZA and GENUPRO for the provision of certain transitional services by ALZA and its Affiliates to GENUPRO or its designated Affiliates and/or Sublicensees.  

“Transition Team” shall have the meaning set forth in Section 6.3 of this Agreement. 

“US” means the United States of America, including its territories, commonwealths and possessions. 

1.2 Miscellaneous Interpretation Aids. 
 (a) Each use in this Agreement of the term “including”, “comprising”, or “containing” (or a variant form thereof) shall be understood to have an open, non-limiting meaning.
Thus, e.g., “including” shall be interpreted as meaning “including without limitation” or “including but not limited to”, regardless of whether the words “without limitation” or “but not limited to”
actually follow the term “including”. Similarly, the terms “such as”, “for example”, and “e.g.” shall be understood as referring to non-limiting illustrations or examples. 

(b) “Herein,” “hereby,” “hereunder,” “hereof,” and other equivalent words shall
be understood as referring to this Agreement in its entirety, and not solely to the particular provision or portion of this Agreement in which any such word is used. 

(c) Wherever used herein, any pronoun or pronouns shall be understood to cover all genders. 

[*] Confidential treatment requested. 

  
 13 

 (d) All references to days, months, quarters, or years shall be understood
to refer, respectively, to calendar days, calendar months, calendar quarters, or calendar years, unless otherwise indicated. 
 (e) Any reference to a supranational, national, federal, state, local, or foreign statute or law shall be understood to refer to the applicable version of the law or statute then in force (as it may have
been amended or superseded) as well as all rules and regulations promulgated thereunder, unless the context requires otherwise. 
 (f) All references to “dollars” or “$” shall mean United States dollars. 

Section 2 Effective Date 
 2.1 This Agreement, and the Parties’ rights and obligations hereunder shall not become effective until all of the agreements and terminations of agreements set forth in clauses a. through (and
including) j. below are fully executed by duly authorized representatives of each party to each such agreement and the other conditions set forth in clauses k. and l. below have been satisfied: 

 

	 	a.	The Menarini Priligy License Agreement (including execution of all ancillary agreements contemplated thereby, including but not limited to a reasonable form of
pharmacovigilance agreement and any other agreements to be negotiated following the execution of the sublicense agreement itself); 

  

	 	b.	The Non-Group E Markets Manufacturing Agreement; 

  

	 	c.	The Non-Group E Markets Quality Agreement; 

  

	 	d.	The GENUPRO Trademark Assignment Agreement; 

  

	 	e.	The Menarini Trademark Assignment Agreement; 

  

	 	f.	The Domain Name Assignment Agreement; 

  

	 	g.	The PV Agreement; 

  

	 	h.	The written agreement(s) terminating the sublicense agreements set forth in Schedule 11.2.18; 

 

	 	i.	The Transition Services Agreement; 

  

	 	j.	The Sales Services Agreement; 

  

	 	k.	 ALZA shall not have suspended or terminated any Ongoing Clinical Studies prior to the Effective Date, other than a suspension or termination resulting
from ALZA’s reasonable determination, after consulting with GENUPRO and providing GENUPRO a reasonable opportunity to comment, that such suspension or termination is necessary to protect subject or patient health or safety or to

  
 14 

	 	
comply with a Legal Requirement (in which case ALZA shall promptly notify GENUPRO in writing of such suspension or termination and the circumstances related thereto supporting such suspension or
termination). In the event that ALZA suspends or terminates any Ongoing Clinical Studies prior to the Effective Date for reasons other than those necessary to protect subject or patient health or safety or to comply with a Legal Requirement, GENUPRO
may, if and as determined in its sole discretion, elect to waive this clause k. as a condition for this Agreement to become effective. In the event that ALZA suspends or terminates any Ongoing Clinical Studies prior to the Effective Date for reasons
necessary to protect subject or patient health or safety or to comply with a Legal Requirement, GENUPRO agrees to waive this clause k. as a condition for this Agreement to become effective; and 

 

	 	l.	Delivery by ALZA of the following Schedules, subject to Section 16.8: Schedules 5.1.1, 5.7 and 11.3.11. 

In the event that the Effective Date under this Section 2.1 has not occurred by the date set forth in
Section 14.1, this Section 2.1 shall be of no further effect and the Effective Date shall be determined according to Section 2.2.[*]2.2 In the event the Effective Date under Section 2.1 has not
occurred by the date set forth in Section 14.1, this Agreement, and the Parties’ rights and obligations hereunder, shall not become effective until all of the agreements and terminations of agreements set forth in clauses a. through
(and including) f. below are fully executed by duly authorized representatives of each Party to each such agreement and the other conditions set forth in clauses g. and h. below have been satisfied: 

a. The GENUPRO Trademark Assignment Agreement as amended or modified under Section 14.2.2; 

b. The GENUPRO PV Agreement under Section 14.2.2; 
 c. The written agreement(s) terminating the sublicense agreements set forth in Schedule 11.2.18; 
 d. The Transition Services Agreement; 
 e. The Sales Services Agreement;

 f. Domain Name Assignment Agreement; 
 g. ALZA shall not have suspended or terminated any Ongoing Clinical Studies prior to the Effective Date, other than a suspension or termination resulting from ALZA’s reasonable determination, after
consulting with GENUPRO and providing GENUPRO a reasonable opportunity to comment, that such suspension or termination is necessary to protect subject or patient health or safety or to comply with a Legal Requirement (in which case ALZA shall
promptly notify GENUPRO in writing of such suspension or termination and the circumstances related thereto supporting such suspension or termination). In the event that ALZA suspends or 

  
 [*] Confidential
treatment requested. 

  
 15 

 
terminates any Ongoing Clinical Studies prior to the Effective Date for reasons other than those necessary to protect subject or patient health or safety or to comply with a Legal Requirement,
GENUPRO may, if and as determined in its sole discretion, elect to waive this clause g. as a condition for this Agreement to become effective. In the event that ALZA suspends or terminates any Ongoing Clinical Studies prior to the Effective Date for
reasons necessary to protect subject or patient health or safety or to comply with a Legal Requirement, GENUPRO agrees to waive this clause g. as a condition for this Agreement to become effective.; and 

h. Delivery by ALZA of the following Schedules, subject to Section 16.8: Schedules 5.1.1, 5.7 and 11.3.11. 

2.3 The Effective Date of this Agreement shall be the last date of signature of the last to be executed of the agreements, and
terminations of agreements: (a) as set forth in Section 2.1 in the event of a Section 2.1 Closing as defined in Section 14.1; or (b) as set forth in Section 2.2 in the event of a Section 2.2
Closing as defined in Section 14.2. 
 Section 3 Termination of License Agreement 

3.1 Termination of Rights and Obligations. ALZA, FURIEX and GENUPRO hereby terminate the License Agreement effective as of the
Effective Date. As of the Effective Date, the License Agreement is hereby superseded by this Agreement and, notwithstanding anything to the contrary in the License Agreement, except for ALZA’s Transitional Rights under Section 4.3
of this Agreement, neither ALZA, FURIEX, nor GENUPRO shall have any surviving rights or obligations thereunder, except that: 
 3.1.1 Termination of the License Agreement shall not release or discharge any Party from the performance of any payment obligation under the License Agreement that accrued prior to the Effective Date and
that remains to be paid as of the Effective Date, including in accordance with Section 3.2 below. 

3.1.2 The confidentiality and other rights and obligations set forth in Sections 6.01, 6.02, 8.01(a), 8.04(a), and 10.01
of the License Agreement shall continue in effect. 
 3.1.3 The obligations with respect to adverse event
reporting under Section 4.06 of the License Agreement will continue for each Party until transition of pharmacovigilance responsibility as provided in Section 6.5 below. 

3.1.4 ALZA shall, on a country-by-country basis, remain obligated to pay royalties due under the License Agreement on
ALZA’s or its Affiliates’ or Third Party licensees’ sales of Agreement Product in Group A Market countries prior to the Effective Date in a manner substantially consistent with the terms of the License Agreement (including Sections
5.03, 5.04, 5.05, 5.06, and 5.08 thereof (as if the License Agreement had not been terminated)). 
 3.2 Final Accounting.
ALZA will make a final accounting and payment to GENUPRO of royalties due for Net Sales (as defined in the License Agreement) of the Agreement Product accrued under the License Agreement with respect to each Group A Market country as of the
Effective Date in accordance with the provisions of the License Agreement. 

  
 16 

 3.3 Release; Covenant Not to Sue; Termination Right. 

3.3.1 Waiver and Release by FURIEX and GENUPRO. Notwithstanding anything to the contrary herein, upon the
Effective Date, FURIEX and GENUPRO, each on behalf of it and all of its predecessors and successors and their respective subsidiaries and assigns and their respective agents, directors, officers, and employees (each a “GENUPRO
Entity”), hereby irrevocably and unconditionally releases ALZA and all of its predecessors and successors, and their respective Affiliates and each of its assigns, and their respective agents, directors, officers, and employees, as well as
their respective shareholders, distributors, and customers thereof (each an “Alza Entity”), from any and all claims, demands, damages, rights of action, debts, liabilities, or controversies of any kind whatsoever, in any
jurisdiction, whether at law or in equity, whether before a local, state, national, or federal court, or state, national, regional, or federal administrative agency, commission, or other tribunal, and whether now known or unknown, liquidated or
unliquidated, which any GENUPRO Entity has, or may have, based on, arising out of, or in any way related to the License Agreement, including all claims known or which reasonably could have been known for breach of contract or tortious injury but
excluding only any such claims for failure to make any payment remaining due by ALZA under the License Agreement, up to and as of the Effective Date (collectively, “Waived Contract Claims”), and hereby waives all Waived Contract Claims,
provided that this Section 3.3.1 shall be subject to, and shall not in any event be construed as limiting, ALZA’s indemnification obligations under Section 12 or otherwise under this Agreement or any Ancillary Agreement
or GENUPRO’s or any GENUPRO Indemnitee’s rights under any of the foregoing. 
 3.3.2 Covenant Not
to Sue by GENUPRO. On the Effective Date, each of FURIEX and GENUPRO hereby covenants and agrees with ALZA that neither FURIEX or GENUPRO nor any other GENUPRO Entity or other person directly or indirectly controlled by FURIEX or GENUPRO or
claiming through FURIEX or GENUPRO, will bring suit based on a Waived Contract Claim or otherwise assert a Waived Contract Claim against ALZA or any other Alza Entity, whether before a local, state, national or federal court, or state, national,
regional or federal administrative agency, commission, or other tribunal, and whether such Waived Contract Claim is now known or unknown, liquidated or unliquidated, or arises before or after the Effective Date, or is based on events which occurred
before or after the Effective Date (“Covenant Not to Sue”). This Covenant Not to Sue shall run with any assignment by FURIEX or GENUPRO of its interest in this Agreement or transfer of GENUPRO’s Product Rights (as may remain
subject to any Transitional Rights retained by ALZA hereunder), and shall bind any assignee or other person or entity to which FURIEX or GENUPRO, jointly or severally, may convey an interest hereunder. For the avoidance of doubt, this Covenant Not
to Sue shall not extend to any cause of action that may be brought by FURIEX or GENUPRO alleging ALZA’s breach of the terms of this Agreement, or to any patent infringement claim that may be brought by FURIEX or GENUPRO after termination of the
license rights and Transitional Rights of ALZA hereunder alleging ALZA’s infringement of any 

  
 17 

 
GENUPRO Patents occurring after any such termination. Notwithstanding anything to the contrary, this Section 3.3.2 shall be subject to, and shall not in any event be construed as
limiting, ALZA’s indemnification obligations under Section 12 or otherwise under this Agreement or any Ancillary Agreement or FURIEX’s, GENUPRO’s, or any GENUPRO Indemnitee’s rights under any of the foregoing.

 3.3.3 Termination Right for Breach Claim. In the event, prior to the Effective Date, GENUPRO files a
lawsuit in any court or other governmental or judicial forum against ALZA or any Affiliate thereof in which GENUPRO claims or seeks any remedies or damages with respect to ALZA’s or any of its Affiliate’s actual or alleged breach of the
License Agreement, ALZA shall be entitled, upon written notice to GENUPRO given prior to the Effective Date, to terminate this Agreement and all of ALZA’s obligations, and GENUPRO’s rights, hereunder. 

3.4 Interpretation of the License Agreement Under the New Lilly License. The Parties hereby agree that the License Agreement is
amended to the extent necessary to cause (a) it to be consistent with the New Lilly License and (b) the terms and conditions of the License Agreement to not themselves constitute or directly result in a breach of the New Lilly License,
with such amendment to be effective as of the date of the New Lilly Agreement. 
 Section 4 Transfer of Certain Intellectual Property

 4.1 License of ALZA Intellectual Property to GENUPRO. 

4.1.1 Subject to the terms and conditions of this Agreement and the Ancillary Agreements (and effective as of the
Effective Date), ALZA hereby grants to GENUPRO an exclusive (even as to ALZA and its Affiliates, subject to any Transitional Rights), perpetual, royalty-free, transferable, worldwide license, with right to sublicense to Affiliates and Third Parties,
under the ALZA Know-How to develop, make, have made, use, offer for sale, sell, import, export, and commercialize Dapoxetine and Agreement Product solely for purposes in the Field. 

4.1.2 Subject to the terms and conditions of this Agreement and the Ancillary Agreements (and effective as of the
Effective Date), ALZA hereby grants to GENUPRO a non-exclusive, perpetual, royalty-free, transferable, worldwide license, with right to sublicense to Affiliates and Third Parties, under the ALZA Know-How to develop, make, have made, use, offer for
sale, sell, import, export, and commercialize Related Products solely for purposes in the Field. 
 4.1.3
Transfer of ALZA Know-How. 
 4.1.3.1 ALZA shall, at [*] expense, provide GENUPRO with a copy of the ALZA
Know-How in documentary or Electronic Media form during each country’s Transition Period according to Section 6. Each Party shall treat the ALZA Know-How as the other Party’s Confidential Information, whether or not marked or
labeled as being confidential, pursuant to the terms and conditions of this Agreement, GENUPRO (and its Affiliates and Sublicensees) shall use it 

  
 [*] Confidential
treatment requested. 

  
 18 

 
solely for the purposes expressly permitted hereunder, and ALZA shall retain ownership of all ALZA Know-How. During the Country Transfer Transition Period and for the period running [*] ([*]) [*]
thereafter, ALZA shall promptly answer any reasonable requests from GENUPRO to decipher or explain any notation within the ALZA Know-How documentation provided to GENUPRO under this Section 4.1.3.1 and Section 6.1.1.

 4.1.3.2 In providing the ALZA Know-How to GENUPRO in documentary or Electronic Media form, ALZA will use
reasonable efforts to redact from copies of the original records listed in the Index all extraneous Know-How contained therein that is not ALZA Know-How or GENUPRO Know-How. GENUPRO acknowledges that, despite such reasonable efforts, in an effort to
expedite the provision of the ALZA Know-How documentation, some extraneous Know-How may be inadvertently included, and that ALZA reserves the right, exercisable on notice to GENUPRO, to correct any documentary form of the ALZA Know-How as promptly
as possible, but in any event within [*] ([*]) [*] after its original provision to GENUPRO, provided that GENUPRO shall not be liable for any internal use of any such extraneous Know-How as permitted hereunder with respect to the ALZA Know-How prior
to receiving notice of such correction. 
 4.1.4 Subject to the terms and conditions of this Agreement and the
Ancillary Agreements (and effective as of the Effective Date), ALZA hereby grants to GENUPRO a perpetual, royalty-free, transferable, exclusive (even as to ALZA and its Affiliates, subject to any Transitional Rights) right and license, with right to
sublicense to Affiliates and Third Parties (including rights of further sublicense by any Affiliates of GENUPRO or Sublicensees), under the Copyrights, to (i) use, copy, modify, reproduce, display, perform or distribute the contents of
ALZA’s or its Affiliates advertising, marketing, promotional and sales materials specific to Dapoxetine or any Agreement Product (such content, the “Licensed Materials”) solely for purposes in the Field (such license excluding,
for the avoidance of doubt, the corporate names and logos of ALZA and its Affiliates and any other content that is not specific to Dapoxetine or any Agreement Product)), (ii) prepare derivative works incorporating all or any portion of the
Licensed Materials (excluding, for the avoidance of doubt, the corporate names and logos of ALZA and its Affiliates), and (iii) to use such derivative works solely for purposes in the Field. For the avoidance of doubt, except as expressly set
forth in this Agreement, nothing in this Section 4.1.4 shall be construed as granting or conveying (whether expressly or by implication) to GENUPRO or its Affiliates any rights to use the names of ALZA or any of its Affiliates or any of
their logos or trademarks owned, licensed, or controlled by ALZA and that are not specific to any Agreement Product but are incorporated in any such advertising, marketing, promotional or sales materials containing content being licensed to GENUPRO
pursuant to this Agreement. 
 4.1.5 ALZA hereby represents and warrants to its knowledge (including upon
reasonable inquiry of its Affiliates) that, as of the Effective Date, except for expired or abandoned ALZA Patents, no ALZA Patents have issued or are pending. In the event, at any time before the Transition Completion Date, ALZA identifies any ALZA
Patents 

  
 [*] Confidential
treatment requested. 

  
 19 

 
claiming Dapoxetine or Agreement Product, for which Regulatory Approval has been obtained or is being sought by or on behalf of ALZA (directly or through an Affiliate) (“Identified ALZA
Patents”), it shall promptly notify GENUPRO in writing (for the purposes of this section the date of such notice being the “Notification Date”). ALZA shall and hereby does, subject to any pre-existing obligations and other
terms of any Third Party agreements as of the Notification Date, grant to GENUPRO an exclusive (even as to ALZA, except as to any Transitional Rights), royalty-free, transferable worldwide license, with right to sublicense to Affiliates and Third
Parties, under the Identified ALZA Patents during the term thereof, to develop, make, have made, use, offer for sale, sell, import, export, and commercialize Dapoxetine and Agreement Product solely for purposes in the Field subject to the terms and
conditions of this Agreement and the Ancillary Agreements. 
 4.1.6 GENUPRO shall have the right to sublicense
or license any of its rights under Section 4.1 or under any Product Rights licensed or transferred to it under this Agreement to any Affiliate or Third Party without ALZA’s prior written consent, provided that the licensing of any
manufacturing, distribution, or commercial rights relating to any Agreement Product, Related Product, or any Product Rights to any Third Party shall be by written agreement, except that GENUPRO shall notify ALZA of any sublicensing of GENUPRO’s
rights to ALZA Know-How or Identified ALZA Patents (if any) to GENUPRO’s Affiliates or Sublicensees and any further sublicensing of ALZA Know-How or Identified ALZA Patents (if any) by its Affiliates or Sublicensees. 

4.1.7 The license rights granted by ALZA under Section 4.1 shall become: (i) fully paid-up upon
satisfaction of all of GENUPRO’s, and its Affiliates’ and Sublicensees’, payment obligations to ALZA under Sections 7.1 and 7.2; and (ii) irrevocable upon expiry of [*] ([*]) [*] after the Effective Date, provided that
GENUPRO or its Affiliates or Sublicensees have not breached any material obligation, warranty or covenant during the period starting on the Effective Date and ending [*] ([*]) [*] after the Effective Date. 

4.2 Assignment of Trademarks, Domain Names. 

4.2.1 As of the Effective Date, ALZA shall assign, and cause its applicable Affiliates to assign, to GENUPRO the
Trademarks with respect to the Group E Market Countries and Domain Names. As of the Effective Date, subject to Menarini having become a Sublicensee of GENUPRO, ALZA shall assign, and cause its applicable Affiliates to assign, to Menarini the
Trademarks with respect to all countries other than the Group E Countries. The Parties shall separately document the assignment to GENUPRO of ownership of the Trademarks with respect to the Group E Market Countries and Domain Names using
commercially reasonable and customary forms of assignments to be negotiated in good faith promptly following the Execution Date (the “GENUPRO Trademark Assignment Agreement” and “Domain Name Assignment Agreement”,
respectively), which shall be executed on or prior to the Effective Date. Subject to Menarini having become a Sublicensee of GENUPRO, the Trademarks concerning such countries other than the Group E Market countries shall be assigned to Menarini
pursuant to, and Menarini’s ownership of such Trademarks, shall be separately documented by 

  
 [*] Confidential
treatment requested. 

  
 20 

 
commercially reasonable and customary forms of assignments to be negotiated in good faith by ALZA promptly following the Execution Date (the “Menarini Trademark Assignment
Agreement”), which shall be executed on or prior to the Effective Date. Notwithstanding the preceding sentence, the Trademarks in Group A Market countries shall be assigned to Menarini on a country-by-country basis on the [*] as defined in
Section 5.3.1.2 in each such country. In the event of a Section 2.2 Closing, the Menarini Trademark Assignment Agreement shall be of no effect and the assignments that would have been made thereunder in accordance with this
Section 4.2.1 shall be made to GENUPRO in the GENUPRO Trademark Assignment Agreement. 
 4.2.2
Notwithstanding the foregoing, GENUPRO and its Affiliates and Sublicensees shall have no rights to Trade Dress under the GENUPRO Trademark Assignment Agreement or the Menarini Trademark Assignment Agreement. 

4.3 Rights Retained by ALZA. 
 4.3.1 ALZA acknowledges that, by virtue of termination of the License Agreement, as of the Effective Date, ALZA’s rights thereunder to develop, have developed, manufacture, have manufactured,
distribute, have distributed, sell, offer for sale, import, and export Licensed Products (as defined in Section 1.22 of the License Agreement) have been terminated or reverted to GENUPRO, except for ALZA’s retention of Transitional Rights
as provided hereunder until the Transition Completion Date. 
 4.3.2 Effective as of the Effective Date, GENUPRO
hereby grants to ALZA a non-exclusive, royalty-free (except for amounts due GENUPRO under the Sales Services Agreement with respect to the sale of Agreement Product by ALZA or its designated Affiliates or Sublicensees), worldwide license, with right
to sublicense to Affiliates and/or Sublicensees, under the GENUPRO Patents, GENUPRO Know-How, Product Rights, ALZA Know-How, and Identified ALZA Patents (if any) transferred or licensed to GENUPRO hereunder, to develop, have developed, make, have
made, use, have used, offer for sale, sell, and import Dapoxetine and the Agreement Product solely for purposes of practicing its Transitional Rights in the Non-Group E Market Countries as provided hereunder until the Transition Completion Date and
performing its obligations under the this Agreement and the Ancillary Agreements. The rights granted hereunder with respect to any GENUPRO Know-How constituting Lilly Know-How, Lilly Manufacturing Know-How, and Lilly Improvements (as defined in the
New Lilly License) shall be subject to the applicable terms of the New Lilly License. Notwithstanding the foregoing, the scope of such rights shall not in any event be broader than such rights previously granted under the License Agreement.

 Section 5 Transfer of Product Rights in the Territory 
 The provisions of this Section 5 are intended to govern the orderly transfer and delivery of Product Rights and the transition of the business specifically related to manufacturing, packaging
and commercialization of the Agreement Product in the applicable countries in the Territory from ALZA to GENUPRO or, if and as requested by GENUPRO, any of its Affiliates 

  
 [*] Confidential
treatment requested. 

  
 21 

 
or Sublicensees. To the extent that any Affiliates of ALZA or Third Party MAH as defined in Section 5.1.1 hold or maintain, or are responsible for holding and maintaining,
Governmental Permits and/or ALZA Regulatory Submissions, and/or are otherwise responsible for the manufacturing, packaging and/or commercialization of Agreement Product in one or more countries in the Territory, ALZA shall (i) cause such
Affiliates or Third Party MAH to undertake and complete such actions as are necessary to enable ALZA to fulfil its obligations under this Agreement and (ii) be liable for the acts and omissions of such Affiliates or Third Party MAH as if such
acts or omissions were those of ALZA hereunder. 
 5.1 Completion of Transfer of Product Rights. Except as expressly
provided for in this Agreement and any Ancillary Agreements, the Transition Team shall decide in writing upon a mutually acceptable date for each applicable country in the Territory that will be the target Country Transfer Date for the completion of
the assignment and transfer of all Product Rights to GENUPRO or its designated Affiliate(s), or Third Party Sublicensee(s), in such country. ALZA shall, subject to the Legal Requirements in such country, assign, transfer, and deliver, or cause to be
assigned, transferred, and delivered, to GENUPRO or its designee(s) the Product Rights on a country-by-country basis in accordance with the terms and conditions of this Agreement and any Ancillary Agreement and, except as otherwise provided below in
Sections 5.3, 5.4, or 5.5, the transfer and delivery of the Product Rights in a country shall be completed and made effective as of [*]. On and after the Effective Date of this Agreement, the Parties shall use good faith efforts to
expedite the transfer and delivery of Product Rights in each of the countries of the Territory. For purposes of clarification but not limitation, GENUPRO may request in writing that any portion of the Product Rights be directly assigned,
transferred, and delivered to a particular Affiliate or other Third Party designee (or any other Sublicensee), and ALZA shall comply with such request, provided that, to the extent any Product Rights are not transferred or assigned to one or more
Affiliates or Third Party designees of GENUPRO pursuant to the foregoing, all remaining Product Rights shall be assigned and transferred, or caused to be assigned and transferred, to GENUPRO. 

5.1.1 Third Party Marketing Authorization Holders. Those Third Parties identified on Schedule 5.1.1 are
under contractual obligations, as set forth in the Distribution Agreements therewith, to ALZA or its Affiliates with respect to the distribution, sale, and promotion of Agreement Product in the corresponding countries noted on Schedule 5.1.1,
and have filed or maintained, respectively, Marketing Applications or ALZA Marketing Authorizations, respectively, on behalf of ALZA or its Affiliates in such countries (each such Third Party, a “Third Party MAH”). In each country
that a Third Party MAH has filed and maintains a Marketing Application, or maintains an ALZA Marketing Authorization, on behalf of ALZA or its designated Affiliate as of the Effective Date, ALZA’s obligations (directly or through its
Affiliates) under this Section 5 to (a) Maintain Marketing Applications and obtain Regulatory Approval therefor, (b) Maintain ALZA Marketing Authorizations, (c) transfer and/or assign such ALZA Marketing Authorizations to
GENUPRO or its designated Affiliate or Sublicensee, and (d) execute such documents as are necessary to give effect to such transfer and/or assignment in such country, shall, subject to Section 5.1.2, be understood to be obligations
of ALZA (directly or through its Affiliates) to cause such Third Party MAH to do the same in such country. 

  
 [*] Confidential
treatment requested. 

  
 22 

 5.1.2 ALZA’s Obligations Subject to Legal Requirements. The
Parties understand and agree that in this Section 5 and throughout this Agreement, ALZA’s obligations to take an action (directly or through its Affiliates), or cause a Third Party MAH to take an action (e.g., transfer an ALZA
Marketing Authorization to GENUPRO or its Affiliate or Sublicensee; or Maintain a Marketing Application), are subject to the Legal Requirements of each particular country or jurisdiction of the Territory. In the event that an obligation of ALZA
under this Agreement to take an action (directly or through its Affiliates), or cause a Third Party MAH to take an action, is not permitted by Legal Requirements in a country, ALZA shall not be in breach of any its obligations, representations and
warranties, or covenants under this Agreement or any Ancillary Agreement so long as ALZA (directly or through its Affiliates) takes, or causes a Third Party MAH to take, a substitute action in compliance with Legal Requirements of such country
reasonably intended to achieve the purpose of ALZA’s corresponding obligation under this Agreement. By way of an illustrative, but not limiting, example: in the event that transfer of an ALZA Marketing Authorization from an ALZA Affiliate or
Third Party MAH to GENUPRO or its designated Affiliate or Sublicensee is not permitted by Legal Requirements in a country or jurisdiction, ALZA’s obligation shall be deemed fulfilled if ALZA (directly or through its Affiliates) withdraws such
ALZA Marketing Authorization and/or takes such other steps reasonably intended to permit and enable GENUPRO or its designated Affiliate or Sublicensee to file a Marketing Application and obtain a corresponding Regulatory Approval in such country or
jurisdiction. 
 5.2 Country Designation as a Group A Market, Group B Market, Group C Market, or Group E Market. The
Parties have used good faith efforts based upon available information to identify countries and designate them in the Regulatory Transition Plan in the applicable group as of the Effective Date according to the following criteria: 

5.2.1 “Group A Market” means countries of the Territory, excluding [*], [*], and [*] (countries other
than [*], collectively, “Non-Group E Market Countries”), where, as of the Effective Date, Agreement Product is [*]. The Group A Markets are set forth on Schedule 5.2A; 

5.2.2 “Group B Market” means Non-Group E Market Countries where there is [*]. The Group B Markets are
set forth on Schedule 5.2B; 
 5.2.3 “Group C Market” means Non-Group E Market Countries
where [*]. Group C Markets are set forth on Schedule 5.2C; and 
 5.2.4 “Group E Market”
means the [*]. 
 5.2.5 Certain Limitations with Respect to ALZA’s Transition Obligations. The
following capitalized terms as used in this Agreement shall have the meanings set forth below in this Section 5.2.5: 
 5.2.5.1. “Maintain”, in reference to any ALZA Marketing Authorization and/or any other existing Governmental Permits obtained by or on behalf of ALZA or any of its Affiliates for
Agreement Product as of the Effective 

  
 [*] Confidential
treatment requested. 

  
 23 

 
Date in a particular country, or ALZA Regulatory Submissions in a particular country following receipt of Regulatory Approval therein, means to use Commercially Reasonable Efforts to undertake
the following, as may be applicable, during the Regulatory Transfer Transition Period: (a) making safety-related labelling changes required by a Regulatory Authority; (b) sending Dear Doctor letters required by a Regulatory Authority;
(c) collecting adverse event reports and filing such reports, and development safety update reports (DSUR), until transfer of pharmacovigilance responsibilities to GENUPRO and/or its designated Affiliates and/or Sublicensees; (d) filing
periodic safety update reports (PSUR) until transfer of pharmacovigilance responsibilities to GENUPRO and/or its designated Affiliates and/or Sublicensees; (e) making renewals of an ALZA Market Authorization and/or any other existing
Governmental Permits or ALZA Regulatory Submissions upon reasonable written request from GENUPRO; (f) responding to Regulatory Authority requests for information; and (g) taking any other actions with respect to any Governmental Permit(s)
in such country as required by any Legal Requirement. The Parties acknowledge and agree that (i) in order for GENUPRO and/or its Affiliates and/or Sublicensees to receive Regulatory Approval in [*] according to the Legal Requirements of that
country, ALZA or its Affiliate shall withdraw its ALZA Marketing Authorization and GENUPRO and/or its Affiliates and/or Sublicensees shall concurrently file a Marketing Application on a date that will be agreed to by ALZA and GENUPRO (“[*]
Date”), and (ii) ALZA’s and its Affiliate’s obligation to Maintain the ALZA Marketing Authorization in [*] shall cease on the [*] Date, which date shall be deemed the Regulatory Transfer Date in [*]. 

5.2.5.2 “Maintain”, in reference to a Marketing Application filed by or on behalf of ALZA or any of its
Affiliates for Agreement Product pending as of the Effective Date in a particular country, means to use Commercially Reasonable Efforts during the Regulatory Transfer Transition Period to seek Regulatory Approval based on such Marketing Application
by (a) timely responding to any Regulatory Authority’s inquiries regarding such Marketing Application or (b) making such filings or submissions, or taking such other actions, including attending meetings requested by Regulatory
Authorities, as reasonably required to obtain such Regulatory Approval, provided that actions shall not, in any event, include the conducting of any clinical trials or other in vivo or in vitro research or development activities.

 For the avoidance of doubt, ALZA shall not be obligated during the Transition Period in any country to:
(a) file any Marketing Application in any country where no such Marketing Application exists as of the Effective Date; (b) make resubmission filings of any Marketing Application, including in [*]; (c) initiate or conduct any new
clinical studies on or after the Effective Date; or (d) initiate or conduct any post-marketing clinical trials that may be required by a Regulatory Authority on or after the Effective Date. 

  
 [*] Confidential
treatment requested. 

  
 24 

 5.3 Rights and Obligations of the Parties Based on Country Designation. 

5.3.1 Group A Market. 
 5.3.1.1 GENUPRO (directly or through its Affiliates and/or Sublicensees) will, subject to any legal obligations ALZA or its Affiliates may have as holder of ALZA Marketing Authorizations or ALZA
Regulatory Submissions prior to [*] or contractual obligations ALZA or its Affiliates may have under any Ancillary Agreement or with respect to a Third Party’s rights to market, promote, distribute and commercialize Agreement Product under a
Distribution Agreement and subject to ALZA’s obligations with respect to the Ongoing Clinical Trials as set forth in Section 5.8.1, assume full responsibility and control over all aspects of the distribution and commercialization of
the Agreement Product in the Group A Market countries as of [*], and the development and manufacture of Agreement Product anywhere for such purposes in each Group A Market country, [*] 

5.3.1.2 ALZA will continue to distribute or have distributed (such as through its Affiliates or Third Parties) Agreement
Product on GENUPRO’s (or its designated Affiliates’ or Third Party Sublicensees’) behalf in each Group A Market country on or after [*] until the ALZA Distribution Termination Date (as defined below) in accordance with and under the
terms of a commercially reasonable and customary form of written agreement to be negotiated in good faith by the Parties (hereinafter “Sales Services Agreement”). 

5.3.1.2.1 ALZA’s obligations under the Sales Services Agreement shall terminate on a country-by-country basis the
earlier of: (i) [*] ([*]) [*] from [*]; or (ii) the [*] in such country (such earlier date, the “ALZA Distribution Termination Date”). 
 5.3.1.2.2 ALZA’s distribution activities under the Sales Services Agreement shall be limited to the services specifically set forth therein. For avoidance of doubt, ALZA shall not be obligated to
engage in sales (except as set forth in the Sales Services Agreement), marketing, promotional, advertising, detailing or, except as set forth in the Sales Services Agreement, any other commercialization activities under such Sales Services
Agreement. 
 5.3.1.3 The Parties will coordinate through the Transition Team (directly or through their
applicable Affiliate or Sublicensees) and make, or cause to be made, the necessary inquiries and file the necessary documents with the Regulatory Authority in each Group A Market country in accordance with Legal Requirements of each such country to
transfer ownership and pharmacovigilance responsibility and, subject to the filing of any such necessary documents for a particular Group A Market country and subject to Legal Requirements in such country, ALZA hereby assigns (or shall cause its
Affiliates or Third Party MAHs to hereby assign) to GENUPRO (or its designated Affiliate or Sublicensee) all 

  
 [*] Confidential
treatment requested. 

  
 25 

 
right, title, and interest in all ALZA Marketing Authorizations and any other existing Governmental Permits and ALZA Regulatory Submissions in such country. ALZA shall execute or cause to be
executed all documents necessary to effect such assignment. Such assignment is subject to approval or acknowledgement by the Regulatory Authority of each country to the extent required in accordance with the Legal Requirements of such country. ALZA
shall (or shall cause its applicable Affiliate or Third Party MAH to) use Commercially Reasonable Efforts to file, and obtain approval of, any variations of any Governmental Permits or ALZA Regulatory Submissions needed to effect such transfer of
the ALZA Marketing Authorization and any other Governmental Permits and ALZA Regulatory Submissions to GENUPRO and/or its Affiliates and/or Sublicensees. 
 5.3.1.4 ALZA’s only other obligations in each Group A Market country will be as follows: 
 (a) beginning on [*], ALZA shall (or shall cause its applicable Affiliate or Third Party MAH to) make inquiries and file such documents as set forth in Section 5.3.1.3, and Maintain the ALZA
Marketing Authorization and any other existing Governmental Permits and ALZA Regulatory Submissions, which obligations shall cease on [*] in each Group A Market country; 
 (b) beginning on [*], if requested in writing by GENUPRO or its designated Affiliate and/or Sublicensee, ALZA shall, subject to Legal Requirements, appoint (or cause its applicable Affiliate or Third
Party MAH to appoint) GENUPRO or its designated Affiliate and/or Sublicensee as its MA Delegate in each requested Group A Market country under a Delegation of Authority, which shall expire on a country-by-country basis on [*] in each country, to
allow GENUPRO or its designated Affiliate and/or Sublicensee to distribute and commercialize Agreement Product prior to [*]. In such case, ALZA’s obligations under the Sales Services Agreement under Section 5.3.1.2 in each such
Group A Market country shall terminate on [*]; 
 (c) beginning on [*], ALZA shall (or cause its applicable Affiliate to)
proceed with the transfer of other Product Rights in each Group A Market country as set forth in this Agreement; 
 (d) ALZA
shall (or shall cause its applicable Affiliate or Third Party MAH to) comply with any legal obligations ALZA or its Affiliates or Third Party MAH may have as holder of ALZA Marketing Authorizations or ALZA Regulatory Submissions prior to [*]; and

 (e) ALZA shall comply with its obligations as set forth in any Ancillary Agreement. 

  
 [*] Confidential
treatment requested. 

  
 26 

 The obligations in clauses (a), (b) and (d) of this Section 5.3.1.4 shall cease on [*]
in each Group A Market country. 
 5.3.2 Group B Market. 

5.3.2.1 GENUPRO (directly or through its Affiliates and/or Sublicensees) will, subject to any legal obligations ALZA or
its Affiliates or Third Party MAHs may have as holder of ALZA Marketing Authorizations or ALZA Regulatory Submissions prior to [*] or contractual obligations ALZA or its Affiliates may have under any Ancillary Agreement or with respect to a Third
Party’s rights to market, promote, distribute and commercialize Agreement Product under a Distribution Agreement and subject to ALZA’s obligations with respect to the Ongoing Clinical Trials as set forth in Section 5.8.1,
assume full responsibility and control over all aspects of the distribution and commercialization of the Agreement Product as of [*] in each Group B Market country, and the development and manufacture of Agreement Product anywhere for such purposes
in each Group B Market country, [*] 
 5.3.2.2 The Parties will coordinate through the Transition Team (directly
or through their applicable Affiliate or Sublicensee) and make the necessary inquiries and file the necessary documents with the Regulatory Authority in each Group B Market country in accordance with the Legal Requirements of such country to
transfer ownership and pharmacovigilance responsibility and, subject to the filing of any such necessary documents for a particular Group B Market country and subject to Legal Requirements in such country, ALZA hereby assigns (or shall cause its
Affiliates or Third Party MAHs to hereby assign) to GENUPRO (or its designated Affiliate or Sublicensee) all right, title, and interest in all ALZA Marketing Authorizations and any other existing Governmental Permits and ALZA Regulatory Submissions
in such country. ALZA shall execute or cause to be executed all documents necessary to effect such assignment. Such assignment is subject to approval or acknowledgement by the Regulatory Authority of each country to the extent required in accordance
with the Legal Requirements of such country. ALZA shall (or shall cause its applicable Affiliate or Third Party MAH to) use Commercially Reasonable Efforts to file, and obtain approval of, any variations needed of any Governmental Permits or ALZA
Regulatory Submissions to effect such transfer, of the ALZA Market Authorization and any other existing Governmental Permits and ALZA Regulatory Submissions to GENUPRO and/or its Affiliates and/or Sublicensees. 

5.3.2.3 ALZA’s only other obligations in each Group B Market country will be as follows: 

(a) beginning on [*], ALZA shall (or shall cause its applicable Affiliate or Third Party MAH to) make inquiries and file
such documents as set forth in Section 5.3.2.2, and Maintain the ALZA Market Authorization and any other existing Governmental Permits and ALZA Regulatory Submissions; 

  
 [*] Confidential
treatment requested. 

  
 27 

 (b) beginning on [*], if requested in writing by GENUPRO or its designated
Affiliate and/or Sublicensee, ALZA shall, subject to Legal Requirements, appoint (or cause its applicable Affiliate or Third Party MAH to appoint) GENUPRO or its designated Affiliate and/or Sublicensee as its MA Delegate in each requested Group B
Market country under a Delegation of Authority, which shall expire on a country-by-country basis on [*] in each country, to allow GENUPRO or its designated Affiliate and/or Sublicensee to distribute and commercialize Agreement Product prior to [*];

 (c) beginning on [*], ALZA shall (or cause its applicable Affiliate to) proceed with the transfer of other
Product Rights in each Group B Market country as set forth in this Agreement; 
 (d) ALZA shall (or shall cause
its applicable Affiliate or Third Party MAH to) comply with any legal obligations ALZA or its Affiliates or Third Party MAH may have as holder of ALZA Marketing Authorizations or ALZA Regulatory Submissions prior to [*]; and 

(e) ALZA shall comply with its obligations as set forth in any Ancillary Agreement. 

The obligations in clauses (a), (b), and (d) of this Section 5.3.2.3 shall cease on [*] in each Group B
Market country. 
 5.3.3 Group C Market. 

5.3.3.1 GENUPRO (directly or through its Affiliates and/or Sublicensees) will, subject to any legal obligations ALZA or
its Affiliates or Third Party MAHs may have as holder of ALZA Marketing Authorizations or ALZA Regulatory Submissions prior to [*] or contractual obligations ALZA or its Affiliates may have under any Ancillary Agreement or with respect to a Third
Party’s rights to market, promote, distribute and commercialize Agreement Product under a Distribution Agreement and subject to ALZA’s obligations with respect to the Ongoing Clinical Trials as set forth in Section 5.8.1,
assume full responsibility and control over all aspects of the distribution and commercialization of the Agreement Product as of [*] in each Group C Market country, and the development and manufacture of Agreement Product anywhere for such purposes
in each Group C Market country, [*] 
 5.3.3.2 ALZA will (or will cause its applicable Affiliate or Third Party
MAH to) Maintain the Marketing Application in each Group C Market country. Upon ALZA’s or its Affiliates’ or Third Party MAHs’ receipt of Regulatory Approval in a Group C Market Country, the Parties will coordinate 

  
 [*] Confidential
treatment requested. 

  
 28 

 
through the Transition Team (directly or through their applicable Affiliate or Sublicensee) and make the necessary inquiries and file the necessary documents with the Regulatory Authority in each
Group C Market country in accordance with the Legal Requirements of such country to transfer ownership and pharmacovigilance responsibility and, subject to the filing of any such necessary documents for a particular Group C Market country and
subject to Legal Requirements in such country, ALZA hereby assigns (and shall cause its Affiliates or Third Party MAHs to hereby assign) to GENUPRO (or its designated Affiliate or Sublicensee) all right, title, and interest in all ALZA Marketing
Authorizations and any other existing Governmental Permits and ALZA Regulatory Submissions in such country. ALZA shall (or shall cause its applicable Affiliate or Third Party MAH to) execute all documents necessary to effect such assignment. Such
assignment is subject to approval or acknowledgement by the Regulatory Authority of each country to the extent required in accordance with the Legal Requirements of such country. ALZA shall (or shall cause its applicable Affiliate or Third Party MAH
to) use Commercially Reasonable Efforts to obtain approval of any variations of any ALZA Regulatory Submissions or resulting Governmental Permits needed to effect such transfer of the ALZA Marketing Authorization and any other existing Governmental
Permits and ALZA Regulatory Submissions to GENUPRO and/or its Affiliates and/or Sublicensees as soon as reasonably possible following receipt of Regulatory Approval in such country or on such earlier date as may be requested in writing by GENUPRO
following [*]. 
 5.3.3.3 ALZA’s only other obligations in each Group C Market country will be as follows:

 (a) ALZA shall (or cause its applicable Affiliate or Third Party MAH to) Maintain the Marketing Application in such country;

 (b) ALZA shall (or cause its applicable Affiliate or Third Party MAH to) make the inquiries and file such documents as set
forth in Section 5.3.3.2, Maintain the Marketing Application, and Maintain any resulting ALZA Marketing Authorization and any other existing Governmental Permits and ALZA Regulatory Submissions, which obligations shall cease on [*] in
each Group C Market country; 
 (b) beginning on [*], ALZA shall (or cause its applicable Affiliate to) proceed with the
transfer of other Product Rights in each Group C Market country as set forth in this Agreement; and 
 (c) ALZA shall comply
with its obligations as set forth in any Ancillary Agreement. 
 The obligations in clauses (a) and
(b) of this Section 5.3.3.3 shall cease on [*] in each Group C Market country. 

  
 [*] Confidential
treatment requested. 

  
 29 

 5.3.4 Group E Market. 

5.3.4.1 GENUPRO (directly or through its Affiliates and/or Sublicensees) will, subject to any legal obligations ALZA or
its Affiliates may have as holder of ALZA Marketing Authorizations or ALZA Regulatory Submissions prior to [*] or contractual obligations ALZA or its Affiliates may have under any Ancillary Agreement and subject to ALZA’s obligations with
respect to the Ongoing Clinical Trials as set forth in Section 5.8.1, assume full responsibility and control over all aspects of the distribution and commercialization of the Agreement Product as [*] in each Group E Market country, and
the development and manufacture of Agreement Product anywhere for such purposes in such Group E Market country, [*]. 
 5.3.4.2 The Parties will coordinate through the Transition Team and file (or shall cause their applicable Affiliate or Sublicensee to file) with the [*] all documents necessary to transfer ownership of
the [*] to GENUPRO such that the [*] and [*] in [*] shall be no later than [*] and subject to the filing of any such necessary documents with the [*], ALZA hereby assigns (and shall cause its Affiliates to hereby assign) to GENUPRO (or its
designated Affiliate or Sublicensee) all right, title, and interest in all ALZA Regulatory Submissions in [*]. ALZA shall execute all documents necessary to effect such assignment. Such assignment is subject to acknowledgement by the [*] to the
extent required in accordance with [*] Legal Requirements. ALZA’s only other obligations with respect to the [*] prior [*] shall be to take any actions necessary to comply with all Legal Requirements applicable to ALZA (or any Affiliate
thereof) as the owner of any ALZA Regulatory Submissions or sponsor of any clinical studies and submit safety reports, including any DSUR. ALZA shall not be obligated to initiate or take any actions, or make any responses, related to any
resubmission or supplementation of the [*] by GENUPRO. 
 5.3.4.3 ALZA’s only other obligations in each
Group E Market country will be: 
 (a) the filing of such applications as set forth in Section 5.3.4.2 and
Maintaining the [*] and any other ALZA Regulatory Submissions, which obligations shall cease on [*] in each Group E Market country; 
 (b) beginning on [*], ALZA shall (or shall cause its applicable Affiliate or Third Party MAH to) transfer the other Product Rights in each Group E Market country as set forth in this Agreement; and

 (c) ALZA’s obligations as set forth in any Ancillary Agreement. 

The obligations in clause (a) of this Section 5.3.4.3 shall cease on [*] in [*]. 

  
 [*] Confidential
treatment requested. 

  
 30 

 5.3.5 No Further ALZA Rights or Obligations in Other Countries. As of [*], ALZA will
have no further rights or obligations with respect to Agreement Product in any country of the Territory other than ALZA’s rights and obligations in the Group A Market, Group B Market, Group C Market, and Group E Market countries as set forth in
this Agreement and the Ancillary Agreements. For all countries that are not in the Group A Market, Group B Market, Group C Market, or Group E Market, the [*] shall be [*]. 

5.3.6 Transition Periods. 

5.3.6.1 Country Transfer Transition Period. For each Group A Market, Group B Market, Group C Market, and Group E
Market country, the Parties shall take Commercially Reasonable Efforts to cause the Country Transfer Date to occur no later than the expiration of the period ending [*] ([*]) [*] from the Effective Date (“Country Transfer Transition
Period”). 
 5.3.6.2 Regulatory Transfer Transition Period. In the event of Governmental
Transfer Delay as defined in Section 5.5 as of expiry of the Country Transfer Transition Period, then the transfer of Governmental Permits and ALZA Regulatory Submissions shall not be subject to the expiry of the Country Transfer
Transition Period, but for each Group A Market, Group B Market, Group C Market, and Group E Market country, the Parties shall take Commercially Reasonable Efforts to cause the Regulatory Transfer Date to occur no later than the expiration of the
period ending [*] ([*]) [*] from the [*] (“Regulatory Transfer Transition Period”). For avoidance of doubt, when the term “Regulatory Transfer Transition Period” is used herein in reference to a particular country, the
Regulatory Transfer Transition Period in such country shall end on the Regulatory Transfer Date in that country. The Parties expect that all transfers of Governmental Permits and ALZA Regulatory Submissions subject to this Agreement will be approved
by the relevant Regulatory Authorities no later than expiry of the Regulatory Transfer Transition Period. Except as set forth in Section 5.3.7, Section 4.1.3.1 and Section 5.3.8, ALZA shall have no obligation to
Maintain, transfer, or assist GENUPRO and its Affiliates and/or Sublicensees to maintain or transfer Governmental Permits and ALZA Regulatory Submissions after the expiry of the Regulatory Transfer Transition Period. 

5.3.7 Transfer of Regulatory Responsibility. Except as expressly set forth in any Ancillary Agreement (and subject
to the Parties’ compliance with, and the terms of, the PV Agreements), ALZA shall be responsible for regulatory matters in each Group A Market, Group B Market, Group C Market, and Group E Market country during the Regulatory Transfer Transition
Period in that country and GENUPRO (directly or through its Affiliates and/or Sublicensees) shall assume regulatory responsibility on the [*] in each country. In the event that action or inaction by a Regulatory Authority in a country prevents
completion of such transfer prior to expiry of the Regulatory Transfer Transition Period, the Parties agree to negotiate in good faith an extension of the Regulatory Transfer Transition Period for that country to effectuate such regulatory transfer,
including compensation for ALZA. Notwithstanding the foregoing, in the event ALZA has performed substantially all activities necessary to effect such regulatory transfer such that only minimal activity is needed by ALZA, ALZA shall complete the
transfer at no cost to GENUPRO. 

  
 [*] Confidential
treatment requested. 

  
 31 

 5.3.8 Regulatory Support. In addition to (and without limitation of)
ALZA’s obligations under the Ancillary Agreements, ALZA will provide to GENUPRO and/or its Affiliates and/or Sublicensees with regulatory support as follows: 

(a) for a period beginning on [*] and ending [*] ([*]) [*] after [*] in each country in the Group A Market, Group B
Market, Group C Market or Group E Market, upon reasonable request from GENUPRO, ALZA will assist GENUPRO and/or its Affiliates and/or Sublicensees with the development of regulatory documents, including the drafting and submission of responses to
Regulatory Authorities. Notwithstanding the foregoing, ALZA shall not be obligated to prepare, or to assist GENUPRO in the preparation of, any U.S. NDA documents; and 

(b) for a period beginning [*] ([*]) [*] from the [*] in each country in the Group A Market, Group B Market, Group C
Market, and Group E Market and ending [*] ([*]) [*] after such [*], ALZA will provide consulting services [*] to GENUPRO and/or its Affiliates and/or Sublicensees regarding regulatory matters. Such consulting services shall be limited to responding
to reasonable requests for information from GENUPRO and/or its Affiliates and/or Sublicensees concerning specific regulatory matters, but shall not include the development of regulatory documents, including the drafting and submission of responses
to Regulatory Authorities. 
 5.4 Disposition of Distribution Agreements. ALZA shall identify and list all Distribution
Agreements in Schedule 5.4 on or before the Effective Date. ALZA shall, or shall cause its Affiliates to, terminate all rights and obligations as to Agreement Product in the Distribution Agreements, subject to ALZA’s obligations under
this Agreement and any Ancillary Agreement, and subject to Legal Requirements, on or before the date [*] ([*]) [*] after [*], except for those Distribution Agreements where the Third Parties to such Distribution Agreements are Third Party
MAHs, ALZA shall, or shall cause its Affiliates to, terminate all rights and obligations as to Agreement Product in such Distribution Agreements subject to Legal Requirements, on a country-by-country basis, on or before [*] ([*]) [*] after [*].

 5.5 Delays in Transfer of ALZA Marketing Authorizations, ALZA Regulatory Submissions, and Product Rights. The
Parties acknowledge that, notwithstanding their good faith diligent efforts to complete the transfer and delivery of all of the Product Rights in each country in the Territory to GENUPRO and/or its designated Affiliates and/or Sublicensees by or on
the applicable [*], there will be some countries in which the transfer of ownership and control of Governmental Permits or ALZA Regulatory Submissions (and possibly certain other Product Rights) to GENUPRO and/or its Affiliates and/or Sublicensees
cannot be completed on or before [*] as a result of (a) processes or conditions imposed by Regulatory Authorities or other governmental authorities and that are outside the reasonable control of the Parties or (b) the requirements
or limitations of any Legal Requirements applicable to such country (all such circumstances in (a) or (b) referred to as “Governmental Transfer Delay”). It is the intention

  
 [*] Confidential
treatment requested. 

  
 32 

 
of the Parties that, to the fullest extent possible under Legal Requirements, such delays in transferring ALZA Marketing Authorizations, other existing Governmental Permits, or ALZA Regulatory
Submissions (and/or other Product Rights, if any) in a country should not result in a delay in the transfer of those Product Rights that can be transferred on or before [*], so that GENUPRO (directly or through its Affiliates and/or Sublicensees)
can assume, to the greatest extent possible pursuant to Legal Requirements, full control and responsibility for the Agreement Product (and become entitled to the benefit of all sales of and other activities with respect to, Agreement Product)
in such country as of [*]. Accordingly, the Parties agree that in the event of any Governmental Transfer Delay: 

5.5.1.1 the Parties will undertake to complete the transfer and delivery of all of the Product Rights that are not the
subject of such Governmental Transfer Delay on or before [*]; 
 5.5.1.2 Subject to Section 5.3.6.2
and Section 5.3.7, ALZA (directly or through its Affiliates) may continue to hold and maintain the Governmental Permits and ALZA Regulatory Submissions (and such other Product Rights, if any, that cannot be transferred on or before
[*]) for the Agreement Product on behalf of and for the sole benefit of GENUPRO and its designated Affiliates and/or Sublicensees only until such time as the transfer of Governmental Permits and ALZA Regulatory Submissions (and any other affected
Product Rights) to GENUPRO or its designated Affiliates and/or its Sublicensees can be completed in such country; 
 5.5.1.3 ALZA (directly or through its Affiliates) will perform certain manufacturing activities (as further described in Section 8 of this Agreement) for GENUPRO and/or its designated
Affiliates and/or Sublicensees in accordance with and under the terms of the Manufacturing Agreements, as applicable; and 
 5.5.1.4 Subject to Section 5.3.6.2 and Section 5.3.7, the Parties will enter into such other agreements or undertake such additional actions as are reasonably necessary to grant
GENUPRO or its designated Affiliates and/or its Sublicensees control and responsibility over the disposition of all such Governmental Permits, ALZA Regulatory Submissions, and other Product Rights in the country that do not transfer on or before the
expiry of [*] as soon as reasonably possible. 
 For the avoidance of doubt, nothing herein shall be construed as obligating
ALZA to undertake or perform any advertising, marketing or promotional services for or on behalf of GENUPRO or its designated Affiliates and/or Sublicensees with respect to the Agreement Product in a country in the Territory on or after [*].

 5.6 Reporting During Transition Period. Until the end of the Transition Period in each country, ALZA shall keep
GENUPRO reasonably informed regarding the material ongoing activities by ALZA (directly or through its Affiliates or Third Party MAHs) for the Agreement Product in the country. 

5.7 Disposition of Product Contracts. ALZA shall use Commercially Reasonable Efforts to identify and list Product Contracts in
Schedule 5.7 on or before [*]. ALZA shall have 

  
 [*] Confidential
treatment requested. 

  
 33 

 
the right to supplement Schedule 5.7 until the expiry of [*] ([*]) [*] after [*]. Any member of the Transition Team shall have the right, in its discretion and promptly following its
reasonable written request with respect thereto, to review any Product Contract(s) listed on Schedule 5.7 during the Transition Period, subject to the applicable confidentiality and consent provisions of such Product Contract(s) that any
member of the Transition Team desires to review. If the Transition Team decides, by [*] according to Section 6.3.2, that a Product Contract is material to GENUPRO’s and/or its designated Affiliate’s and/or Sublicensee’s
rights to manufacture, use, sell, market, develop, distribute or commercialize Agreement Product (“Material Product Contract”), ALZA shall, or shall cause its Affiliates to, use Commercially Reasonable Efforts to terminate
with respect to Agreement Product, or allow to expire, such Material Product Contract, such termination subject to ALZA’s pre-existing obligations and other terms of such Material Product Contract and subject to ALZA’s obligations under
this Agreement and any Ancillary Agreement, on or before [*] ([*]) [*] after the decision date documented in writing according to Section 6.3.2, except in the [*], where ALZA shall, or shall cause its Affiliates to, use
Commercially Reasonable Efforts to terminate with respect to Agreement Product, or allow to expire, such Material Product Contract on a country-by-country basis no later than the later of: (i) [*] ([*]) [*] after [*] or (ii) [*] ([*]) [*]
after [*] for each such country. Without limitation of any more stringent requirements with respect to any particular Product Contract(s) explicitly provided in this Agreement, ALZA shall, or shall cause its Affiliates to, use Commercially
Reasonable Efforts to terminate with respect to Agreement Product, or allow to expire, all other Product Contracts material to GENUPRO’s and/or its designated Affiliate’s and/or Sublicensee’s rights to manufacture, use, sell, market,
distribute or commercialize Agreement Product no later than [*] ([*]) [*] after [*]. If, after review of the Product Contracts listed in Schedule 5.7, GENUPRO identifies in writing to ALZA such a material Product Contract concerning solely
Agreement Product (and not concerning any unrelated products) that GENUPRO reasonably requests to have assigned to it, its Affiliate, or a designated Sublicensee or indicates whether or not GENUPRO wishes such material Product Contract to be
terminated, allowed to expire, or to remain in effect, ALZA shall, or shall cause its Affiliates to, use Commercially Reasonable Efforts to assign such Product Contract to GENUPRO, and/or its designated Affiliates and/or Sublicensee, subject
to the assignment provision of such Product Contract or comply with GENUPRO’s reasonable request with respect to termination, expiration, or survival thereof. 
 5.8 Responsibility for Transitional Development. 
 5.8.1
Ongoing Clinical Studies. The Parties acknowledge that, as of the Effective Date, ALZA (directly or through its Affiliates) is supporting, conducting or otherwise responsible for the ongoing clinical studies listed in Schedule 5.8.1
(“Ongoing Clinical Studies”). Beginning on [*], ALZA (directly or through its Affiliates) shall use Commercially Reasonable Efforts to complete all Ongoing Clinical Studies by [*] (the “Study Transition Date”),
where completion of a study means closing out the study, analyzing the study results, and generating a study report (if any) required for submission to the relevant Regulatory Authorities, which shall be provided to GENUPRO (or its designated
Affiliate or Sublicensee). In the event that, on or after the Effective Date, either Party reasonably determines in good faith that any Ongoing Clinical Study cannot or will not be completed by the Study Transition Date or should be suspended
or terminated prior to such date, it shall promptly notify the other Party in writing to that 

  
 [*] Confidential
treatment requested. 

  
 34 

 
effect. Promptly after such notice, the Transition Team will meet and review the status of the relevant Ongoing Clinical Study and attempt to decide, by mutual agreement of the Parties, whether
(i) ALZA will terminate/discontinue such Ongoing Clinical Study (effective no later than [*]) or (ii) the responsibility for (and control over) such Ongoing Clinical Study will be transferred to GENUPRO or its designated Affiliate or
Sublicensee, provided that if the Parties cannot mutually agree on the disposition of such Ongoing Clinical Study, [*] shall have the final decision with respect to such matter, in its sole discretion. If it is decided pursuant to the foregoing that
such uncompleted Ongoing Clinical Study will be terminated/discontinued, ALZA will be responsible for arranging for termination of such Ongoing Clinical Study on or prior to [*] in a manner consistent with Legal Requirements. If it is decided that
responsibility for such Ongoing Clinical Study will be transferred to GENUPRO or its designated Affiliate or Sublicensee, then the Parties shall use Commercially Reasonable Efforts, and collaborate in good faith, to transfer responsibility for the
study to GENUPRO (or its designated Affiliate or Sublicensee) as soon as reasonably practicable in a manner consistent with Legal Requirements. Notwithstanding anything to the contrary, nothing shall prohibit ALZA from suspending or terminating any
Ongoing Clinical Study due to reasonable concerns regarding patient/subject safety or where required by the applicable Regulatory Authority. ALZA shall not be obligated to submit to any Regulatory Authority any report regarding Ongoing Clinical
Studies except as required to be submitted by such Regulatory Authority. 
 5.8.2 [*] shall be responsible for
[*] costs and expenses related to the conduct of the Ongoing Clinical Studies prior to [*]. In the event of a [*] then, as of [*], GENUPRO shall be responsible for [*] Development Costs incurred with respect to the conduct of the Ongoing Clinical
Studies following [*] including any and all reasonable, documented costs and expenses incurred by ALZA and its Affiliates in the event that an Ongoing Clinical Study is terminated, discontinued or transferred to GENUPRO according to
Section 5.8.1, up to a total of Nineteen Million Dollars (US $19,000,000), and [*] shall be responsible for [*] costs and expenses incurred with respect to the Ongoing Clinical Studies in which [*]is still participating. ALZA shall
invoice the Development Costs, in U.S. dollars (USD), [*], due under this Section 5.8.2 within [*] ([*]) [*] after the end of each [*]. Payments must be sent within [*] ([*]) [*] following GENUPRO’s receipt of invoice. By way of
example, an illustrative invoice is shown in Schedule 5.8.2B. GENUPRO shall not have any payment or reimbursement obligations with respect to the Ongoing Clinical Studies unless [*]. 

5.8.3 Manner of Payment. All sums due to ALZA shall be payable by bank wire transfer in immediately available
funds to such bank account as ALZA shall designate in writing to GENUPRO. GENUPRO shall notify ALZA’s Finance designee as to the date and amount of any such wire transfer two (2) business days prior to such transfer. All payments shall be
made in USD. 
 5.8.4 Currency Conversion. If any payments to be made in USD under this Agreement are
earned in a currency other than USD, such payments, and the expenses used to calculate such payments, shall be converted to USD using the receiving Party’s standard conversion methodology determined in accordance with standard internal policies
and procedures and accounting standards consistently applied throughout ALZA and its Affiliates. 

  
 [*] Confidential
treatment requested. 

  
 35 

 5.8.5 Interest on Late Payments. If GENUPRO shall fail to make a
timely payment, any such payment that is not paid on or before the date such payment is due under this Agreement shall bear interest [*] but in no event higher than the highest rate permissible under Legal Requirements, effective for the first date
on which payment was delinquent and calculated on the number of days such payment is overdue. 
 5.8.6
Records; Inspection. ALZA shall keep complete, true and accurate books of accounts and records for the purpose of determining the basis and accuracy of the payments to be made for the On-Going Clinical Trials. Such records shall be kept in
accordance with ALZA’s standard internal policies and procedures and accounting standards consistently applied throughout ALZA and its Affiliates (which shall be commercially reasonable). Such books and records shall be kept for at least [*]
([*]) [*] following the end of the [*] to which they pertain. Such records will be open for inspection by GENUPRO during such [*] ([*]) [*] period by independent accountants reasonably acceptable to ALZA, solely for the purpose of verifying the
basis and accuracy of amounts in the payment statements hereunder. Such inspections shall be made no more than [*] each [*], at reasonable time and on reasonable notice and shall be limited to information related to On-Going Clinical Trials. Results
of any such inspection shall be deemed to be Confidential Information of ALZA. If any errors in favor of ALZA are discovered in the course of such inspection, then within [*] ([*]) [*] of written request by GENUPRO, ALZA shall pay GENUPRO those
amounts that GENUPRO should not have paid in the absence of such errors, plus interest pursuant to and in accordance with Section 5.8.5. Inspections conducted under this Section 5.8.6 shall be at the expense of [*], unless a
variation or error in favor of [*] exceeding [*] percent ([*]%) of the amount due for the period covered by the inspection is established in the course of such inspection, whereupon [*] costs relating to the inspection for such period will be paid
promptly by [*]. 
 5.8.7 Data Collection. The Parties acknowledge that, as of the Effective Date, ALZA
(directly or through its Affiliates) is supporting, conducting or otherwise responsible for the medical affairs activities listed in Schedule 5.8.7, the responsibility for which shall be transferred to GENUPRO and/or its designated Affiliates
or Sublicensees effective when [*] has occurred for all countries in the Territory. 
 5.8.8 For the avoidance
of doubt, nothing herein shall be construed as authorizing a Party or its Affiliates to make any commitments or representations to Third Parties on behalf of the other Party or its Affiliates regarding any clinical studies or registries without the
prior written consent of the other Party. 
 Section 6     Diligence and Coordination of Efforts 

6.1 Diligence and Cooperation. On and after the Effective Date, the Parties shall cooperate diligently in coordinated efforts to
timely complete the various transfers and delivery of Product Rights provided for in Section 5 of this Agreement. Each of ALZA and GENUPRO 

  
 [*] Confidential
treatment requested. 

  
 36 

 
shall undertake, and shall cause their respective Affiliates and/or Sublicensees, as applicable, to undertake any actions reasonably necessary to timely complete the various transfers and
delivery of Product Rights to GENUPRO and/or its designated Affiliates and/or Sublicensees as provided in Section 5 of this Agreement, including by causing the execution of any documents necessary to transfer and/or assign the ALZA
Regulatory Submissions and Governmental Permits for Agreement Product to GENUPRO or its designated Affiliates or Sublicensees. 
 6.1.1 Disposition of Development Records. Without limitation of any of ALZA’s representations, warranties, or covenants regarding the Electronic Media, and their contents under
Section 11, in connection with the transfer and delivery of Product Rights to GENUPRO or its designated Affiliates or Sublicensees, ALZA agrees that during each country’s Transition Period it shall, and shall cause its applicable
Affiliates to, transfer and deliver to GENUPRO or its designated Affiliates or Sublicensees all material Development Records in ALZA’s or its Affiliates’ possession or control that may be relevant to such country. The Parties will
coordinate the timing and prioritization of Development Records to be transferred and delivered to GENUPRO or its designated Affiliates or Sublicensees pursuant to this Section 6.1.1. The Parties will use Commercially Reasonable Efforts
to complete the transfer and delivery of Development Records as soon as reasonably possible following the Effective Date. For the avoidance of doubt, copies of Development Records to be provided in Electronic Media or documentary form shall include,
without limitation, the documents identified in Schedule 6.1.1. ALZA shall also provide GENUPRO (or any designated Affiliate or Sublicensee thereof) with all records and information related to or resulting from the conduct of the Ongoing
Trial Studies by or on behalf of ALZA, all of which shall be deemed included in and a part of the Product Rights to be assigned to GENUPRO (or any designated Affiliate or Sublicensee thereof) hereunder, in a manner reasonably acceptable to GENUPRO.

 6.1.1.1 Index of Transferred Development Records. ALZA shall list all material Development Records
transferred to GENUPRO or its designated Affiliates or Sublicensees in an Index of Transferred Development Records (“Index”). Schedule 6.1.1.1 lists the categories of documents to be listed in the Index. ALZA shall first
provide the Index to GENUPRO by means of Electronic Media on [*] and thereafter shall provide to GENUPRO an update to the Index by means of Electronic Media on each succeeding [*], each [*] and on [*]. 

6.1.2 Development Records in Electronic Form. For the avoidance of doubt, to the extent that data and information
included within the Development Records to be transferred and delivered to GENUPRO or its designated Affiliates or Sublicensees pursuant to this Agreement are maintained by ALZA or its Affiliates in electronic form, the obligation of ALZA to
transfer and deliver such Development Records to GENUPRO or its designated Affiliates or Sublicensees shall be limited to providing GENUPRO or its designated Affiliates or Sublicensees with such Development Records as part of the Electronic Media in
a mutually agreed format that permits GENUPRO or its designated Affiliates or Sublicensees to access the data and information and is reasonably acceptable to both Parties. Nothing herein shall be construed as obligating ALZA to transfer to GENUPRO
or its designated Affiliates or Sublicensees or to otherwise provide GENUPRO or its designated Affiliates or Sublicensees with access to or rights to use any 

  
 [*] Confidential
treatment requested. 

  
 37 

 
proprietary software (including Third Party or licensed software and/or software that is owned by ALZA or its Affiliates) that may be utilized by ALZA or its Affiliates from time to time in
connection with such electronic data and information included within Development Records. ALZA represents that, to its knowledge, any and all Third Party software platforms or tools (including the relevant version number and Third Party
vendors/licensors from which such software was obtained) utilized by or on behalf of ALZA or any Affiliate thereof in connection with such electronic data and information are identified on Schedule 6.1.2, other than those platforms or tools
for which the failure to include in Schedule 6.1.2 or otherwise provide to GENUPRO would not be reasonably anticipated to have a material adverse effect on GENUPRO’s, any GENUPRO Affiliate’s, or any Sublicensee’s ability to
utilize and/or access the Development Records or otherwise make, have made, use, sell, offer for sale, develop, commercialize, or seek or obtain Regulatory Approval for any Agreement Product or Related Product. 

6.1.3 ALZA Quality Assurance Records. Notwithstanding anything to the contrary herein, documentation related to
quality assurance (QA) audit activities related to Agreement Product (including with respect to clinical trials thereof) conducted by or on behalf of ALZA will not be transferred as part of the Agreement, except to the extent contained or referenced
in, or supporting, any ALZA Regulatory Submissions or Governmental Permits prior to the Effective Date, previously made public, required to be provided to any Regulatory Authority, or required by Legal Requirement to be disclosed. At GENUPRO’s
prior written request, ALZA shall permit individuals employed by GENUPRO’s or its Affiliates’ or Sublicensee’s quality assurance department to review, by appointment during normal business hours, at a facility identified by ALZA, the
quality assurance audit reports for the Ongoing Clinical Studies (see Section 5.8.1), however, no copies in full or in part will be provided except as set forth herein above. In addition, GENUPRO agrees that, except to the extent
contained or referenced in, or supporting, any ALZA Regulatory Submissions or Governmental Permits existing as of the Effective Date, previously made public, required to be provided to any Regulatory Authority, or required by Legal Requirement to be
disclosed, these quality assurance audits will not be referenced within any Regulatory Authority filing and will be held in strict confidence. Notwithstanding the foregoing, this Section 6.1.3 shall not be construed to limit ALZA’s
liability for any breach of the representations, warranties, or covenants made under Section 11. 

6.1.4 ALZA Retained Rights to Development Records. The Parties acknowledge and agree that ALZA and its Affiliates
shall be permitted to retain copies of Development Records being transferred and delivered to GENUPRO or its designated Affiliates or Sublicensees pursuant to this Section 6.1 solely to the extent necessary, and for the limited purposes
of: (i) complying with all Legal Requirements with respect thereto (including without limitation compliance with GMP, generally accepted accounting principles, external financial reporting obligations, and Sarbanes-Oxley); (ii) compliance
with internal corporate policies and standard operating procedures regarding the creation and retention of books and records; (iii) performing its obligations under this Agreement, and/or the Ancillary Agreements; and (iv) maintaining an
archival copy for legal purposes. If and to the extent ALZA or its Affiliates do retain copies of any 

  
 38 

 
Development Records on and after the relevant [*], ALZA and its Affiliates shall only use such Development Records for the specific purposes identified in the preceding sentence and not for any
other purpose. 
 6.1.5 Additional Information. 

6.1.5.1 In addition to the Development Records to be provided pursuant to Section 6.1.1, GENUPRO has requested
and ALZA is willing to provide GENUPRO or its designated Affiliates or Sublicensees with certain additional types of information material to the Agreement Product as listed on Schedule 6.1.5. Without limitation of the representations,
warranties, and covenants of ALZA under Section 11, to the extent all such information has not as of the Effective Date or already been provided to GENUPRO or its designated Affiliates or Sublicensees and included in Electronic Media,
ALZA agrees that during each country’s Transition Period, ALZA shall, and shall cause its Affiliates to, collect and provide this additional information as identified in the Index to GENUPRO or its designated Affiliates or Sublicensees as soon
as reasonably possible. 
 6.1.5.2 In addition to the foregoing, the Parties acknowledge that at any time prior
to [*], GENUPRO or its Affiliates and/or Sublicensees may request by notice to ALZA that ALZA provide additional data or information material to the development, packaging, marketing, promotion, distribution or sale of Agreement Product in one or
more countries in the Territory. Except as otherwise provided in Section 6.1.6, all such requests shall be copied and coordinated through the Transition Team. ALZA will use Commercially Reasonable Efforts to (x) promptly satisfy any
such requests by GENUPRO or its Affiliates and/or Sublicensees for additional data or information and (y) notify GENUPRO in writing of any such material information of which ALZA becomes aware at any time after the Effective Date and provide
GENUPRO such information; provided, however, nothing herein shall be construed as obligating ALZA or its Affiliates to (i) generate or procure any data or information that is not in its or their possession or control, (ii) provide GENUPRO
or its Affiliates and/or Sublicensees with data or information to the extent that it is owned or controlled by a Third Party and was made available to ALZA or its Affiliates under terms and conditions that do not permit its disclosure or transfer to
others, (iii) provide GENUPRO or its Affiliates and/or Sublicensees with any data or information related to any products other than Agreement Product, or (iv) provide GENUPRO or its designated Affiliates and/or Sublicensees with any data
or information to the extent precluded by Legal Requirements (including without limitation, antitrust or competition law). 
 6.1.6 Communication with ALZA Affiliates. Promptly after the Effective Date, the Transition Team shall exchange relevant contact information and permit direct communications between their
respective global regulatory personnel, and upon Transition Team agreement the Transition Team shall exchange relevant contact information and permit direct communications between their respective regional and

  
 [*] Confidential
treatment requested. 

  
 39 

 
local regulatory personnel with copy of all such communications to the relevant global regulatory personnel, as each Party may designate in those regions and/or countries in the Territory in
order to facilitate planning and implementation of certain aspects of the Regulatory Transition Plan. The Transition Team will also agree in writing upon the specific subject matter for such direct interactions. As of the Effective Date, no other
direct interactions with Affiliates of ALZA have been authorized and GENUPRO shall not, and shall use Commercially Reasonable Efforts to cause its Affiliates and/or Sublicensees to not, communicate requests for data, information or materials
directly to any of ALZA’s Affiliates in any country in the Territory unless and solely to the extent (i) expressly authorized in advance by ALZA in writing or (ii) required by Legal Requirement, provided that GENUPRO shall provide
ALZA with prompt notice of such Legal Requirement. Any request or proposal for direct interactions between GENUPRO or its Affiliates and/or Sublicensees and any of ALZA’s applicable Affiliates not permitted by clause (i) or (ii) above
shall be communicated through the Transition Team, and ALZA will reasonably consider any such requests; provided, however, that nothing herein shall be construed as obligating ALZA to agree to any such request or proposal, provided, however, that
(a) any failure by ALZA to satisfy any such request or proposal shall not limit any other obligations of ALZA and its Affiliates hereunder and (b) ALZA shall, notwithstanding anything to the contrary herein, provide any information or
documentation in its or any of its Affiliates’ possession or control to the extent requested of it (directly or through any of its Affiliates, GENUPRO, or any of GENUPRO’s Affiliates, Sublicensees, or independent contractors of any of the
foregoing) by any Regulatory Authority or as necessary to comply with any Legal Requirement or enable the transfer of Product Rights to GENUPRO in a timely fashion. If ALZA does agree to permit its applicable Affiliates in one or more regions or
countries in the Territory to engage in direct interactions with GENUPRO and its Affiliates and/or Sublicensees, the Parties shall agree in advance and in writing on the specific subject matter and scope of those permitted interactions, shall
communicate that information to their respective Affiliates and/or Sublicensees, as applicable, and shall exchange relevant contact information identifying their respective representatives who will participate in those interactions. 

6.2 Transition Manager. Each Party shall appoint a senior representative (each, a “Transition Manager”) who
possesses a basic understanding of the relevant operational, regulatory and commercial issues to manage the transfer obligations to GENUPRO envisioned under this Agreement (the “Transition”). The initial Transition Manager for each
Party is set forth in Schedule 6.2, and either Party may later replace such Transition Manager by providing written notice thereof to the other Party (which notice shall identify the new Transition Manager and provide contact information
therefor), provided that any replacement Transition Manager shall possess reasonably sufficient expertise to reasonably satisfy the intended role of the Transition Manager under this Agreement and leadership responsibilities within the relevant
Party that are substantially similar to or more senior than those of the preceding Transition Manager. Each Party’s Transition Manager shall be the primary contact with the other Party in connection with the on-going implementation,
communication and voting on matters within the Transition Team’s authority concerning the Transition and shall lead his/her Party’s Transition Team (as defined below). 

  
 40 

 6.3 Transition Team. 

6.3.1 The Parties will establish a joint committee (the “Transition Team”) to facilitate and oversee the
planning and implementation of strategic and tactical plans to effect the transfer and delivery of Product Rights in each applicable country in the Territory in accordance with the terms of this Agreement and to make decisions pursuant to
Section 6.3.2 expressly authorized by this Agreement, and to discuss transitional issues and to facilitate communications between the Parties with respect to such matters. The Transition Team shall also serve as a forum to address supply
chain and inventory management matters during all Transition Periods and to discuss transitional issues and to facilitate communications between the Parties with respect to such matters. Each Party shall appoint reasonably appropriate
representatives to the Transition Team, which may include personnel involved with clinical development, regulatory, manufacturing, packaging, distribution, marketing and/or sales of Agreement Product. The Transition Team shall meet (whether by
teleconference, in person or by video-conference) (i) at least weekly until specific, written strategic and tactical plans are in place, with detailed timelines for specific actions, to transfer and deliver Product Rights from ALZA to GENUPRO
and/or GENUPRO’s designated Affiliates and/or Sublicensees, and (ii) at least monthly until the transfer of all Product Rights has occurred hereunder (i.e., until the Final Transfer Date has occurred for all countries), provided that the
Transition Team may elect to meet with less frequency during the period described in (ii) based on the obligations of each Party, and the progress of the Parties’ efforts, to implement such transfers. The specific times and places of all
meetings shall be determined by the Transition Managers in a manner consistent with the foregoing obligations and reasonably acceptable to the Parties. The Transition Team may also establish sub-teams or working groups to address specific areas or
topics related to the process for transferring the Product Rights in the Territory. 
 6.3.2 The Transition Team
may make decisions expressly within its authority under this Agreement, and such decisions shall be binding on the Parties, [*], and the Transition Team shall document such decisions in a writing signed by authorized team representatives of both
Parties. For the avoidance of doubt, the Transition Team shall have no authority to modify any term in the body of this Agreement. If the Transition Team is unable to reach consensus regarding any matter within its decision-making authority before
it (including any matter that was unable to be resolved by any subcommittee), the matter shall be presented to [*] and [*] or his designee (the “Applicable Senior Officers”) for decision. Once a matter has been presented to the
Applicable Senior Officers, they shall have [*] ([*]) [*] to make a decision on the matter. In the event that the Applicable Senior Officers are unable to reach a mutual decision within such [*] ([*]) [*] period, then the matter shall be considered
a Dispute under Section 16.6 and shall be resolved in accordance therewith. 
 6.4 Regulatory Transition
Plan. The Transition Team will agree on a regulatory transition plan (the “Regulatory Transition Plan”) setting forth the timelines and activities to be performed by the Parties and/or their Affiliates and/or Sublicensees
pursuant to this Agreement to effect the transfer and delivery of all Governmental Permits, ALZA Regulatory Submissions, and certain other Product Rights to GENUPRO. The Parties shall use 

  
 [*] Confidential
treatment requested. 

  
 41 

 
Commercially Reasonable Efforts to complete the activities by the various dates set forth in the Regulatory Transition Plan. Each Party shall promptly notify the other Party in the event that it
determines that the activities and/or timelines set forth in the Regulatory Transition Plan require modification. The Transition Team shall be responsible for periodically reviewing and approving any changes to the Regulatory Transition Plan that
are proposed by a Party and/or that are necessary to address any requests or requirements that may be imposed by Regulatory Authorities in the Territory with respect to the transfer to GENUPRO or its Affiliates and/or Sublicensees of any
Governmental Permits or ALZA Regulatory Submissions. In such event, the Transition Team shall use good faith efforts to agree upon a mutually acceptable means to address the relevant issues. 

6.4.1 Cooperation by the Parties. At all times prior to [*] in a particular country, ALZA shall, and shall cause
its applicable Affiliates to, reasonably cooperate with GENUPRO and/or its designated Affiliates and/or Sublicensees to facilitate communications or other interactions with Regulatory Authorities and/or other governmental authorities in any country
that are reasonably necessary in connection with ALZA’s performance of its obligations under Section 5.3 or GENUPRO’s and/or its Affiliates’ and/or Sublicensees’ planning and preparations for the transfer of
Governmental Permits or ALZA Regulatory Submissions, including, without limitation, by providing GENUPRO and/or its Affiliates and/or Sublicensees with copies of any material communications with or from Regulatory Authorities (including meeting
minutes). ALZA shall consider and grant any reasonable requests by GENUPRO and/or its designated Affiliates and/or Sublicensees for any consent or authorizations necessary to enable GENUPRO and/or its designated Affiliates and/or Sublicensees to
engage in direct communications with Regulatory Authorities in connection with the maintenance, filing, seeking, or transfer of ALZA Regulatory Submissions and Governmental Permits for Agreement Product. GENUPRO shall not, and shall cause its
Affiliates and/or Sublicensees to not, knowingly and intentionally take any actions in the course of any such direct communications with any Regulatory Authorities in connection with any such transfer which (i) may reasonably be expected to
materially damage or impair the goodwill or reputation of ALZA or its Affiliates and/or (ii) would, without the prior written consent of ALZA, impose any new obligations or commitments (financial or otherwise) upon ALZA or its Affiliates
related to or in connection with the development, registration or commercialization of Agreement Product in such country (except such obligations as ALZA has expressly agreed to under this Agreement or any Ancillary Agreement). Prior to the Final
Transfer Date for a particular country, ALZA shall keep GENUPRO and/or its designated Affiliates and/or Sublicensees reasonably informed, and provide GENUPRO and/or its designated Affiliates and/or Sublicensees a reasonable opportunity to comment,
as to any of ALZA’s or its Affiliates’ communications with Regulatory Authorities, filing or amendment of any Marketing Applications, pursuit of Regulatory Approvals, and/or other developments related to the transition of Governmental
Permits, ALZA Regulatory Submissions, or any other Product Rights, including but not limited to those actions contemplated by Section 5.3, and in particular shall promptly notify GENUPRO and/or its designated Affiliates and/or
Sublicensees with respect to any new developments related to such activities, including but not limited to those that may materially and adversely affect (x) the development, manufacture, or 

  
 [*] Confidential
treatment requested. 

  
 42 

 
commercialization of Agreement Product in a country by GENUPRO and/or its designated Affiliates or Sublicensees and/or (y) the rights and responsibilities of the Parties with respect to,
and/or the timing of, the transfer and delivery of the Product Rights in a country to GENUPRO and/or its Affiliates and/or Sublicensees. Prior to the Final Transfer Date in a particular country, ALZA shall provide GENUPRO and/or its designated
Affiliates and/or Sublicensees with reasonable advance notice of any scheduled meeting or conference call between ALZA or its Affiliate and any Regulatory Authority relating to any Governmental Permits or ALZA Regulatory Submissions, and GENUPRO
and/or its Affiliates and/or Sublicensees shall have a right to have up to [*] ([*]) representatives of GENUPRO, [*], [*], and, if and as reasonably requested by GENUPRO and/or [*], participate in, any such meeting. Prior to [*] in a particular
country, GENUPRO and/or its designated Affiliates and/or Sublicensees shall keep ALZA reasonably informed as to any of GENUPRO’s and/or its designated Affiliates’ and/or Sublicensees’ communications with Regulatory Authorities and/or
other developments related to the transition of Governmental Permits, ALZA Regulatory Submissions, or any other Product Rights, and in particular shall promptly notify ALZA with respect to any new developments related to such activities that may
materially and adversely affect (x) the sale of Agreement Product in a country by ALZA and/or its Affiliates under the Sales Services Agreement and/or (y) the rights and responsibilities of the Parties with respect to, and/or the timing
of, the transfer and delivery of the Product Rights in a country to GENUPRO and/or its Affiliates and/or Sublicensees. The rights and obligations of the Parties under this Section 6 are in addition to, and without limitation of, the
Parties’ rights and obligations under the PV Agreements or any other Ancillary Agreement with respect to the matters addressed in this Section 6. 
 6.5 Pharmacovigilance Responsibilities and Product Inquiries. In the event of a Section 2.1 Closing, the responsibilities of the Parties and Menarini for pharmacovigilance activities
respecting Agreement Product following the Effective Date, and the transfer of such responsibilities from ALZA to Menarini (with respect to the Non-Group E Market countries and the global safety database), shall be set forth in a commercially
reasonable and customary form of pharmacovigilance agreement to be negotiated in good faith by the Parties; (the “PV Agreement”). In the event of a Section 2.2 Closing, the Parties shall negotiate in good faith a
pharmacovigilance agreement between ALZA and GENUPRO (“GENUPRO PV Agreement”) setting forth the responsibilities of the Parties for pharmacovigilance activities respecting Agreement Product following the Effective Date under
Section 2.2, and the transfer of such responsibilities from ALZA to GENUPRO with respect to the Group A Market, Group B Market, Group C Market and Group E Market countries and the global safety database. 

6.6 Other External Communications Related to Agreement Product. As soon as practicable after the Effective Date, the Transition
Team shall develop in writing, and from time to time thereafter during the applicable Transition Period in each country update as necessary, one or more external communications plans related to the transfer of Product Rights with respect thereto,
which the Parties shall then implement in accordance with this Section 6.6. Until the Final Transfer Date for a particular country, the Transition Managers from GENUPRO and ALZA will coordinate review of any Party’s proposed press
releases, public statements or similar communications with Third Parties with respect to the transfer of the 

  
 [*] Confidential
treatment requested. 

  
 43 

 
Product Rights in such country, the contents of which shall be limited to publicly available information unless approved in advance by both Parties, such approval not to be unreasonably withheld,
or required by any Legal Requirement or rule of any securities exchange. To the extent reasonably practicable, each Party will provide the other Party a reasonable opportunity to review and comment on any such planned communication concerning a
country prior to such country’s Final Transfer Date, at least [*] ([*]) [*] prior to its planned release or implementation and use good faith efforts to address any comments or concerns raised by the other Party with respect to the timing
and/or content of the planned communication. Neither Party shall have the right to use the names, logos or trademarks of the other Party (or any of such other Party’s Affiliates or Sublicensees) in any such communications in a particular
country prior to such country’s Final Transfer Date without the prior written consent of such Party, such approval not to be unreasonably withheld, except to the extent required by Legal Requirement. For the avoidance of doubt, the Parties
acknowledge that GENUPRO and/or its designated Affiliates and/or Sublicensees will have the right to use the Trademarks and Domain Names in any communications issued pursuant to this Section 6.6. 

6.7 NO WARRANTIES. EXCEPT AS MAY OTHERWISE BE EXPRESSLY SET FORTH IN THIS AGREEMENT, AND WITHOUT LIMITATION OF ANY REPRESENTATIONS
AND WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, NOTHING HEREIN SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY (WHETHER EXPRESS OR IMPLIED) BY ALZA OR ITS AFFILIATES WITH RESPECT TO ANY MATERIAL, DATA OR INFORMATION PROVIDED OR OTHERWISE
MADE AVAILABLE TO GENUPRO AND/OR ITS AFFILIATES AND/OR SUBLICENSEES PURSUANT TO THIS SECTION 6, ALL OF WHICH ARE BEING PROVIDED TO GENUPRO AND/OR ITS AFFILIATES AND/OR SUBLICENSEES “AS IS, WHERE IS”, EXCEPT AS EXPRESSLY SET FORTH IN
THIS AGREEMENT, AND ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE EXPRESSLY DISAVOWED. 
 Section 7
Payment and Financial Matters 
 7.1 Document Transfer Payments. GENUPRO shall reimburse ALZA or its designated
Affiliates for all reasonable, documented Out of Pocket Expenses incurred by ALZA and its Affiliates with respect to the collection from its Affiliates or Third Party record-keeping or archiving vendors, and delivery to GENUPRO or its designated
Affiliate(s) or Sublicensee(s), of clinical trial data (in accordance with Legal Requirements, including those respecting privacy) and documents as set forth in Section 6.1 and elsewhere in this Agreement as such expenses are incurred by
ALZA, up to a maximum of one million US dollars ($1,000,000). Payments must be received by ALZA within [*] ([*]) [*] after GENUPRO’s receipt of each detailed invoice from ALZA with respect thereto and shall be paid in the manner set forth in
Sections 5.8.3-5.8.5. 
 7.2 Transition Services Payments. In the event that a Section 2.1 Closing occurs by
the Final Section 2.1 Closing Date, then, in consideration of the services to be provided by ALZA and its Affiliates under the Transition Services Agreement, GENUPRO shall pay to ALZA or its designated Affiliate fifteen million US Dollars
($15,000,000.00) as follows: the first payment of [*] ($[*]), shall be paid within [*], and a payment of [*] ($[*]) shall be paid within [*] ([*]) [*] of the [*] of the [*] that begin following [*]. Payment shall be made in the manner 

  
 [*] Confidential
treatment requested. 

  
 44 

 
set forth in Sections 5.8.3-5.8.5. In the event that a Section 2.2 Closing occurs and GENUPRO or its Affiliates license, assign or otherwise convey rights to Dapoxetine or Agreement
Product to Menarini within [*] ([*]) [*] of the Final Section 2.1 Closing Date, then, in consideration of the services to be provided by ALZA and its Affiliates under the Transition Services Agreement, GENUPRO shall pay to ALZA or its
designated Affiliate fifteen million US Dollars ($15,000,000.00) [*] of the execution of such license, assignment or otherwise conveyance. Payment shall be made in the manner set forth in Sections 5.8.3-5.8.5. 

7.3 Service Fees. In consideration of the distribution activities to be performed by ALZA (directly or through its Affiliates) in
any countries pursuant to Section 5.3.1.2 of this Agreement, GENUPRO shall compensate ALZA or its designated Affiliate as provided by the financial terms set forth in the Sales Services Agreement. 

7.4 Taxes. 
 7.4.1 Income Tax. Subject to Section 7.4.2.1 below, [*] (or its designated Affiliate) shall be responsible for the collection, remittance and payments of any or all Taxes
(including income taxes, charges, duties, levies, assessments or other fees) of any kind imposed by governmental or other authority in respect of the amounts received by ALZA (or its designated Affiliate) from GENUPRO pursuant to this Agreement.

 7.4.2 Withholding. 

7.4.2.1 GENUPRO will make all payments to ALZA (or its designated Affiliate) under this Agreement without deduction or
withholding for Taxes except to the extent that any such deduction or withholding is required by Legal Requirements in effect at the time of payment, in which case GENUPRO shall be entitled to withhold such amount from the amount due ALZA (or its
designated Affiliate) under this Agreement and pay such amount in accordance with Section 7.4.2.2. 

7.4.2.2 Any Tax required to be withheld on amounts payable under this Agreement will promptly be paid by [*] on behalf of
[*] (or its designated Affiliate) to the appropriate governmental authority, and [*] will furnish [*] (or its designated Affiliate) with proof of payment of such Tax. Any such Tax required to be withheld will be an expense of and borne by [*] (or
its designated Affiliate). 
 7.4.2.3 GENUPRO and ALZA (or its designated Affiliate) will reasonably cooperate
with respect to all documentation required by any taxing authority or reasonably requested by GENUPRO to secure a reduction in the rate or amount of applicable withholding taxes. 

7.4.2.4 If GENUPRO had a duty to withhold Taxes in connection with any payment it made to ALZA (or its designated
Affiliate) under this Agreement but GENUPRO failed to withhold, and such Taxes were assessed against and paid by GENUPRO, then ALZA (or its designated Affiliate) will indemnify and hold harmless GENUPRO from and against such Taxes (including
interest). 

  
 [*] Confidential
treatment requested. 

  
 45 

 
If GENUPRO makes a claim under this Section 7.4.2.4, it will comply with the obligations imposed by Section 7.4.2.2 as if GENUPRO had withheld Taxes from a payment to ALZA
(or its designated Affiliate). 
 7.4.3 Indirect Taxes. The Parties acknowledge that all payment amounts
specified in this Agreement, if any, are exclusive of any sales, use, value added taxes, excise taxes or other similar taxes, duties, or charges (but excluding taxes on income or similar taxes) that may be imposed by governmental authorities in the
relevant jurisdictions with respect to the transactions contemplated hereby (collectively, “Indirect Taxes”). In the event that any Indirect Taxes will be due pursuant to Legal Requirements with respect to any payments to be made
pursuant to this Agreement, if any, [*] (directly or through its designated Affiliate or its Sublicensee) shall pay these Indirect Taxes to [*] (or its designated Affiliate, as applicable) upon receipt of a fully compliant invoice as defined by the
relevant jurisdictions applying the applicable and correct rates. 
 7.5 Regulatory Fees and Other Costs and Expenses.
The Parties agree that the Party (or its designated Affiliate or Sublicensee) required by Legal Requirements in a particular country of the Territory to make application in such country for transfer of ownership of Governmental Permits or ALZA
Regulatory Submissions shall be responsible for any fees imposed by Regulatory Authorities and other governmental agencies in connection with such application. [*] (or its designated Affiliate) shall also be solely responsible for all other direct
and indirect costs and expenses (including all internal FTE costs, administrative and overhead costs, and out-of-pocket costs and expenses) that are incurred by [*] (directly or through its Affiliates) in connection with the transfer and delivery of
the Product Rights in the Territory as contemplated in accordance with Section 5 of this Agreement. 

7.5.1 For the avoidance of doubt, nothing in this Agreement shall be construed (whether expressly or by implication) as
obligating [*] or its Affiliates to undertake or share in the conduct or costs of any additional clinical studies or other additional development work to generate any additional data related to Agreement Product that may be requested or required by
Regulatory Authorities following the Effective Date in support of or in connection with the transfer of any Governmental Permits for the Agreement Product in the Territory as contemplated hereunder, provided that the foregoing shall not be construed
as limiting [*] and its Affiliates’ obligations under Section 5.8 or 6.5. 
 7.5.2
FDA User Fee. GENUPRO hereby accepts responsibility for any FDA user fees incurred after the [*] in connection with any Agreement Product, and ALZA (or its designated Affiliate) will transfer to GENUPRO, and GENUPRO will accept, ALZA’s
FDA user fee under Sec. 736 of the Federal Food, Drug and Cosmetic Act, codified at 21 USC § 379(h) (Authority to Assess and Use Drug Fees). 
 7.6 Accounts Receivable on Pre-Transfer Sales. The Parties acknowledge that all sales of Agreement Product by ALZA and/or its designated Affiliates in a given country in the Territory prior to the
[*] shall be [*] the calculation of Net Sales, [*]. The Parties further acknowledge and agree that all accounts receivable arising from such sales of Agreement Product in a country in the Territory ([*]) [*]. [*] (directly or through its Affiliates)
shall remain 

  
 [*] Confidential
treatment requested. 

  
 46 

 
solely responsible for the collection of, and shall use Commercially Reasonable Efforts to collect, such accounts receivable at all times as may be outstanding during, on and after expiry of the
Transition Period with respect to [*] sales of Agreement Product, and, subject to [*], nothing herein shall be construed as granting or conveying to [*] or its [*] any rights or interest in or to such accounts receivable. 

Section 8 Manufacturing and Supply Matters 
 8.1 Manufacturing and Supply Agreement(s). On or prior to the Effective Date, ALZA and Menarini will, except in the event a Section 2.1 Closing does not occur by the Final Section 2.1
Closing Date, execute a mutually acceptable Non-Group E Market Manufacturing Agreement. Except in the event a Section 2.1 Closing does not occur by the Final Section 2.1 Closing Date, ALZA and GENUPRO agree to negotiate in good faith and
execute a mutually acceptable Group E Market Manufacturing Agreement which shall provide for the supply of Agreement Product to GENUPRO for at least one year following Regulatory Approval in the US. In the event a Section 2.1 Closing does not
occur by the Final Section 2.1 Closing Date, the Non-Group E Market Manufacturing Agreement and the Group E Market Manufacturing Agreement shall be of no effect and, subject to Section 14.2.2.2, ALZA and GENUPRO shall negotiate in
good faith a GENUPRO Manufacturing Agreement and GENUPRO Quality Agreement under which ALZA will supply Agreement Product to GENUPRO for a limited time in those Group A Market, Group B Market, Group C Market and Group E Market countries where
GENUPRO intends to use or sell Agreement Product. 
 Section 9 Ancillary Agreements 

The Parties acknowledge that, in connection with the transfer and delivery of Product Rights to GENUPRO (and/or its designated Affiliates
or Sublicensees) and/or the continued operation of the business related to Agreement Product thereafter, ALZA has agreed to perform certain transitional services and enter into certain agreements, including but not limited to those related to:
(i) distribution and sale of Agreement Product, on a country-by-country basis in the Group A Market countries, as described in Section 5.3.1.2 and/or (ii) the manufacturing of Agreement Product for use or sale in one or more
countries in the Territory as described in Section 8, and including, in any case: 
 (a) In the event of a
Section 2.1 Closing: Non-Group E Markets Manufacturing Agreement, Group E Markets Manufacturing Agreement, Non-Group E Markets Quality Agreement, Group E Markets Quality Agreement, GENUPRO Trademark Assignment Agreement, Menarini Trademark
Assignment Agreement, Domain Name Assignment Agreement, PV Agreement, Delegations of Authority (if any), Transition Services Agreement, and Sales Services Agreement; or 
 (b) In the event of a Section 2.2 Closing: GENUPRO Manufacturing Agreement, GENUPRO Quality Agreement, GENUPRO Trademark Assignment Agreement, Domain Name Assignment Agreement, GENUPRO PV Agreement,
Delegations of Authority (if any), Transition Services Agreement, and Sales Services Agreement. 

  
 [*] Confidential
treatment requested. 

  
 47 

 On or as soon as reasonably practicable after the Execution Date, the Parties shall negotiate in good faith
and, to the extent each Party is intended to be a party thereto (e.g. GENUPRO is not a party to the Menarini Trademark Assignment Agreement), enter into commercially reasonable, customary, and mutually acceptable written forms of all of the
foregoing consistent with the terms hereof, including but not limited to agreements specifying customary and commercially reasonable terms governing the distribution and sale of Agreement Product, the manufacturing services, and the Parties’
related rights and obligations. The specific manufacturing activities to be performed by ALZA and its Affiliates shall be set forth in the Manufacturing Agreements. For the avoidance of doubt, the PV Agreement or GENUPRO PV Agreement, as applicable,
shall be considered Ancillary Agreements. 
 Section 10 Certain Provisions Regarding Distribution, Sale and Supplies of Agreement
Product 
 10.1 Orders for Agreement Product. On and after the Effective Date, ALZA shall not, and shall cause its
Affiliates to not, (i) solicit orders for Agreement Product from any prospective Third Party purchasers for the relevant country, (ii) accept or fulfill any orders for Agreement Product for such country, or (iii) deliver or tender (or
cause to be delivered or tendered) any Agreement Product to any purchaser in such country, except as, in each case, specifically provided for in the Sales Services Agreement under Section 5.3.1.2 or any other Ancillary Agreement.

 10.2 Labelling and Packaging. The Parties agree to use their respective Commercially Reasonable Efforts and to
cooperate to obtain, pursuant to Legal Requirement, in an expeditious manner Regulatory Authority approval in each applicable country in the Territory for Agreement Product labelling bearing GENUPRO’s or its designated Affiliate’s and/or
Sublicensee’s name, trademark, and/or trade dress for use after the transfer of Regulatory Approval in each country in the Group A Market and Group B Market or after the obtaining of Regulatory Approval in each country in the Group C Market,
provided that, if and as requested by GENUPRO or any Sublicensee thereof for a particular Group C Market country, ALZA and its Affiliates shall use Commercially Reasonable Efforts to obtain approval of such labelling as part of its efforts to obtain
Regulatory Approval in any such countries under Section 5.3. Except as otherwise expressly set forth in this Agreement or the Manufacturing Agreements contemplated by Section 8, ALZA shall have no obligation to assist GENUPRO
with respect to any labelling changes for the Agreement Product. Where it is permissible under Legal Requirements to continue on and after the ALZA Distribution Termination Date for a particular Group A Market country to package Agreement Product
for distribution and sale by GENUPRO or its designated Affiliates and/or Sublicensees in such Group A Market country with trademarks, logos and/or trade dress (other than Trademarks) Controlled by ALZA, then, upon written request from GENUPRO or its
designated Affiliates and/or Sublicensees, ALZA shall package and supply such Agreement Product in accordance with the terms and conditions of the Manufacturing Agreements on a country-by-country, product-by-product basis until no later than the
applicable Implementation Date or such earlier date as the Parties mutually agree. As used herein the term “Implementation Date” means, on a country-by-country basis, the earlier of (i) the date that on which [*] or
(ii) the date which is [*] ([*]) [*] after the date on which the applicable Governmental Permits for the Agreement Product in such country are legally transferred, in accordance with all Legal Requirements, to GENUPRO or its designated
Affiliate or Sublicensee. 

  
 [*] Confidential
treatment requested. 

  
 48 

 10.3 Recalls. 

10.3.1 [*] (directly or through its designated Affiliates or Sublicensees) shall have responsibility and control over any
recalls, withdrawals, or field corrections of Agreement Product or its, its Affiliates’, or any GENUPRO Sublicensee’s Related Product (collectively, “Recalls”) in a country that occurs on or after the [*]. However, if such
a Recall involves one or more lots of Agreement Product that were distributed and sold both (i) by ALZA or its Affiliates in one or more countries and (ii) by or on behalf of GENUPRO or its Affiliates and/or Sublicensees in one or more
countries in the Territory (each, a “Split Lot”), then the Parties shall notify each other immediately upon becoming aware of any possible Recall (or any circumstances reasonably justifying a Recall) that may affect such Split Lot.
The Parties shall, to the extent reasonably possible, meet prior to instituting any such Recall with respect to Agreement Product in an attempt to come to a mutually acceptable decision regarding such Recall; provided, however, that [*] in a country
at the time of Recall (the “Responsible Party”) shall [*] in such case as to whether to institute a Recall (regardless of whether such Recall is mandated by a Regulatory Authority or voluntarily instituted by the Responsible Party)
in such country. [*] shall have the right, solely [*], to contact any Regulatory Authority with respect to Agreement Product if [*] has a reasonable good faith belief that such Agreement Product may not meet the representations and warranties set
forth with respect thereto in this Agreement or any of the Manufacturing Agreements in a manner that may reasonably justify a Recall. Except as may otherwise be provided for in this Agreement or any of the Manufacturing Agreements, [*] shall,
subject to Sections 12.3 and 12.4, indemnify [*] and its Affiliates against all reasonable, documented costs and expenses incurred in connection with any Recall of Agreement Product that is distributed and/or sold on or after [*] or
otherwise by [*] or any of its Affiliates or Sublicensees. 
 10.3.2 [*] shall have responsibility and control
over any Recalls of Agreement Product in a country that occur following [*] and prior to the [*] for such country, provided that (i) [*] shall, to the extent reasonably practicable, provide written notice of any such proposed Recall as promptly
as reasonably possible, with such notice to include detailed information concerning the amount of Agreement Product to be Recalled, the circumstances justifying or supporting such Recall, and copies of any correspondence with Regulatory Authorities
or other government agencies concerning such Recall, and [*] shall provide [*] a reasonable opportunity to comment on the proposed scope of such Recall or the manner in which such Recall shall be conducted. Further, in the event of any such Recall
in any country that may have a material adverse impact on the development, marketing, sale, or distribution of Agreement Product in such country, [*] shall, if and as requested by [*] in writing and in addition to any Recall, immediately suspend all
further distribution of Agreement Product in such country under any Sales Services Agreement. 

  
 [*] Confidential
treatment requested. 

  
 49 

 Section 11 Representations, Warranties, and Covenants 

11.1 Mutual Representations. Each Party hereby represents, warrants and undertakes to the other that: 

11.1.1 it has the requisite power and authority to execute, deliver and perform its obligations under this Agreement and
each Ancillary Agreement, and the execution, delivery and performance by each Party of this Agreement and the Ancillary Agreements have been duly and validly authorized by all necessary corporate action on the part of such Party, and each
constitutes (or in the case of Ancillary Agreements to be entered into at or by the Effective Date, will constitute), or, with respect to the agreements set forth herein to be executed following the Execution Date, when executed and delivered will
constitute, a valid and binding obligation of each Party, enforceable against each Party in accordance with its terms, except that enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization or other similar laws
affecting creditors’ rights, generally and by principles of equity regarding the availability of remedies; 

11.1.2 the execution, delivery and performance by it of its obligations under this Agreement will not result in a breach
of, or constitute a default under, any instrument or agreement to which it is a party or by which it is bound or result in a violation of any law or regulation in any jurisdiction or of any order, judgement or decree of any court or governmental
agency by which it is bound, except as would not, individually or in the aggregate, materially adversely affect the ability of either Party to perform its obligations hereunder or under any Ancillary Agreement or GENUPRO’s, its
Affiliates’, or its Sublicensees’ ability to exploit the Product Rights or Agreement Product; and 

11.1.3 it is duly organized, validly existing and in good standing under the laws of the state or country of its
organization. 
 11.2 By ALZA. GENUPRO acknowledges and agrees that, except as otherwise set forth in this Agreement, and
without limitation of the representations and warranties set forth above or below, the Product Rights are conveyed by ALZA to GENUPRO hereunder “as is, where is”. GENUPRO agrees to accept, subject to the terms and conditions set forth in
this Agreement, the Product Rights on the Country Transfer Date or Regulatory Transfer Date as defined herein in the condition they are in at the place(s) where they are located on the Country Transfer Date or Regulatory Transfer Date based on its
own inspection, examination and determination with respect to all matters, and without reliance upon any express or implied representations or warranties of any nature made by, or on behalf of, or imputed to ALZA other than the representations and
warranties expressly set forth in this Agreement. Without limiting the generality of the foregoing, GENUPRO acknowledges that (x) ALZA makes no representation or warranty, express or implied, with respect to (i) any forecasts, projections,
estimates or budgets provided or made available to GENUPRO of future revenues, future results of operations, future cash flows or future financial condition relating to Agreement Product (“Forward-Looking Statements”); or
(ii) any other information made available to GENUPRO with respect to Agreement Product, except as expressly set forth in this Agreement and the Schedules hereto; and (y) GENUPRO is taking full responsibility for making its own evaluation
of the adequacy and accuracy of all Forward-Looking Statements and is not relying on any Forward-Looking Statements in any manner whatsoever. 

  
 50 

 Except as set forth on Schedule 11 (the parts of which are numbered to correspond to
the individual section numbers of this Section 11, provided that any information set forth in one section or subsection of Schedule 11 will be deemed to apply to each other section or subsection of Schedule 11 and this
Section 11 to which a cross-reference is expressly made) or otherwise disclosed in this Agreement, ALZA hereby represents and warrants to GENUPRO that, as of the Effective Date, each Country Transfer Date, Regulatory Transfer Date, and
each Final Transfer Date (except such representation and warranty that are of a specific date shall only be given as of such date): 
 11.2.1 Qualification. ALZA, directly and/or through its Affiliates, has all requisite corporate power and authority to own, operate, lease, license, transfer, assign, practice, develop,
commercialize, and exploit the Product Rights as exploited as of the Effective Date, except to the extent, in each case, as would not, individually or in the aggregate, materially and adversely affect the ability of either Party to perform its
obligations hereunder or under any Ancillary Agreement or GENUPRO’s, its Affiliates’, or its Sublicensees’ exploitation of the Product Rights or Agreement Product. Each of ALZA and its designated Affiliates is duly qualified to do
business in, and are in good standing in, all jurisdictions in which the ownership or control of the Product Rights makes such qualification necessary. ALZA has all requisite corporate power and authority to execute and deliver this Agreement
and the Ancillary Agreements, to perform and consummate the transactions contemplated hereby and thereby, and to cause its Affiliates to comply with all applicable obligations hereunder. 

11.2.2 Title to Assets. 
 11.2.2.1 ALZA, directly or through its Affiliates or Third Party MAHs, has good and transferable title, or the right to assign and transfer (or cause to be assigned and transferred) hereunder such
title, to each of the Product Rights to be transferred hereunder: 
 (a) Development Records as identified in
the Index; 
 (b) Manufacturing Records as identified in the Index; 

(c) Trademarks as identified in Schedules 4.2B1 and 4.2B2; 

(d) Domain Names as identified in Schedule 4.2A; and 

(e) All ALZA Marketing Authorizations, ALZA Regulatory Submissions and pricing and reimbursement approvals as identified on Schedule
11.2.15.1A, Schedule 11.2.15.1B, and Schedule 11.2.15.1C, respectively, all ALZA Regulatory Submissions made and Governmental Permits obtained following 

  
 51 

 
the Effective Date, and, with respect to any ALZA Regulatory Submissions referenced above, all Governmental Permits resulting from the Maintenance thereof as contemplated by this Agreement.

 11.2.2.2 ALZA, directly or through its Affiliates or Third Party MAH, has the right to transfer and assign,
or cause to be transferred and assigned, to GENUPRO (or its designated Affiliate(s) or Sublicensee(s)) such Product Rights as set forth in (a) to (e) above, free and clear of all liens, claims, and encumbrances, except Permitted Liens, and
upon the consummation of the transactions contemplated by this Agreement and the Ancillary Agreements, or the relevant date set forth herein therefor, GENUPRO shall acquire good and marketable title to, and all right, title and interest of ALZA and
its Affiliates in and to such Product Rights as set forth in (a) to (e) above, free and clear of all liens, claims, and encumbrances except Permitted Liens. ALZA, directly or through its Affiliates, owns sufficient right, title, and
interest in the ALZA Know-How and Licensed Materials material to the development, manufacture, use, and commercialization of Agreement Product to grant the rights granted thereto under this Agreement without material breach or conflict of any
existing contract, agreement, or arrangement ALZA or any of its Affiliates may have with any Third Party. 

11.2.3 Sufficiency. Except with respect to any Governmental Permits or ALZA Regulatory Submissions that cannot be
transferred and assigned under this Agreement due to limitations imposed by Legal Requirement, as contemplated by Section 5.1.2, which limitations shall be addressed as described in Section 5.1.2, as of the Effective Date,
the Product Rights, Copyrights, and ALZA Know-How identified in the Index or the Schedules constitute all material intellectual property and contractual rights, other than (i) the rights licensed to ALZA under the License Agreement and, solely
to the extent providing for the manufacture, use, sale, marketing, distribution, development, commercialization, import, or export of Agreement Product by the relevant Third Party on behalf of ALZA or an Affiliate thereof (and not required for the
manufacture, use, sale, marketing, distribution, development, commercialization, import, or export of Agreement Product generally), (ii) Distribution Agreements and Product Contracts, owned or controlled by ALZA, its Affiliates, and Third Party
MAHs necessary for manufacture, use, sale, marketing, distribution, development, commercialization, import, or export of Agreement Product as approved in the Territory prior to the Effective Date. 

11.2.4 Exercise of Rights under License Agreement Limited to Agreement Product. Prior to the Effective Date, the
only product clinically developed, manufactured, used and commercialized by ALZA (directly or through its Affiliates and Sublicensees) under the License Agreement was Agreement Product. ALZA makes no further representation or warranty regarding
whether or not ALZA (or its Affiliates or Sublicensees) engaged in the development, manufacture, use, or commercialization of any Licensed Product other than the Agreement Product in the course of its exercise of rights under the License Agreement.

  
 52 

 11.2.5 Proceedings. 

11.2.5.1 Other than Regulatory Proceedings, there are no actions, suits, or other Proceedings instituted, pending, or, to
the knowledge of ALZA (including upon reasonable inquiry of its Affiliates), threatened in writing against ALZA or any Affiliate thereof with respect to any Trademarks, Copyrights, Domain Names, Identified ALZA Patents (if any), ALZA Know-How,
Product Rights, ALZA Regulatory Submissions, Regulatory Approvals, Governmental Permits, or Agreement Product. 

11.2.5.2 There are no actions, suits or other Proceedings instituted, pending, or, to the knowledge of ALZA (including
upon reasonable inquiry of its Affiliates), threatened in writing against ALZA or any Affiliate thereof which present a claim that would materially restrain, materially prohibit, or materially and adversely affect the transactions contemplated in
this Agreement or any Ancillary Agreement or that would otherwise materially and adversely affect any Product Rights or GENUPRO’s (or any Affiliate’s or Sublicensee’s) ability to exploit Product Rights or develop or commercialize
Agreement Product following the Effective Date. 
 11.2.6 Ownership. ALZA (directly or through its
Affiliates or Third Party MAHs) exclusively owns (or, in the case of any of the following owned by Third Party MAHs) controls) all right, title, and interest in the Trademarks listed in Schedules 4.2B1 and 4.2B2, Domain Names listed in
Schedule 4.2A, and Product Rights listed in the Index or the Schedules, free and clear of all liens, claims, and encumbrances, except Permitted Liens. 
 11.2.7 Infringement/Misappropriation of Third Party Rights. ALZA has no knowledge (including upon reasonable inquiry of its Affiliates) that the use of ALZA Know-How as contemplated and permitted
under this Agreement with respect to the use, manufacture, sale, offering for sale, import, export, development, or commercialization of Agreement Product as carried on by or on behalf of ALZA or its applicable Affiliates prior to and as of the
Effective Date, would constitute a misappropriation of a Third Party’s trade secrets or infringement of any Third Party’s Patents. Neither ALZA nor, to ALZA’s knowledge (including reasonable inquiry of its Affiliates), any Affiliate
thereof has received any written notice from any Third Party alleging any infringement of any Third Party’s Patents or misappropriation of any Third Party’s trade secrets, with respect to the Agreement Product in the Territory due to the
manufacture, use, sale, marketing, or import thereof. 
 11.2.8 Infringement/Misappropriation by Third
Parties. ALZA has no knowledge (including upon reasonable inquiry of its Affiliates) that any Third Party (i) is misappropriating, has misappropriated, or has threatened to misappropriate any trade secret ALZA Know-How material to Agreement
Product or (ii) is infringing, has infringed, or has threatened to infringe any of the Lilly Patents, or GenuPro Patents, and neither ALZA nor any Affiliate thereof has made any written claims or threats, or engaged in any legal action or
Proceeding of any kind, involving any claim or allegation 

  
 53 

 
that a Third Party misappropriated any trade secret ALZA Know-How or GENUPRO Know-How material to any Agreement Product, or infringed any Lilly Patents, or GenuPro Patents. ALZA hereby expressly
makes no representations or warranties under Section 11.2.8(ii) relating to Internet Offers, as defined in that portion of Schedule 11 referring to this Section 11.2.8, prior to, or after, the Effective Date.

 11.2.9 Agreement Product Trademarks. 

11.2.9.1 No Agreement Product is being commercialized, sold or offered for sale anywhere in the Territory by or on behalf
of ALZA, or its Affiliates under any proprietary brand name, trademark, trade name, or logo for the Agreement Product other than the Trademarks. The Trademarks are valid, enforceable, and subsisting, and all necessary registration, maintenance, and
renewal fees have been made as of the Effective Date and all necessary documentation, recordations, and certifications have been filed with relevant authorities for purposes of maintaining such registrations. 

11.2.9.2 ALZA has no knowledge (including upon reasonable inquiry of its Affiliates) that the use of Trademarks as
contemplated and permitted under this Agreement with respect to the use, manufacture, sale, offering for sale, import, export, development, or commercialization of Agreement Product as carried on by or on behalf of ALZA or its applicable Affiliates
prior to and as of the Effective Date, would constitute an infringement of any Third Party’s trademarks. Neither ALZA nor, to ALZA’s knowledge (including reasonable inquiry of its Affiliates), any Affiliate thereof has received any written
notice from any Third Party alleging any infringement of any Third Party’s trademarks with respect to the Agreement Product in the Territory due to the manufacture, use, sale, marketing, or import thereof. 

11.2.9.3 ALZA has no knowledge (including upon reasonable inquiry of its Affiliates) that any Third Party is infringing,
has infringed, or has threatened to infringe any of the Trademark rights, and neither ALZA nor any Affiliate thereof has made any written claims or threats, or engaged in any legal action or Proceeding of any kind, involving any claim or allegation
that a Third Party infringed any Trademark rights. 
 11.2.10 Domain Names. The Domain Names constitute
all the domain names, and registrations and applications therefor, used in connection with the supply, development, marketing, sale, offering for sale, and distribution of Agreement Product in the Territory prior to and as of the Effective Date.
ALZA has registered each of the Domain Names with an accredited domain name registrar and is up to date and paid in full as of the Effective Date with respect to the payment of all fees due to such registrar(s) in connection with the Domain Names.

 11.2.11 Distribution Agreements. All Distribution Agreements are listed, with the corresponding Third
Party MAH (if applicable) and country clearly identified with respect thereto, on Schedule 5.1.1. To the knowledge of ALZA (including reasonable 

  
 54 

 
inquiry of its Affiliates), ALZA (or the relevant Affiliate thereof) is, and at all times since its execution has been, in compliance with all material applicable terms of each Distribution
Agreement, and to the knowledge of ALZA (including reasonable inquiry of its Affiliates), each Third Party that has any rights or obligations under any Distribution Agreement is, and at all times has been, in compliance with all material applicable
terms of such Distribution Agreement, except as would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on either Party’s ability to perform its obligations under this Agreement or any Ancillary
Agreement, the exploitation of the Product Rights, or the use, development, manufacture, sale, marketing, import, export, or commercialization of Agreement Product. 

11.2.12 Product Contracts. ALZA and, to its knowledge (including reasonable inquiry of its Affiliates), its
Affiliates are, and at all times have been, in compliance with all material applicable terms of each Product Contract, and to the knowledge of ALZA (including reasonable inquiry of its Affiliates), each Third Party that has any obligation to ALZA or
any Affiliate thereof under any Product Contract is, and at all times has been, in compliance with all material applicable terms of such Product Contract, except as would, in either case, not reasonably be expected, individually or in the aggregate,
to have a material adverse effect on either Party’s ability to perform its obligations under this Agreement or any Ancillary Agreement, the exploitation of the Product Rights, or the use, development, manufacture, sale, marketing, import,
export, or commercialization of Agreement Product. 
 11.2.13 License Agreement. As of the Effective
Date, to ALZA’s knowledge (including reasonable inquiry of its Affiliates), there are no Product-Related Improvements (as defined in the License Agreement) or Product-Related Improvement Patents (as defined in the License Agreement) that are
incorporated in or utilized by (or, in the case of Product-Related Improvement Patents, that cover the composition, manufacture, or use of) any products in, or that have previously been the subject of, preclinical or clinical development or are
being, or have previously been, commercialized by ALZA or its Affiliates. 
 11.2.14 Compliance With Legal
Requirements; Regulatory Authorizations. 
 (a) Except as expressly set forth in this Agreement, ALZA and its Affiliates
are, and at all times have been, in compliance with all Legal Requirements applicable to the Product Rights, Copyrights, Trademarks, ALZA Know-How, Agreement Product, or the use, development, manufacture, sale, marketing, import, export, or
commercialization of Agreement Product, except as would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on either Party’s performance of its obligations under this Agreement or any Ancillary
Agreement, the exploitation of the Product Rights, or the use, development, manufacture, sale, marketing, import, export, or commercialization of Agreement Product. 

  
 55 

 (b) ALZA and its Affiliates have all authorizations of Regulatory Authorities necessary for
the conduct of its and their business (solely as it relates to the Agreement Product or Product Rights) as conducted as of the Effective Date, except as would not reasonably be expected, individually or in the aggregate, to have a material adverse
effect on either Party’s performance of its obligations under this Agreement or any Ancillary Agreement, the exploitation of the Product Rights, or the use, development, manufacture, sale, marketing, import, export, or commercialization of
Agreement Product. 
 (c) The Development Records, Manufacturing Records, Governmental Permits, and ALZA Regulatory Submissions
as identified in the Index have been maintained in accordance with all Legal Requirements. 
 11.2.15
Regulatory Matters. 
 11.2.15.1 The ALZA Marketing Authorizations set forth in Schedule
11.2.15.1A, ALZA Regulatory Submissions set forth in Schedule 11.2.15.1B and pricing and reimbursement approvals set forth in Schedule 11.2.15.1C are the only ALZA Regulatory Submissions or Governmental Permits obtained, filed,
submitted, or in effect as of the Effective Date with respect to Agreement Product; 
 11.2.15.2 The
Governmental Permits and ALZA Regulatory Submissions have at all times been filed and maintained in material compliance with all Legal Requirements, and ALZA’s normal and customary business practices. The ALZA Marketing Authorizations are in
full force and effect. There are no Proceedings pending or, to the knowledge of ALZA (including upon reasonable inquiry of its Affiliates), threatened by written notice seeking, or that would reasonably be anticipated to lead to, the revocation or
suspension of, or have any other material adverse effect on, any ALZA Marketing Authorization or ALZA Regulatory Submission. All maintenance and other fees related to the ALZA Marketing Authorizations or ALZA Regulatory Submissions occurring or
coming due prior to the Effective Date have been paid. Neither ALZA nor any Affiliate thereof has received since the effective date of the License Agreement: (i) any FDA Form 483’s or foreign equivalents thereof concerning Agreement
Product or (ii) warning letters from any Regulatory Authority concerning the Agreement Product in which it is asserted that the operations of ALZA, any Affiliate thereof, or any Third Party manufacturer or contractor of any of the foregoing (to
the extent they relate to the Agreement Product or Product Rights) or the Agreement Product were not in compliance with any Legal Requirements in any material respect. There are no outstanding consent decrees entered into by ALZA or any of its
Affiliates or sublicensees with respect to Agreement Product. 
 11.2.16 Electronic Media. As of each
Country Transfer Date (on a country-by-country basis with respect to that portion of the items below relevant to the applicable country), each Regulatory Transfer Date (on a country-by-country basis with

  
 56 

 
respect to that portion of the items below relevant to the applicable country) and the Transition Completion Date, the Electronic Media collectively contain copies, which in all material respects
are complete and accurate, of the following records as identified in the Index: 
 (a) the Development Records; 

(b) the Manufacturing Records; 
 (c) Governmental Permits; 
 (d) ALZA Regulatory Submissions; 

(e) all material information referenced on Schedule 6.1.5; and 

(f) any other material information, document, or correspondence material to Agreement Product or Product Rights. 

The Electronic Media contain all serious adverse event reports received by ALZA, any Affiliate thereof, any Third Party MAH, or any
contractor, agent, or representative of any of the foregoing that relate to the Agreement Product. All of the records and information in items (a) to (f) referenced above and as identified in the Index have been in material compliance with
Legal Requirements and ALZA’s normal and customary business practices. To ALZA’s knowledge, the Index identifies and contains an index of all documents and records that are, on a country-by country basis as of the relevant Country Transfer
Date or Regulatory Transfer Date, material to or necessary for the development, use, manufacture, sale, offering for sale, import, export, or commercialization of the Agreement Product in such country, except, as of a particular Country Transfer
Date or Regulatory Transfer Date, those records and information to be transferred for such country following, or resulting from activities of ALZA and its Affiliates taking place following, such Country Transfer Date or Regulatory Transfer Date and
prior to the Transition Completion Date as contemplated by this Agreement. 
 11.2.17 Governmental Reports,
Proceedings, Notices. 
 (a) As of the Effective Date, ALZA and, to ALZA’s knowledge (including reasonable inquiry of
its Affiliates and Third Party MAHs), its Affiliates and Third Party MAHs have completed and filed, in a timely and professional manner, all reports required by Regulatory Authorities and Legal Requirements in order to maintain Governmental Permits
for Agreement Product that is the subject of a Regulatory Approval (including all Agreement Product marketed by or on behalf of ALZA and its Affiliates and Third Party MAHs prior to the Effective Date), except for those reports not due within the
six (6) months following the Effective Date. 

  
 57 

 (b) As of the Effective Date, neither ALZA nor, to ALZA’s knowledge (including
reasonable inquiry of its Affiliates or Third Party MAH), any Affiliate thereof or Third Party MAH has received any written notice of any actions or Proceedings (including those from a Regulatory Authority) alleging that the Agreement Product or the
manufacture, storage, warehousing, packaging, handling, use, testing, sale, offering for sale, marketing, distribution, import, or export thereof is in violation of any Legal Requirements, except as would not reasonably be expected, individually or
in the aggregate, to have a material adverse effect on either Party’s performance of its obligations under this Agreement or any Ancillary Agreement, the exploitation of the Product Rights, or the use, development, manufacture, sale, marketing,
import, export, or commercialization of Agreement Product. 
 (c) As of the Effective Date, neither ALZA nor, to ALZA’s
knowledge (including reasonable inquiry of its Affiliates), any Affiliate thereof, has received any written notice that any Regulatory Authority or other government agency has initiated, or threatened to initiate, any action to recall, suspend or
otherwise restrict or adversely affect the manufacture, use, development, sale, marketing, distribution, commercialization, import, or export of Agreement Product. To the knowledge of ALZA (including upon reasonable inquiry of its Affiliates), as of
the Effective Date, there are no pending proceedings or requests for information, voluntary or involuntary market withdrawals, field corrective actions (including recalls), safety alerts, or notices of other regulatory or governmental enforcement
actions from any Regulatory Authority related to the Agreement Product. 
 (d) In the course of clinically developing,
manufacturing, using and commercializing Agreement Product prior to the Effective Date, and for the purposes of providing services under this Agreement from the Effective Date until the Transition Completion Date, neither ALZA nor, to ALZA’s
knowledge (including reasonable inquiry of its Affiliates) any Affiliate thereof (i) has been debarred, or is subject to a pending debarment, or has used or is using in any capacity any person who has been debarred pursuant to section 306 of
the FDCA, 21 U.S.C. § 335a, (ii) has been listed by any federal and/or state agencies, excluded, debarred, suspended or otherwise been made ineligible to participate in United States federal or state healthcare programs or federal
procurement or non-procurement programs (as that term is defined in 42 U.S.C. 1320a-7b(f), (iii) has been convicted of a criminal offense related to the provision of healthcare items or services or (iv) is subject to any such pending
action, or is the subject of a conviction or pending action described in such sections. ALZA agrees to notify GENUPRO in writing as soon as reasonably possible if, in performing services under this Agreement, ALZA, or to ALZA’s knowledge
(including reasonable inquiry of its 

  
 58 

 
Affiliates) any Affiliate thereof, or any person used by ALZA, or to ALZA’s knowledge (including reasonable inquiry of its Affiliates) any Affiliate thereof, is subject to any of the
foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending. 

11.2.18 Sublicenses. All material sublicenses (excluding Distribution Agreements) granted by ALZA or any Affiliate
thereof with respect to Agreement Product, the rights licensed to ALZA under the License Agreement, or the Product Rights are set forth in Schedule 11.2.18. Unless otherwise agreed by the Parties in writing, ALZA shall, subject to the terms
of such agreements, terminate such agreements on or before the Effective Date.  
 11.2.19 Taxes.
ALZA and its Affiliates have completed and duly and timely filed in correct form with the appropriate government, regulatory, or taxing authority, all material returns, reports and declarations of estimated tax for Taxes related to the Agreement
Product and Product Rights that were required to be filed by it (the “Tax Returns”). All such Tax Returns are correct and complete in all material respects. ALZA and its Affiliates have paid in full or made adequate provision for
all amounts shown to be due and owing on its Tax Returns. There are no tax liens upon the Agreement Product or Product Rights. No action for the assessment or collection of Taxes of ALZA or any Affiliate thereof with respect to the Agreement Product
or Product Rights is pending or has been threatened in writing and no written claim or deficiency against ALZA or any Affiliate thereof for the assessment or collection of any Taxes with respect to the Agreement Product or Product Rights has been
asserted or proposed which written claim or deficiency has not been settled with all amounts determined to have been due and payable having been timely paid (taking into account any granted extension of the due date for payment of such Taxes).

 11.2.20 Brokers. ALZA, and to ALZA’s knowledge (including reasonable inquiry of its Affiliates
and Third Party MAHs) its Affiliates and Third Party MAHs have not incurred any obligation or liability, contingent or otherwise, for brokerage or finders’ fees or agents’ commissions or other similar payment (including those of or to any
Third Party MAH) in connection with this Agreement or the transfer of Agreement Product and Product Rights pursuant hereto. 
 11.2.21 Product Distribution Practices. ALZA and, to ALZA’s knowledge (including reasonable inquiry of its Affiliates and Third Party MAHs), its Affiliates and Third Party MAHs have shipped
and sold the Agreement Product, at all times since (and including) January 1, 2011 until the Effective Date in quantities and at prices consistent with past Agreement Product demand and shipment and sales practices in all material respects (and
not in quantities in excess of the historical demand for the Agreement Product) and, in particular, neither ALZA nor, to ALZA’s knowledge (including reasonable inquiry of its Affiliates and Third Party MAHs), any Affiliate thereof nor Third
Party MAHs has engaged in (a) stop or slow shipping of any Agreement Product; (b) sales practices for any Agreement Product unreasonably requiring any customer thereof to purchase a specific or larger-than-desired amount of Agreement
Product solely for purposes, or with the primary effect, of bringing forward future sales or maximizing 

  
 59 

 
short-term sales (i.e. not tied to batch sizes or reasonable or customary minimum purchase obligations); (c) encouraging or requiring customers of Agreement Product, in a manner inconsistent
with generally-accepted customary sales practices, to, as a condition or requirement to gain access to the Agreement Product in any amount, to purchase a specific or larger-than-desired amount of Agreement Product solely for purposes, or with the
primary effect, of bringing forward future sales or maximizing short-term sales (i.e., not tied to batch sizes or reasonable or reasonable or customary minimum purchase obligations). 

11.2.22 Government Sponsored Research and Development. No governmental agency or authority has any material right,
title or interest in or to any of the ALZA Know-How, Identified ALZA Patents, Trademarks, Domain Names, Governmental Permits, ALZA Regulatory Submissions, Development Records, Manufacturing Records, or any other Product Rights, except as would not
reasonably be expected, individually or in the aggregate, to have a material adverse effect on either Party’s performance of their obligations under this Agreement or any Ancillary Agreement, the exploitation of the Product Rights, or the use,
development, manufacture, sale, marketing, import, export, or commercialization of Agreement Product. Neither ALZA nor, to ALZA’s knowledge (including reasonable inquiry of its Affiliates), any Affiliate thereof received or currently receives
funds or other resources provided by a governmental agency or authority with respect to any research or development of the Agreement Product. 
 11.2.23 Clinical Trials. As of the Effective Date, there are no clinical trials being conducted by or on behalf of ALZA or, to ALZA’s knowledge (including reasonable inquiry of its
Affiliates), its Affiliates with respect to the Agreement Product other than the Ongoing Clinical Studies. 

11.2.24 Market Definitions. As of the Effective Date, the countries set forth on Schedules 5.2A, 5.2B
and 5.2C, respectively, accurately reflect the descriptions thereof set forth in Sections 5.2.1, 5.2.2 and 5.2.3, respectively. 
 11.3 ALZA Covenants. 
 11.3.1 To the extent any
circumstances arise after the Effective Date and on or before the Transition Completion Date that, to ALZA’s knowledge, would render any of the representations and warranties set forth in Section 11.2 no longer true or accurate,
ALZA shall provide detailed written notice thereof to GENUPRO and the Transition Team shall discuss and recommend in good faith the reasonable actions to be taken by the Parties to mitigate the effects of any such circumstances (and the Parties
shall use Commercially Reasonable Efforts to agree in writing to any such reasonable recommendation). 
 11.3.2
At all times following the Effective Date, ALZA shall, and shall cause its Affiliates to, complete and duly and timely file in correct, complete, and accurate form with the appropriate government, regulatory, or taxing authority, all material Tax
Returns (as defined in Section 11.2.19) and pay in full or make adequate provision for all amounts due and owing on such Tax Returns. 

  
 60 

 11.3.3 ALZA shall not, and shall cause its Affiliates to not, enter into any
licenses or sublicenses or other contracts with respect to any Product Rights or other rights to Licensed Products (including any rights under the License Agreement) following the Effective Date without GENUPRO’s prior written consent, except
for any contracts (i) reasonably necessary for ALZA to fulfil its obligations hereunder or under any Ancillary Agreements and (ii) of which GENUPRO is informed of by ALZA in writing and reasonably in advance of the execution thereof by
ALZA. 
 11.3.4 ALZA shall use Commercially Reasonable Efforts (and shall use Commercially Reasonable Efforts to
cause its Affiliates to use Commercially Reasonable Efforts) to comply with all Legal Requirements with respect to all Governmental Permits, ALZA Regulatory Submissions, and all of its (and its Affiliates’) activities and other obligations with
respect to Agreement Product following the Effective Date. 
 11.3.5 ALZA shall pay (directly or through its
Affiliates) all necessary registration, maintenance, and renewal fees that come due or may arise with respect to any Trademark in any particular country prior to the assignment thereof to GENUPRO under this Agreement, and ALZA shall use Commercially
Reasonable Efforts to file (directly or through its Affiliates) all necessary documentation, recordations, and certifications with relevant authorities for purposes of maintaining trademark registrations therefor until such assignment. 

11.3.6 ALZA shall use Commercially Reasonable Efforts to cause all Domain Name registrations and related fees to be
maintained up to date and paid in full with respect to all Domain Names prior to the assignment thereof to GENUPRO under this Agreement. 
 11.3.7 ALZA shall pay, or cause to be paid, all maintenance and other fees imposed by Regulatory Authorities and other governmental agencies related to the ALZA Marketing Authorizations or ALZA Regulatory
Submissions incurred or coming due prior to the Regulatory Transfer Date (even if payable after the Regulatory Transfer Date). Notwithstanding the preceding sentence, the Party (or its designated Affiliate or Sublicensee) required by Legal
Requirements in a particular country of the Territory to make application in such country for transfer of ownership of Governmental Permits or ALZA Regulatory Submissions shall be responsible for any fees imposed by Regulatory Authorities and other
governmental agencies in connection with such application as set forth in Section 7.5. 
 11.3.8
ALZA shall, beginning on the Effective Date and during the Transition Period, transfer to GENUPRO by means of the Electronic Media all ALZA Regulatory Submissions, Governmental Permits, Development Records, Manufacturing Records, or other
information, materials, or documentation material to the Product Rights set forth in the Schedules appended hereto or in the Index or development, manufacture, or commercialization of Agreement Product, in accordance with Section 6.1.1. ALZA
shall 

  
 61 

 
update the Electronic Media until the Transition Completion Date with such of the foregoing not initially included in the Electronic Media as soon as reasonably possible upon ALZA becoming aware
thereof (whether pursuant to notice or request by GENUPRO or otherwise), and provide written notice to GENUPRO upon any update thereof (which notice shall identify with reasonable detail the material being added to the Electronic Media). ALZA shall
deliver to GENUPRO copies of the contents of the Data Room, which ALZA may do electronically in a form reasonably acceptable to GENUPRO, within five (5) business days of the Effective Date (which copies shall represent the contents of the Data
Room as of the Effective Date) and, from and after the Effective Date until the later of (a) such time as ALZA delivers the final contents of the Data Room in electronic form to GENUPRO as set forth above or (b) the date ninety
(90) days following the Effective Date, ALZA shall continue to permit GENUPRO to access the Data Room, including the ability to print documents therefrom. 
 11.3.9 Without limitation of ALZA’s rights and obligations with respect to Ongoing Clinical Studies, ALZA shall not (and shall cause its Affiliates, sublicensees, and subcontractors to not) initiate
any clinical trials of any Licensed Product following the Effective Date without GENUPRO’s written consent (which may be granted or withheld in GENUPRO’s sole discretion). 

11.3.10 On or after the Effective Date, neither ALZA nor any Affiliate thereof, nor any Third Party acting on behalf of
ALZA or any Affiliate thereof (under a Distribution Agreement or otherwise), shall sell, market, or commercially distribute any Agreement Product in any country other than in a Group A Market country under the Sales Services Agreement in accordance
with Section 5.3.1.2 without GENUPRO’s prior written consent. 
 11.3.11 Consents and
Approvals. ALZA shall, or shall cause its Affiliates or Third Party MAH to, obtain the following: (a) each consent, approval, authorization, registration or filing with any Governmental Authority and (b) each consent, approval,
authorization of or notice to any other Third Party, which, in each case, is required in connection with the consummation by ALZA of the transactions contemplated by this Agreement and the Ancillary Agreements, including the consents described in
Schedule 11.3.11; except to the extent as, in each case, would not, individually or in the aggregate, materially and adversely affect the ability of either Party to perform its obligations hereunder or under any Ancillary Agreement or
GENUPRO’s, its Affiliates’, or its Sublicensees’ ability to exploit the Product Rights or Agreement Product. 
 11.3.12 ALZA Permitted Liens. ALZA shall, and shall cause its Affiliates to, promptly take all actions and make all payments reasonably necessary to avoid the existence, imposition, maintenance,
survival, or creation of any ALZA Permitted Liens or, to the extent ALZA and its Affiliates are unable to avoid the existence, imposition, maintenance, survival, or creation of any ALZA Permitted Liens or otherwise fail to prevent the existence,
imposition, maintenance, survival, or creation thereof, ALZA shall, and shall cause its Affiliates, to promptly take all such actions and make all payments necessary to avoid, extinguish, terminate, or remove any ALZA Permitted Liens. 

  
 62 

 11.4 EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT OR MANDATED BY APPLICABLE LAW
WITHOUT THE RIGHT TO WAIVE OR DISCLAIM, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY WITH RESPECT TO ANY AGREEMENT PRODUCT, PRODUCT RIGHTS, KNOW-HOW, PATENTS, ONGOING CLINICAL STUDIES, DATA, RECORDS, GOODS, RESULTS, OR OTHER RIGHTS, MATERIALS,
OR SUBJECT MATTER UNDER THIS AGREEMENT, AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, CONDITIONS AND REPRESENTATIONS OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING IMPLIED WARRANTIES OF PERFORMANCE, MERCHANTABILITY, SATISFACTORY QUALITY, FITNESS FOR A
PARTICULAR PURPOSE AND NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 
 11.5 Each Party agrees that, in the
event that of a breach by the other Party of both a representation and warranty under this Agreement and the same or a substantially similar representation and warranty in one or more Ancillary Agreements, such Party shall only be entitled to make a
single claim against the other Party with respect to such breach, under either this Agreement or one of the Ancillary Agreements. 
 Section
12 Liability and Indemnification 
 12.1 By GENUPRO. 

12.1.1 Subject to Sections 12.3 and 12.4, and except as otherwise expressly provided for in the Ancillary
Agreements, GENUPRO shall indemnify, defend and hold harmless ALZA and its Affiliates, and their respective directors, officers, employees, agents and representatives (and each of their respective successors and permitted assigns) (collectively, the
“ALZA Indemnitees”) from and against (a) any and all Third Party claims and resulting Damages which any ALZA Indemnitee may sustain, incur or suffer arising out of, or directly or indirectly resulting from, the ownership,
possession, manufacture, research, development, use, distribution, marketing, promotion, offering for sale, sale, import, export or commercialization of Agreement Product or any other Licensed Product (if any) by (or by any Third Party on behalf of)
GENUPRO or any of its Affiliates or Sublicensees anywhere in the Territory (including, but not limited to, any product liability or personal injury claims as a result of the manufacture, sale, distribution or use of any end-product sold by GENUPRO
or any of its Affiliates or Sublicensees that incorporates any Agreement Product or any other Licensed Product (if any), or any claims made with respect to any intellectual property or materials used by GENUPRO or any of its Affiliates or
Sublicensees in connection with any Agreement Product or any other Licensed Product (if any)), and (b) any and all Third Party claims and resulting Damages which any ALZA Indemnitee may sustain, incur or suffer arising out of, or directly or
indirectly resulting from, the infringement or misappropriation of such Third Party’s intellectual property rights (including Patents) by GENUPRO or any of its Affiliates or Sublicensees (or by any Third Party on any of their behalf) with
respect to any of the activities described in clause (a), except in each case to the extent resulting from (x) any ALZA Indemnitee’s breach of this Agreement (including any representation, warranty, or covenant of ALZA contained herein) or
any Ancillary Agreement, failure to comply with any Legal Requirement, negligence, or intentional misconduct or (y) any matter subject to indemnification by ALZA pursuant to Section 12.2 or any Ancillary Agreement. 

  
 63 

 12.1.2 Furthermore, subject to Sections 12.3 and 12.4, and
except as otherwise expressly provided for in the Ancillary Agreements, GENUPRO shall indemnify, defend and hold harmless the ALZA Indemnitees from and against any Third Party claims and resulting Damages that any ALZA Indemnitee may sustain, suffer
or incur arising out of, or directly or indirectly resulting from: (i) the negligence or intentional misconduct of GENUPRO or any of its Affiliates or Sublicensees in connection with the performance of GENUPRO’s, its Affiliates’ or
Sublicensees’ obligations or exercise of GENUPRO’s rights under this Agreement, (ii) the breach of one or more of GENUPRO’s covenants, agreements or obligations under this Agreement (including any breach by GENUPRO of its
representations and warranties set forth in Section 11) or any Ancillary Agreement, (iii) any failure by GENUPRO or any of its Affiliates or Sublicensees to comply with any Legal Requirement with respect to Licensed Products (as
defined in Section 1.22 of the License Agreement), or (iv) any of GENUPRO’s, its Affiliates’, or GENUPRO’s or its Affiliates’ licensees’, distributors’, or contractors’ exploitation, use, or practice of
any Product Rights or rights under the ALZA Know-How, except in each case to the extent resulting from (x) any ALZA Indemnitee’s breach of this Agreement (including any representation, warranty, or covenant contained herein) or any
Ancillary Agreement, failure to comply with any Legal Requirement, negligence, or intentional misconduct or (y) any matter subject to indemnification by ALZA pursuant to Section 12.2 or any Ancillary Agreement. 

12.2 By ALZA. 
 12.2.1 Subject to Sections 12.3 and 12.4, and except as otherwise expressly provided for in the Ancillary Agreements, ALZA shall indemnify, defend and hold harmless GENUPRO and its
Affiliates, and all of the foregoing’s respective directors, officers, employees, agents, and representatives (and each of their respective successors and permitted assigns) (collectively, the “GENUPRO Indemnitees”) from and
against any and all Third Party claims and resulting Damages which any GENUPRO Indemnitee may sustain, incur or suffer arising out of, or directly or indirectly resulting from, (a) the ownership, possession, manufacture, research, development,
use, distribution, marketing, promotion, offering for sale, sale, import, export or commercialization of Agreement Product or any other Licensed Product (if any) by or on behalf of ALZA or any Affiliate thereof anywhere in the Territory prior to the
Effective Date, or (b) any claim by a Third Party with respect to any infringement or misappropriation of such Third Party’s intellectual property rights (including Patents) with respect to any of the activities prior to the Effective Date
described in clause (a), except in each case to the extent resulting from (x) any GENUPRO Indemnitee’s breach of this Agreement (including any representation, warranty, or covenant contained herein) or any Ancillary Agreement, failure to
comply with any Legal Requirement, negligence, or intentional misconduct or (y) any matter subject to indemnification by GENUPRO pursuant to Section 12.1 or any Ancillary Agreement. 

  
 64 

 12.2.2 Furthermore, subject to Sections 12.3 and 12.4, and
except as otherwise expressly provided for in the Ancillary Agreements, ALZA shall indemnify, defend and hold harmless the GENUPRO Indemnitees from and against any and all Third Party claims and resulting Damages which any GENUPRO Indemnitee may
sustain, incur or suffer arising out of, or directly or indirectly resulting from: (i) the negligence or intentional misconduct of ALZA or any Affiliate thereof in connection with this Agreement or the performance of ALZA’s or its
Affiliates’ obligations or exercise of ALZA’s rights under this Agreement, (ii) the breach of one or more of ALZA’s covenants, agreements or obligations under this Agreement (including any breach by ALZA of its representations
and warranties set forth in Section 11) or any Ancillary Agreement, or (iii) ALZA’s or any Affiliate’s failure to comply with any Legal Requirement related to Agreement Product or any other Licensed Product (or the use,
development, manufacture, sale, distribution, promotion, marketing, import, or export thereof), except in each case to the extent resulting from (x) any GENUPRO Indemnitee’s breach of this Agreement (including breach of any representation,
warranty, or covenant contained herein) or any Ancillary Agreement, failure to comply with any Legal Requirement, negligence, or intentional misconduct or (y) any matter subject to indemnification by GENUPRO pursuant to Section 12.1
or any Ancillary Agreement. 
 12.3 Procedures. Each Party shall promptly give the other Party written notice of any
claim for which indemnification may be sought under this Agreement. However, failure of a Party with a right to be indemnified hereunder (an “Indemnified Party”) to provide notice of a claim shall only affect the Indemnified
Party’s right to indemnification if and to the extent that such failure has a material adverse effect on the ability of the other Party (the “Indemnifying Party”) to defend the claim and/or the nature or amount of such claim
The Indemnifying Party shall have the right to assume control of the defense of the suit or claim, and the Indemnified Party shall cooperate as reasonably requested by the Indemnifying Party (at the expense of the Indemnifying Party) in the defense
of any claim subject to indemnification hereunder; provided, however, that if, in the reasonable judgment of the Indemnified Party, such suit or claim involves an issue or matter which could have a materially adverse effect on the business
operations or assets of the Indemnified Party, the Indemnified Party may, by written notice to the Indemnifying Party, waive its rights to indemnity under this Agreement and control the defense or settlement thereof, but in no event shall any such
waiver be construed as a waiver of any rights which such Party may have at law or in equity. If the Indemnifying Party controls the defense of the suit or claim, the Indemnified Party may fully participate in (but not control) the defense thereof
and be represented by counsel at its sole cost and expense. 
 12.4 Settlements. Notwithstanding the foregoing, neither
Party may settle a claim or action that is subject to the terms of this Section 12 without the prior written consent of the other Party if such settlement would (i) impose any non-indemnified monetary obligation on the other Party,
(ii) admit fault or wrongdoing on the part of the other Party, (iii) require the other Party to submit to an injunction, (iv) limit the other Party’s rights under this Agreement or any Ancillary Agreement, or surviving rights
under the License Agreement, or (v) limit or otherwise adversely affect either Party’s (or its Affiliates’ or Sublicensees’) rights or ability to make, have made, use, sell, offer for sale, import, export, market, distribute,
develop, or commercialize Agreement Product or any other Licensed Product (if any) to the extent it retains or otherwise has such rights 

  
 65 

 
hereunder or under the Product Rights. Any payment required pursuant to any settlement agreement entered into in violation of this Section 12.4 shall be at the settling Party’s
own cost and expense. 
 12.5 NO CONSEQUENTIAL DAMAGES. THE PARTIES EXPRESSLY AGREE THAT IN NO EVENT SHALL EITHER PARTY
OR ITS AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY, LOSS OF PROFITS OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER
TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT, PROVIDED THAT, NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, THE FOREGOING SHALL NOT BE CONSTRUED TO LIMIT: (i) THE INDEMNITY OBLIGATIONS SET FORTH ABOVE OR IN ANY ANCILLARY AGREEMENT; OR
(ii) EITHER PARTY’S LIABILITY FOR FRAUD, GROSS NEGLIGENCE, OR PATENT INFRINGEMENT. 
 12.6 Insurance. During
the term of and for a period of not less than five years after a Party’s and/or its Affiliates’ and/or its Sublicensees’ ownership, possession, manufacture, research, development, use, distribution, marketing, promotion and/or sale of
Agreement Product (or by any Third Party on behalf of that Party and/or its Affiliates and/or its Sublicensees) such Party and/or its Affiliates and/or its Sublicensees shall maintain commercial general liability insurance and product liability
insurance covering the Agreement Product in amounts not less than $[*] per occurrence and $[*] annual aggregate. Such insurance shall include worldwide coverage. In addition, during each Party’s and/or its Affiliates’ and/or its
Sublicensees’ conduct of clinical trials such Party and/or its Affiliates and/or its Sublicensees conducting clinical trials shall maintain clinical trial insurance where required by and compliant with regulations in those territories where
clinical trials are conducted. Upon written request, each Party and/or its Affiliates and/or its Sublicensees shall provide the other Party and/or its Affiliates and/or its Sublicensees with written evidence of the required insurance. The amounts of
insurance required herein shall not be construed to create a limit of liability with respect to each Party’s indemnification rights and obligations under this Agreement. 
 Section 13 Confidentiality 
 13.1 “Confidential
Information” means any proprietary and confidential information that is disclosed orally, visually or in writing, by one Party (directly or through its Affiliates and/or Sublicensees, as applicable) (“Disclosing Party”) to
the other Party (directly or through its Affiliates and/or Sublicensees, as applicable) (“Receiving Party”) pursuant to this Agreement, provided that, notwithstanding the foregoing, all such information related to Product Rights,
Agreement Product, and Related Products shall, following the Effective Date, be treated as the Confidential Information of each Party, and each Party shall be deemed the Disclosing Party (and the Receiving Party) with respect thereto, regardless of
whether any information may have been first disclosed hereunder by or on behalf of ALZA to GENUPRO or any Affiliate thereof; for the avoidance of doubt, however, any such information that is ALZA Know-How shall remain the property of ALZA unless
expressly provided otherwise hereunder. 

  
 [*] Confidential
treatment requested. 

  
 66 

 13.2 Non-Disclosure and Non-Use. The Receiving Party shall keep confidential and
shall not disclose to any Third Parties and shall not use for any purpose, other than as, in either case, provided for in this Agreement, the Transition Services Agreement, Sales Services Agreement, the Manufacturing Agreements, or any other
Ancillary Agreement, any Confidential Information of the Disclosing Party for a period of [*] ([*]) [*] from disclosure, except for any identified as trade secrets, for which the obligation shall continue. The obligations with respect to
confidentiality and non-use shall no longer apply, however, to a Disclosing Party’s Confidential Information to the extent that such information: 
 (a) is or becomes published or generally known to the public through no fault or omission on the part of the Receiving Party; or 

(b) was known or used by the Receiving Party prior to its disclosure by the Disclosing Party to the Receiving Party as
evidenced by its written records, provided that this clause (b) shall not apply to Confidential Information that is confidential to both parties as set forth in Section 13.1; or 

(c) is provided to the Receiving Party without obligation of confidentiality or limitation on use by a Third Party having
the right to do so; provided that such Third Party was not bound by any agreement to keep such information confidential or otherwise prohibited from transmitting the information by a contractual, legal or fiduciary obligation; or 

(d) was independently developed by the Receiving Party as evidenced by its contemporaneous written records without
reference to or the aid, application or use of Confidential Information of the Disclosing Party. 
 For the avoidance of doubt,
Confidential Information pertaining to a combination of published elements shall not be deemed to be in the public domain because the individual elements of such confidential combination are in the public domain, unless the specific combination of
those elements is also in the public domain. Furthermore, upon the transfer of ownership of any Product Rights from ALZA to GENUPRO, Confidential Information disclosed by or on behalf of ALZA to GENUPRO pertaining to such Product Rights shall be
deemed confidential to GENUPRO as well, as set forth in Section 13.1 above. Additionally, notwithstanding anything to the contrary herein, the duration of the confidentiality obligation will continue indefinitely as to any unpublished
Confidential Information pertaining to the manufacture of Agreement Product that by its nature is commonly recognized in the industry as constituting valuable trade secret information, including any such information that is not accessible by the
public in the Chemistry, Manufacturing and Controls (CMC) section of drug applications submitted to Regulatory Authorities or other Regulatory Submissions, except as provided in Section 13.3 below. 

13.3 Permitted Disclosures. The confidentiality and non-disclosure obligations contained in Sections 13.1 and 13.2
above with respect to a Disclosing Party’s Confidential Information shall not apply to the extent that the Receiving Party is required: 

  
 [*] Confidential
treatment requested. 

  
 67 

 (a) to disclose information by Legal Requirements or order of a governmental agency or a
court of competent jurisdiction, provided that the Receiving Party shall, to the extent reasonably possible, (i) give reasonable prior written notice thereof to the Disclosing Party, (ii) provide the Disclosing Party with reasonably
sufficient opportunity to prevent or limit any such disclosure or to request confidential or protective treatment thereof, and (iii) give reasonable assistance to the Disclosing Party, as reasonably requested thereby, to protect the information
as confidential; 
 (b) to, in the case of either Party in exercise of its rights hereunder or under the Ancillary Agreements,
disclose information to any Regulatory Authority for purposes of obtaining approval to test, develop, manufacture, use, sell, offer for sale, import, export, market, or otherwise commercialize any Agreement Product or Related Product; 

(c) to satisfy either Party’s duty of disclosure in the prosecution of any Patents concerning Dapoxetine or any Agreement Product or
Related Product before governmental patent agencies, provided that a Receiving Party shall, to the extent reasonably possible, take Commercially Reasonable Efforts to protect the confidentiality of the other Party’s Confidential Information; or

 (d) to disclose to its Affiliates and its and its Affiliates’ employees, directors, contractors, or licensees who have a
need to know for purposes of this Agreement or, in the case of either Party in exercise of its rights hereunder or under the Ancillary Agreements, the practice of the Product Rights or manufacture, use, sale, offering for sale, import, development,
or commercialization of Agreement Product or Related Products and are under an obligation of confidentiality with respect thereto substantially equivalent to that of the Receiving Party. 

13.4 Disclosure of Financial and Other Terms. Except as required by Legal Requirement, the Parties agree that the terms and
existence of this Agreement will be considered Confidential Information of both Parties. Notwithstanding the foregoing, either Party may disclose: (a) such terms as are required to be disclosed in its publicly-filed financial statements or
other public statements pursuant to Legal Requirements and stock market or exchange rules or regulations (e.g., the U.S. Securities and Exchange Commission, NASDAQ, NYSE, London Stock Exchange, or any other securities exchange on which
securities issued by a Party or its Affiliates are, or may be, issued); provided that the disclosing Party shall, to the extent reasonably practicable, provide the other Party with a draft of the proposed text of such statement or disclosure
(including any Schedules containing this Agreement) sufficiently in advance of the scheduled release or publication thereof to afford the other Party a reasonable opportunity to review and comment upon the proposed text (including redacted versions
of this Agreement), which comments shall be reasonably considered by the disclosing Party; and (b) the material terms of this Agreement under confidentiality undertakings to any potential or actual acquirer, acquisition or merger target, or
merger partner, licensee, licensor, manufacturer, or other strategic partner with respect to any Agreement Product, Related Product, or the Product Rights or in exercise of the Party’s rights hereunder or under the Ancillary Agreements, or
potential providers of financing (whether equity, debt, or otherwise) and their advisors. Neither Party 

  
 68 

 
shall make any other statement to the public regarding the execution and/or any other aspect of the subject matter of this Agreement, except: (i) where a Party reasonably believes disclosure
is required under Legal Requirements or applicable stock market rules; and (ii) either Party may use the text of a statement previously disclosed in accordance with this Agreement; and (iii) GENUPRO shall be free, as it may determine in
its reasonable discretion, to make public statements and/or public disclosures regarding GENUPRO’s or its Affiliates’ or Sublicensees’ manufacture, commercialization or development of Agreement Product or Related Products following
the Effective Date, subject to the terms and conditions of this Agreement. 
 13.5 No Use of Name. Except as otherwise
provided herein or required by Legal Requirement, government authority, or the rule of any applicable securities exchange, neither Party shall use the name, mark or logo of the other Party or any of its Affiliates, or the name of any of their
respective employees or agents, in any sales, promotion, advertising or other forms of publicity, without the prior written approval of the other Party. 
 13.6 Publicity. Each of GENUPRO and ALZA agrees not to issue any press releases or public announcements concerning this Agreement (and to cause their respective Affiliates to not do so) without the
prior written consent (which may be sent by e-mail from an authorized representative) of the other Party as to the form, timing and content of any such release or announcement, except as required by a governmental authority, Legal Requirement, or
rule of any applicable securities exchange. The Parties may agree on an initial form of press release in relation to the transfer to GENUPRO of the Product Rights to be issued by one or both of the Parties. 

Section 14 Failure of Effective Date under Section 2.1 to Occur 

14.1 In the event that the Effective Date under Section 2.1 has not occurred on or before [*] (such date, the “Final
Section 2.1 Closing Date”), then beginning on the Final Section 2.1 Closing Date the Effective Date shall be determined under Section 2.2, and Section 2.1 shall have no further effect. The occurrence of the
Effective Date by the Final Section 2.1 Closing Date under Section 2.1 shall be referred to herein as a “Section 2.1 Closing”. 
 14.2 In the event that a Section 2.1 Closing does not occur by the Final Section 2.1 Closing Date, the Parties agree that the terms of this Agreement shall become effective, and the Effective
Date shall occur, only upon the satisfaction of the conditions as expressly set forth in Sections 2.2, 14.2.1, and 14.2.2 and elsewhere in this Agreement. The occurrence of the Effective Date following the Final Section 2.1
Closing Date pursuant to Section 2.2 and this Section 14 shall be referred to herein as a “Section 2.2 Closing”. 
 14.2.1 Payments. In the event that a Section 2.1 Closing does not occur by the Final Section 2.1 Closing Date, [*]. Notwithstanding anything to the contrary, GENUPRO shall be obligated to
make the payments to ALZA set forth in Section 7.1 and in Section 7.3. 

  
 [*] Confidential
treatment requested. 

  
 69 

 14.2.2 Ancillary Agreements. In the event that a Section 2.1
Closing does not occur by the Final Section 2.1 Closing Date, the Parties shall negotiate in good faith the following Ancillary Agreements: 
 14.2.2.1 The GENUPRO PV Agreement; 
 14.2.2.2 The GENUPRO
Manufacturing Agreement, and the GENUPRO Quality Agreement appended thereto, under which ALZA will supply Agreement Product to GENUPRO for a limited time in those Group A Market, Group B Market, Group C Market and Group E Market countries where
GENUPRO intends to use or sell Agreement Product. In the event that the GENUPRO Manufacturing Agreement and the GENUPRO Quality Agreement are not both effective on or before the date that is [*] ([*]) [*] from the Effective Date under
Section 2.2, ALZA shall have no further obligation to negotiate such agreements; 
 14.2.2.3 The
GENUPRO Trademark Assignment Agreement to assign Trademarks to GENUPRO in the Group A Market, Group B Market, Group C Market and Group E Market countries; and 
 14.2.2.4 The Domain Name Assignment Agreement. 
 Section 15 Termination and Survival

 15.1 The term of this Agreement shall commence on the Effective Date as determined under Section 2.1 or under
Section 2.2 and expire on the latest of: (i) Transition Completion Date; (ii) expiration of the last payment obligation under Section 5.8.2, 7.1, 7.2, or 7.3, as applicable according to
Section 14.2.1; or (iii) expiration of the last-to-expire Ancillary Agreement. 
 15.2 Termination or
expiration of this Agreement for any reason will be without prejudice to any rights or obligations that will have accrued to the benefit of any Party prior to such termination or expiration. The following shall survive termination or expiration of
this Agreement: [*] For avoidance of doubt, reference in the above list to a Section number shall not include subsections thereof unless specifically indicated to include subsections thereof. 
 Section 16 General 
 16.1 Entire Agreement/Integration. This
Agreement and the Ancillary Agreements constitute the entire understanding of the Parties, and supersedes any and all prior agreements, understandings and arrangements whether oral or written, between the Parties relating to the subject matter
hereof. No amendments to this Agreement shall be effective unless agreed in writing signed by the Parties hereto. The Parties agree that in the event of any conflict between the terms of this Agreement and the terms of any Manufacturing Agreement,
the Transition Services Agreement, the Sales Services Agreement, or other Ancillary Agreements that may be entered into by the Parties or their Affiliates in furtherance of this Agreement, the terms of this Agreement shall control. 

  
 [*] Confidential
treatment requested. 

  
 70 

 16.2 Notice. All notices required hereunder shall be in writing and shall be deemed
given when delivered personally or by facsimile transmission (receipt verified), five (5) days after mailed by registered or certified mail (return receipt requested), postage prepaid, or two (2) days after sent by express courier service
or Express Mail, to the other Party at the following addresses (as may be updated by notice hereunder): 
  

							
		 	 To GENUPRO:
	  	GenuPro, Inc.
		 		  	 3900 Paramount Parkway, Suite 150
 Morrisville, NC 27560
 Fax Number: [*]
 Attention: [*]

			
		 	 Copy to:
	  	GenuPro, Inc.
		 		  	 3900 Paramount Parkway, Suite 150
 Morrisville, NC 27560
 Fax Number: [*]
                Attention: [*]

			
		 	 To ALZA:
	  	Janssen Pharmaceutica NV
		 		  	 Turnhoutseweg 30

B-2340 Beerse
 Belgium

Attention: CEO and President
  
 and
  
 ALZA
Corporation
 700 Eubanks Drive

Vacaville, CA 95688
 USA

Fax Number: [*]
 Attention:
[*]

			
		 	 Copy to:
	  	Johnson & Johnson
		 		  	 Office of General Counsel
 One Johnson & Johnson Plaza
 New Brunswick, NJ 08933

Fax Number: [*]
 Attention:
[*]

 16.3 No Third Party Beneficiaries. Nothing in this Agreement shall be construed as giving any
person or entity, other than the Parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or any provision hereof, provided that the foregoing shall not be construed as limiting the
rights of any Sublicensee or other Third Party under any Product Rights that may be granted thereto by GENUPRO or any Affiliate thereof. 

  
 [*] Confidential
treatment requested. 

  
 71 

 16.4 Assignment. Neither Party may assign or transfer this Agreement, in whole or in
part, nor any rights or obligations hereunder, by merger, operation of law or otherwise, without the prior written consent of the other, except that (i) a Party may make such an assignment without the other Party’s consent to any of its
Affiliates and (ii) either Party may make such an assignment without the other’s consent in connection with the transfer or sale of all or substantially all of the assigning Party’s assets or business (or that portion thereof related,
in either case, to this Agreement and the Ancillary Agreements), or in the event of a Party’s merger, consolidation, change in control, reorganization, or similar transaction; provided that, in either case, the assigning Party provides the
other Party with written notice of such assignment and the assignee agrees to be bound to all of the terms and conditions of this Agreement applicable to such assigned or transferred rights and obligations. Any permitted assignment shall be binding
on the successors of the assigning Party. In the event a Party assigns this Agreement to an Affiliate other than a successor to such Party, the assigning Party shall remain liable to the other Party for the performance of the assignee Affiliate for
so long as such assignee remains an Affiliate of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 16.4 shall be null and void and of no legal effect. 

16.5 Compliance. Each Party hereby agrees that it shall comply, and shall procure that its Affiliates and Sublicensees (as
applicable) comply, with all Legal Requirements in connection with the performance of, and compliance with, its obligations and exercise of its rights under this Agreement. 
 16.6 Governing Law and Dispute Resolution. 
 16.6.1 The
Parties recognize that a bona fide dispute as to certain matters arising out of this Agreement or relating to the interpretation of this Agreement or performance hereunder, including any such controversy or claim involving a Party (a
“Dispute”) may from time to time arise. In the event of the occurrence of any Dispute, including any question regarding the Agreement’s existence, validity or termination, or performance of a Party’s obligations (directly
or through any Affiliates), such Dispute shall be resolved in accordance with this Section 16.6. Either Party may initiate Dispute resolution by written notice to the other, in which event such Dispute shall be referred to the
Parties’ respective executives designated below or the executive’s successor, for attempted resolution by good faith negotiations within [*] ([*]) [*] after such notice is received. The Parties’ designated executives for this purpose
are as follows: (a) for GENUPRO: June Almenoff, President and Chief Medical Officer; and (b) for ALZA: Managing Director of Janssen Pharmaceutica NV or his designee. No statements made during executive mediation under this
Section 16.6.1, which shall be held in confidence, shall be admissible in any arbitration under Section 16.6.2. 
 16.6.2 In the event that the respective executives are unable to resolve a Dispute by executive mediation within thirty (30) days of the disputing Party’s notice (unless the Parties agree in
writing to extend that period), the Dispute shall be resolved by binding arbitration in accordance with the Commercial Arbitration Rules of the AAA (“AAA Rules”; see www.adr.org) and the Federal Arbitration Act,
9 U.S.C. §1 et seq. The arbitration shall be conducted in New York, New York by three (3) independent, neutral arbitrators reasonably experienced in the pharmaceutical industry appointed as follows. 

  
 [*] Confidential
treatment requested. 

  
 72 

 
GENUPRO and ALZA shall each be entitled to select one (1) such arbitrator, with the two (2) such arbitrators so selected selecting the third (3rd) such arbitrator. In the event either Party fails to select its
arbitrator within ten (10) business days of notice from either Party initiating arbitration hereunder, the arbitrator selected by the other Party within such ten (10) business day period shall be entitled to select such arbitrator. The
arbitration shall be conducted in English. The decision of the arbitrators will be final and binding on the Parties, and any decision of the arbitrators may be enforced in any court of competent jurisdiction. Each Party shall bear its own expenses
and an equal share of the reasonable, documented expenses of the arbitration panel and any fees required by AAA to submit such matter to arbitration, unless the panel determines that any such fees or expenses are to be paid by the non-prevailing
Party. 
 16.6.3 The arbitrators shall follow the ICDR Guidelines for Arbitrators Concerning Exchanges of
Information in managing and ruling on requests for discovery. Each arbitrator, by accepting appointment, undertakes to exert her or his best efforts to conduct the process so as to issue an award as soon as reasonably possible, but in any event
within three (3) months of her or his appointment, provided that failure to meet that timetable shall not affect the validity of the award. 
 16.6.4 The arbitrators shall decide the Dispute in accordance with the substantive law of the State of New York, U.S.A., without regard to the choice of law provisions thereof, which law shall govern the
interpretation of this Agreement. The arbitrators may not award punitive or consequential damages, nor may the arbitrators apply any multiplier to any award of actual damages, except as may be required by statute or permitted by this Agreement (i.e.
to the extent such damages are not precluded by Section 12.5). The award of the arbitrators may be entered in any court of competent jurisdiction. The award of arbitration shall be final and binding upon both Parties. The Parties waive
all rights to seek review of the award for errors of law or fact in any court. 
 16.6.5 The Parties hereby
irrevocably and unconditionally submit to the jurisdiction of the AAA for the purposes of the arbitration proceedings, and any counterclaims that relate in any respect to the Agreement. 

16.6.6 Notwithstanding the foregoing, either Party may seek injunctive, equitable, or similar relief from a court of
competent jurisdiction as necessary to enforce its rights or protect its interests hereunder without the requirement of arbitration. 
 16.7 Execution in Counterparts; Facsimile Signatures. This Agreement may be executed in counterparts, each of which, when so executed and delivered, shall be deemed to be an original, and all of
which counterparts, taken together, shall constitute one and the same instrument even if both Parties have not executed the same counterpart. Signatures for this Agreement (and the Transition Services Agreement, Sales Services Agreement,
Manufacturing Agreements, and other Ancillary Agreements entered into in connection herewith) that are provided by facsimile transmission or PDF file shall be deemed to be original signatures. 

  
 73 

 16.8 Schedules. Alza shall have the right from time to time prior to the Effective
Date, except as expressly set forth elsewhere in this Agreement, to supplement those Schedules to the Agreement delivered on the Execution Date. Any such supplemental or amended disclosure delivered to the other Party shall be deemed to modify any
provision made in this Agreement for all purposes. 
 [Signature page to follow.] 

  
 74 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
authorized representatives as set forth below. 
  

											
	ALZA CORPORATION	 	GENUPRO, INC.	  	
						
	 By:
	 	 	 		 	By:	 	 	  	
						
	 Name:
	 	 	 		 	Name:	 	 	  	
						
	 Title:
	 	 	 		 	Title:	 	 	  	
						
	 Date:
	 	 	 		 	Date:	 	 	  	
			
	JANSSEN PHARMACEUTICA N.V.	 	FURIEX PHARMACEUTICALS, INC.	  	
						
	 By:
	 	 	 		 	By:	 	 	  	
						
	 Name:
	 	 	 		 	Name:	 	 	  	
						
	 Title:
	 	 	 		 	Title:	 	 	  	
						
	 Date:
	 	 	 		 	Date:	 	 	  	
				
	 JANSSEN PHARMACEUTICA N.V.
	 		 		  	
						
	 By:
	 	 	 		 		 		  	
						
	 Name:
	 	 	 		 		 		  	
						
	 Title:
	 	 	 		 		 		  	
						
	 Date:
	 	 	 		 		 		  	

 SIGNATURE PAGE OF LICENSE AND ASSET TRANSFER AGREEMENT BY AND BETWEEN ALZA CORPORATION AND JANSSEN PHARMACEUTICA, NV
AND FURIEX PHARMACEUTICALS, INC., AND GENUPRO, INC. (A WHOLLY-OWNED SUBSIDIARY OF FURIEX PHARMACEUTICALS, INC.) 

 Portions of this exhibit marked [*] are requested to be treated confidentially. 

Schedule 4.2A 
 Domain Names 
  

									
	 Domain Name
	 	 registry
	 	 Domain Translation
	 	 Registrant
	 	 Registration Date

	aboutpe.co.nz	 	New Zealand	 	About Premature Ejaculation	 	Johnson & Johnson	 	June 19, 2009
	aboutpe.com.au	 	Australia	 	about premature ejaculation	 	Johnson & Johnson Pacific Pty. Ltd	 	April 16, 2009
	aboutpe.com.my	 	Malaysia	 	about premature ejaculation	 	Johnson & Johnson SDN BHD	 	July 8, 2009
	aboutpriligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	accademiaep.it	 	Italy	 	pe -> premature eiaculation accedemy	 	Johnson & Johnson SPA	 	August 5, 2009
	aitopriligy.com	 	Global	 	genuine priligy	 	Johnson & Johnson	 	January 29, 2009
	aitopriligy.fi	 	Finland	 	genuine priligy	 	Janssen-Cilag Oy	 	February 3, 2009
	aktapriligy.com	 	Global	 	genuine priligy	 	Johnson & Johnson	 	January 29, 2009
	äktapriligy.com	 	Global	 	Genuine Priligy	 	Johnson & Johnson	 	February 12, 2009
	aktapriligy.se	 	Sweden	 	genuine priligy	 	Johnson & Johnson	 	January 31, 2009
	äktapriligy.se	 	Sweden	 	genuinepriligy	 	Johnson & Johnson	 	February 12, 2009
	beatpe.com.my	 	Malaysia	 	beat Premature Ejaculation	 	Johnson & Johnson SDN BHD	 	April 2, 2010
	beatpe.net	 	Global	 	beat Premature Ejaculation	 	Johnson & Johnson	 	March 24, 2010
	buydapoxetinepriligy.com	 	Global	 	buy dapoxetine priligy	 	Johnson & Johnson	 	August 28, 2010
	buypriligy.com	 	Global	 	buy priligy	 	Johnson & Johnson	 	March 10, 2009
	buy-priligy.com	 	Global	 	buy priligy	 	Johnson & Johnson	 	February 10, 2009
	buypriligy.info	 	Global	 	buy priligy	 	Johnson & Johnson	 	July 1, 2009
	buy-priligy.net	 	Global	 	buy priligy	 	Johnson & Johnson	 	March 2, 2010
	buy-priligy-dapoxetine.com	 	Global	 	buy priligy dapoxetine	 	Johnson & Johnson	 	May 19, 2010
	buypriligyonline.com	 	Global	 	buy priligy online	 	Johnson & Johnson	 	February 3, 2009
	buy-priligy-online.com	 	Global	 	buy priligy online	 	Johnson & Johnson	 	February 3, 2009

									
	cheappriligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	checkpriligy.co.kr	 	Korea	 	n/a	 	Johnson & Johnson Korea Ltd.	 	November 11, 2009
	comprarpriligy.com	 	Global	 	compare priligy	 	Johnson & Johnson	 	July 8, 2009
	comprar-priligy.com	 	Global	 	compare priligy	 	Johnson & Johnson	 	August 16, 2010
	comprarpriligy.es	 	Spain	 	compare Priligy	 	Johnson & Johnson	 	March 16, 2010
	comprarpriligy.org	 	Global	 	compare Priligy	 	Johnson & Johnson	 	August 3, 2010
	contralaeyaculacionprecoz.com	 	Global	 	againstprematureeyaculation	 	Johnson & Johnson	 	June 2, 2009
	controlatueyaculacion.com	 	Global	 	control your eyaculation	 	Johnson & Johnson	 	February 24, 2009
	controlep.com.ar	 	Argentina	 	premature eyaculation control	 	Johnson & Johnson de Argentina SACel	 	November 19, 2009
	controleyaculacion.cl	 	Chile	 	ejaculation control	 	Johnson & Johnson	 	December 17, 2009
	controlpe.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	controlpe.com.my	 	Malaysia	 	control premature ejaculation	 	Johnson & Johnson SDN BHD	 	April 19, 2010
	controlpe.com.sg	 	Singapore	 	control premature ejaculation	 	Johnson & Johnson PTE. LTD.	 	July 7, 2010
	controlpe.my	 	Malaysia	 	control premature ejaculation	 	Johnson & Johnson SDN BHD	 	April 19, 2010
	dapaxatine.biz	 	Global	 	None	 	Johnson & Johnson	 	June 28, 2005
	dapaxatine.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapaxatine.info	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	dapaxatine.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapaxatine.org	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxeteen.biz	 	Global	 	None	 	Johnson & Johnson	 	June 28, 2005
	dapoxeteen.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxeteen.info	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	dapoxeteen.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxeteen.org	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetin.at	 	Austria	 	None	 	Johnson & Johnson	 	August 26, 2005
	dapoxetina.cl	 	Chile	 	dapoxetine	 	Johnson & Johnson	 	August 20, 2009
	dapoxetina.com.bo	 	Bolivia	 	dapoxetine	 	Johnson & Johnson	 	August 25, 2009
	dapoxetina.com.br	 	Brazil	 	n/a	 	Janssen-Cilag Farmacêutica Ltda	 	April 11, 2008

									
	dapoxetina.com.ec	 	Ecuador	 	dapoxetine	 	Johnson & Johnson	 	August 28, 2009
	dapoxetina.com.pe	 	Peru	 	dapoxetine	 	Johnson & Johnson	 	August 19, 2009
	dapoxetina.com.py	 	Paraguay	 	dapoxetine	 	Johnson & Johnson	 	August 24, 2009
	dapoxetina.com.uy	 	Uruguay	 	dapoxetine	 	Johnson & Johnson	 	September 15, 2009
	dapoxetina.com.ve	 	Venezuela	 	dapoxetina	 	Johnson & Johnson	 	September 9, 2009
	dapoxetina.es	 	Spain	 	None	 	Johnson & Johnson	 	November 11, 2005
	dapoxetinapriligy.com	 	Global	 	dapoxetine priligy	 	Johnson & Johnson	 	December 20, 2010
	dapoxetine.at	 	Austria	 	dapoxetine	 	Johnson & Johnson	 	September 26, 2008
	dapoxetine.biz	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	dapoxetine.ca	 	Canada	 	dapoxetine	 	Johnson & Johnson	 	September 26, 2008
	dapoxetine.com	 	Global	 	None	 	Johnson & Johnson	 	July 9, 2002
	dapoxetine.com.au	 	Australia	 	dapoxetine	 	Johnson & Johnson Pacific Pty. Ltd	 	September 29, 2008
	dapoxetine.com.tw	 	Taiwan	 	n/a	 	Johnson & Johnson Taiwan Ltd.	 	January 20, 2009
	dapoxetine.dk	 	Denmark	 	None	 	Johnson & Johnson	 	March 31, 2006
	dapoxetine.es	 	Spain	 	dapoxetine	 	Johnson & Johnson	 	September 26, 2008
	dapoxetine.eu	 	European Union	 	None	 	Janssen Pharmaceutica N.V.	 	April 7, 2006
	dapoxetine.fi	 	Finland	 	dapoxetine.fi	 	Janssen-Cilag Oy	 	January 10, 2009
	dapoxetine.fr	 	France	 	dapoxetine	 	Johnson & Johnson Consumer France SAS	 	September 26, 2008
	dapoxetine.info	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	dapoxetine.md	 	Moldova	 	None	 	Johnson & Johnson	 	May 10, 2004
	dapoxetine.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetine.org	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetine.se	 	Sweden	 	dapoxetine	 	Johnson & Johnson	 	September 26, 2008
	dapoxetinekills.biz	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	dapoxetinekills.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetinekills.info	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	dapoxetinekills.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005

									
	dapoxetinekills.org	 	Global	 	None	 	Johnson & Johnson	 	June 21, 2005
	dapoxetine-priligy.com	 	Global	 	priligy dapoxetine	 	Johnson & Johnson	 	March 25, 2010
	dapoxetine-priligy.info	 	Global	 	priligy dapoxetine	 	Johnson & Johnson	 	November 29, 2009
	dapoxetinesucks.biz	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	dapoxetinesucks.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetinesucks.info	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetinesucks.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetinesucks.org	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetinetruth.biz	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	dapoxetinetruth.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetinetruth.info	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	dapoxetinetruth.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dapoxetinetruth.org	 	Global	 	None	 	Johnson & Johnson	 	June 21, 2005
	depoxetine.biz	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	depoxetine.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	depoxetine.info	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	depoxetine.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	depoxetine.org	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	discountpriligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	dupoxetine.biz	 	Global	 	None	 	Johnson & Johnson	 	June 28, 2005
	dupoxetine.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dupoxetine.info	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dupoxetine.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	dupoxetine.org	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	early-male-climax.biz	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	early-male-climax.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	early-male-climax.info	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	early-male-climax.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	edorpe.com	 	Global	 	Erectile Dysfunction or Premature Ejaculation	 	Johnson & Johnson	 	March 9, 2005
	ejaculacaoprecoce.com	 	Global	 	None	 	Johnson & Johnson	 	February 8, 2005

									
	ejaculacao-precoce.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	ejaculacaoprecoce.com.pt	 	Portugal	 	precoce ejaculation	 	Johnson & Johnson	 	May 1, 2009
	ejaculacaoprecoce.info	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	ejaculacaoprecoce.mobi	 	Global	 	portuguese	 	Johnson & Johnson	 	August 14, 2009
	ejaculacaoprecoceonline.com.br	 	Brazil	 	premature ejaculation online	 	Janssen-Cilag Farmacêutica Ltda	 	August 15, 2009
	ejaculacaoprematura.com.pt	 	Portugal	 	premature ejaculation	 	Johnson & Johnson	 	May 1, 2009
	ejaculacaorapidaonline.com.br	 	Brazil	 	rapid ejaculation online	 	Janssen-Cilag Farmacêutica Ltda	 	August 15, 2009
	ejacularapido.com.br	 	Brazil	 	rapid ejaculation	 	Janssen-Cilag Farmacêutica Ltda	 	August 15, 2009
	ejaculationprematurée.com	 	Global	 	Premature Ejaculation	 	Johnson & Johnson	 	December 2, 2009
	ejaculationprematuree.fr	 	France	 	Premature Ejaculation	 	Johnson & Johnson Consumer France SAS	 	October 26, 2009
	ejaculatiopracox.de	 	Germany	 	None	 	Johnson & Johnson	 	August 29, 2011
	ejaculatiopracox.info	 	Global	 	None	 	Johnson & Johnson	 	December 8, 2005
	ejaculatiopraecox.at	 	Austria	 	None	 	Johnson & Johnson	 	August 26, 2005
	ejaculatio-praecox.at	 	Austria	 	None	 	Johnson & Johnson	 	August 26, 2005
	ejaculorapidinho.com.br	 	Brazil	 	portuguese	 	Janssen-Cilag Farmacêutica Ltda	 	August 15, 2009
	ejakulatioskontroll.se	 	Sweden	 	ejaculation control	 	Johnson & Johnson	 	March 14, 2009
	ejeculacaoprecoce.com.pt	 	Portugal	 	precoce ejaculation	 	Johnson & Johnson	 	April 22, 2009
	ejeculacaoprematura.com.pt	 	Portugal	 	premature ejaculation	 	Johnson & Johnson	 	April 22, 2009
	ellosyalohanhecho.com	 	Global	 	theyhavealreadydoneit	 	Johnson & Johnson	 	September 29, 2009
	ellosyalohanhecho.es	 	Spain	 	theyhavealreadydoneit	 	Johnson & Johnson	 	October 6, 2009
	ennenaikainensiemensyoksy.fi	 	Finland	 	premature ejaculation . fi	 	Janssen-Cilag Oy	 	March 5, 2009
	ennenaikainensiemensyöksy.fi	 	Finland	 	premature-ejaculation.fi	 	Janssen-Cilag Oy	 	March 6, 2009
	everymaleclimax.biz	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	everymaleclimax.com	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	everymaleclimax.info	 	Global	 	None	 	Johnson & Johnson	 	June 27, 2005
	everymaleclimax.net	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005
	everymaleclimax.org	 	Global	 	None	 	Johnson & Johnson	 	June 20, 2005

									
	exyaculacionprecoz.com	 	Global	 	exprematureeyaculation.com	 	Johnson & Johnson	 	June 2, 2009
	eyaculacion-precoz.com.mx	 	Mexico	 	None	 	Johnson & Johnson	 	August 31, 2005
	eyaculacionprecoz.com.ve	 	Venezuela	 	Premature Ejaculation	 	Johnson & Johnson	 	September 9, 2009
	eyaculacionycontrol.com.ar	 	Australia	 	eyaculation and control	 	Johnson & Johnson de Argentina SACel	 	November 19, 2009
	fakedapoxetine.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	fakepriligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	foldingthelaundry.com	 	Global	 	Dapoxetine	 	Johnson & Johnson	 	June 8, 2005
	foldingthelaundry.net	 	Global	 	Dapoxetine	 	Johnson & Johnson	 	June 8, 2005
	foldingthelaundry.org	 	Global	 	Dapoxetine	 	Johnson & Johnson	 	June 8, 2005
	fortidigutlosning.se	 	Sweden	 	premature ejaculation	 	Johnson & Johnson	 	February 27, 2009
	freepriligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	fruehersamenerguss.de	 	Germany	 	rapid ejaculatio	 	Johnson & Johnson	 	August 29, 2011
	frueher-samenerguss.de	 	Germany	 	zu schneller samenerguss - too quick ejaculation	 	Johnson & Johnson	 	August 29, 2011
	fruehzeitiger-samenerguss.at	 	Austria	 	fruehzeitiger samenerguss - too quick ejaculation	 	Johnson & Johnson	 	August 26, 2005
	garforfort.se	 	Sweden	 	goes too fast	 	Johnson & Johnson	 	March 14, 2009
	garforsnabbt.se	 	Sweden	 	goes too soon	 	Johnson & Johnson	 	February 27, 2009
	garfortidigt.se	 	Sweden	 	goes too soon	 	Johnson & Johnson	 	February 27, 2009
	genericpriligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	genericpriligy.info	 	Global	 	generic priligy	 	Johnson & Johnson	 	July 1, 2009
	genericpriligy.org	 	Global	 	generic priligy	 	Johnson & Johnson	 	April 27, 2010
	generic-priligy.org	 	Global	 	generic priligy	 	Johnson & Johnson	 	November 13, 2010
	genuinepriligy.ca	 	Canada	 	genuine priligy	 	Johnson & Johnson	 	April 17, 2009
	genuinepriligy.cn	 	China	 	Genuine PRILIGY	 	Johnson & Johnson HK Ltd.	 	December 2, 2010
	genuinepriligy.co.nz	 	New Zealand	 	n/a	 	Johnson & Johnson	 	October 2, 2009
	genuinepriligy.com	 	Global	 	genuine priligy	 	Johnson & Johnson	 	January 29, 2009
	genuinepriligy.com.au	 	Australia	 	genuine priligy	 	Johnson & Johnson	 	February 2, 2009
	genuinepriligy.com.cn	 	China	 	Genuine PRILIGY	 	Johnson & Johnson HK Ltd.	 	December 2, 2010

									
	genuinepriligy.com.hk	 	Hong Kong	 	genuine priligy	 	Johnson & Johnson (HK) Ltd	 	May 19, 2009
	genuinepriligy.com.my	 	Malaysia	 	n/a	 	Johnson & Johnson SDN BHD	 	October 7, 2009
	genuinepriligy.com.ph	 	Philippines	 	n/a	 	Johnson & Johnson	 	October 5, 2009
	genuinepriligy.com.sg	 	Singapore	 	n/a	 	Johnson & Johnson	 	September 24, 2009
	genuinepriligy.eu	 	European Union	 	genuine priligy	 	Janssen Pharmaceutica N.V.	 	January 30, 2009
	genuinepriligy.hk	 	Hong Kong	 	genuine priligy	 	Johnson & Johnson (HK) Ltd	 	May 19, 2009
	gercekpriligy.com	 	Global	 	real(genuine) priligy	 	Johnson & Johnson	 	February 17, 2010
	gercekpriligy.info	 	Global	 	real(genuine) priligy	 	Johnson & Johnson	 	February 17, 2010
	getpriligy.com	 	Global	 	get priligy	 	Johnson & Johnson	 	May 20, 2009
	ilmoittaudu-priligy.fi	 	Finland	 	register-priligy	 	Janssen-Cilag Oy	 	March 5, 2009
	kommaforfort.se	 	Sweden	 	comes too fast	 	Johnson & Johnson	 	March 14, 2009
	kommaforsnabbt.se	 	Sweden	 	comes too fast	 	Johnson & Johnson	 	March 14, 2009
	kontrolli.info	 	Global	 	control.info in finnish	 	Johnson & Johnson	 	February 24, 2009
	laengergeniessen.de	 	Germany	 	Enjoy longer	 	Johnson & Johnson	 	August 29, 2011
	laenger-geniessen.de	 	Germany	 	enjoy longer	 	Johnson & Johnson	 	August 29, 2011
	laeyaculacionprecoz.bo	 	Bolivia	 	premature eyaculation	 	Johnson & Johnson	 	November 19, 2009
	laeyaculacionprecoz.com.py	 	Paraguay	 	premature eyaculation	 	Johnson & Johnson	 	January 22, 2010
	laeyaculacionprecoz.com.uy	 	Uruguay	 	premature eyaculation	 	Johnson & Johnson	 	November 16, 2009
	laeyaculacionprecoz.ec	 	Ecuador	 	premature eyaculation	 	Johnson & Johnson	 	November 13, 2009
	laeyaculacionprecoz.es	 	Spain	 	theprematureeyaluculation.es	 	Johnson & Johnson	 	June 4, 2009
	laeyaculacionprecoz.info	 	Global	 	theprematureeyaculation.com / info	 	Johnson & Johnson	 	June 1, 2009
	laeyaculacionprecoz.pe	 	Peru	 	premature eyaculation	 	Johnson & Johnson	 	November 13, 2009
	maleclimax.biz	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	maleclimax.com	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	maleclimax.info	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	maleclimax.net	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	maleclimax.org	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	managepe.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005

									
	mannkannlänger.at	 	Austria	 	man is able longer	 	Johnson & Johnson	 	April 5, 2010
	mascontrol-mastiempo.com	 	Global	 	morecontrol-moretime	 	Johnson & Johnson	 	October 9, 2009
	mascontrolmastiempo.com.mx	 	Mexico	 	morecontrolmoretime	 	Johnson & Johnson	 	October 12, 2009
	mascontrol-mastiempo.com.mx	 	Mexico	 	morecontrol-moretime	 	Johnson & Johnson	 	October 12, 2009
	mascontrolmastiempo.mx	 	Mexico	 	morecontrolmoretime	 	Johnson & Johnson	 	October 23, 2009
	mascontrol-mastiempo.mx	 	Mexico	 	morecontrol-moretime	 	Johnson & Johnson	 	October 23, 2009
	mehrzeitzuzweit.de	 	Germany	 	more time twosome	 	Johnson & Johnson	 	August 29, 2011
	mehr-zeit-zu-zweit.de	 	Germany	 	more time twosome	 	Johnson & Johnson	 	August 29, 2011
	mejorcontrol.com	 	Global	 	bettercontrol	 	Johnson & Johnson	 	April 5, 2010
	onlinepriligy.com	 	Global	 	priligy online	 	Johnson & Johnson	 	February 3, 2009
	pe.co.at	 	Austria	 	None	 	Johnson & Johnson	 	September 7, 2005
	pedebate.com	 	Global	 	Premature Ejaculation Debates	 	Johnson & Johnson	 	March 1, 2010
	pedebate.info	 	Global	 	Premature Ejaculation Debates	 	Johnson & Johnson	 	March 1, 2010
	pedebates.com	 	Global	 	Premature Ejaculation Debates	 	Johnson & Johnson	 	March 1, 2010
	pedebates.info	 	Global	 	Premature Ejaculation Debates	 	Johnson & Johnson	 	March 1, 2010
	pediscussion.com	 	Global	 	Premature Ejaculation discussion	 	Johnson & Johnson	 	March 10, 2010
	pediscussion.info	 	Global	 	Premature Ejaculation discussion	 	Johnson & Johnson	 	March 10, 2010
	pediscussions.com	 	Global	 	Premature Ejaculation discussions	 	Johnson & Johnson	 	March 10, 2010
	pediscussions.info	 	Global	 	Premature Ejaculation discussions	 	Johnson & Johnson	 	March 10, 2010
	pefacts.com	 	Global	 	None	 	Johnson & Johnson	 	January 27, 2005
	pe-kontrolle.at	 	Austria	 	None	 	Johnson & Johnson	 	August 30, 2005
	pemedia.biz	 	Global	 	pe = Pre-ejaculation	 	Johnson & Johnson	 	November 4, 2004
	pemedia.info	 	Global	 	pe = Pre-ejaculation	 	Johnson & Johnson	 	November 4, 2004
	pemedia.org	 	Global	 	pe = Pre-ejaculation	 	Johnson & Johnson	 	November 4, 2004
	pemedication.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	peored.com	 	Global	 	Premature Ejaculation or Erectile Dysfunction	 	Johnson & Johnson	 	March 9, 2005

									
	pesupportcompany.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	pirligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	prematureejaculation.com	 	Global	 	None	 	Johnson & Johnson	 	March 23, 2005
	prematureejaculation.com.my	 	Malaysia	 	premature ejaculation	 	Johnson & Johnson SDN BHD	 	June 23, 2009
	prematureejaculation.com.sg	 	Singapore	 	n/a	 	Johnson & Johnson PTE. LTD.	 	June 25, 2010
	premature-ejaculation.gr	 	Greece	 	n/a	 	Johnson & Johnson	 	February 1, 2009
	prematureejaculation.md	 	Moldova	 	None	 	Johnson & Johnson	 	May 10, 2004
	premature-ejaculation.md	 	Moldova	 	None	 	Johnson & Johnson	 	May 10, 2004
	prematureejaculation.my	 	Malaysia	 	premature ejaculation	 	Johnson & Johnson SDN BHD	 	June 23, 2009
	prematureejaculationfacts.com	 	Global	 	None	 	Johnson & Johnson	 	January 27, 2005
	prematureejaculationtruth.com	 	Global	 	None	 	Johnson & Johnson	 	January 27, 2005
	prematurejaculation.se	 	Sweden	 	premature ejaculation	 	Johnson & Johnson	 	February 27, 2009
	prematurejakulasyon.com	 	Global	 	Premature Ejaculation	 	Johnson & Johnson	 	October 30, 2009
	preventpe.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	prilagy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	prilegy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	prilgiy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	priligi.de	 	Germany	 	n/a	 	Johnson & Johnson	 	August 29, 2011
	priligy.at	 	Austria	 	priligy	 	Johnson & Johnson	 	October 1, 2008
	priligy.biz	 	Global	 	None	 	Johnson & Johnson	 	June 9, 2004
	priligy.ca	 	Canada	 	priligy	 	Johnson & Johnson	 	October 1, 2008
	priligy.cl	 	Chile	 	priligy	 	Johnson & Johnson	 	August 20, 2009
	priligy.co.nz	 	New Zealand	 	PRILIGY	 	Johnson & Johnson	 	June 19, 2009
	priligy.com	 	Global	 	None	 	Johnson & Johnson	 	June 9, 2004
	priligy.com.au	 	Australia	 	priligy	 	JOHNSON JOHNSON PACIFIC PTY LIMITED	 	October 2, 2008
	priligy.com.bo	 	Bolivia	 	priligy	 	Johnson & Johnson	 	August 24, 2009
	priligy.com.br	 	Brazil	 	priligy	 	Janssen-Cilag Farmacêutica Ltda	 	August 15, 2009

									
	priligy.com.ec	 	Ecuador	 	priligy	 	Johnson & Johnson	 	August 28, 2009
	priligy.com.hk	 	Hong Kong	 	priligy	 	Johnson & Johnson (HK) Ltd	 	May 19, 2009
	priligy.com.mx	 	Mexico	 	None	 	Johnson & Johnson	 	September 6, 2005
	priligy.com.my	 	Malaysia	 	about premature ejaculation - product site	 	Johnson & Johnson SDN BHD	 	November 30, 2007
	priligy.com.pe	 	Peru	 	priligy	 	Johnson & Johnson	 	August 19, 2009
	priligy.com.py	 	Paraguay	 	priligy	 	Johnson & Johnson	 	January 8, 2010
	priligy.com.tr	 	Turkey	 	Priligy	 	Johnson & Johnson	 	December 2, 2010
	priligy.com.tw	 	Taiwan	 	n/a	 	Johnson & Johnson Taiwan Ltd.	 	January 20, 2009
	priligy.com.uy	 	Uruguay	 	priligy	 	Johnson & Johnson	 	September 15, 2009
	priligy.com.ve	 	Venezuela	 	Priligy	 	Johnson & Johnson	 	September 9, 2009
	priligy.de	 	Germany	 	priligy	 	Johnson & Johnson	 	August 29, 2011
	priligy.dk	 	Denmark	 	priligy	 	Johnson & Johnson	 	October 1, 2008
	priligy.es	 	Spain	 	None	 	Janssen Pharmaceutica N.V.	 	September 30, 2005
	priligy.eu	 	European Union	 	priligy	 	Janssen Pharmaceutica N.V.	 	September 26, 2008
	priligy.fi	 	Finland	 	priligy	 	Janssen-Cilag Oy	 	January 10, 2009
	priligy.fr	 	France	 	priligy	 	Johnson & Johnson Consumer France SAS	 	October 1, 2008
	priligy.gr	 	Greece	 	n/a	 	Johnson & Johnson	 	January 26, 2009
	priligy.hk	 	Hong Kong	 	priligy	 	Johnson & Johnson (HK) Ltd	 	May 19, 2009
	priligy.info	 	Global	 	None	 	Johnson & Johnson	 	June 9, 2004
	priligy.it	 	Italy	 	priligy	 	Johnson & Johnson SPA	 	October 3, 2008
	priligy.mobi	 	Global	 	priligy mobile apps?	 	Johnson & Johnson	 	February 3, 2009
	priligy.my	 	Malaysia	 	about premature ejaculation - product site	 	Johnson & Johnson SDN BHD	 	June 23, 2009
	priligy.net	 	Global	 	None	 	Johnson & Johnson	 	June 9, 2004
	priligy.org	 	Global	 	None	 	Johnson & Johnson	 	June 9, 2004
	priligy.pt	 	Portugal	 	priligy	 	Janssen Pharmaceutica N.V.	 	October 15, 2008

									
	priligy.se	 	Sweden	 	priligy	 	Johnson & Johnson	 	October 1, 2008
	priligy.us	 	US	 	None	 	Johnson & Johnson	 	June 14, 2004
	priligyautentico.com	 	Global	 	genuine priligy	 	Johnson & Johnson	 	January 29, 2009
	priligyautentico.com.pt	 	Portugal	 	authentic prigliy	 	Johnson & Johnson	 	March 20, 2009
	priligyautentico.es	 	Spain	 	authentic prigliy	 	Johnson & Johnson	 	March 20, 2009
	priligyauthentique.ca	 	Canada	 	authentic prigliy	 	Johnson & Johnson	 	March 20, 2009
	priligyauthentique.com	 	Global	 	authentic prigliy	 	Johnson & Johnson	 	March 20, 2009
	priligyauthentique.fr	 	France	 	authentic prigliy	 	Johnson & Johnson Consumer France SAS	 	April 1, 2009
	priligybuy.com	 	Global	 	priligy buy	 	Johnson & Johnson	 	February 3, 2009
	priligy-buy.com	 	Global	 	priligy buy	 	Johnson & Johnson	 	March 25, 2010
	priligy-canada.com	 	Global	 	canada priligy	 	Johnson & Johnson	 	June 21, 2010
	priligyconsult.com	 	Global	 	consult priligy	 	Johnson & Johnson	 	April 28, 2010
	priligy-dapoxetina.com	 	Global	 	priligy dapoxetine	 	Johnson & Johnson	 	August 27, 2010
	priligydapoxetine.com	 	Global	 	priligy dapoxetine	 	Johnson & Johnson	 	March 31, 2010
	priligy-dapoxetine.com	 	Global	 	priligy dapoxetine	 	Johnson & Johnson	 	March 31, 2010
	priligydapoxetine.org	 	Global	 	priligy dapoxetine	 	Johnson & Johnson	 	August 8, 2009
	priligydapoxetinereview.com	 	Global	 	review priligy	 	Johnson & Johnson	 	May 5, 2010
	priligyecht.at	 	Austria	 	genuine priligy	 	Johnson & Johnson	 	February 3, 2009
	priligyecht.ch	 	Switzerland	 	genuine priligy	 	Johnson & Johnson	 	February 2, 2009
	priligyecht.com	 	Global	 	genuine priligy	 	Johnson & Johnson	 	January 29, 2009
	priligyecht.de	 	Germany	 	genuine priligy	 	Johnson & Johnson	 	September 20, 2010
	priligyfacts.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	priligyfaq.com	 	Global	 	priligy frequently asked questions	 	Johnson & Johnson	 	October 7, 2005
	priligyfrance.com	 	Global	 	priligy France	 	Johnson & Johnson	 	May 11, 2010
	priligygenuino.com	 	Global	 	genuine priligy	 	Johnson & Johnson	 	January 29, 2009
	priligygenuino.com.br	 	Brazil	 	genuine priligy	 	Janssen-Cilag Farmacêutica Ltda	 	November 17, 2009
	priligygenuino.es	 	Spain	 	genuine priligy	 	Johnson & Johnson	 	January 31, 2009

									
	priligyinfo.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	priligykills.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	priligymexico.com	 	Global	 	priligy Mexico	 	Johnson & Johnson	 	June 21, 2010
	priligynews.com	 	Global	 	priligy news	 	Johnson & Johnson	 	September 16, 2005
	priligynotes.com	 	Global	 	priligy notes	 	Johnson & Johnson	 	April 28, 2010
	priligynow.com	 	Global	 	priligy now	 	Johnson & Johnson	 	February 3, 2009
	priligyny.com	 	Global	 	priligy ny (new york?)	 	Johnson & Johnson	 	April 28, 2010
	priligynyc.com	 	Global	 	priligy nyc (new york city?)	 	Johnson & Johnson	 	April 28, 2010
	priligy-online.net	 	Global	 	online priligy	 	Johnson & Johnson	 	November 18, 2010
	priligy-online.org	 	Global	 	online priligy	 	Johnson & Johnson	 	November 13, 2010
	priligyoriginal.at	 	Austria	 	original priligy	 	Johnson & Johnson	 	February 10, 2009
	priligyoriginal.com	 	Global	 	original priligy	 	Johnson & Johnson	 	February 6, 2009
	priligyoriginal.de	 	Germany	 	original priligy	 	Johnson & Johnson	 	August 29, 2011
	priligyoriginale.com	 	Global	 	original priligy	 	Johnson & Johnson	 	January 29, 2009
	priligyoriginale.it	 	Italy	 	original priligy	 	Johnson & Johnson SPA	 	February 5, 2009
	priligypublicationtoolkit.com	 	Global	 	n/a	 	Johnson & Johnson	 	October 15, 2008
	priligyresource.com	 	Global	 	priligy resource	 	Johnson & Johnson	 	April 28, 2010
	priligyreview.com	 	Global	 	priligy review	 	Johnson & Johnson	 	February 17, 2009
	priligysmart.com	 	Global	 	priligy smart	 	Johnson & Johnson	 	April 28, 2010
	priligysucks.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	prillagy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	prillegy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	prilligi.de	 	Germany	 	n/a	 	Johnson & Johnson	 	August 29, 2011
	prilligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	prilligy.de	 	Germany	 	n/a	 	Johnson & Johnson	 	August 29, 2011
	prillogy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	prligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	rapidejaculation.biz	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	rapid-ejaculation.biz	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	rapidejaculation.com	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003

									
	rapidejaculation.info	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	rapid-ejaculation.info	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	rapidejaculation.md	 	Moldova	 	None	 	Johnson & Johnson	 	May 10, 2004
	rapid-ejaculation.md	 	Moldova	 	None	 	Johnson & Johnson	 	May 10, 2004
	rapidejaculation.net	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	rapid-ejaculation.net	 	Global	 	None	 	Johnson & Johnson	 	October 14, 2003
	rechtzeitigstattvorzeitig.de	 	Germany	 	timely-instead of-premature	 	Johnson & Johnson	 	August 29, 2011
	rechtzeitig-statt-vorzeitig.de	 	Germany	 	timely-instead of-premature	 	Johnson & Johnson	 	August 29, 2011
	registera-priligy.se	 	Sweden	 	register priligy	 	Johnson & Johnson	 	March 14, 2009
	talkaboutpe.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	talkingaboutpe.asia	 	Asia	 	Talking About Premature Ejaculation	 	Johnson & Johnson PTE.LTD.	 	September 7, 2010
	talkingaboutpe.cn	 	China	 	Talking About Premature Ejaculation	 	Johnson & Johnson HK Ltd.	 	December 2, 2010
	talkingaboutpe.co.id	 	Indonesia	 	Talking About Premature Ejaculation	 	Johnson & Johnson Indonesia	 	September 15, 2010
	talkingaboutpe.co.in	 	India	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 7, 2010
	talkingaboutpe.co.kr	 	Korea	 	Talking About Premature Ejaculation	 	Johnson & Johnson Korea Ltd.	 	September 15, 2010
	talkingaboutpe.co.nz	 	New Zealand	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 8, 2010
	talkingaboutpe.com	 	Global	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	August 27, 2010
	talkingaboutpe.com.au	 	Australia	 	Talking About Premature Ejaculation	 	Johnson & Johnson Pty Ltd	 	September 8, 2010
	talkingaboutpe.com.cn	 	cina	 	Talking About Premature Ejaculation	 	Johnson & Johnson HK Ltd.	 	December 2, 2010
	talkingaboutpe.com.hk	 	Hong Kong	 	Talking About Premature Ejaculation	 	Johnson & Johnson HK Ltd.	 	September 8, 2010
	talkingaboutpe.com.my	 	Malaysia	 	Talking About Premature Ejaculation	 	Johnson & Johnson SDN BHD	 	September 7, 2010
	talkingaboutpe.com.ph	 	Philippines	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 3, 2010
	talkingaboutpe.com.sg	 	Singapore	 	Talking About Premature Ejaculation	 	Johnson & Johnson PTE. LTD.	 	September 8, 2010

									
	talkingaboutpe.com.tw	 	Taiwan	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 8, 2010
	talkingaboutpe.com.vn	 	Vietnam	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 8, 2010
	talkingaboutpe.hk	 	Hong Kong	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 8, 2010
	talkingaboutpe.in	 	India	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 7, 2010
	talkingaboutpe.jp	 	Japan	 	Talking About Premature Ejaculation	 	Johnson & Johnson K.K.	 	September 8, 2010
	talkingaboutpe.kr	 	Korea	 	Talking About Premature Ejaculation	 	Johnson & Johnson Korea Ltd.	 	September 15, 2010
	talkingaboutpe.mobi	 	Global	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 2, 2010
	talkingaboutpe.my	 	Malaysia	 	Talking About Premature Ejaculation	 	Johnson & Johnson SDN BHD	 	September 7, 2010
	talkingaboutpe.ph	 	Philippines	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 9, 2010
	talkingaboutpe.sg	 	Singapore	 	Talking About Premature Ejaculation	 	Johnson & Johnson PTE. LTD	 	September 8, 2010
	talkingaboutpe.tw	 	Taiwan	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 8, 2010
	talkingaboutpe.vn	 	Vietnam	 	Talking About Premature Ejaculation	 	Johnson & Johnson	 	September 8, 2010
	thetruthaboutpe.com	 	Global	 	None	 	Johnson & Johnson	 	January 27, 2005
	thetruthaboutprematureejaculation.com	 	Global	 	None	 	Johnson & Johnson	 	January 27, 2005
	tidigutlosning.se	 	Sweden	 	premature ejaculation .se	 	Johnson & Johnson	 	March 4, 2009
	treatpe.co.nz	 	New Zealand	 	Treat Premature Ejaculation	 	Johnson & Johnson	 	June 19, 2009
	treatpe.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	treatpe.com.au	 	Australia	 	Treat Premature Ejaculation	 	Johnson & Johnson	 	September 25, 2009
	truthaboutpe.com	 	Global	 	None	 	Johnson & Johnson	 	January 27, 2005
	truthaboutpe.net	 	Global	 	None	 	Johnson & Johnson	 	February 28, 2005
	truthaboutpe.org	 	Global	 	None	 	Johnson & Johnson	 	February 28, 2005
	truthaboutprematureejaculation.com	 	Global	 	None	 	Johnson & Johnson	 	January 27, 2005
	truthaboutpriligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005

									
	trypriligy.com	 	Global	 	None	 	Johnson & Johnson	 	September 29, 2005
	understandingpe.ca	 	Canada	 	Understanding PE	 	Johnson & Johnson	 	June 29, 2009
	understandingpe.com	 	Global	 	None	 	Johnson & Johnson	 	December 15, 2004
	understandingprematureejaculations.ca	 	Canada	 	Understanding Premature Ejaculations	 	Johnson & Johnson	 	June 29, 2009
	understandingprematureejaculations.com	 	Global	 	Understanding Premature Ejaculations	 	Johnson & Johnson	 	June 29, 2009
	uzunsursun.com	 	Global	 	Last longer	 	Johnson & Johnson	 	August 31, 2009
	validarpriligy.com	 	Global	 	validate priligy	 	Johnson & Johnson	 	January 29, 2009
	vorzeitigkommen.de	 	Germany	 	vorzeitig kommen - prematurely coming	 	Johnson & Johnson	 	August 30, 2011
	vorzeitig-kommen.de	 	Germany	 	vorzeitig kommen - prematurely coming	 	Johnson & Johnson	 	August 30, 2011
	whatispe.ca	 	Canada	 	What is PE	 	Johnson & Johnson	 	June 29, 2009
	whatispe.com	 	Global	 	What is PE	 	Johnson & Johnson	 	June 29, 2009
	zufruehkommen.de	 	Germany	 	zu frueh kommen - coming too quickly	 	Johnson & Johnson	 	August 30, 2011
	zu-frueh-kommen.de	 	Germany	 	zu frueh kommen - coming too quickly	 	Johnson & Johnson	 	August 30, 2011
	zuschnellersamenerguss.de	 	Germany	 	zu schneller samenerguss - too quick ejaculation	 	Johnson & Johnson	 	August 30, 2011
	zu-schneller-samenerguss.de	 	Germany	 	zu schneller samenerguss - too quick ejaculation	 	Johnson & Johnson	 	August 30, 2011

 Schedule 4.2B1 

Trademarks to be Assigned to GENUPRO 
  

													
	 Trademark name
	  	 Country
	  	 Filing
number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	PRILIGY	  	CANADA	  	1221594	  	18-Jun-04	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	CANADA	  	1267689	  	8-Aug-05	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	JAPAN	  	76599	  	16-Aug-05	  	4949950	  	12-May-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	JAPAN	  	71912	  	4-Aug-04	  	4858569	  	22-Apr-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	JAPAN	  	15093	  	23-Feb-05	  	4910950	  	2-Dec-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	JAPAN	  	84184	  	8-Sep-05	  	4958979	  	9-Jun-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	UNITED STATES OF AMERICA	  	77/749577	  	2-Jun-09	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	UNITED STATES OF AMERICA	  	77/749584	  	2-Jun-09	  		  		  	J&J ONE J&J PLAZA - USA
	PRILOGY	  	UNITED STATES OF AMERICA	  	85/261793	  	9-Mar-11	  		  		  	J&J ONE J&J PLAZA - USA

 Schedule 4.2B2 

Trademarks to be Assigned to Menarini 
  

													
	 Trademark
name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	PRILIGY	  	ALBANIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	ALGERIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	ANTIGUA	  	6432	  	27-Sep-04	  	6432	  	27-Sep-04	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	ARGENTINA	  	2528136	  	16-Jul-04	  	2070127	  	2-Mar-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	ARMENIA	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	ARMENIA	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	ARMENIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	ARUBA	  	**	  	9-Nov-04	  	23191	  	8-Nov-04	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	AUSTRALIA	  	1010194	  	8-Jul-04	  	1010194	  	4-Mar-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	AZERBAIJAN	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	AZERBAIJAN	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	AZERBAIJAN	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	BAHAMAS	  	27181	  	16-Nov-04	  	27181	  	16-Nov-08	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	BAHRAIN	  	81732	  	7-Jun-10	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	BANGLADESH	  	86712	  	15-Jul-04	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	BARBADOS	  	81/19650	  	21-Jul-04	  	81/19650	  	21-Jul-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	BELARUS	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	BELARUS	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	BELARUS	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	BENELUX	  	1083189	  	11-Aug-05	  	770678	  	18-Aug-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	BENELUX	  	1056959	  	11-Jun-04	  	749301	  	11-Jun-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	BENELUX	  	1083190	  	11-Aug-05	  	770679	  	18-Aug-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	BERMUDA	  	41229	  	21-Jul-04	  	41229	  	2-Mar-05	  	J&J ONE J&J PLAZA - USA

													
	 Trademark
name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	PRILIGY	  	BOLIVIA	  	1949	  	29-Jun-04	  	102045-C	  	25-Jan-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	BOSNIA-HERZEGOVINA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	BRAZIL	  	826692826	  	13-Jul-04	  	826692826	  	21-Aug-07	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	BULGARIA	  	79737	  	28-Jun-05	  	62921	  	16-Jan-08	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	BULGARIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	BURUNDI	  	**	  	11-Oct-04	  	4221	  	11-Oct-04	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	CAMBODIA (ex-KAMPUCHEA)	  	20847	  	5-Jul-04	  	20223	  	5-Jul-04	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	CHILE	  	654045	  	21-Jul-04	  	709529	  	23-Nov-04	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	 CHINA, PEOPLES
 REPUBLIC
(PRC)
	  	7644176	  	25-Aug-09	  	7644176	  	21-Nov-10	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	 CHINA, PEOPLES
 REPUBLIC
(PRC)
	  	4152873	  	5-Jul-04	  	4152873	  	7-May-07	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	 CHINA,PEOPLES
 REPUBLIC
(PRC)
	  	4697667	  	3-Jun-05	  	4697667	  	14-Nov-08	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	 CHINA, PEOPLES
 REPUBLIC
(PRC)
	  	9177193	  	7-Mar-11	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	 CHINA, PEOPLES

REPUBLIC (PRC)
	  	7644175	  	25-Aug-09	  	7644175	  	21-Nov-10	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	CONGO, DEMOCRATIC REPUBLIC (ex- Zaire)	  	353	  	15-Jul-04	  	10431	  	15-Jul-04	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	COSTA RICA	  	5162	  	14-Jul-04	  	153508	  	11-Aug-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY	  	CROATIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	CUBA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY	  	CYPRUS [REPUBLIC]	  	71282	  	8-Apr-05	  	71282	  	8-Apr-05	  	J&J ONE J&J PLAZA - USA

													
	 Trademark
name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	 PRILIGY
	  	CZECH REPUBLIC	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	DENMARK	  	2405	  	18-Jun-04	  	2129	  	1-Jul-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	DOMINICAN REPUBLIC	  	59698	  	23-Jul-04	  	144251	  	15-Oct-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	ECUADOR	  	146701	  	20-Jul-04	  	1508	  	27-Oct-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	EGYPT	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	EL SALVADOR	  	41852	  	21-Apr-05	  	185/37	  	21-Apr-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	ESTONIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	ETHIOPIA	  	5584	  	6-Sep-03	  	5584	  	6-Sep-03	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	EUROPEAN COMMUNITY (EUROPEAN UNION)	  	8907925	  	24-Feb-10	  	8907925	  	18-Aug-10	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	FRANCE	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	GAZA STRIP	  	9561	  	21-Aug-04	  	9561	  	21-Aug-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	GEORGIAN REPUBLIC	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	GEORGIAN REPUBLIC	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	GEORGIAN REPUBLIC	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	GHANA	  	34693	  	26-Jun-04	  	34693	  	26-Jun-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	GREECE	  	149810	  	25-Jun-04	  	149810	  	25-Jun-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	GUATEMALA	  	5340	  	20-Jul-04	  	137304	  	17-Aug-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	GUYANA	  	20298A	  	15-Jul-04	  	20298	  	15-Jul-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HAITI	  	*	  	16-Jul-04	  	355/144	  	30-Nov-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HONDURAS	  	12683	  	10-Jan-05	  	93024	  	10-Jan-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HONG KONG	  	300572742	  	26-Jan-06	  	300572742	  	26-Jan-06	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HONG KONG	  	300243459	  	3-Jul-04	  	300243459	  	30-Jul-04	  	J&J ONE J&J PLAZA - USA

													
	 Trademark
name
	  	 Country
	  	 Filing
number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	 PRILIGY
	  	HONG KONG	  	300384002	  	11-Mar-05	  	300384002	  	11-Mar-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HONG KONG	  	300383986	  	11-Mar-05	  	300383986	  	11-Mar-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HONG KONG	  	300410200	  	27-Apr-05	  	300410200	  	27-Apr-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HONG KONG	  	300410192	  	27-Apr-05	  	300410192	  	2-Sep-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HONG KONG	  	300383995	  	11-Mar-05	  	300383995	  	11-Mar-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HONG KONG	  	300383977	  	11-Mar-05	  	300383977	  	11-Mar-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	HUNGARY	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	ICELAND	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	INDIA	  	1296820	  	19-Jul-04	  	1296820	  	19-Jul-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	INDONESIA	  	21260-21425	  	27-Jul-04	  	66611	  	27-Jul-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	IRAN	  	8304015	  	21-Jun-04	  	114415	  	22-Sep-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	IRAQ	  	57934	  	24-Nov-10	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	IRELAND	  	1310	  	21-Jun-04	  	229755	  	14-Dec-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	ISRAEL	  	173069	  	28-Jun-04	  	173069	  	28-Jun-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	JAMAICA	  	45548	  	27-Jul-04	  	45548	  	27-Jul-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	JORDAN	  	75781	  	23-Jun-04	  	75781	  	21-Mar-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	KAZAKHSTAN	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	KAZAKHSTAN	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	KAZAKHSTAN	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	KENYA	  	55347	  	22-Feb-05	  	55347	  	22-Feb-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	KIRGHIZISTAN (Kyrgyz Republic)	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	KIRGHIZISTAN (Kyrgyz Republic)	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	KIRGHIZISTAN (Kyrgyz Republic)	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	KOREA (NORTH)	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	KOSOVO	  	7946	  	19-Nov-08	  	**	  	19-Nov-08	  	JANSSEN PHARMACEUTICA NV - I3090

													
	 Trademark
name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	 PRILIGY
	  	KUWAIT	  	68852	  	19-Feb-05	  	62507	  	19-Feb-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	LAOS	  	11446	  	19-Jul-04	  	10936	  	19-Jul-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	LATVIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	LIBERIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	LIBYA	  	4663	  	30-Jul-05	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	LIECHTENSTEIN	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	LITHUANIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	MACAO	  	14325	  	6-Jul-04	  	14325	  	8-Oct-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	MACEDONIA (F.Y.R.)	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	MALTA	  	42302	  	18-Jun-04	  	42302	  	18-Jun-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	MOLDOVA (REP)	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	MOLDOVA (REP)	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	MOLDOVA (REP)	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	MONACO	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	MONTENEGRO	  	831673	  	1-Dec-07	  	831673	  	1-Dec-07	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	MOROCCO	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	MYANMAR (ex-BURMA)	  	4981	  	27-Aug-04	  	4981	  	27-Aug-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	NETHERLANDS ANTILLES	  	400372	  	23-Jul-04	  	10715	  	23-Jul-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	NICARAGUA	  	1383	  	20-Apr-06	  	703313	  	10-Dec-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	NIGERIA	  	100146	  	13-Apr-05	  	71153	  	4-Oct-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	NORWAY	  	6827	  	6-Jul-04	  	227670	  	12-Aug-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	OMAN	  	33718	  	29-Jun-04	  	33718	  	16-May-06	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	PAKISTAN	  	200723	  	8-Sep-04	  	200723	  	8-Sep-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	PANAMA	  	136886	  	19-Aug-04	  	136886	  	19-Aug-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	PARAGUAY	  	16931	  	28-Jun-04	  	274584	  	15-Dec-04	  	J&J ONE J&J PLAZA - USA

													
	 Trademark
name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	 PRILIGY
	  	PERU	  	213910	  	30-Jun-04	  	100176	  	23-Sep-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	POLAND	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	QATAR	  	33147	  	22-Jul-04	  	33147	  	13-Nov-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	ROMANIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	RUSSIAN FEDERATION	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	RUSSIAN FEDERATION	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	RUSSIAN FEDERATION	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	RWANDA	  	5300	  	21-Sep-04	  	5300	  	21-Sep-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	SAN MARINO	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	SAUDI ARABIA	  	90266	  	15-Jun-04	  	789/62	  	31-May-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	SERBIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	SIERRA LEONE	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	SLOVAK REPUBLIC	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	SLOVENIA	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	SOUTH AFRICA	  	4902	  	8-Mar-06	  	2006/04902	  	17-Dec-09	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	SRI LANKA	  	121132	  	30-Aug-04	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	ST. KITTS & NEVIS	  	2006/0200	  	4-May-06	  	2006/0200	  	4-May-06	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	ST. LUCIA	  	210	  	22-Jul-04	  	210	  	14-Jan-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	SUDAN	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	SURINAME	  	19215	  	9-Jul-04	  	19215	  	9-Jul-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	SWITZERLAND	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	TADJIKISTAN (TAJIKISTAN)	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	TADJIKISTAN (TAJIKISTAN)	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090

													
	 Trademark
name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	 PRILIGY
	  	TADJIKISTAN (TAJIKISTAN)	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	TAIWAN	  	25058	  	27-May-05	  	1185649	  	16-Dec-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	TAIWAN	  	29466	  	28-Jun-04	  	1147857	  	16-Apr-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	TANZANIA, UNITED REPUBLIC	  	6337	  	15-Jul-05	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	THAILAND	  	557744	  	5-Jul-04	  	212477	  	5-Jul-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	TRINIDAD & TOBAGO	  	35171	  	12-Jul-04	  	35171	  	9-Mar-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	TUNISIA	  	EE041724	  	17-Aug-04	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	TURKEY	  	8546	  	15-Mar-05	  	8546	  	15-Mar-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	TURKMENISTAN	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	TURKMENISTAN	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 TURKMENISTAN
	  		  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	UKRAINE	  	8684	  	29-Jul-05	  	73419	  	15-Mar-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	UKRAINE	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	UKRAINE	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	UKRAINE	  	8682	  	29-Jul-05	  	73418	  	15-Mar-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	UKRAINE	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	UNITED ARAB EMIRATES	  	63015	  	17-Aug-04	  	51200	  	14-Feb-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	UNITED KINGDOM (Great Britain)	  	2366357	  	22-Jun-04	  	2366357	  	26-Nov-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	URUGUAY	  	355616	  	30-Jun-04	  	355616	  	17-Jan-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	UZBEKISTAN	  	866466	  	6-Oct-05	  	866466	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	UZBEKISTAN	  	831673	  	11-Jun-04	  	831673	  	13-Aug-04	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY
	  	UZBEKISTAN	  	866467	  	6-Oct-05	  	866467	  	6-Oct-05	  	JANSSEN PHARMACEUTICA NV - I3090

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	 PRILIGY
	  	VENEZUELA	  	10361	  	7-Jul-04	  	P261699	  	18-Jul-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	VIETNAM	  	7170	  	20-Jul-04	  	69579	  	17-Jan-06	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	WEST BANK	  	10980	  	21-Dec-04	  	10980	  	29-May-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	YEMEN, REPUBLIC OF	  	52876	  	22-Sep-10	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	ZAMBIA	  	458	  	30-Jul-04	  	458	  	29-Mar-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY
	  	ZIMBABWE	  	536	  	14-Jul-04	  	536	  	1-Nov-04	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	ALBANIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	ALGERIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	ANTIGUA	  	*	  	1-Jan-06	  	6642	  	1-Jan-06	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	ARGENTINA	  	2631743	  	15-Feb-07	  	2142449	  	15-Feb-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	ARMENIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	ARUBA	  	25095	  	12-Aug-05	  	25095	  	12-Aug-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	AUSTRALIA	  	1070657	  	17-Aug-05	  	1070657	  	15-Dec-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	AZERBAIJAN	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	BAHAMAS	  	28175	  	6-Oct-05	  	28175	  	6-Oct-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	BAHRAIN	  	81733	  	7-Jun-10	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	BANGLADESH	  	95087	  	25-Oct-05	  		  		  	J&J ONE J&J PLAZA - USA

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	 PRILIGY LOGO
	  	BARBADOS	  	*	  	22-Aug-05	  	81/20907	  	14-Nov-08	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	BELARUS	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	BENELUX	  	1082717	  	2-Aug-05	  	770282	  	8-Aug-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	BOLIVIA	  	4188	  	9-Nov-05	  	110177-C	  	20-Aug-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	BOSNIA-HERZEGOVINA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	BRAZIL	  	827954417	  	29-Nov-05	  	827954417	  	27-Jan-09	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	BULGARIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	BURUNDI	  	4426	  	4-Oct-05	  	4426	  	4-Oct-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	CAMBODIA (ex-KAMPUCHEA)	  	23354	  	29-Aug-05	  	23354	  	29-Aug-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	CHILE	  	701360	  	19-Aug-05	  	741210	  	1-Dec-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	CHINA, PEOPLES REPUBLIC (PRC)	  	4893424	  	13-Sep-05	  	4893424	  	14-Jan-09	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	CONGO, DEMOCRATIC REPUBLIC (ex- Zaire)	  	570	  	14-Sep-05	  	11285	  	3-Nov-06	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	COSTA RICA	  	165667	  	26-Jan-07	  	165667	  	26-Jan-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	CROATIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	 PRILIGY LOGO
	  	CUBA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	CYPRUS [REPUBLIC]	  	71896	  	22-Nov-05	  	71896	  	22-Nov-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	CZECH REPUBLIC	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	DENMARK	  	3344	  	16-Aug-05	  	3375	  	5-Sep-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	DOMINICAN REPUBLIC	  	151659	  	30-Dec-05	  	151659	  	30-Dec-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	ECUADOR	  	165538	  	16-Dec-05	  	1126	  	20-Nov-06	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	EGYPT	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	EL SALVADOR	  	53426	  	16-Nov-05	  	173/66	  	20-Jul-06	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	ESTONIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	ETHIOPIA	  	2723	  	6-Apr-07	  	5609	  	20-Sep-07	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	FRANCE	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	GAZA STRIP	  	10329	  	22-Oct-05	  	10329	  	22-Dec-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	GEORGIAN REPUBLIC	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	GHANA	  	*	  	15-Sep-05	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	GREECE	  	150856	  	10-Aug-05	  	150856	  	10-Aug-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	GUATEMALA	  	142530	  	10-Jul-06	  	142530	  	10-Jul-06	  	J&J ONE J&J PLAZA - USA

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	 PRILIGY LOGO
	  	GUYANA	  	21017A	  	6-Sep-05	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	HAITI	  	*	  	30-Aug-05	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	HONDURAS	  	31342	  	27-Jul-06	  	97577	  	27-Jul-06	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	HONG KONG	  	300488331	  	2-Sep-05	  	300488331	  	2-Sep-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	HUNGARY	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	ICELAND	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	INDIA	  	1396999	  	7-Nov-05	  	1396999	  	7-Nov-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	INDONESIA	  	18851	  	13-Sep-05	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	IRAN	  	84052076	  	20-Aug-05	  	126237	  	20-Aug-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	IRAQ	  	57937	  	24-Nov-10	  		  		  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	IRELAND	  	1674	  	16-Aug-05	  	232455	  	16-Aug-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	ISRAEL	  	183085	  	17-Aug-05	  	183085	  	17-Aug-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	JAMAICA	  	47445	  	3-Oct-05	  	47445	  	3-Oct-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	JORDAN	  	81143	  	14-Aug-05	  	81143	  	14-Aug-05	  	J&J ONE J&J PLAZA - USA
	 PRILIGY LOGO
	  	KAZAKHSTAN	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	PRILIGY LOGO	  	KENYA	  	58089	  	23-Sep-05	  	58089	  	23-Sep-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	KIRGHIZISTAN (Kyrgyz Republic)	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	KOREA (NORTH)	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	KUWAIT	  	72172	  	22-Aug-05	  	59496	  	22-Aug-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	LAOS	  	13160	  	30-Aug-05	  	12710	  	30-Aug-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	LATVIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	LIBERIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	LIBYA	  	21712	  	15-Dec-10	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	LIECHTENSTEIN	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	LITHUANIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	MACAO	  	18796	  	21-Sep-05	  	18796	  	5-Jan-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	MACEDONIA (F.Y.R.)	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	MALTA	  	43833	  	4-Aug-05	  	43833	  	7-Apr-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	MOLDOVA (REP)	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	MONACO	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	MOROCCO	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	PRILIGY LOGO	  	MYANMAR (ex-BURMA)	  	7199	  	1-Sep-05	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	NETHERLANDS ANTILLES	  	500458	  	19-Aug-05	  	11546	  	19-Aug-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	NICARAGUA	  	2010-003355	  	29-Oct-10	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	NIGERIA	  	105151	  	28-Sep-05	  	74976	  	28-Sep-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	NORWAY	  	8176	  	29-Aug-05	  	232184	  	26-Apr-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	OMAN	  	37356	  	27-Aug-05	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	PAKISTAN	  	216394	  	15-Dec-05	  	216394	  	15-Dec-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	PANAMA	  	147353	  	7-Dec-05	  	147353	  	7-Dec-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	PARAGUAY	  	34664	  	10-Nov-05	  	332948	  	31-May-10	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	PERU	  	260505	  	15-Nov-05	  	113690	  	28-Mar-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	POLAND	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	QATAR	  	36753	  	23-Aug-05	  	36753	  	7-Apr-08	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	ROMANIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	RUSSIAN FEDERATION	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	 PRILIGY LOGO
	  	RWANDA	  	5604	  	5-Sep-05	  	5604	  	5-Sep-05	  	J&J ONE J&J PLAZA - USA

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	PRILIGY LOGO	  	SAN MARINO	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	SAUDI ARABIA	  	99224	  	15-Aug-05	  	861/55	  	27-Aug-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	SERBIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	SIERRA LEONE	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	SLOVAK REPUBLIC	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	SLOVENIA	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	SOUTH AFRICA	  	2005/17253	  	22-Aug-05	  	2005/17253	  	11-Mar-10	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	SPAIN	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	SRI LANKA	  	128763	  	11-Nov-05	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	ST. KITTS & NEVIS	  	2006/0230	  	19-May-06	  	2006/0230	  	19-May-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	ST. LUCIA	  	182	  	25-Aug-05	  	182	  	2-Mar-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	SUDAN	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	SURINAME	  	19813	  	29-Aug-05	  	19813	  	29-Aug-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	SWITZERLAND	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	TADJIKISTAN (TAJIKISTAN)	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	TAIWAN	  	43223	  	9-Sep-05	  	1211043	  	1-Jun-06	  	J&J ONE J&J PLAZA - USA

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	PRILIGY LOGO	  	TANZANIA, UNITED REPUBLIC	  	*	  	26-Aug-05	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	THAILAND	  	600144	  	17-Aug-05	  	238272	  	17-Aug-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	TRINIDAD & TOBAGO	  	36385	  	26-Aug-05	  	36385	  	28-Mar-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	TUNISIA	  	EE052873	  	22-Dec-05	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	TURKEY	  	2010/63092	  	4-Oct-10	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	UGANDA	  	32477	  	26-Oct-09	  	32477	  	26-Oct-09	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	UKRAINE	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	UNITED ARAB EMIRATES	  	73368	  	21-Sep-05	  	62009	  	21-Sep-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	UNITED KINGDOM (Great Britain)	  	2398554	  	4-Aug-05	  	2398554	  	30-Dec-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	URUGUAY	  	366804	  	10-Nov-05	  	366804	  	13-Oct-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	UZBEKISTAN	  	869784	  	16-Sep-05	  	869784	  	16-Sep-05	  	JANSSEN PHARMACEUTICA NV - I3090
	PRILIGY LOGO	  	VENEZUELA	  	25600	  	21-Nov-05	  	***	  	17-Nov-09	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	VIETNAM	  	15032	  	9-Nov-05	  	81520	  	25-Apr-07	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	WEST BANK	  	12154	  	29-Jan-06	  	12154	  	29-Jan-06	  	J&J ONE J&J PLAZA – USA
	PRILIGY LOGO	  	YEMEN, REPUBLIC OF	  	52877	  	22-Sep-10	  		  		  	J&J ONE J&J PLAZA - USA

													
	 Trademark name
	  	 Country
	  	 Filing
number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	PRILIGY LOGO	  	ZAMBIA	  	673/2005	  	4-Nov-05	  	673/2005	  	4-Nov-05	  	J&J ONE J&J PLAZA - USA
	PRILIGY LOGO	  	ZIMBABWE	  	934/2005	  	24-Aug-05	  	934/2005	  	23-Jan-06	  	J&J ONE J&J PLAZA - USA
	PRILIGY MAS CONTROL MAS TIEMPO	  	EL SALVADOR	  	E-104407-2010	  	12-Oct-10	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY MAS CONTROL MAS TIEMPO	  	NICARAGUA	  	2011-001133	  	8-Apr-11	  		  		  	J&J ONE J&J PLAZA - USA
	PRILIGY-MAS CONTROL MAS TIEMPO	  	PERU	  	425245	  	1-Jul-10	  	169618	  	4-Nov-10	  	J&J ONE J&J PLAZA - USA
	PRILIGY-MAS CONTROL MAS TIEMPO	  	TRINIDAD & TOBAGO	  	42554	  	30-Jul-10	  	42554	  	7-Jul-11	  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	ARGENTINA	  	3004273	  	20-May-10	  		  		  	J&J ONE J&J PLAZA - USA

													
	 Trademark name
	  	 Country
	  	 Filing
number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	MAS CONTROL MAS TIEMPO	  	BAHAMAS	  	33899	  	9-Jun-10	  		  		  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	BARBADOS	  	*	  	11-Jun-10	  		  		  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	BENELUX	  	1203539	  	25-May-10	  	881940	  	26-May-10	  	JANSSEN PHARMACEUTICA NV - I3090
	MAS CONTROL MAS TIEMPO	  	BERMUDA	  	49808	  	25-May-10	  	49808	  	25-May-10	  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	BOLIVIA	  	SM-2014-2010	  	19-May-10	  	124920-C	  	30-Dec-10	  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	COSTA RICA	  	2010-004857	  	28-May-10	  	205444	  	19-Nov-10	  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	CUBA	  	1061570	  	26-May-10	  	1061570	  	6-Dec-10	  	JANSSEN PHARMACEUTICA NV - I3090
	MAS CONTROL MAS TIEMPO	  	ECUADOR	  	230269	  	31-May-10	  	6104-10	  	1-Dec-10	  	J&J ONE J&J PLAZA - USA

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	MAS CONTROL MAS TIEMPO	  	GUYANA	  	23755A	  	4-Jun-10	  		  		  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	HAITI	  	*	  	7-Jun-10	  		  		  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	JAMAICA	  	55716	  	28-May-10	  	55716	  	28-May-10	  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	PANAMA	  	190243	  	24-May-10	  	190243	  	24-May-10	  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	PARAGUAY	  	18885	  	14-May-10	  		  		  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	PHILIPPINES	  	4-2010-005687	  	27-May-10	  	4-2010-005687	  	4-Nov-10	  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	ST. KITTS & NEVIS	  	81/2010	  	17-May-10	  	81/2010	  	25-Jan-11	  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	ST. VINCENT & GRENADINES	  	81/2010	  	17-May-10	  	81/2010	  	25-Jan-11	  	J&J ONE J&J PLAZA - USA

													
	 Trademark name
	  	 Country
	  	 Filing number
	  	 Filing date
	  	 Reg. #
	  	 Reg. date
	  	 Owner

	MAS CONTROL MAS TIEMPO	  	SURINAME	  	22543	  	4-Jun-10	  		  		  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	TRINIDAD & TOBAGO	  	42557	  	30-Jul-10	  		  		  	J&J ONE J&J PLAZA - USA
	MAS CONTROL MAS TIEMPO	  	URUGUAY	  	414151	  	15-Jul-10	  		  		  	J&J ONE J&J PLAZA - USA

 Schedule 5.1.1 

Third Party MAHs 
  

					
	 [*]
	  	[*]	  	[*]
			
	 [*]
	  	[*]	  	[*]
			
	 [*]
	  	[*]	  	[*]
			
	 [*]
	  	[*]	  	[*]
			
	 [*]
	  	[*]	  	[*]

  
 [*] Confidential
treatment requested. 

 Schedule 5.2A 

Group A Markets 

[*] 

  
 [*] Confidential
treatment requested. 

 Schedule 5.2B 

Group B Markets 

[*] 
 [*] 

  
 [*] Confidential
treatment requested. 

 Schedule 5.2C 

Group C Markets 

[*] 

  
 [*] Confidential
treatment requested. 

 Schedule 5.4 

Distribution Agreements1 

 

					
	
	 [*]

			
	 [*]
	  	[*]	  	
			
	 [*]
	  	[*]	  	[*]
			
	 [*]
	  	[*]	  	[*]
			
	 [*]
	  	[*]	  	[*]
			
	 [*]
	  	[*]	  	
			
	 [*]
	  	[*]	  	
			
	 [*]
	  	[*]	  	
			
	 [*]
	  	[*]	  	
	
	 [*]

			
	 [*]
	  	[*]	  	[*]
			
	 [*]
	  	[*]	  	[*]
			
	 [*]
	  	[*]	  	

 [*] Confidential treatment requested. 

 
  

	1 	 Schedule does not include any wholesale distribution agreements. 

 Schedule 5.7 

Product Contracts 
  

					
	PRILIGY WHOLESALER AGREEMENT (28.2012)
			
	 [*]
	  	    [*]    	  	    [*]    
			
	 OTHER AGREEMENTS
	  		  	
	 [*]
	  		  	

  
 [*] Confidential
treatment requested. 

 Schedule 5.8.1 

Ongoing Clinical Studies 
 R096769-PRE-1005—A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Assessing the Pharmacodynamic Effects of Dapoxetine Concomitantly Administered in Subjects Taking Terazosin

 R096769PRE3008—A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety
of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor; COUPLE: COncomitant Use of PriLigy in Men Treated for Erectile Dysfunction 

R096769-PRE-4001—A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGYTM or Alternate Care; The
PAUSE Study (Premature Ejaculation—Actual Use Safety and Effectiveness Study) 
 R096769PRE4005—PRILIGY Usage Patterns in Selected
Populations 

 Schedule 5.8.2A[*]ALZA Universal Calendar 

[*] 
  

  
 [*] Confidential
treatment requested. 

 Schedule 5.8.2B[*]Example Invoice 

[*] 
  

  
 [*] Confidential
treatment requested. 

 Schedule 5.8.7 

Post-marketing clinical study reporting obligations 
 [*] 
  

  
 [*] Confidential
treatment requested. 

 Schedule 6.1.1 

Documents to be Included in Development Records 
 1. Copies of the complete dossiers and related source documents for all ALZA Marketing Authorizations and ALZA Regulatory Submissions (including without limitation all material communications with
Regulatory Authorities in the Territory). 
 2. To the extent not included in the items referenced in item 1 above, [*]. 

3. To the extent not included in the items referenced in item 1 above, copies of [*], including [*] Agreement Product for [*]. 

4. Copies of any DMFs filed by ALZA in existence with respect to any Agreement Product. 

 

  
 [*] Confidential
treatment requested. 

 Schedule 6.1.1.1 

Listing of Record Categories in Index of Transferred Development Records 

[*] 
  

  
 [*] Confidential
treatment requested. 

 Schedule 6.1.2 

Third Party Software 
  

			
	 Software Product
	  	 File extensions

		
	 MS Office
	  	All office file types for Office 2000, 2003, 2007
		
	 Adobe Acrobat
	  	pdf (v5.0 or higher)
		
	 Internet Explorer
	  	xml, .html
		
	 SasViewer
	  	.lst. .xpt (V9.2 or lower)
		
	 Wordpad
	  	.txt
		
	 Any Image Viewer
	  	.tif
		
	 Hangul (Korean word processor)
	  	.hwp
		
	 eCTD Tools
	  	.mod, .dtd, .xml

 Schedule 6.1.5 

Additional Information to be Included in Electronic Media and Provided to GENUPRO 

1. A copy of the most current (2011) promotional visual aids and other promotional materials developed and distributed by ALZA or any of its
Affiliates for use in promoting the Agreement Product in the Territory for treatment of premature ejaculation in men. 
 2. A list identifying
those countries in the Territory where reimbursement approval for the Agreement Product is being sought or has been granted by the relevant Regulatory Authorities or other governmental authorities, along with the relevant approval date or submission
date in each country, as applicable. A copy of the current reimbursement dossier for Agreement Product will also be provided with respect to each country in the Territory where reimbursement or pricing approval has been granted. In addition, copies
of reimbursement or pricing dossiers submitted to (where possible together with responses from) Regulatory Authorities for those countries where reimbursement was denied. 
 3. A list of ALZA’s or its Affiliate’s current (2011) pricing for Agreement Product in those countries in the Territory in which it is being marketed and sold as of the Effective Date.

 4. [*] gross sales, net sales, and other material financial information for Agreement Product, and to the extent any country’s
Transition Period extends into [*], monthly and quarterly information of the type referenced above shall be provided within [*] ([*]) [*] of [*]. 
 5. A list of any and all pending and current tender offers for the purchase of Agreement Product in 2011 ([*]) involving governments (e.g. country, state or region), hospitals or other institutions.

 6. A listing of the investigators/institutions and current status for all ongoing (i.e., those studies for which the final study report has
not yet been issued) investigator-initiated studies, patient registries (if any), or other medical affairs studies for Agreement Product being supported, financially or otherwise (e.g. by supply of or access to Agreement Product) by or on behalf of
ALZA or its Affiliates anywhere in the Territory. 
  

  
 [*] Confidential
treatment requested. 

 Schedule 6.2 

Initial Transition Managers 
 ALZA [*] 
 Furiex [*] 
  

  
 [*] Confidential
treatment requested. 

 Schedule 11 
 Exceptions to Representations and Warranties in Section 11.2.5 
 [*]

 Exceptions to Representations and Warranties in Section 11.2.8 

[*] 
 Exceptions to Representations and
Warranties in Section 11.2.23 
 [*] 

 

  
 [*] Confidential
treatment requested. 

 Schedule 11.2.15.1A 

Alza Marketing Authorizations 
  

					
	 Authorization Country
	  	 Registration Number
	  	 Product Name

	Argentina	  	55.412	  	Priligy 30 + 60 mg Tablets
	Aruba	  	Registration No. 15.12.02.306	  	Priligy 30 mg Tablets
	Aruba	  	Registration No. 15.12.02.305	  	Priligy 60 mg Tablets
	Australia	  	ARTG No. AUST R 147946	  	Priligy 30 mg Tablets
	Austria	  	Zul Nr. 1-28010	  	Priligy 30 mg Tablets
	Austria	  	Zul Nr. 1-28011	  	Priligy 60 mg Tablets
	Bolivia	  	II-41872/2010	  	Priligy 30mg Tablets
	Bolivia	  	II-41879/2010	  	Priligy 60mg Tablets
	Brazil	  	1.1236.3397	  	Priligy 30 mg + 60 mg Tablets
	Chile	  	Registro I.S.P. No. F-18,266/10	  	Priligy 30 mg Tablets
	Chile	  	Registro I.S.P. No. F-18,267/10	  	Priligy 60 mg Tablets
	PRC	  	H20100806	  	Priligy 30 mg Tablets
	PRC	  	H20100807	  	Priligy 60 mg Tablets
	Colombia	  	2010M-0011743	  	Priligy 30 mg Tablets
	Colombia	  	2010M-0011709	  	Priligy 60 mg Tablets
	Curacao	  	10.10.017	  	Priligy 30 mg Tablets
	Curacao	  	10.10.018	  	Priligy 60 mg Tablets
	El Salvador	  	No. F039917082011	  	Priligy 30 mg Tablets
	El Salvador	  	No. F041224082011	  	Priligy 60 mg Tablets
	Finland
	  	24353	  	Priligy 30 mg Tablets

					
	 Authorization Country
	  	 Registration Number
	  	 Product Name

	Finland	  	24354	  	Priligy 60 mg Tablets
	Germany	  	71669.00.00	  	Priligy 30 mg Tablets
	Germany	  	71670.00.00	  	Priligy 60 mg Tablets
	Ghana	  	FDB/SD.113-2072	  	Priligy 30 mg Tablets
	Ghana	  	FDB/SD.111-5268	  	Priligy 60 mg Tablets
	Guatemala	  	PF-4599-2011	  	Priligy 30 mg Tablets
	Guatemala	  	PF-45600-2011	  	Priligy 60 mg Tablets
	Honduras	  	M-17828	  	Priligy 30 mg Tablets
	Honduras	  	M-17828	  	Priligy 60 mg Tablets
	Hong Kong	  	Permit No. HK-60174	  	Priligy 30 mg Tablets
	Hong Kong	  	Permit No. HK-60175	  	Priligy 60 mg Tablets
	Italy	  	039041052/M	  	Priligy 30 mg Tablets, 1 tablet pack
	Italy	  	039041076/M	  	Priligy 60 mg Tablets, 1 tablet pack
	Italy	  	039041064/M	  	Priligy 30 mg Tablets, 2 tablet pack
	Italy	  	039041088/M	  	Priligy 60 mg Tablets, 2 tablet pack
	Italy	  	039041037/M	  	Priligy 60 mg Tablets, 3 tablet pack
	Italy	  	039041025/M	  	Priligy 30 mg Tablets, 6 tablet pack
	Italy	  	039041049/M	  	Priligy 60 mg Tablets, 6 tablet pack
	Republic of Korea	  	4945-92	  	Priligy 30 mg Tablets
	Republic of Korea	  	4945-91	  	Priligy 60 mg Tablets

					
	 Authorization Country
	  	 Registration Number
	  	 Product Name

	Lebanon	  	Reg No. 10/218715	  	Priligy 30 mg Tablets
	Lebanon	  	Reg No. 10/218716	  	Priligy 60 mg Tablets
	Macau	  	AIC039041013/M (import permit)	  	Priligy 30 mg Tablets
	Macau	  	AIC039041037/M (import permit)	  	Priligy 60 mg Tablets
	Malaysia	  	Reg No. MAL20102027AR	  	Priligy 30 mg Tablets
	Malaysia	  	Reg No. MAL20102028AR	  	Priligy 60 mg Tablets
	Mexico	  	Reg San No. 132M2009 SSA	  	Priligy 30 mg + 60 mg Tablets
	New Zealand	  	TT50-8048	  	Priligy 30 mg
	New Zealand	  	TT50-8048a	  	Priligy 60 mg Tablets
	Peru	  	Reg No. E22537	  	Priligy 30 mg Tablets
	Philippines	  	BFAD Reg No. DR-XY37906	  	Priligy 30 mg Tablets
	Philippines	  	BFAD Reg No. DR-XY37907	  	Priligy 60 mg Tablets
	Portugal	  	5178215	  	Priligy 30 mg Tablets, 3 tablet pack
	Portugal	  	5178231	  	Priligy 60 mg Tablets, 3 tablet pack
	Portugal	  	5178223	  	Priligy 30 mg Tablets, 6 tablet pack
	Portugal	  	5178249	  	Priligy 60 mg Tablets, 6 tablet pack
	Singapore	  	Product License No. SIN13880P	  	Priligy 30 mg Tablets
	Singapore	  	Product License No. SIN13881P	  	Priligy 60 mg Tablets
	Spain	  	70.874	  	Priligy 30 mg Tablets
	Spain	  	70.875	  	Priligy 60 mg Tablets
	Sweden	  	MTnr 26319	  	Priligy 30 mg Tablets

					
	 Authorization Country
	  	 Registration Number
	  	 Product Name

	Sweden	  	MTnr 26320	  	Priligy 60 mg Tablets
	Taiwan	  	 025417
 DHA00202541701
	  	Priligy 30 mg Tablets
	Turkey	  	 Registration Certificate No :
 14.07.2011- 131/76
	  	Priligy 30 mg tablets
	Uruguay	  	Reg. No. 42800	  	Priligy 30 mg Tablets
	Uruguay	  	Reg. No. 42801	  	Priligy 60 mg Tablets

 Schedule 11.2.15.1B 

Alza Regulatory Submissions 
  

					
	 Applicant Country
	  	 Filing Date
	  	 Application Number

	 Canada
	  	6 JUN 08	  	NDS 120605/File 9427-J0921-101
	South Africa	  	3 SEP 08	  	 30 mg: 430692
 60 mg: 430693

	Venezuela	  	27 Jan 11	  	 30 mg: 110033
 60 mg: 110034

	Israel	  	27 Apr 09	  	MOH rejected application 30 AUG 11 – application closed
	Thailand	  	26 JUN 09	  	Due to the flooding in Thailand, no one is working at the local office, and all records were moved from the ground floor to higher floors or were moved
offsite. Retrieval remains ongoing.
	Indonesia	  	05 AUG 10	  	210242030 (30mg and 60mg)
	Panama	  	30 DEC 09	  	 30mg: 20091243411
 60mg: 20091243412

	Costa Rica	  	18 JAN 10	  	application withdrawn due to no commercial interest
	Paraguay	  	18 FEB 10	  	60 mg: 4407 30 mg: 4409
	Nicaragua	  	N/A	  	never officially submitted, commercial team may not be interested in product
	Dominican Republic	  	25 MAY 10	  	Priligy 30 mg - solicitud 0201-03593-2010
Priligy 60 mg - solicitud 0201-03601-2010

					
	 Applicant Country
	  	 Filing Date
	  	 Application Number

	Russia	  	15 APR 10	  	 30 mg,60 mg:
 414954, 23/05/2011

	Jamaica	  	28 JUN 10	  	Application was rejected by HA (26Jan11)
	Vietnam	  	31 AUG 10	  	 NN-11136, NN-11136
 (30mg and 60mg)

	Switzerland	  	6 SEP 10	  	No application number
	Jordan	  	14 JUN 11	  	dapoxetine

 Schedule 11.2.15.1C 

Pricing Approvals 

Canada 

 Schedule 11.2.18 

ALZA Sublicenses 

[*] 

  
 [*] Confidential
treatment requested. 

  

 Schedule 11.3.11 

Required Consents[*] 
 [*] 

  
 [*] Confidential
treatment requested.EX-10.27

 Exhibit 10.27 
 Portions of this exhibit marked [*] are requested to be treated confidentially.  
 PRILIGY LICENSE AGREEMENT 
 This License Agreement 

(hereinafter referred to as the “Agreement”) 
 made and entered into as of this May 14, 2012. 
 by and between 

GENUPRO, INC. 
 a
corporation organized under the laws of the State of North Carolina 
 having its registered office at 3900 Paramount Parkway,
Suite 150 
 Morrisville, NC 27560 
 (hereinafter referred to as “LICENSOR”) 
 and 

BERLIN CHEMIE AG 

(MENARINI GROUP) 

a corporation organised under the laws of Germany 
 having its registered office at Glienicker Weg 125, 12489 Berlin Germany 

(hereinafter referred to as “LICENSEE”) 
 WITNESSETH 
 WHEREAS, LICENSOR and its Affiliates own or have licensed certain
intellectual property related to the Product (as defined herein below), 
 WHEREAS, LICENSEE desires to have the right to manufacture,
promote, market, distribute and sell the Product within the Territory (as defined herein below); and 
 NOW, THEREFORE, LICENSOR and
LICENSEE, in consideration of the premises and of the mutual agreement, covenants and conditions hereinafter set forth, agree and convene as follows: 
  

	1	DEFINITIONS 

  

	1.1	“Acquired Entity” means, in the event LICENSOR or any Affiliate thereof acquires any Third Party or all or substantially all of the stock, assets, or
business of a Third Party or otherwise obtains control of a Third Party (with “control”, for purposes of this definition, having the meaning set forth below in the definition of “Affiliate”), such Third Party or any Affiliate
thereof. 

  

	1.2	“Acquiring Entity” means any entity that, following the Effective Date, acquires all or substantially all of the stock, assets, or business of LICENSOR (or
all or substantially all of the assets or business thereof related, in either case, to this Agreement) or otherwise obtains control of LICENSOR (with “control”, for purposes of this definition, having the meaning set forth below in the
definition of “Affiliate”), or any Affiliate of such an entity. 

	1.3	“Active Ingredient” means Dapoxetine. 

  

	1.4	“Adverse Event” or “AE” has the same meaning as in the ICH guidelines (E2A, E2C and E2D) relating to the collection, maintenance analysis and
reporting of an adverse event or experience. 

  

	1.5	“Affiliate(s)” means, with respect to either party hereto or any Third Party, any person or entity controlling, controlled by or in common control with such
party. For purposes of this definition, “control” shall mean to possess, directly or indirectly, the power to affirmatively direct the management and policies of such person, corporation or other business entity, whether through ownership
of at least fifty percent (50%) of the voting securities or by contract relating to voting rights or corporate governance. 

  

	1.6	“ALZA” means ALZA Corporation, a company incorporated in the State of Delaware and having offices at 700 Eubanks Drive, Vacaville, California 95688.

  

	1.7	“ALZA Distribution Agreements” means all agreements between ALZA (and/or its Affiliates) and any Third Party granting such Third Party rights to market,
promote, distribute and commercialize Agreement Product, which are set forth on Schedule 2.1(a). 

  

	1.8	“ALZA Know-How” means any Know-How licensed to LICENSOR by ALZA under the Asset Transfer Agreement that specifically relates to Existing Product and was used
in ALZA’s and its Affiliates’ and sublicensees’ development, use, manufacture, importation, sale, offering for sale, distribution, or commercialization of, Dapoxetine or Existing Product, including any Know-How resulting from any
On-Going Clinical Studies, but excluding any Know-How to the extent specifically relating to any Derivative. 

  

	1.9	“Annual Indemnified Third Party IP Claim Costs” means, as measured in the aggregate over all countries in the Territory, all amounts, costs, and expenses
incurred by LICENSOR in any particular Calendar Year with respect to any and all Indemnified Third Party IP Claims, and any damages, liabilities, expenses and/or losses, including reasonable legal expenses and reasonable attorneys’ fees,
related thereto (other than any amounts due any Third Party(ies) pursuant to a license executed in conjunction with the settlement, judgment, court-based determination or action, or other disposition thereof). 

 

	1.10	“Annual Third Party Licensing Costs” means, as measured in the aggregate over all countries in the Territory, all amounts, costs, and expenses incurred by
LICENSOR in any particular Calendar Year (x) with respect to any and all licenses obtained in accordance with Section 7.9(a) granting rights under any Third Party intellectual property rights for the manufacture, use, sale, or import of
Products in the Territory or entered into in conjunction with the settlement, judgment, court-based determination, or other disposition of any Indemnified Third Party IP Claims as contemplated by Section 9.3(d)(i) or (y) in negotiating any
such licenses. 

  
 2 

	1.11	“Applicable Laws” means all applicable laws, rules, regulations and guidelines that may apply to the development, marketing, manufacturing or sale of
Products, the performance of either party’s obligations, or the exercise of either party’s rights under this Agreement, including but not limited to all laws, regulations and guidelines governing the import, export, development, marketing,
distribution and sale of the Product in the Territory and, to the extent relevant, all GCP, GLP or GMP standards or guidelines promulgated by any Regulatory Authorities, or the ICH. 

 

	1.12	“Assigned Trademarks” means those trademarks to be assigned by ALZA or its Affiliate to LICENSEE pursuant to the Priligy Trademark Assignment.

  

	1.13	“Calendar Quarter” means each of the three (3) month periods beginning January 1, April 1, July 1, and October 1; provided,
however, that the first Calendar Quarter will be starting as of the First Commercial Sale. 

  

	1.14	 “Calendar Year” means each twelve (12) month period beginning on
January 1st and ending on December 31st; provided however, that the first Calendar Year under this Agreement
will be starting as of the First Commercial Sale. 

  

	1.15	“Clinical Trial Application” or “CTA” means an application to a regulatory or other government agency as necessary to perform human clinical trials
in conformance with Applicable Laws. 

  

	1.16	“Commercially Reasonable Efforts” means the carrying out of obligations or tasks in a manner consistent with the exercise of reasonable, customary scientific
and business practices within the pharmaceutical industry for, and of a level no less than consistent with the efforts a party devotes to, the research, manufacturing, development or marketing of a pharmaceutical product or products of similar
market potential, profit potential or strategic value, taking into account technical and regulatory factors, target product profiles, product labeling, costs, economic return, the regulatory environment and competitive market conditions in the
therapeutic or market niche, all based on conditions then prevailing. “Commercially Reasonable” shall have a corresponding meaning. 

  

	1.17	“Commercialize” means all activities that relate to the commercial manufacture, launch, marketing and sale of Product for human use, including but not limited
to advertising, education, planning, marketing, promotion, distribution, market and product support studies, product-related public relations, governmental affairs activities for reimbursement and formulary acceptance, sales force training,
trademark selection, filing, prosecution and enforcement. The terms “Commercialize” and “Commercializing” shall have a corresponding meaning. 

 

	1.18	 “Confidential Information” means all information, know-how, documentation and data relating to the Active Ingredient, any Product, trade
secrets and other activities of LICENSOR or LICENSEE and/or its Affiliates provided by one party (the “disclosing party”) to the other party (the “receiving party”) under this Agreement,

  
 3 

	 	
including without limitation regulatory dossier, ideas, know-how, formulas, technology, practices, processes, methods of production, manufacturing processes documentation, pre-clinical or
clinical data, pharmaceutical, toxicological, pharmacological and pharmacokinetic data, manufacturing formulae, instructions, specifications, standards and analytical procedures, whether technical or non-technical, unpatented, patented or
patentable, as well as product samples or specifications (whether orally or in writing or any other medium, and whether or not the information is expressly stated to be confidential or marked as such). Notwithstanding the foregoing, (a) the
terms of this Agreement shall be deemed the Confidential Information of both parties and (b) any information (i) provided to LICENSEE by or on behalf of ALZA or any Affiliate thereof or (ii) related to any Improvement shall be deemed
the Confidential Information of LICENSOR, and LICENSOR shall be deemed the disclosing party, and LICENSEE the receiving party, with respect thereto. 

  

	1.19	“Control” means that a party (or, if applicable, Affiliate thereof) owns or has a license to such intellectual property and has the ability to grant a license
or sublicense as provided for in this Agreement without violating the law or the terms of any agreement or other arrangement with any Third Party. 

  

	1.20	“Cover” means that the use, manufacture, sale, offer for sale, development, commercialization or importation of the subject matter in question by an
unlicensed entity would infringe a Valid Claim of a Patent. 

  

	1.21	“Develop” means all activities directed towards obtaining Product Registration of a Product in the Field in the Territory, including but not limited to
engaging in clinical research, other research or development activities, and the submission and/or prosecution of filings or submissions with Regulatory Authorities. 

 

	1.22	“Dapoxetine” means (a) (+/-)-N,N-dimethyl-l -phenyl-3-(1-naphthalenyloxy)-propanamine,
(b) (S)-(+)-N,N-dimethyl-l-phenyl-3-(1-naphthalenyloxy)-propanamine, (c) (R)-(-)-N,N-dimethyl-l-phenyl-3-(1-naphthalenyloxy)-propanamine, (d) (+/-)-N,N-dimethyl-a-[2-(1-naphthalenyloxy)
ethyl-benzenemethanamine, (e) (S)-(+)-N,N-dimethyl-a-[2-(1-naphthalenyloxy) ethyl-benzenemethanamine,
(f) (R)-(-)-N,N-dimethyl-a-[2-(1-naphthalenyloxy) ethyl-benzenemethanamine, (g) any pharmaceutically acceptable salt of any of the foregoing, (h) any active metabolite of any of the
foregoing, including without limitation mono-desmethyl dapoxetine and di-desmethyl dapoxetine, or (i) or any Derivative of any of the foregoing. 

  

	1.23	“Derivative” means, with respect to any chemical compound, any analog, isomer, tautomer, enantiomer, diastereomer, prodrug, metabolite, ester, salt, hydrate,
solvate, racemate, or polymorph thereof. 

  

	1.24	“Delegation of Authority” means a written agreement between ALZA or its Affiliate and LICENSEE delegating authority from ALZA or its Affiliate to LICENSEE to
distribute Product in a country or countries under ALZA’s Existing Product Registration(s) for Existing Product in such country/countries, such authority terminating country-by-country on the Regulatory Transfer Date in the applicable country.

  
 4 

	1.25	“Development Costs” means FTE Costs and Out-of-Pocket Costs incurred by the Parties and their Affiliates (including, in the case of LICENSOR, any of the
foregoing charged to it by ALZA or its Affiliates) in support of Priligy On-Going Clinical Trials, including but limited to: (a) all Out-of-Pocket Costs and FTE Costs incurred for activities in the Priligy On-Going Clinical Trials; (b) the
FTE Costs of scientific, medical, technical and other personnel directly engaged in performing clinical study activities; and (c) the Out-of-Pocket Costs and FTE Costs of clinical supplies for the Priligy On-Going Clinical Trials, including
(i) the supply cost of clinical supply of the Product; (ii) costs and expenses incurred to purchase or package Third Party comparator or Third Party combination drugs or devices; and (iii) costs and expenses of disposal of clinical
samples. 

  

	1.26	“Distribution Law” means any applicable federal, state, local or foreign law, statute, rule or regulation, including, to the extent applicable, the U.S.
Foreign Corrupt Practices Act (15 U.S.C. § 78 dd-1 et seq.) and the principles of OECD Anti Bribery Convention and UN Convention taken with resolution 58/4 of October 31, 2003. 

 

	1.27	“Effective Date” has the meaning set forth in Section 1A. 

  

	1.28	“Euro” means the currency of the Eurozone. 

  

	1.29	“Execution Date” means May             , 2012. 

 

	1.30	“Existing Product” means the Product described in any Product Registration approved by, or applied for at, any Regulatory Authority prior to the Effective
Date, to the extent such Product is manufactured or was manufactured by ALZA and its Affiliates as of the Effective Date and as specifically described in the Product Registrations granted or applied for as of the Effective Date (including but not
limited to the chemistry, manufacturing, and controls or similar portions of such Product Registrations), including any such Product manufactured by or on behalf of LICENSEE, any Affiliate thereof, or any Sublicensee. 

 

	1.31	“Existing Product Registration” has the meaning set forth in Section 1.4 in Schedule 4 of this Agreement. 

 

	1.32	“Field” means premature ejaculation. 

  

	1.33	“First Commercial Sale” means with respect to any country the first commercial sale for monetary value of a Product by LICENSEE, its Affiliates, or a
Sublicensee to Third Party(ies) for use, consumption or resale of such Product in a country in the Territory where Product Registration of such Product has been obtained. 

 

	1.34	“FTE” means a full time equivalent person year of professional scientific and/or technical work or managerial work to the extent working on or directly
involved in the development of Product. 

  
 5 

	1.35	“FTE Cost” means [*] ($[*]) USD per FTE, which amount shall be adjusted [*], as published by the [*], upon each [*] of the Effective Date during the Term.

  

	1.36	“GAAP” means United States’ generally accepted accounting principles, consistently applied. 

 

	1.37	“Good Clinical Practice” or “GCP” means the then current standards for clinical trials for pharmaceuticals, as set forth in the ICH guidelines and
applicable regulations promulgated thereunder, as amended from time to time, and such standards of good clinical practice as are required by the European Union and other organizations and governmental agencies in countries in which a Product is
intended to be sold to the extent such standards are not less stringent than the ICH guidelines. 

  

	1.38	“Good Laboratory Practices” or “GLP” means, with respect to the United States, the then-current requirements for non-clinical (animal or laboratory)
trials that will be submitted to a Regulatory Authority to support a marketing application, specified in 21 C.F.R. § 58, as may be amended, and, with respect to any other country or jurisdiction, the equivalent regulations in such other country
or jurisdiction, including any such standards or guidelines set forth by ICH. 

  

	1.39	“Good Manufacturing Practice” or “GMP” means such standards of good manufacturing practice as are required by the European Union and other
organizations and governmental agencies in countries in which a Product is intended to be manufactured or sold. 

  

	1.40	“Group A Market Country” shall have the meaning set forth in Section 2 of Schedule 4 of this Agreement. 

 

	1.41	“Group B Market Country” shall have the meaning set forth in Section 2 of Schedule 4 of this Agreement. 

 

	1.42	“Group C Market Country” shall have the meaning set forth in Section 2 of Schedule 4 of this Agreement. 

 

	1.43	“ICH” means International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use. 

 

	1.44	“IFRS” means International Financial Reporting Standards promulgated by the International Accounting Standards Board, applied on a basis consistent throughout
the periods indicated and consistent with each other. 

  

	1.45	“Improvement(s)” means any inventions, discoveries, or improvements, whether or not patentable, (i) made or conceived by employee(s) or agent(s) of a
party (or its Affiliates), solely or jointly with the other party, any Affiliate thereof, or any Third Party, and (ii) derived from Licensed Intellectual Property, or otherwise resulting from the research, development, or use of the Active
Ingredient or any Product by a party or a party’s (or its Affiliates’) access to or knowledge of the other party’s Confidential Information. 

  
 [*]
Confidential treatment requested. 

  
 6 

	1.46	“Key Market Territory” means each of the following four territories: (a) the European Union countries as described on Schedule 1.46-A and the
Republic of Turkey (collectively, the “EUT Countries”), (b) countries of the Commonwealth of Independent States as described on Schedule 1.46-B (the “CIS Countries”), (c) countries of the Asia Pacific region as
described on Schedule 1.46-C (the “Asia Pacific Countries”) and (d) the countries of the South and Central America region as described on Schedule 1.46-D (the “SCA Countries”). 

 

	1.47	“Know-How” means, to the extent non-public and proprietary, any information, results and data of any type whatsoever, in any tangible, written, documentary,
electronic, or digital form, including without limitation, instructions, processes, compositions, materials, expert opinions, databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill,
experience, test data, including without limitation pharmacological, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal
information or descriptions. 

  

	1.48	“LIBOR” means London Interbank Offered Rates. 

  

	1.49	“Licensed Intellectual Property” means Licensed Patents, Licensed Trade IP, and Licensed Know-How. 

 

	1.50	“Licensed Know-How” means any Know-How Controlled by LICENSOR that is necessary for the registration, manufacture, use, or sale of Products in the Field in
the Territory, provided that, notwithstanding the foregoing, Licensed Know-How shall not include any Know-How (a) concerning any active ingredients other than the Active Ingredient, (b) concerning any Product other than the Existing
Product, or (c) that is owned, licensed, or otherwise controlled at any time by any Acquiring Entity or Acquired Entity, or comes under the control of LICENSOR pursuant to a transfer or assignment to LICENSOR from any Acquired Entity (the
“Acquired Know-How”), except to the extent such Acquired Know-How was already included within the Licensed Know-How immediately prior to the date of the transaction by which such Acquiring Entity or Acquired Entity, respectively, first
became an Acquiring Entity or Acquired Entity, respectively. 

  

	1.51	“Licensed Patents” means, with respect to the Territory, the Patents listed in Schedule 1.51, together with any and all renewals, amendments or
extensions thereof, including Supplementary Protection Certificates granted in the European Economic Area or equivalent rights in the Territory as set forth in Schedule 1.51, and, upon the Parties’ written agreement on economic terms
related to the inclusion of any Improvement Patents under the licenses granted LICENSEE in this Agreement as contemplated by Section 2.8, any Patents in the Territory Controlled by LICENSOR claiming LICENSOR Improvements that are necessary for
the manufacture, use, or sale of Products in the Field in the Territory. 

  

	1.52	“Licensed Trade IP” means, to the extent Controlled by LICENSOR, trade dress pertaining exclusively to Products and the domain name(s) set forth on
Schedule 1.52. Licensed Trade IP shall not include any trademarks. 

  
 7 

	1.53	“LICENSOR Improvement” means an Improvement made or conceived by employee(s) or agent(s) of LICENSOR (or any Affiliate thereof), solely or jointly with the
other party, any Affiliate thereof, or any Third Party. 

  

	1.54	“Lilly” means Eli Lilly and Company, a corporation organized under the laws of the State of Indiana (USA). 

 

	1.55	“Lilly Agreement” means that certain Termination and License Agreement, dated December 18, 2003, between Lilly, LICENSOR, and certain Affiliates of
LICENSOR, a complete copy of which LICENSOR has provided to LICENSEE, pursuant to which Lilly assigned certain Licensed Patents, and granted certain intellectual property rights related to the Active Ingredient and Products, to LICENSOR and/or its
Affiliates. 

  

	1.56	“[*]” means the letter executed by [*] be attached hereto as Schedule 1.56. 

 

	1.57	“Manufacturing Agreement” means the supply agreement for Product between ALZA or an Affiliate thereof and LICENSEE to be negotiated and executed as
contemplated by the License and Asset Transfer Agreement (as defined in Section 1A(a) and Section 1A(b). 

  

	1.58	“LICENSEE Know-How” means all Know-How Controlled by LICENSEE or any Affiliate thereof as of the Effective Date, or coming under the Control of LICENSEE or
any Affiliate thereof following the Effective Date that is necessary or useful for LICENSOR’s manufacture, use, sale, development, commercialization, import, or export of Active Ingredient or Products. 

 

	1.59	“Net Sales” means the [*] (or, if not [*]) by LICENSEE, its Affiliates, or Sublicensees on all sales of Products to independent Third Parties,
following the Effective Date (which shall include but not be limited to all sales that may occur under any Delegation of Authority Agreement or similar arrangement) less [*], for: (a) [*]; (b) [*]; and (c) [*]. For purposes of
calculating Net Sales, in the case of a sale or other disposal of Product for value other than in an arm’s-length transaction exclusively for money, such as a barter or counter-trade, the amount of such sale shall be calculated using the [*]
pursuant to the foregoing, effective in any country in the Territory of such Product in the country of disposition. 

  

	1.60	“Out of Pocket Expenses” means all Third Party invoiced expenses incurred for activities to support the Product. 

 

	1.61	“Patents” means all (i) patents (including but not limited to utility patents and certificates of invention), together with any and all substitutions,
extensions and term restorations (including but not limited to supplemental protection certificates or pediatric data exclusivity extension), registrations, confirmations, re-examinations, reissues, renewals, and foreign counterparts thereof, and
(ii) pending applications for patents, including but not limited to, provisionals, divisionals, continuations, and continuations-in-part of any of the foregoing, all foreign counterparts of any of the foregoing and patents issuing therefrom.

  
 [*]
Confidential treatment requested. 

  
 8 

	1.62	“Patent Term Extension” means any patent term extension, adjustment or restoration, supplementary protection certificate, or other form of market exclusivity
conferred by any Applicable Laws or Regulatory Authority. 

  

	1.63	“Permitted Seller” means LICENSEE, any Affiliate thereof, and any Sublicensee having the right to sell Product in the Field in the Territory in accordance
with this Agreement. 

  

	1.64	“Priligy Trademark Assignment” means the agreement between ALZA and LICENSEE under which ALZA (or its Affiliates) transfer to LICENSEE all right, title and
interest Controlled by ALZA to Assigned Trademarks, provided that such right, title, and interest with respect to Assigned Trademarks in each Group A Market Country shall be assigned, on a country-by-country basis, on the earlier of (i) [*]
from the Effective Date or (ii) the [*] in such country. 

  

	1.65	“Product” means any pharmaceutical product(s) containing Active Ingredient. 

 

	1.66	“Product-Related Materials” means all advertising and promotional materials (including but not limited to flyers, brochures, pamphlets and electronic media),
labeling and packaging materials, and any materials or items similar to the foregoing to the extent, in each case, pertaining exclusively to any Products in the Territory and in the possession or control of LICENSEE or any Affiliate thereof, and all
copyright and similar rights to the contents thereof, provided that the foregoing rights shall not include any rights to any trademark, logos, or the like other than Product Trade IP. 

 

	1.67	“Product Registration” means any marketing authorisation granted by any Regulatory Authority allowing the lawful marketing and sales of the Product in the
Field in the Territory, provided Product Registration, where applicable, shall include Pricing Approval. Product Registrations and Pricing Approvals as of the Effective Date shall be set forth in Schedule 1.67, the final, updated form of
which shall be provided by LICENSOR prior to or on the Effective Date. For the purpose of this Section 1.66, “Pricing Approval” means any pricing and reimbursement approvals which must be obtained before placing a Product on the
market in a particular jurisdiction in the Territory. 

  

	1.68	“Product Registration Applications” means any applications for Product Registration in the Territory or equivalent filings with any Regulatory Authority.
Product Registration Applications submitted prior to the Effective Date shall be set forth in Schedule 1.68, the final, updated form of which shall be provided by LICENSOR prior to or on the Effective Date. 

 

	1.69	“Product Trade IP” means all trademarks, logos, tradedress, tradenames, internet domain names, and the like used (or intended for use) in the Territory
pertaining, in each case, exclusively to Products, and all registrations for any of the foregoing (or applications therefor) in the Territory, and which shall include but not be limited to Product Trademarks and Assigned Trademarks.

  

	1.70	“Product Trademarks” means all trademarks, logos, and the like used (or intended for use) in the Territory, and registrations for any of the foregoing (or
applications therefor) in the Territory, pertaining, in each case, exclusively to Products, and which shall include but not be limited to Assigned Trademarks. 

  
 [*]
Confidential treatment requested. 

  
 9 

	1.71	“PVG Agreement” means the agreement between LICENSOR and LICENSEE that shall have the meaning set forth in Section 11.3. 

 

	1.72	“Regulatory Authority” means any governmental or regulatory body, agency, department or entity responsible for granting any health approvals, registrations,
licenses, or clearances to be obtained for the import, promotion, distribution, marketing, use or sale of Product in the Territory for any human therapeutic use. 

 

	1.73	“Regulatory Exclusivity” means a right or protection, granted by a Regulatory Authority or other governmental (or supranational) authority in a jurisdiction
in the Territory, providing, with respect to a Product: (a) marketing exclusivity that prevents a Regulatory Authority from accepting an application submitted by a party other than LICENSEE (or its Affiliates or Sublicensees), for a generic of
the Product, including but not limited to exclusivity achieved through any drug exclusivity designation by any national, supra-national (e.g., the European Commission, the Council of the European Union, or EMEA), regional, state or local regulatory
agency, department, bureau, commission, council or other governmental entity in the Territory; (b) data protection for regulatory data submitted by LICENSOR, LICENSEE, or their Affiliates or licensees relating to the Product; (c) a
prohibition on reference, without the consent of the owner, to the clinical and other data that is contained in any application for marketing or regulatory approval; (d) any other form of market exclusivity, including but not limited to Patent
Term Extensions or protection against unfair commercial use or public release consistent with, or no less stringent than, World Trade Organization TRIPS Article 39.3. 

 

	1.74	“Regulatory Exclusivity Period” means any period during which any form of Regulatory Exclusivity is effective with respect to a particular Product and
jurisdiction in the Territory. 

  

	1.75	“Regulatory Transfer Date” shall have the meaning set forth in Section 1.11 of Schedule 4 of this Agreement. 

 

	1.76	“Regulatory Transfer Transition Period” shall have the meaning set forth in Section 1.12 of Schedule 4 of this Agreement. 

 

	1.77	“Re-launch of the Product” means the first sale of the Product in a given country of the Territory made by or on behalf of LICENSEE, any Affiliate thereof, or
any Sublicensee to a Third Party labelling reflecting the corporate name or trademarks of LICENSEE, any Affiliate thereof, or any Sublicensee (which, if applicable in a country under Applicable Law, shall occur after such labelling has been
approved, to the extent necessary, by the appropriate Regulatory Authority that has been affixed or included on the package of the Product). 

  

	1.78	“Stock Product” means inventory of Existing Product manufactured by ALZA, or its Affiliate, and identified with the Existing Product label of ALZA, or its
Affiliate, that is in stock on the Effective Date or produced after the Effective Date (including any such Existing Product that may be re-labeled or re-packaged as needed by LICENSEE). 

  
 10 

	1.79	“Sublicensee” means a Third Party that has been granted a license to make, use, offer to sell, import or sell Products by LICENSEE or any Affiliate thereof in
accordance with this Agreement. 

  

	1.80	“Term” means, on a country-by-country and Product-by-Product basis, the period starting from the Effective Date of this Agreement and expiring on the later
among (i) the expiry of the last to expire Valid Claim of a Licensed Patent Covering a particular Product in a particular country, (ii) the expiry of the Regulatory Exclusivity Period for a particular Product in a particular country, or
(iii) entry of a Third Party product containing Active Ingredient that has been approved by the relevant Regulatory Authority for use, on an as needed basis, in the Field, and in a particular country. 

 

	1.81	“Territory”, subject to any termination of this Agreement with respect to any portion of the Territory pursuant to Section 3.2, means the world,
excluding the United States of America and its territories and protectorates (which shall include but not be limited to the Commonwealth of Puerto Rico), Canada, and Japan. 

 

	1.82	“Third Party” means any individual, corporation, partnership, limited liability company or other entity other than (i) LICENSEE, (ii) LICENSOR, or
(iii) an Affiliate of LICENSEE or LICENSOR. 

  

	1.83	“USD” means United States dollars. 

  

	1.84	“Valid Claim” means a claim of any Patent that has not been dedicated to the public, disclaimed, abandoned or held invalid or unenforceable by a court or
other body of competent jurisdiction from which no further appeal can be taken, and that has not been explicitly disclaimed, or admitted in writing to be invalid or unenforceable or of a scope not Covering a particular product through reissue,
disclaimer or otherwise. 

  

	1A	EFFECTIVE DATE 

 This
Agreement, and the Parties’ rights and obligations hereunder shall not become effective until all of the conditions set forth below have been satisfied or such requirement has been waived by the Parties in writing (“Conditions
Precedent”): 
 (a) the License and Asset Transfer Agreement has been executed by duly authorized representatives of each
party to the License and Asset Transfer Agreement and all provisions thereof become fully effective in accordance with its terms. The License and Asset Transfer Agreement means the agreement between LICENSOR and ALZA for the transfer of ALZA assets
related to Dapoxetine, and the license of ALZA Know-How, to LICENSOR or its sublicensee. Notice of the full effectiveness of the License and Asset Transfer Agreement will be sent by LICENSOR to LICENSEE within 2 (two) business days of such
effectiveness. 

  
 11 

 (b) the [*]), including execution of a related [*]”); 

(c) the Priligy Trademark Assignment Agreement has been executed by LICENSEE and ALZA (or an Affiliate thereof); 

(d) the PVG Agreement has been executed by LICENSEE, LICENSOR and ALZA (or an Affiliate thereof); and 

(e) the [*] has been executed by [*]. 
 If all Conditions Precedent have not been satisfied, or the satisfaction thereof has not been waived in writing by the Parties, prior to or on [*], (“Final Date”) this Agreement shall terminate
effective upon such date and Section 13.7(b) shall apply with respect to such termination. 
 Each Party agrees to use
Commercially Reasonable Efforts, acting in good faith, to complete the Conditions Precedent prior to or on the Final Date. 
  

	2	RIGHTS 

  

	2.1	Patent and Know-How License Grant. During the Term and subject to the terms and conditions of this Agreement, LICENSOR hereby grants LICENSEE and its
Affiliates a royalty-bearing, exclusive license (with the right to further sublicense as provided in Section 2.3) under Licensed Intellectual Property to produce (or have produced) the Active Ingredient and the Product and to make (or have
made), use, promote, market, distribute, offer to sell, sell, and import the Product in the Field in the Territory, provided that, notwithstanding the foregoing or anything to the contrary: 

(a) such license shall be co-exclusive with ALZA, LICENSOR, Affiliates of either of the foregoing, and licensees of ALZA or its
Affiliates (X) until the end of the last to expire Regulatory Transfer Transition Period to the extent necessary to (i) permit ALZA, its Affiliates, and licensees of ALZA or its Affiliates to perform activities related to the transition of
rights from ALZA to LICENSEE contemplated by this Agreement and Schedule 4 or (ii) permit ALZA, LICENSOR, Affiliates of either of the foregoing, and licensees of ALZA or its Affiliates to engage in the manufacture, distribution, sale, and
commercialization of Stock Product in each Group A Market Country until the First Commercial Sale in such country by or on behalf of LICENSEE; (Y) to the extent necessary to provide for ALZA’s, or its Affiliates, and Third Parties’
exercise of rights and performance of obligations under Distribution Agreements, , the termination of which is addressed in Section 12.7(a), and (Z) to the extent necessary to provide for the exercise of rights and performance of
obligations under any contracts, other than ALZA Distribution Agreements (“Other ALZA Product Contracts”), between ALZA or its Affiliates and Third Parties with respect to Product remaining in effect as of the Effective Date, the
termination of which is addressed in Section 12.7(b); 

  
 [*]
Confidential treatment requested. 

  
 12 

 (b) such license under ALZA Know-How shall be non-exclusive with respect to any Products
other than Existing Product; 
 (c) such license shall be non-exclusive to the extent necessary or useful for (i) LICENSOR,
its Affiliates, and any licensees of either of the foregoing to make, have made, use, sell, offer for sale, or import Active Ingredient and Products in the Territory for any purposes related to the research, development, commercialization, or
manufacture of Products for countries outside the Territory or (ii) the conduct of the Priligy On-Going Clinical Trials; 

(d) such license shall be non-exclusive with respect to the use of Licensed Patents or Licensed Know-How, or the practice of the
technology Covered by the Licensed Patents, by or on behalf of LICENSOR, its Affiliates, Lilly, any Affiliate thereof, or any research partners of Lilly or any Affiliate thereof for any such entity’s or individual’s internal research
purposes in the Field; 
 (e) such license shall be nonexclusive with respect to the Licensed Patent designated [*] and any
other Licensed Patents claiming priority thereto in [*]; and 
 (f) as partial consideration for the grant of rights to Licensed
Trade IP, LICENSEE agrees that (X) upon written request of LICENSOR, with respect to any of LICENSEE’s (or its Affiliates’ or Sublicensees’) websites or publicly accessible internet content for any Product, including but not
limited to any websites or content residing or hosted at or appearing at any of the Domain Names, LICENSEE, its Affiliates, and Sublicensees shall (i) include language and content (which may include LICENSOR’s, its Affiliates’, or
LICENSOR’s or its Affiliates’ licensees’ corporate trademarks or logos or any trademarks or logos developed for or used with any Product by LICENSOR, any Affiliate thereof, or any licensee of LICENSOR or any Affiliate thereof) clearly
and prominently indicating that parties seeking information concerning any Product outside the Territory should direct such inquiries and efforts towards LICENSOR, or its Affiliate or any licensee of LICENSOR or any Affiliate thereof, as applicable,
and their respective websites and internet content for such Products, in any form(s), and containing any content, reasonably proposed by LICENSOR and (ii) include one or more clearly marked active links on LICENSEE’s, its Affiliates’,
and Sublicensees’ websites and in their internet content concerning any Products reasonably enabling parties seeking information concerning any Product outside the Territory to be redirected towards LICENSOR’s, its Affiliates’, and/or
their licensees’ website(s) and internet content concerning Products outside the Territory and (Y) LICENSEE shall ensure that all Affiliates and Sublicensees comply with the requirements of this subsection (f) and shall include
corresponding requirements in any sublicense agreement. The Parties agree to negotiate in good faith and execute any agreement or other document necessary to affect the purposes of this subsection (f). 

 

	2.2	Trademark and Licensed Trade IP. 

 (a) LICENSOR shall use Commercially Reasonable Efforts to cause ALZA or an Affiliate thereof to negotiate and execute the Priligy Trademark Assignment. 

  
 [*]
Confidential treatment requested. 

  
 13 

 (b) The Parties acknowledge and agree that each Party has an interest in maintaining a
positive image of the Assigned Trademarks (or foreign equivalents thereof) throughout the world. The Parties hereby agree that: (i) LICENSEE shall only obtain any right, title, and interest in the Assigned Trademarks in each Group A Market
Country, on a country-by-country basis, on the earlier of (x) the date [*] from the Effective Date or (y) the [*] in such country; (ii) the goods marketed and sold under the Assigned Trademarks (or foreign equivalents thereof, in the
case of LICENSOR) by a Party shall be of high standard and of good quality, appearance and style; (iii) that such goods will be manufactured, sold and distributed in accordance with Applicable Laws (or foreign equivalents thereof, in the case
of LICENSOR); (iv) that the manner of advertising, marketing and sale of such goods, and all associated advertising, promotional and display materials, shall be of a high standard and shall not reflect adversely upon the Assigned Trademarks (or
foreign equivalents thereof in the case of LICENSOR); (v) a Party will not license or otherwise authorize any person or entity outside its Respective Territory to use the Assigned Trademarks (or foreign equivalents thereof in the case of
LICENSOR) for purposes of the marketing or commercial sale of Products to health care providers, patients, pharmacies, hospitals, health maintenance organizations, pharmacy benefit organizations, or similar wholesale or retail customers outside its
Respective Territory; (vi) each Party shall be responsible for the registration and maintenance of any registrations for Assigned Trademarks (or foreign equivalents thereof in the case of LICENSOR) in its Respective Territory, at its own
expense, and each Party shall have reasonable discretion as to the registration and maintenance of such registrations; and (vii) to the extent any Assigned Trademarks (or foreign equivalents thereof in the case of LICENSOR) are the subject of a
registration (or application therefor), a Party shall use the Assigned Trademarks (or foreign equivalents thereof in the case of LICENSOR) only on or in connection with the definition of the goods as set forth in such registration therefor (or
application therefor) in its Respective Territory unless it has received the written approval of the other Party, which shall not be unreasonably withheld. For purposes of this Section 2.2(b), “Respective Territory” shall mean the
Territory with respect to LICENSEE and all countries outside the Territory with respect to LICENSOR. Each Party shall ensure that its Affiliates comply with this Section 2.2(b) and use Commercially Reasonable Efforts to ensure that its
licensees and sublicensees with respect to Product and the Assigned Trademark(s) (or foreign equivalents thereof in the case of Licensor) comply with the obligations set forth in this Section 2.2(b). 

 

	2.3	Right to Sublicense.  

 (a) With respect to the license granted to LICENSEE in Section 2.1 above, such license shall include the right of LICENSEE to sublicense to any party, including without limitation an Affiliate, so
long as such sublicense is consistent with the terms of this Agreement and contains terms reasonably sufficient to enable LICENSEE to comply with the provisions of this Agreement and satisfy its obligations hereunder. LICENSEE shall be responsible
for its Affiliates’ and Sublicensees’ compliance with this Agreement and the performance by its Sublicensees of all obligations imposed on LICENSEE under the terms of this Agreement. 

  
 [*]
Confidential treatment requested. 

  
 14 

 (b) LICENSEE shall provide LICENSOR in writing the name of any Third Party sublicensee of
LICENSEE with respect to any of the rights granted by LICENSOR to LICENSEE hereunder within ten (10) business days of issuing such sublicense. 
 (c) LICENSEE shall only be entitled to grant any sublicense under any of the rights granted hereunder to a Third Party to Develop or Commercialize a Product in all or substantially all of any of one or
more of the four Key Market Territories with LICENSOR’s prior written consent, such consent not to be unreasonably withheld. LICENSEE shall provide LICENSOR written notice of its intent to grant such a sublicense and identify the potential
Third Party sublicensee with respect thereto (“Sublicense Notice”), and LICENSOR shall respond to LICENSEE’s Sublicense Notice within thirty (30) days of receipt. 

(d) With respect to a grant of a sublicense covering Licensed Know-How or Licensed Patents Controlled by LICENSOR through a license from
ALZA, LICENSEE shall provide LICENSOR prompt written notice of each such sublicense. 
  

	2.4	No Transfer. Except for use for the purposes of and to the extent defined in this Agreement, no right, title, interest, or license in or to any Licensed
Intellectual Property or any other intellectual property right of LICENSOR is granted to LICENSEE under this Agreement. 

  

	2.5	No Other Rights. Except as otherwise expressly provided herein, this Agreement does not grant LICENSEE any license or other right under Licensed
Intellectual Property. 

  

	2.6	Right to Distribute Stock Product. 

 (a) With respect to the license granted to LICENSEE in Section 2.1 above, such license shall include the right (but not the obligation) of LICENSEE to distribute Stock Product in any Group A Market
Country upon the earliest of (i) the date twelve (12) months from the Effective Date, (ii) the Regulatory Transfer Date for such country, or (iii) the date upon which LICENSEE has elected, by written notice to LICENSOR, to
distribute Stock Product prior to the occurrence of clause (i) or (ii) and executed a Delegation of Authority for such country with ALZA or an Affiliate thereof. LICENSEE shall enter into a Delegation of Authority with respect to a Group A
Market Country if (X) LICENSEE elects by written notice to LICENSOR to distribute Existing Product prior to the occurrence of the earlier of the Regulatory Transfer Date or first anniversary of the Effective Date or (Y) if the first
anniversary of the Effective Date occurs prior to such an election for such country and the Regulatory Transfer Date for such country. 
 (b) Pursuant to the rights set forth in this Section 2.6, and notwithstanding anything to the contrary, prior to LICENSEE or an Affiliate being the Product Registration holder in a country,
(i) if the label on such Stock Product bears the corporate trade dress of ALZA or any Affiliate thereof, LICENSEE may only distribute and not market, advertise or promote Stock Product in a country to the extent permitted by a Delegation of
Authority or other agreement between ALZA or an Affiliate thereof and LICENSEE, (ii) if (Y) LICENSEE, or an Affiliate thereof, has been appointed distributor by ALZA or its Affiliate in such country and such

  
 15 

 
appointment has been approved by the appropriate Regulatory Authority in such country and (Z) such Stock Product is appropriately labeled with the name of LICENSEE or an Affiliate thereof in
accordance with Applicable Laws, LICENSEE may distribute and market, advertise or promote Stock Product in such country to the extent permitted by a Delegation of Authority or other agreement with respect thereto between ALZA or an Affiliate thereof
and LICENSEE, and (iii) LICENSEE shall have no other rights to sell, offer for sale, or distribute Stock Product in such country under this Agreement prior to LICENSEE or an Affiliate being the Product Registration holder in a country. LICENSEE
shall only have the right to market and promote Existing Product if the Existing Product has been labelled with LICENSEE trademarks, including logos, and trade dress and LICENSEE is the Product Registration holder in the country. 

(c) LICENSEE shall be responsible for forecasting and purchasing any manufacturing services from ALZA or its Affiliates pursuant to the
ALZA MSA to obtain Stock Product or Existing Product. 
 (d) Should LICENSEE decide not to proceed with the distribution of the
Stock Product in a particular Group A Country prior to the earlier of the one year anniversary of the Effective Date or the Regulatory Transfer Date in such country, LICENSOR shall use Commercially Reasonable Efforts to cause ALZA (or any Affiliate
thereof) to continue the distribution of the Stock Product in [*] until the earlier of the one year anniversary of the Effective Date or the Regulatory Transfer Date in such country. 

 

	2.7	Right to Perform Research and Development; LICENSOR License and Right of Reference.  

 

	 	(a)	All clinical and other studies or trials for or in relation to the Product (each, a “Product Study”) that LICENSEE intends to perform shall, unless
specifically otherwise agreed in writing between the parties, be subject to the prior written consent of LICENSOR, such consent not to be unreasonably denied by LICENSOR. LICENSEE shall provide LICENSOR with written notice of its intent to perform a
Product Study and a copy of the protocol for such Product Study. In the event LICENSOR consents to performance of a Product Study, LICENSEE shall report any data, results, and safety findings from a Project Study to LICENSOR pursuant to
Section 11.3 herein. LICENSEE shall provide to LICENSOR an annual status report of any clinical and nonclinical development activities (“Product Study Report”). Delivery of each Product Study Report shall coincide with the development
safety update report (“DSUR”) reporting period and include a summary of all safety and efficacy information collected since the prior Product Study Report, the final study report when available, and worldwide Product Registration or
Product Registration Application status. LICENSEE shall bear any and all costs and expenses related to the conduct or termination of any Product Study. 

  

	 	(b)	LICENSEE hereby grants LICENSOR and its Affiliates the non-exclusive, perpetual, irrevocable, royalty-free, fully-paid, unrestricted, world-wide, transferable right,
without any obligation to LICENSEE and with rights of sublicense, to all LICENSEE Know-How, including any and all information, data and results of such studies or trials, including data on the safety of the Product, for any and all purposes, inside

  
 [*]
Confidential treatment requested. 

  
 16 

	 	
or outside the Territory, related to the manufacture, use, research, or development of Products intended to be commercialized outside the Territory, which right to use for commercialization
purposes shall be exclusive outside the Territory. Such right granted to LICENSOR and its Affiliates shall include a transferable, sublicenseable right of reference to all Product Registrations and Product Registration Applications owned or
controlled by LICENSEE, any Affiliate thereof, or any Sublicensee and all data and information contained therein. 

  

	2.8	Use of LICENSOR Improvements. Any LICENSOR Improvement shall only be included within the scope of LICENSEE’s rights hereunder effective upon and
subject to written agreement between the parties on the commercial economic and other terms governing the addition of any LICENSOR Improvement (or related Patents) to Licensed Know-How (or Licensed Patents), which terms shall take into account,
inter alia, the then existing commercial terms of this Agreement. LICENSOR shall provide written notice to LICENSEE of any LICENSOR Improvement promptly following LICENSOR’s knowledge of the generation or conception thereof. Upon written notice
from LICENSEE, given to LICENSOR within thirty (30) days of LICENSOR’s notice to LICENSEE of a LICENSOR Improvement, indicating LICENSEE’s interest in licensing such LICENSOR Improvement, the parties shall enter into good faith
negotiations concerning the inclusion thereof under the licenses granted to LICENSEE under this Agreement. 

  

	3	DEVELOPMENT AND COMMERCIALIZATION OF PRODUCT BY LICENSEE 

  

	3.1	General Principle. During the term of this Agreement, LICENSEE shall use Commercially Reasonable Efforts to Develop and Commercialize Products in the
Territory, including but not limited to those countries in which a Product Registration Application for the Existing Product has, as of the Effective Date, been filed. LICENSEE shall have responsibility for obtaining and maintaining all necessary
Product Registrations to do so. 

  

	3.2	Minimum Sales. LICENSEE shall use Commercially Reasonable Efforts to maximize Net Sales but shall at least achieve aggregate Net Sales of the Product in
the Territory equal to or exceeding [*] Euro within [*] ([*]) [*] after Re-launch of the Product has occurred in all [*] of the following countries: [*]. In the event that LICENSEE does not achieve such Net Sales by such date, LICENSOR shall
have the right, as a sole and unique remedy with respect thereto, to terminate this Agreement within [*] ([*]) days from the expiration of the aforesaid [*] ([*]) [*] period on [*] ([*]) [*] written notice to LICENSEE. LICENSEE may extend the
above-referenced [*] ([*]) [*] period by paying LICENSOR (USD$[*]), such payment to be made no later than within [*] ([*]) [*] from any written notice provided by LICENSOR, given within the [*] ([*]) [*] following expiration of such [*] ([*]) [*]
period, requesting such payment, and any such payment by LICENSEE shall be credited towards the first milestone payment due pursuant to Section 7.3 if the aggregate Net Sales triggering such payment have not already been achieved as of the
expiration of the initial [*] ([*]) [*] period referenced in this Section 3.2. Upon such payment, LICENSEE shall have an additional [*] ([*]) [*] period after the expiration of the aforesaid [*] ([*]) [*] period to achieve aggregate Net Sales
of the Product in the Territory equal to or exceeding [*] Euro. In the event that LICENSEE makes the above-referenced [*] USD ($[*]) payment 

  
 [*]
Confidential treatment requested. 

  
 17 

	 	
but, notwithstanding the additional period of [*] ([*]) [*], LICENSEE does not achieve such aggregate Net Sales of Product equal to or exceeding [*] Euro by expiration of such additional [*]
([*]) [*] period, LICENSOR shall have the right, as a sole and unique remedy with respect thereto, to terminate this Agreement within [*] ([*]) [*] from the expiration of such additional [*] ([*]) [*] period on [*] ([*]) [*] written notice to
LICENSEE. 

  

	3.3	Sales Force. LICENSEE agrees to employ, maintain and use an active sales and an organizational force sufficient for the full promotion, marketing, sales
and distribution of the Product and satisfaction of its obligations under Section 3.1 and achievement of the sales levels described in Section 3.2, and, without limitation of its obligations under Section 3.1, to use its Commercially
Reasonable Efforts to promote and develop the market for the Product throughout the Territory. 

  

	3.4	Annual Marketing Reports and Forecasts. LICENSEE agrees to prepare and provide LICENSOR with an annual marketing plan, sales estimates and non-binding [*]
sales forecast as soon as possible following the determination by the Transition Team of the regulatory plan for transfer of the Existing Product Registrations and LICENSEE shall provide each subsequent forecast within [*] of the end of each
calendar year. Within [*] after the end of each Calendar Quarter, LICENSEE shall prepare and provide LICENSOR with a sales report, in units and in value, for the previous Calendar Quarter. Such sales report shall include the Product-specific
advertising budget and the number of sales representatives materially dedicated to the Product in each country. 

  

	3.5	LICENSEE Product Inventory. LICENSEE shall procure and keep sufficient stock of the Product to be able to effectively launch and market the Product
hereunder, and meet foreseeable market demand therefor, in the Territory. 

  

	3.6	Marketing Materials. LICENSEE shall bear full and sole responsibility for the cost, nature, content and use of all advertising and promotional materials
for the Product (“Marketing Materials”). LICENSEE, and any Affiliate thereof or Sublicensee, shall ensure that all of its Marketing Materials and Commercialization practices conform to Applicable Laws in the Territory.

  

	3.7	Recall. 

  

	 	(a)	LICENSEE agrees that ALZA shall have responsibility and control over any recall, withdrawal, or field correction of Existing Product (“Recall”) in a country
that occurs prior to the Regulatory Transfer Date for such country and that ALZA shall have the right, solely before the Regulatory Transfer Date, to contact any Regulatory Authority with respect to Product if ALZA has a reasonable good faith belief
that such Product may not meet specifications for the Product in a manner that may reasonably justify a Recall. To the extent provided to LICENSOR by ALZA and available to LICENSOR, LICENSOR shall provide LICENSEE advance written notice of any such
Recall and provide LICENSEE an opportunity to comment on such Recall. Further, in the event of any such Recall in any country in the Territory that may have a material adverse impact on the development, marketing, sale, or distribution of Existing
Product in such country, 

  
 [*]
Confidential treatment requested. 

  
 18 

	 	
LICENSOR shall, if and as requested by LICENSEE in writing, request that ALZA suspend all further development, marketing, distribution, and sale of Existing Product in such country. However, if
such a Recall involves one or more lots of Product that were distributed and sold both (i) by ALZA or its Affiliates in one or more countries in the Territory and (ii) by or on behalf of LICENSEE in one or more countries in the Territory
(each, a “Split Lot”), then LICENSOR shall notify LICENSEE or LICENSEE shall notify LICENSOR, as the case may be, immediately upon becoming aware of any possible Recall (or any circumstances reasonably justifying a Recall) that may affect
such Split Lot. LICENSEE agrees, to the extent reasonably possible, to meet with ALZA prior to instituting any such a Recall with respect to Product in an attempt to come to a mutually acceptable decision regarding such Recall; provided, however,
that the holder of the applicable Product Registration in a country at the time of Recall (the “Responsible Party”) shall retain sole discretion in such case as to whether to institute a Recall (regardless of whether such Recall is
mandated by a Regulatory Authority or voluntarily instituted by the Responsible Party) in such country. 

  

	 	(b)	In the event that: 

  

	 	i.	any governmental agency or authority issues, demands, or requires a recall, withdrawal, or field correction with respect to any Product, or takes similar action in
connection with any Product, sold or distributed by or on behalf of LICENSEE, any Affiliate thereof, or any Sublicensee in the Territory, 

  

	 	ii.	a court of competent jurisdiction orders a recall, withdrawal, or field correction of any Product in the Territory, or 

 

	 	iii.	a voluntary recall, withdrawal, or field correction of any Product in the Territory is contemplated by LICENSEE, any Affiliate thereof, or any Sublicensee,

 then LICENSEE shall, as soon as reasonably possible (and in the event of i. or ii., within [*] of such recall,
withdrawal, or field correction (or order or requirement thereof) coming to its knowledge), advise LICENSOR by written notice, and, with respect to any such notice received for a particular country after the Regulatory Transfer Date for such country
or otherwise governing the conduct of a Recall following such country’s Regulatory Transfer Date, LICENSOR and LICENSEE shall use good faith efforts to agree on an appropriate course of action. Any such recall, withdrawal, or field correction
to be undertaken in a country in the Territory that is not the responsibility of ALZA under Section 3.7(a) shall be the responsibility of LICENSEE, its Affiliates, and Sublicensees, and shall be carried out by LICENSEE, its Affiliates, or its
Sublicensees in as reasonable, prudent, and expeditious a manner as possible to preserve the goodwill and reputation of the Product and the goodwill and reputation of the parties. LICENSEE shall maintain records of all sales and distribution of
Product and customers in the Territory sufficient to reasonably adequately administer any recall, withdrawal, or field correction. As between the Parties, LICENSEE shall bear any and all costs and expenses related to any such recall, withdrawal, or
field correction with respect to Product sold or distributed by or on behalf of LICENSEE, any Affiliate thereof, or any Sublicensee in the Territory. 

  
 [*]
Confidential treatment requested. 

  
 19 

	4	TECHNOLOGY TRANSFER AND TRANSITION PERIOD 

 Matters concerning or related to technology transfer and the transition of Product Registrations and Product Registration Applications, and Parties’ rights and obligations with respect thereto and
during such transition are, to the extent not addressed in the body of this Agreement, addressed in Schedule 4 to this Agreement, which is attached hereto and incorporated herein by reference. 

 

	5	OBLIGATIONS OF LICENSEE 

  

	5.1	Product Defects. Consistent with Section 3.7 above, LICENSEE agrees, upon gaining knowledge thereof, to promptly notify LICENSOR in writing of any
defects and inspections or notifications from any governmental authorities regarding inspection deficiencies, issuances, regulatory documents or court actions that relate to the Product being manufactured by or on behalf of LICENSEE, any Affiliate
thereof, or any Sublicensee. 

  

	5.2	Regulatory Approvals. Starting upon the Effective Date for all countries in the Territory where no Product Registration has been granted in all countries
in the Territory except Group A Market Countries, Group B Market Countries, or Group C Market Countries, LICENSEE shall use Commercially Reasonable Efforts to obtain, at its sole cost and expense, such health registrations, approvals and consents,
including without limitation all Product Registrations for the Product as may be necessary to permit or facilitate the lawful manufacture, import, marketing, promotion, distribution, use and sale of Products in the Territory. Starting on the
Regulatory Transfer Date, LICENSEE shall use Commercially Reasonable Efforts to obtain, at its sole cost and expense, Product Registrations in all Group C Market Countries for the Product as may be necessary to permit or facilitate the lawful sale
of Products therein. To the extent not prohibited by Applicable Law or otherwise contemplated by the Parties, and subject to the assignment of Product Registration Applications and Product Registrations existing as of the Effective Date to LICENSEE
on the Effective Date or thereafter as contemplated by Schedule 4, all Product Registration Applications and Product Registrations in the Territory shall be in the name of LICENSEE or its Affiliates. LICENSEE undertakes to pay any fees payable
pursuant to, or for the maintenance of all health registrations, approvals and consents, including without limitation the Product Registrations for the Products as determined or required by any Regulatory Authorities or other relevant government (or
supranational) agencies. LICENSEE or its Affiliates shall maintain all Product Registration Applications and Product Registrations in good standing under Applicable Laws and notify LICENSOR in writing of any events that fail to meet regulatory
requirements related to a Product Registration. Should any competent Regulatory Authority in the Territory require any clinical or other trials or studies with respect to any Product (or for purposes of obtaining Product Registration for any
Product), other than the Priligy On-Going Clinical Trials (which are addressed separately in this Agreement), LICENSEE shall in its reasonable discretion, consistent with the use of Commercially Reasonable Efforts to Develop and Commercialize the
Product, determine whether to continue pursuit of Product Registration by performing such clinical or other trials or studies, and shall be solely responsible for the cost if such trials or studies are performed. 

  
 20 

	5.3	Withdraw of Product Registrations. In the event of withdrawal of a Product Registration in any country in the Territory, LICENSEE shall bear any and all
costs and expenses related to withdrawal of such Product from the market in such country. 

  

	5.4	Regulatory Compliance. LICENSEE and its Affiliates will at all times be in compliance with any other Applicable Laws while performing any activities
related to LICENSEE’s rights under this Agreement, including the Development, manufacture, sale, marketing, import, export, or Commercialization of any Product. LICENSEE shall, during normal business hours, allow access to LICENSOR to audit
LICENSEE’s records for purposes of assessing regulatory compliance concerning a Product. LICENSOR shall provide LICENSEE at least four (4) weeks notification prior to scheduling an audit. LICENSOR shall only be permitted two
(2) annual audits. 

  

	5.5	Insurance. LICENSEE shall maintain comprehensive Third Party general liability and product liability insurance from an internationally recognized,
creditworthy insurance company, which coverage shall insure against Third Party liability, including but not limited to bodily injury or property damage, arising out of the manufacture, use, sale, distribution, marketing, Development or
Commercialization of Products, with endorsements for product liability and coverage limits of not less than USD$[*] per occurrence and USD$[*] in the aggregate. The minimum level of insurance set forth herein shall not be construed to create a limit
on LICENSEE’s liability hereunder. Within [*] following any written request from LICENSOR, LICENSEE shall furnish to LICENSOR a certificate of insurance evidencing such coverage. In the case of a cancellation or change of such coverage,
LICENSEE shall promptly provide LICENSOR with a new certificate of insurance evidencing that LICENSEE’s new or amended coverage meets the requirements in the first sentence of this Section 5.5. LICENSEE’s obligations hereunder shall
survive the termination or expiration of this Agreement until the later of (i) [*] after such termination or expiration or (ii) the date that all statutes of limitation covering claims or suits that may be brought for personal injury based
on the manufacture, sale, or use of a Product have expired in all jurisdictions in the Territory. Notwithstanding the foregoing, and except for any reasonable deductible amount under the insurance noted above (which shall not be considered
self-insurance hereunder), LICENSEE may self-insure any or a portion of the above required insurance if (i) such self-insurance is effected through a captive insurance company duly authorized by an appropriate authority in a favourably
recognized domicile; or (ii) LICENSEE can demonstrate to have proceeded with adequate accruals in its balance sheet destined only for product liability self-insurance. 

 

	6	OBLIGATIONS OF LICENSOR 

  

	6.1	On-Going Clinical Trials. LICENSOR shall use Commercially Reasonable Efforts to ensure that ALZA or its Affiliates performs, directly or indirectly, the
on-going clinical trials set forth in Schedule 6.1 (“Priligy On-Going Clinical Trials”), provided that, if ALZA or LICENSOR reasonably determines that the Priligy On- 

  
 [*]
Confidential treatment requested. 

  
 21 

	 	
Going Clinical Trials cannot or will not be completed by, or should be suspended or terminated prior to, [*], (i) LICENSOR shall provide written notice of such determination to LICENSEE,
(ii) LICENSOR’S obligation under this Section 6.1 shall terminate, and (iii) LICENSOR shall have the right, in its discretion, to cause the termination of the Priligy On-Going Clinical Trials or to instruct ALZA to transfer
responsibility for conducting the Priligy On-Going Clinical Trials to LICENSOR. 

  

	7	CONSIDERATION 

  

	7.1	License Fee. Within [*] after the Effective Date, LICENSEE shall pay to LICENSOR the sum of fifteen million USD ($15,000,000). 

 

	7.2	Regulatory Milestones. LICENSEE shall give written notice of the occurrence of a milestone event described below within [*] thereof. LICENSEE shall make
each milestone payment set forth below to LICENSOR within [*] of the later of (i) the occurrence of the related milestone event or (ii) the Effective Date. Each milestone payment set forth below shall be payable once under this Agreement,
with respect to the first occurrence of the related milestone event for the first Product to achieve such milestone. The Parties agree that, notwithstanding anything to the contrary, if any milestone described below is achieved on or prior to the
Effective Date (whether by ALZA, any Affiliate thereof, any licensee of either of the foregoing, LICENSEE, any Affiliate thereof, any Sublicensee, or otherwise), the corresponding milestone payment set forth below shall be paid to LICENSOR within
[*] of the Effective Date. 

  

			
	 Milestone Event
	  	 Milestone Payment in USD

	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [* ]
	  	[*]

 Notwithstanding anything to the contrary, if [*], and no milestone payment has previously been triggered
above with respect to a [*] (i.e. neither the third or fourth milestone event above has been achieved), USD$[*] shall be due with respect to such simultaneous [*] (i.e. the third and fourth milestone payments shall be due concurrently). 

 

	7.3	Sales-Based Milestones. LICENSEE shall give LICENSOR written notice of the achievement of any of the Net Sales levels described below within [*] thereof.
LICENSEE shall pay to LICENSOR milestone payments in accordance with the schedule set forth below, based on [*] of [*] in the [*] for any [*] or [*] of [*] during which such Net Sales are achieved, such payment to be made within [*] of after the
achievement of such Net Sales. Each of the milestone payments shall be payable only once regardless of the number of times Products achieve such Net Sales. 

  
 [*]
Confidential treatment requested. 

  
 22 

			
	 [*]
	  	Milestone Payment in USD
	 [*]
	  	[*] USD ($[*])
	 [*]
	  	[*] USD ($[*])
	 [*]
	  	[*] USD ($[*])
	 [*]
	  	[*] USD ($[*])

 For purposes of clarification, but not limitation, if more than one milestone payment set forth above
shall be payable with respect to the same [*] or [*] the same [*], both payments shall be made as set forth above and, as an example of the intent and purpose of the reference to [*] and [*] above, Net Sales shall be measured, solely for purposes of
determining whether or not a milestone payment has been triggered under this Section 7.3, from [*] of one [*] to [*] of the [*], or from [*] to [*] of the [*], and, if equalling or exceeding a particular amount specified above during either [*]
period, trigger one or more payments hereunder. 
  

	7.4	Royalties. In accordance with the terms of Article 8 of this Agreement, LICENSEE shall pay to LICENSOR the royalties set forth below on Net Sales of all
Products in the Territory during the Term. 

  

					
	 Aggregate Annual Calendar Year Net

Sales of All Products in the
 Territory
	  	Royalty Rate	 
	 [*]
	  	 	[*] percent ([*]%) of Net Sales	  
	 [*]
	  	 	[*] percent ([*]%) of Net Sales	  
	 [*]
	  	 	[*] percent ([*]%) of Net Sales	  

 For example, if [*] of [*] in the [*] in a [*] totals [*] USD ($[*]), the royalty due LICENSOR under this
Section 7.4 with respect to such Net Sales shall equal [*] USD ($[*]), i.e. ([*]% x $[*]) + ([*]% x $[*]) + ([*]% x $[*]) = $[*]). 
  

	7.5	Payments under the Lilly Agreement. In the event the Term expires for a particular country in the Territory, and world-wide Net Sales (as defined in the
Lilly Agreement; “Lilly Sales”) of Product in the Calendar Year (as defined in the Lilly Agreement; a “Lilly Year”) during which such expiration occurs or any Lilly Year thereafter exceed eight hundred million USD ($800,000,000),
LICENSEE agrees to pay Lilly, on behalf of LICENSOR and its Affiliates, five percent (5%) of any Lilly Sales of Products in such country in the Territory, on which LICENSEE would not otherwise have any royalty obligation under this Agreement in
such country in any such Lilly Year until the later of (a) the [*] anniversary of first commercial sale of Product in such country or (b) the expiration in such country of the last-to-expire Licensed Patent with a Valid Claim (as defined
in the Lilly Agreement) in a manner sufficient to satisfy the related obligations under the Lilly Agreement and Sections 8.2 and 8.5 of this Agreement shall apply to such Lilly Sales of Products in such country(ies), notwithstanding anything to the
contrary. 

  
 [*]
Confidential treatment requested. 

  
 23 

	7.6	Payments for Priligy On-Going Clinical Trials. 

  

	 	(a)	The Priligy On-Going Clinical Trials shall be performed at LICENSEE’s expense. The Parties acknowledge that ALZA will invoice LICENSOR for Development Costs, in
USD, quarterly, within [*] after the end of each Calendar Quarter. LICENSOR will invoice LICENSEE for the amount charged by ALZA and LICENSEE shall pay such invoice within [*] from receipt of the invoice. The maximum cost to be paid by LICENSEE
under the Agreement for completing the Priligy On-Going Clinical Trials shall be Nineteen Million USD ($19,000,000). Subject to Section 6.1, LICENSOR shall have no financial or performance obligation with respect to any Priligy On-Going
Clinical Trials. 

  

	 	(b)	All sums due to LICENSOR shall be payable by bank wire transfer in immediately available funds to such bank account as LICENSOR shall designate in writing to LICENSEE.
LICENSOR shall notify LICENSEE’s Finance designee as to the date and amount of any such wire transfer [*] prior to such transfer. All payments shall be made in USD. 

 

	 	(c)	LICENSOR shall keep, and use Commercially reasonable Efforts to ensure that ALZA and its Affiliates keep, complete, true and accurate books of accounts and records in
accordance with their standard internal policies and procedures and accounting standards, for the purpose of determining the basis and accuracy of the payments to be made for the Priligy On-Going Clinical Trials. Such books and records shall be kept
for at least three (3) years following the end of the Calendar Quarter to which they pertain. During such three (3) year period, LICENSEE may request LICENSOR to verify the basis and accuracy of amounts in the payment statements received
pursuant to Section 7.6(a) above using independent accountants selected by LICENSEE and that are reasonably acceptable to LICENSOR. Such inspections shall be made no more than [*] each Calendar Year, at reasonable time and on reasonable notice
and shall be limited to information related to On-Going Clinical Trials. Results of any such inspection shall be deemed to be Confidential Information of LICENSOR. If any overpayment is discovered in the course of such inspection, then LICENSOR
shall pay LICENSEE those amounts that LICENSEE should not have paid in the absence of such errors. Inspections conducted under this Section 7.6(c) shall be at the expense of LICENSEE, unless a variation or overpayment exceeding [*] percent
([*]%) of the amount properly due for the period covered by the inspection is established in the course of such inspection, whereupon all reasonable, documented costs relating to the inspection for such period will be paid to LICENSEE.

  

	7.7	Payments for Licensed Patents. [*] shall be responsible for [*] costs and expenses associated with LICENSOR’s filing, prosecution, maintenance and
patent term extension of Licensed Patents in the Territory (including but not limited to the costs incurred by [*] with its outside patent counsel). 

  
 [*]
Confidential treatment requested. 

  
 24 

	7.8	Payments for Regulatory Fees. [*] shall, [*], be responsible for [*] fees imposed by Regulatory Authorities and other governmental agencies in connection
with the maintenance and transfer of ownership of Product Registrations or Product Registration Applications in the Territory that are not paid by [*] pursuant to *] obligations set forth in Schedule 4 attached hereto, including but not limited to
those fees to be paid when [*] is the applicant for transfer of a Product Registration. 

  

	7.9	License Payments to Third Parties.  

 (a) [*] shall pay amounts due to any Third Party under a license agreement with respect to any grant of any Third Party patent or trade secret rights that may be necessary for LICENSEE’s, its
Affiliates’, or their Sublicensees’ manufacture, use, sale, offering for sale, or import of Product in the Territory as contemplated by this Agreement, provided that (X) [*] shall not be responsible for any amounts incurred or due
with respect to any license to the extent concerning (i) any technology or intellectual property rights that are not utilized in, infringed by, or necessary for the manufacture, use, or sale of the Existing Product as it is made, used or sold
on the Effective Date (any such technology or intellectual property rights not utilized in, infringed by, or necessary for the manufacture, use, or sale of the Existing Product as of the Effective Date (“LICENSEE-Added IP”), or
(ii) any trademarks or copyrights; (Y) any payment under a license agreement resulting from an Indemnified Third Party IP Claim is addressed as set forth in Section 9.3(d); and (Z) [*] shall only be responsible for [*] percent
([*]%) of such amounts due under a Third Party license agreement as described under this Section 7.9(a) (taking into account clauses (X) and (Y) above), and [*] shall be responsible for all other amounts due under such license. [*]
shall pay [*] the portion of any amounts due under a license for which [*] has financial obligations under this subsection (a) (such a license or any license resulting from or related to an Indemnified Third Party IP Claim under
Section 9.3(d), a “Supported Third Party License”) to be borne by [*] within [*] of receiving an invoice therefor from [*]. 
 [*] shall [*] reasonably cooperate, with [*], as requested thereby, in any efforts to negotiate any Supported Third Party License, and [*] shall provide [*] a reasonable opportunity to review and comment
on any proposed Supported Third Party License. However, [*], acting reasonably and with the aim at preserving the commercial viability of the Product in the Territory, shall retain sole control over the final terms of any Supported Third Party
License, [*] shall not discuss, negotiate, attempt to obtain, or obtain such a license from any such Third Party[*] without [*] prior written consent, and [*] shall not be responsible for any amounts incurred or due with respect to any license
negotiated or executed by [*] without [*] prior written consent. 
  

	(b)	In the event, upon termination of the Lilly Agreement, LICENSEE acquires the obligations of LICENSOR under the Lilly Agreement pursuant to the Lilly Comfort Letter set
forth in Section 1.55 hereof, LICENSOR agrees to fulfill the obligation set forth in Section 3.1(d) of the Lilly Agreement to pay milestone, royalty and other payments Lilly may owe to Third Parties pursuant to an agreement Lilly may have
with a Third Party covering rights relating to Existing Product in accordance with the terms and conditions set forth in the Lilly Agreement. 

  
 [*]
Confidential treatment requested. 

  
 25 

	(c)	Notwithstanding anything to the contrary (including but not limited to Section 9.3(d)(i)), if, for a particular Calendar Year, the sum of (x) all Annual
Indemnified Third Party IP Claim Costs plus (y) all Annual Third Party Licensing Costs plus (z) all amounts due Lilly under the Lilly Agreement with respect to Lilly Sales in the Territory during such Calendar Year exceeds all amounts
payable by LICENSEE to LICENSOR under Section 7.4 (as it may be adjusted pursuant to Section 13.7(a)) with respect to all Net Sales of Products occurring in the Territory during such Calendar Year, (a) LICENSEE shall be financially
responsible for such excess and pay LICENSOR the amount of such excess within [*] of receiving an invoice therefor from LICENSOR and, without limitation of such obligation (which shall survive termination or expiration of this Agreement), and
(b) LICENSEE shall be entitled to (X) terminate this Agreement upon six (6) months’ written notice to LICENSOR given within [*] of LICENSEE’s receipt of an invoice from LICENSOR under this Section 7.9(c) or
(Y) request termination of LICENSEE’s rights under this Agreement in specified country(s) in the Territory by providing LICENSOR written notice within [*] of LICENSEE’s receipt of an invoice from LICENSOR under this
Section 7.9(c) (“Country Termination Notice”). In the event LICENSEE provides LICENSOR with a Country Termination Notice, the Parties shall negotiate in good faith the termination of LICENSEE’s rights to the specified country(s)
based upon whether such termination is Commercially Reasonable and in the best interest of preserving the overall commercial value of the Product. 

  

	7.10	Costs/Expenses. [*] shall, unless expressly agreed otherwise in this Agreement, bear [*] costs and expenses of its activities and performance in
connection with this Agreement, including without limitation any investments and expenditures in its corporate infrastructure, marketing and sales organisations and activities, or otherwise, which investments and expenditures shall be at the sole
risk and cost of [*]. 

  

	7.11	Sales Upon Invoicing. A sale of Product shall be deemed to have occurred upon the invoicing of such Product; or if not invoiced, then when delivered,
shipped, or paid for, whichever first occurs. 

  

	8	RECORDS, REPORTS AND PAYMENTS 

  

	8.1	Wire and Currency. All payments to LICENSOR pursuant to Article 7 shall be made by electronic wire transfer in USD in immediately available funds to an
account designated in writing by LICENSOR. For purposes of calculation of payments owed under Sections 7.3 and 7.4 for Net Sales invoiced or expensed in a currency other than USD, such Net Sales shall first be converted to USD and then combined to
calculate the total Net Sales. All payments to Lilly under Section 7.5 shall be paid concurrently with the royalty report set forth in Section 8.2 and be paid in U.S. dollars by electronic wire transfer in immediately available funds to an
account designated in writing by LICENSOR or Lilly (unless otherwise instructed by Lilly or LICENSOR in writing). 

  
 [*]
Confidential treatment requested. 

  
 26 

	8.2	Reports and Records. Within [*] after the end of each Calendar Quarter in which there are any Net Sales subject to the payment of royalties or other
amounts under this Agreement (including any Lilly Sales for which payments are due under Section 7.5), LICENSEE shall furnish to LICENSOR a statement of Net Sales of each Product for such Calendar Quarter setting forth the gross sales and Net
Sales of Products for each country in which Products were sold during such Calendar Quarter, a calculation of Net Sales (including a detailed description of deductions used to calculate Net Sales from gross sales pursuant to Section 1.58), and
a calculation of royalties due pursuant to Article 7, together with a payment of royalties due for such Calendar Quarter. LICENSEE will mail and e-mail such report to LICENSOR to Marshall Woodworth, CFO, Furiex Pharmaceuticals, Inc., 3900 Paramount
Parkway, Suite 150, Morrisville, North Carolina 27560, e-mail address [*] or to whom LICENSOR shall designate from time to time. The amount of royalty payment due to LICENSOR shall be paid by LICENSEE concurrently with the remittance of each royalty
report. Interest shall accrue on any payments due under this Agreement (including but not limited to royalties) not paid when due through and including the date upon which LICENSOR has collected the funds in accordance herewith at a rate equal to
the lesser of: (a) the sum of [*] percent ([*]%) plus the LIBOR prime rate of interest quoted in the Money Rates (or equivalent) section of The Wall Street Journal (or any substitute source mutually agreed to by the Parties), calculated
daily on the basis of a three hundred sixty (360) day year; or (b) the maximum interest rate allowed by Applicable Law. All royalty reports provided with respect to LICENSEE’s obligations under Section 7.5 shall contain
information sufficient to enable LICENSOR to satisfy its corresponding obligations under the Lilly Agreement. 

  

	8.3	Taxes.  

 (a)
LICENSEE will make all payments to LICENSOR under this Agreement without deduction or withholding of any taxes or other similar amount owed by either party (or any Affiliate thereof to which any such obligation may apply) under applicable law, rule,
or regulation. Any tax or other amount required to be withheld or paid on, or as a result of, any amounts payable to LICENSOR under this Agreement (“Withholding Taxes”) will promptly be paid by LICENSEE on behalf of LICENSOR (or any
applicable Affiliate thereof) to the appropriate governmental authority, without any deduction from or reduction of any amounts that LICENSEE is required to pay LICENSOR hereunder (except as otherwise set forth in Section 8.3(b), if and as
applicable). LICENSEE will furnish LICENSOR with proof of payment of such tax. Without limitation of LICENSOR’s obligations to pursue recovery of any Withholding Taxes paid by LICENSEE (as described, and subject to the limitations set forth
below in this Section 8.3) or LICENSEE’s right to be paid any recovered Withholding Taxes (as described below in this Section 8.3), any such tax required to be paid or withheld will be an expense of and borne by LICENSEE (subject to
Section 8.3(b), if and as applicable). LICENSOR and LICENSEE, respectively, will provide LICENSEE or LICENSOR, respectively, with reasonable advance notice of any such tax withholding or payment obligations to which LICENSOR or LICENSEE,
respectively, reasonably believes that LICENSOR (or any Affiliate thereof) or any payments under this Agreement are subject. Such Withholding Taxes shall be paid by LICENSEE to the proper taxing authority for LICENSOR’s (or, if applicable, its
Affiliate’s) account in a timely manner and an 

  
 [*]
Confidential treatment requested. 

  
 27 

 
official tax certificate or other written evidence of such tax obligations, together with relevant written proof of payment, sufficient to enable LICENSOR to claim or demonstrate payment of such
Withholding Taxes will be secured and sent to LICENSOR as soon as reasonably possible, but in any event within one (1) month of such payment. The parties will do all such lawful acts and things and sign or file all such lawful deeds and
documents as either party may request under any applicable legislation, treaty, regulation, rule, or law from or of the other party to enable LICENSOR, its Affiliates, LICENSEE, its Affiliates, or any Sublicensees to take advantage of any applicable
legal provision or any treaty provisions with the object of being exempted or minimizing the legal amount of Withholding Taxes (and, therefore, minimizing LICENSEE’s payment obligations (or, if applicable under Section 8.3(b), maximizing
LICENSOR’s ability to recover or obtain, directly or indirectly, an exemption for any Withholding Taxes paid by LICENSEE and deducted from amounts due LICENSOR hereunder) with respect to any Withholding Taxes under this Section 8.3) and
LICENSEE shall reimburse LICENSOR’s out of pocket expenses thereof. LICENSOR will provide LICENSEE with all reasonable assistance and will provide LICENSEE with all documentation requested as useful or necessary under any applicable
legislation, treaty, regulation, rule, or law to enable LICENSEE to be exempted from or to recover any Withholding Taxes as permitted by applicable law, rule, or regulation or, if, under such law, rule, or regulation, any such Withholding Taxes paid
by LICENSEE are only recoverable by LICENSOR (or any applicable Affiliate thereof), LICENSOR shall, on LICENSEE’s instructions, file or submit any documentation required to recover such Withholding Taxes and, upon any recovery thereof, promptly
pay LICENSEE the amount of any such Withholding Taxes so recovered (except, if Withholding Taxes paid by LICENSEE and deducted from amounts due LICENSOR pursuant to Section 8.3(b), LICENSEE shall provide LICENSOR with reasonable assistance and
documentation to enable LICENSOR to, directly or indirectly, recover or obtain an exemption for any Withholding Taxes and LICENSEE shall use Commercially Reasonable Efforts to obtain any recovery thereof that may be available to it and pay such
recovered amounts to LICENSOR, and LICENSOR shall have no payment obligation to LICENSEE with respect to any such recovered or exempted amounts). 
 (b) If, during the term of this Agreement, LICENSOR takes any action that eliminates or reduces the Parties’ exemption from, or recovery of, any Withholding Taxes under any applicable legislation,
treaty, regulation, rule, or law (including but not limited to (i) any assignment of this Agreement or the benefits thereof by LICENSOR to any Third Party not eligible for an exemption from, or the recovery of, the Withholding Taxes or
(ii) LICENSOR’s moving its corporate residence or domicile to a country or jurisdiction outside the United States), then to the extent following such action Withholding Taxes are due and an exemption from, or recovery of, Withholding Taxes
is no longer available to either Party as a direct result of such action by LICENSOR, LICENSEE shall be entitled to deduct the amount of such Withholding Taxes from its corresponding payments due LICENSOR hereunder. 

(c) With respect to any payment obligations to Lilly under Section 7.5, LICENSEE’s obligations under this Section 8.3 shall
be with respect to or on behalf of Lilly instead of LICENSOR, and Lilly or LICENSOR shall be entitled to enforce 

  
 28 

 
such provisions for Lilly’s benefit with respect to any payment obligations under Section 7.5, provided that any breach by LICENSEE of such obligations shall remain a breach of this
Agreement for which LICENSOR may seek and/or obtain legal or equitable remedy and further provided that, if LICENSOR or Lilly wishes to have the benefit of LICENSOR bearing the expense of any Withholding Taxes due with respect to any payment
obligation under Section 7.5 without any corresponding deduction from any payments due Lilly under Section 7.5 being made by LICENSEE, LICENSOR shall use Commercially Reasonable Efforts to cause Lilly to comply with LICENSOR’s
obligations provided for in this Section 8.3 with regards to LICENSEE’s payment obligations under Section 7.5. LICENSEE agrees that such Commercially Reasonable Efforts to be used by LICENSOR to cause Lilly to comply with
LICENSOR’s obligations provided for in this Section 8.3 shall not include any payment obligation by LICENSOR to Lilly. 
  

	8.4	Foreign Exchange. With respect to Net Sales invoiced or expenses incurred in a currency other than USD, such Net Sales invoiced or expenses incurred will
be converted into USD using a rate of exchange that corresponds to quarterly average of the daily buying rate as published by the Wall Street Journal, Eastern U.S. Edition on the last business day of the applicable quarter (or such other publication
as agreed upon in writing by the Parties). 

  

	8.5	Records Inspection. LICENSEE agrees to maintain, and shall require its Permitted Sellers to keep, complete, true and accurate books of accounts and
records for the purpose of determining the basis and accuracy of payments to be made under this Agreement. Such records shall show Net Sales on country-by-country and Product-by-Product basis, and LICENSEE’s or its Permitted Sellers’ usual
internal practices and procedures (which shall be commercially reasonable), consistently applied, and GAAP or IFRS, consistently applied. Such books and records shall be kept for at least [*] following the end of the Calendar Quarter to which they
pertain. Such records will be open for inspection by LICENSOR during such [*] period by LICENSOR or independent certified public accountants, solely for the purpose of verifying the basis and accuracy of amounts in the payment statements hereunder.
If requested by notice from LICENSOR, LICENSEE shall make, and cause to be made, such records available during normal business hours to enable such accountant to verify the accuracy of any payments made in accordance with this Agreement. Such
inspections shall be made no more than [*] each Calendar Year, at reasonable time and on reasonable notice. Such accountant shall promptly report to LICENSOR only whether LICENSEE’s payments for the Product(s) and calculations thereof are
correct or incorrect, and, if incorrect, what, in said accountant’s professional opinion, the correct amounts should have been. If any errors in favor of LICENSEE are discovered in the course of such inspection, then upon written notice by
LICENSOR to LICENSEE, LICENSEE shall pay to LICENSOR within [*] any amount owed to LICENSOR in accordance with the findings plus interest pursuant to and in accordance with Section 8.2. The fees and expenses associated with any such audit shall
be borne by LICENSOR, provided that LICENSEE shall reimburse LICENSOR for the same in the event the audit reveals an underpayment by LICENSEE of more than [*] percent ([*]%) of the amount due for the period covered by the inspection. In the event of
overpayment to LICENSOR, any amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding Calendar Quarter. 

  
 [*]
Confidential treatment requested. 

  
 29 

	9	INTELLECTUAL PROPERTY 

  

	9.1	Ownership. 

  

	(a)	Priligy On-Going Clinical Trials. LICENSOR shall own the entire right, title and interest in the data and other information that is derived from the
Priligy On-Going Clinical Trials (or Control such data and information by license from ALZA), provided that such data and information shall be included in Licensed Know-How. 

 

	(b)	Improvements. Any and all Improvements shall be the sole and exclusive property of LICENSOR. LICENSEE hereby assigns all right, title, and interest in all
Improvements, and all intellectual property rights related thereto, to LICENSOR. LICENSEE agrees to reasonably cooperate with LICENSOR, to take any actions or execute any documents, and to cause any Affiliate of LICENSEE or Sublicensee to take any
actions or execute any documents, as necessary or desirable to secure or perfect LICENSOR’s legal rights and worldwide ownership in Improvements and all related intellectual property rights, including, but not limited to documents relating to
Patents Covering Improvements (“Improvement Patents”). LICENSEE shall not at any time, in any manner, during or after this Agreement, under any circumstances, be entitled to or claim any right, title or interest herein or any commission,
fee or other direct or indirect benefit from LICENSOR or Affiliate, in respect of such Improvements created by LICENSEE hereunder except to the extent Improvements are included in Licensed Patents and Licensed Know-How pursuant to Section 2.8.

  

	9.2	Patent Prosecution and Maintenance. 

  

	(a)	 Licensed Patents. LICENSOR shall have the right to control, and shall use Commercially Reasonable Efforts with respect to, the
preparation, filing, prosecution, maintenance and, except with respect to the defence addressed by Section 9.3(c), defence of Licensed Patents in the Territory. Notwithstanding, however, LICENSEE acknowledges and agrees that
(a) LICENSOR does not guarantee the issuance, validity, or enforceability of any Licensed Patent or any claim thereof resulting from its efforts hereunder, and (b) LICENSOR shall not have any liability to LICENSEE with respect to the
content of any particular draft patent application or office action response prepared after the Execution Date to the extent: (i) LICENSEE had a reasonable opportunity (but in no event less than [*]) to review and comment on such draft patent
application or office action response; (ii) LICENSOR made reasonably available and accessible to LICENSEE for discussion and information-sharing purposes with respect to such application or office action response the patent attorney(s)
primarily responsible for the prosecution and maintenance of the relevant patent application(s) (who may be an employee of LICENSOR or an Affiliate thereof); (iii) LICENSOR provided LICENSEE reasonable access to a dedicated patent attorney (who
may be an employee of LICENSOR or an Affiliate thereof) to discuss patent strategy and satisfy any requests for additional information made by LICENSEE with respect to such draft patent application or office action response (e.g., available prior
art 

  
 [*]
Confidential treatment requested. 

  
 30 

	 	
with respect to any proposed patent application); and (iv) LICENSEE either (A) approved such draft application or office action response or failed to provide any comments with respect
thereto or (B) provided substantive comments with respect to such draft application or office action response and such comments were considered in good faith by LICENSOR. 

 

	9.3	Infringement of Patent Rights. 

  

	(a)	Warranty. LICENSOR represents and warrants that, to the best of its knowledge as of the Execution Date, no written claim has been received from or is
threatened in writing by a Third Party alleging that the distribution and/or sale of the Existing Products in the Territory infringe any Patents of any Third Party. 

 

	(b)	Notice. Without prejudice to other provisions in this Agreement, each party shall use Commercially Reasonable Efforts to promptly inform the other party
in writing of (i) any invalidation proceeding related to any Licensed Patent initiated through a government agency or any other form of patent authority (“Invalidation Proceeding”) or (ii) any actual or potential infringement or
threat thereof of the Licensed Patents in the Territory and provide reasonable assistance in protecting against such infringements. 

  

	(c)	 Enforcement and Defence of Licensed Patents. With respect to (i) the defence of any Invalidation Proceeding, or (ii) any
actual, potential or suspected infringement of Licensed Patents as they relate to the Commercialization of Products in a country in the Territory following the Re-launch in each country in the Territory where Existing Product is being sold as of the
Effective Date or the launch date in a country in the Territory in which Existing Product has not been sold as of the Effective Date, respectively, LICENSEE shall, subject to the remainder of this Section 9.3(c), have the first and primary
right, but not the obligation, to, in its sole discretion, initiate, prosecute, defend and/or control any action or legal proceedings, and/or enter into a settlement, including any declaratory judgment action, on its behalf or in LICENSOR’s
name, if necessary, with respect thereto. If, within [*] of the notice in Section 9.3(b) above with respect to any such actual, potential, or suspected infringement of the Licensed Patents, LICENSEE: (X) shall have been unsuccessful in
persuading the alleged infringer to desist; (Y) shall not have brought and shall not be diligently prosecuting an infringement action; or (Z) has not entered into bona fide and substantive settlement discussions with respect to such
infringement, or if LICENSEE notifies LICENSOR that it has decided not to undertake any of the foregoing against any such alleged infringer, then LICENSOR shall then have the right to bring suit to enforce such Licensed Patents in such country in
the Territory at its own expense. If, within [*] of notice in Section 9.3(b) being provided with respect to an Invalidation Proceeding or at any time thereafter, LICENSEE is not actively defending the Licensed Patent(s) being challenged in such
Invalidation Proceeding to LICENSOR’s reasonable satisfaction, or if LICENSEE notifies LICENSOR in writing at any time that it has decided not to undertake or to cease such defence, LICENSOR shall then have the right to undertake the defence of
the relevant Licensed Patent(s) in such Invalidation Proceeding, at its own expense and under its sole control. If either party brings any defence, infringement action or proceeding under this Section 9.3(c), the other party agrees, subject to
the 

  
 [*]
Confidential treatment requested. 

  
 31 

	 	
remainder of this Section 9.3(c), to be joined, upon written request, as a plaintiff (or, in the case of any Invalidation Proceeding defence, defendant, if and as applicable) and, at the
expense of the other party, to give the party undertaking such infringement suit or other action reasonable assistance and authority to control, file and prosecute, or defend such the suit or proceeding as necessary. 

 

	(d)	Infringement of Third Party Rights. If LICENSEE’s or any Permitted Seller’s conduct or exercise of its rights under this Agreement or
manufacture, use, sale, import, export, or distribution of any Product in a country of the Territory becomes the basis of a claim of infringement or misappropriation of any patent or trade secret of any Third Party in the Territory (a “Third
Party IP Claim”), LICENSEE shall promptly give written notice to LICENSOR and the Parties shall confer to consider the claim and an appropriate course of action. 

(i) If, following the First Commercial Sale in each country in the Territory where Existing Product is being sold as of the Effective
Date or the launch date in a country in the Territory in which Existing Product has not been sold as of the Effective Date, a Third Party institutes a patent infringement or trade secret misappropriation suit against LICENSEE in a country in the
Territory alleging that the manufacture, sale, use or importation of a Product by or on behalf of LICENSEE in such country in the Territory under this Agreement infringes the patents or misappropriates the trade secrets of a Third Party, and such
claim is not based on any LICENSEE-Added IP (such suit (or series of directly related such suits in such country by or on behalf of the same Third Party with respect to the same manufacture, sale, use, or importation by or on behalf of LICENSEE) to
the extent not based on any LICENSEE-Added IP, an “Indemnified Third Party IP Claim”), LICENSOR shall defend before any competent forum and indemnify and hold harmless LICENSEE, its Affiliates and any other Permitted Seller with respect to
such claim, subject to the following two paragraphs. 
 It is however understood that, notwithstanding anything to the contrary
in this Agreement, LICENSEE shall pay, on a country-by-country basis, the initial €[*] Euro) incurred with respect to the sum of any Indemnified Third Party IP Claim (or the defence thereof) in a particular country in the Territory (including
any associated damages, liabilities, expenses and/or loss, reasonable legal expenses and reasonable attorneys’ fees directly resulting therefrom) plus any amounts due under any Supported Third Party License related thereto, which are addressed
in Section 7.9 (such costs related to Indemnified Third Party IP Claim and Supported Third Party License, collectively, “IP Claim Costs”)). In the event IP Claim Costs exceed €[*] Euro) in a particular country of the Territory
for any particular Indemnified Third Party IP Claim, LICENSOR shall pay [*]% ([*] percent) of IP Claim Costs with respect thereto in such country and LICENSEE shall pay [*]% ([*] percent) of the IP Claim Costs with respect thereto in such country of
the Territory. LICENSEE shall pay its portion of any IP Costs to LICENSOR as determined in accordance with the foregoing within [*] of receiving an invoice therefor from LICENSOR. 

LICENSOR shall, acting reasonably and with the aim at preserving the commercial viability of the Product in the Territory, have the sole
right to assume direction and control of the defence, settlement, and disposition of any Indemnified Third 

  
 [*]
Confidential treatment requested. 

  
 32 

 
Party IP Claim (which right may, notwithstanding anything to the contrary, be assigned and transferred to Lilly or any Third Party). Section 9.3(e) notwithstanding, neither LICENSEE, any
Affiliate thereof, nor any Sublicensee shall have the right to settle or otherwise dispose of any claim subject to this Section 9.3(d)(i) without the prior written consent of LICENSOR and, if LICENSEE, any Affiliate thereof, or any Sublicensee
does settle or voluntarily dispose of any Indemnified Third Party IP Claim without LICENSOR’s prior written consent, LICENSOR shall not have any obligation or liability under this Section 9.3(d)(i) or Section 7.9 with respect thereto
or with respect to any damages, liabilities, expenses and/or losses, including reasonable legal expenses and reasonable attorneys’ fees, related to such Indemnified Third Party IP Claim, settlement, judgment, court-based determination or
action, or other disposition thereof or any licenses executed in conjunction with any of the foregoing. 
 (ii) With respect to
any Third Party IP Claim other than an Indemnified Third Party IP Claim, LICENSEE will have the first right (but, except as provided in Section 14.2, not the obligation), at its sole expense, to assume direction and control of the defence of
such claims as they relate to Products. Should LICENSEE determine not to pursue the defence of a particular claim subject to this Section 9.3(d)(ii), LICENSEE shall notify LICENSOR within [*] after notice from LICENSOR requesting it to do so,
and LICENSOR will have the right (but not the obligation), at its sole expenses, to assume direction and control of such claims (which right may, notwithstanding anything to the contrary, be assigned and transferred to Lilly or any Third Party).
Section 9.3(e) notwithstanding, LICENSEE shall not have the right to settle or otherwise dispose of any claim subject to this Section 9.3(d)(ii) without the consent of LICENSOR, which consent will not be unreasonably withheld. 

 

	(e)	 Litigation Control. The party pursuing or controlling any action or defense under Section 9.3(c) or 9.3(d) (the “Controlling
Party”) shall be free to enter into a settlement, consent judgment, or other voluntary disposition of any such action or defense, provided, however, that (i) the Controlling Party shall consult with the other party (the “Secondary
Party”) prior to entering into any settlement or voluntary disposition thereof, (ii) any settlement, consent judgment or other voluntary disposition of such actions which (1) subjects the Secondary Party to any non-indemnified
liability or obligation or (2) admits fault or wrongdoing on the part of Secondary Party must, in each case, be approved in writing by Secondary Party, such approval not to be unreasonably withheld, and (iii) any settlement, consent
judgment or other voluntary disposition of such actions which materially limits the scope, validity, or enforceability of, or otherwise may adversely affect, any Licensed Patents, or that may relate in any material way to the use of the Active
Ingredient outside the Field, shall not be entered into, consented to, approved, or agreed upon without LICENSOR’s prior written approval. With respect to clause (ii) above, the Secondary Party shall provide the Controlling Party notice of
its approval or denial of such approval within [*] of any request for such approval by the Controlling Party, provided that (X) in the event Secondary Party wishes to deny such approval, such notice shall include a written description of
Secondary Party’s reasonable objections to the proposed settlement, consent judgment, or other voluntary disposition and (Y) Secondary Party shall be deemed to have approved such proposed settlement, consent judgment, or other voluntary

  
 [*]
Confidential treatment requested. 

  
 33 

	 	
disposition in the event it fails to provide such notice within such [*] period. Any recovery or damages received by the Controlling Party with respect to the infringement of the rights to
Licensed Patents granted under this Agreement, or defence of any Invalidation Proceeding concerning any Licensed Patent(s) under this Agreement, shall be used first to reimburse the Parties for unreimbursed reasonable, documented expenses incurred
in connection with such action, and the remainder (X) shall be split [*] percent ([*]%) to Controlling Party and [*] percent ([*]%) to Secondary Party. Any recovery or damages received by the Controlling Party with respect to any other
infringement of the Licensed Patents (i.e. outside the scope of rights granted under this Agreement) shall be used first to reimburse the Parties for unreimbursed reasonable, documented out of pocket or external expenses incurred in connection with
such action, and the remainder shall be retained by LICENSOR (in the event of any action, settlement, or voluntary disposition entered into by LICENSOR) or paid to LICENSOR by LICENSEE (in the event of any action, settlement, or voluntary
disposition entered into by LICENSEE). Notwithstanding the foregoing, and subject to Section 9.3(d), the Secondary Party, at its expense, shall have the right to be represented by counsel of its choice in any proceeding governed by this
Section 9.3(e), except that LICENSEE, if it is the Secondary Party with respect to the defence of any Invalidation Proceeding, shall not be entitled to such representation or any other participation in such Invalidation Proceeding except to the
extent permitted by LICENSOR in writing. 

  

	(f)	Cooperation. For any action or proceeding brought or defended by a Controlling Party under Section 9.3(c) or 9.3(d), the Secondary Party shall, as
reasonably requested by the Controlling Party, cooperate reasonably in any such effort, and the Parties shall reasonably cooperate to address new facts or circumstances that come to light during the course of any such action, proceeding, or defence
that may affect the need for one Party or the other to participate or cooperate in such action. The Secondary Party agrees to be joined as a party plaintiff in any such action if needed for the Controlling Party to bring or continue an infringement
action, or defend an Invalidation Proceeding, hereunder. All reasonable, documented out of pocket or external costs reasonably incurred by a Secondary Party in rendering any such cooperation and assistance requested by the Controlling Party shall be
borne by the Controlling Party. 

  

	(g)	Reimbursement. Each party shall invoice the other party for any reasonable, documented out of pocket or external costs incurred that are to be borne by
the other party pursuant to this Section 9.3. Each party shall pay the other party such amounts within [*] of its receipt of any such invoice, except to the extent such amounts are the subject of a good faith dispute, in which the amounts
subject to such dispute shall be due within [*] of the resolution of such dispute. 

  

	9.4	Patent Term Extensions. LICENSEE shall promptly notify LICENSOR of the issuance of each Product Registration. LICENSEE may request in writing that
LICENSOR shall apply for (and, if applicable, grant LICENSEE rights under) Patent Term Extensions for Licensed Patents in the country of such Product Registration if permissible and/or available. The Parties shall cooperate with each other in
obtaining such patent term extensions. 

  
 [*]
Confidential treatment requested. 

  
 34 

	9.5	Patent Challenge. LICENSEE and its Affiliates shall not take any actions that may adversely affect the Licensed Patents. If LICENSEE, any of its
Affiliates, or any Sublicensees directly, or knowingly, intentionally, or indirectly through assistance granted to a Third Party (save where such assistance is ordered by a court, patent office, or other tribunal or is required by applicable law,
rule, or regulation), commences any interference or opposition proceeding, challenges the validity or enforceability in any patent office or court proceedings of, or opposes any extension of or the grant of a supplementary protection certificate
with respect to any Licensed Patent(s) (each such action, a “Patent Challenge”), (a) LICENSEE shall provide at least [*] prior written notice to LICENSOR of such Patent Challenge and (b) where the Patent Challenge is
unsuccessful, LICENSEE shall reimburse LICENSOR’s reasonable, documented expenses incurred in defending against or taking any other action with respect to such Patent Challenge, with such reimbursement to be made within thirty (30) days of
receiving an invoice with respect to the same from LICENSOR. 

  

	9.6	Patent Marking. To the extent permitted by Applicable Laws, LICENSEE agrees to mark, and to cause any Permitted Seller Commercializing any Product to mark
Products (through a marking on containers, packaging or labels, and/or an Orange Book or like listing) made, sold, or otherwise disposed of by it or them with any notice of patent rights reasonably necessary, in any country in the Territory where
Products are sold, to (a) comply with Applicable Laws, (b) enable Licensed Patents (to the extent, in each case, relating to Products) to be enforced to their full extent, and (c) ensure the availability of all potential legal or
equitable remedies with respect to any infringement of any Licensed Patents, (to the extent, in each case, relating to Products) by any Third Party. 

  

	10	CONFIDENTIALITY 

  

	10.1	Treatment of Confidential Information. Both Parties shall hold and treat, and cause its employees, personnel and representatives (hereinafter referred to
as “Employees”) to hold and treat, all Confidential Information of the other party in confidence and not, and cause its Employees not to, publish it or disclose it to any Third Party, including its Affiliates, agents or advisers, nor use
the Confidential Information received from the other party for any purposes other than the purpose of this Agreement or as otherwise permitted hereby. Except as explicitly permitted by this Agreement, each party shall make Confidential Information
available only to those of its Employees who need to know the Confidential Information for the purpose of this Agreement. The Confidentiality and non-use obligations contained in this Section 10.1 shall survive the termination or expiration of
this Agreement for whatsoever reason and shall remain in effect for a period of [*] from the earlier or normal termination or expiration of this Agreement or, if this Agreement is terminated by LICENSEE pursuant to Section 13.2 and, in
accordance with Section 13.7(a), LICENSEE exercises its right to be granted a post-termination license pursuant to Section 13.7(a), [*] from the last date on which LICENSEE, any Affiliate thereof, or any Sublicensee exercises its rights
under such license. 

  
 [*]
Confidential treatment requested. 

  
 35 

	10.2	Exceptions. Information shall not be considered Confidential Information if, as shown by documentary evidence, it: 

 

	(a)	is in the public domain at the time of its receipt, or becomes part of the public domain thereafter through no act or omission, or breach of agreement by the receiving
party or its Employees; 

  

	(b)	is disclosed to the receiving party, without obligation of confidentiality, by a Third Party (other than ALZA or any Affiliate thereof) who was under no obligation of
confidentiality, directly or indirectly, to disclosing party, or to an agent, licensee or Affiliate of disclosing party; or 

  

	(c)	is required to be disclosed under law or by order of a court of competent jurisdiction, provided, however, that disclosing party is granted due advance notice of such a
requirement in order to be able to contest the same and then only to the minimum extent of disclosure so required. 

  

	10.3	Authorized Disclosure. A party may disclose the other party’s Confidential Information to the extent such disclosure is reasonably necessary in the
following instances: 

  

	(a)	Filing or prosecuting patents related to the Product; 

  

	(b)	Regulatory filings related to the Product and prosecution or maintenance thereof; 

 

	(c)	Prosecuting or defending litigation related to the Product; 

  

	(d)	To the extent such disclosure is required by Applicable Law; 

  

	(e)	Disclosure, in connection with the performance of or exercise of rights under this Agreement, to Sublicensees, manufacturers, collaborators, contractors, employees,
consultants, or other agents or representatives of a party or its Affiliates, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use substantially as protective as those set forth in this Article 10; or

  

	(f)	Disclosure in connection with business discussions with actual or potential investment bankers, investors, lenders, or other financing parties, consultants,
collaborators, licensees (including but not limited to Sublicensees), licensors, other strategic partners, acquirers, or acquisition or merger targets, provided that the Third Parties to whom Confidential Information of the other party is disclosed
are bound by similar obligations of confidentiality and non-use at least substantially equivalent in scope to those set forth in this Article 10; 

 provided, however, that, with respect to clauses (d) above, such disclosure shall be permitted only if, to the extent reasonably practicable, the party making such disclosure gives the other
party advance notice of such required disclosure, limits the disclosure to that actually required, and cooperates, as reasonably and promptly requested by the other party and at the other party’s expense, in the other party’s reasonably
attempts to obtain a protective order or confidential treatment of the Confidential Information required to be disclosed. 

  
 36 

	10.4	Publicity; Public Disclosure of Agreement.  

  

	(a)	The Parties agree that the public announcement of the execution of this Agreement shall be substantially in the form of the press release attached as Schedule
10.4. 

  

	(b)	Except as provided in Section 10.4(a), neither party shall disclose the existence or terms of this Agreement or any information relating to this Agreement in any
oral or written public announcement, press release or other public document (a “Public Announcement”) without the prior written consent of such other party, provided that, in the case of a Public Announcement which either party is required
by applicable law, rule, or regulation, or pursuant to the rules of any national securities exchange (e.g. NASDAQ) to make, issue or release, the making, issuing or releasing of any such Public Announcement, by the party so required to do so shall
not constitute a breach of this Agreement if such party shall have given, to the extent reasonably possible without failing to comply with any applicable law, rule, or regulation or rule of any applicable national securities exchange, reasonable
prior notice to the other party, and shall have allowed, to the extent reasonably possible, the other party to review such Public Announcement, such review to be limited to determining whether such Public Announcement contains any confidential or
proprietary information of such other party and the use of such other party’s trademarks therein. To the extent the non-disclosing party requests the deletion of any information in the Public Announcement, the disclosing party shall delete such
information, unless in the reasonable judgment of the disclosing party’s legal counsel, such information is required by applicable law, rule, or regulation, or the rules of any applicable national securities exchange, to be disclosed. Other
than any use of Product Trade IP in the Territory by LICENSEE following the Effective Date or use of any corresponding or similar trademarks by LICENSOR with respect to its Product-related activities, neither party will, without prior written
consent of the other party, use in advertising or publicity the name, trademark, logo, symbol, or other image of the other party or that party’s Affiliates, employees or agents, except as may be required in conjunction with a Public
Announcement permitted pursuant to the preceding portion of this Section 10.4(b). In any event, the parties agree to use Commercially Reasonable Efforts to avoid disclosure of the other party’s Confidential Information except as permitted
by this Agreement. 

  

	10.5	Limitations on Publications. The Parties agree that, except to the extent required by Applicable Law, LICENSEE shall not publish the results of any
studies, whether conducted by its own employees or in conjunction with a Third Party, carried out pursuant to this Agreement or Confidential Information received from LICENSOR, ALZA, or any Affiliate of either of the foregoing that relates to the
Product, without the prior written approval of LICENSOR. LICENSEE agrees to provide LICENSOR with a copy of any proposed abstracts, presentations, manuscripts, or any other disclosure which discloses clinical study results relating to the Product or
LICENSOR’S Confidential Information at least one hundred twenty (120) days prior to their intended submission for publication and agrees not to submit or present such disclosure unless and until LICENSOR provides its prior written
approval. 

  
 37 

	11	RELATIONSHIP OF PARTIES 

  

	11.1	LICENSEE not an Agent of LICENSOR. It is mutually agreed and understood that LICENSEE is not authorized to act as agent for LICENSOR or to represent
LICENSOR in any matter or in any other capacity except as specifically provided for in this Agreement, nor does LICENSEE have any authority or power to contract in the name of or create any liability against or otherwise bind LICENSOR in any way for
any purpose. All sales of the Product in the Territory shall be in LICENSEE's own name, at its own risk and for its own account. 

  

	11.2	Liability for Costs. All costs and expenses connected with the activities and performance of a Party under this Agreement, unless otherwise specified in
this Agreement or separately agreed beforehand in writing, are to be borne solely by such Party. 

  

	11.3	Pharmacovigilance. To guarantee that all applicable regulatory requirements as well as the Parties’ interests regarding pharmacovigilance of the
Product can be met, the parties shall exchange appropriate information. The parties shall negotiate in good faith a separate Pharmacovigilance and Safety Data Exchange Agreement (“PVG Agreement”), which shall be consistent with Parties
rights and responsibilities inside and outside the Territory and relevant Applicable Laws, and executed no later than the Effective Date. Once agreed upon by the Parties, the PVG Agreement will be attached to this Agreement as Schedule 11.3
and made part of this Agreement by reference. 

  

	12	REPRESENTATIONS, WARRANTIES AND COVENANTS 

  

	12.1	Mutual Authority; No Conflict; Future Encumbrances. LICENSEE and LICENSOR each represents and warrants to the other that: (a) it is duly organized
and validly existing under the laws of the country, state or jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; (b) it has taken all corporate action
necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement; (c) this Agreement is a legal and valid obligation of such party, binding upon such party and enforceable against
such party in accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy or other debtor’s rights laws and regulations; (d) it has the authority and right to enter into and perform this
Agreement; and (e) its execution, delivery and performance of this Agreement will not conflict in any material fashion with the terms of any other agreement to which it is a party or by which it is bound. 

 

	12.2	Performance by Affiliates; Performance Guarantee. The Parties recognize that each Party may perform some or all of its obligations under this Agreement
through such Party’s Affiliates, provided, however, that each Party shall remain responsible for the payment and performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection
with such performance. Further, any act, omission, or breach under this Agreement by an Affiliate of a Party shall be deemed the act, omission, or breach of such Party, who shall be liable and responsible for such act, omission, or breach as if such
Party had engaged in such act, omission, or breach. 

  
 38 

	12.3	LICENSOR Representations and Warranties. LICENSOR represents, warrants, and covenants that: 

 

	(a)	LICENSOR shall, as of the Effective Date, have the right to grant the rights granted LICENSEE under this Agreement without the consent or approval of any Third Party,
except as provided in Schedule 12.3(a). 

  

	(b)	To LICENSOR’s best knowledge as of the Execution Date, and [*]. 

  

	(c)	LICENSOR has not entered into any agreement with any Third Party which is in conflict with the rights granted to LICENSEE pursuant to this Agreement.

  

	(d)	LICENSOR has shown to LICENSEE the complete, unredacted text of all provisions of the Lilly Agreement as it exists as of the Execution Date, including any amendments or
modifications to such agreement made prior to the Execution Date. 

  

	(e)	LICENSOR shall refrain from amending the Lilly Agreement or any other agreement it has executed in such a way to create prejudice to the rights granted to LICENSEE
hereunder. 

  

	(f)	LICENSEE shall have no contractual obligations under any Distribution Agreement or Other ALZA Product Contract. 

 

	12.4	Disclaimer of Other Warranties by LICENSOR. EXCEPT AS EXPLICITLY PROVIDED UNDER THIS AGREEMENT, LICENSOR DOES NOT MAKE ANY WARRANTIES, EITHER
EXPRESS OR IMPLIED, AS TO ANY MATTER, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, AND LICENSOR DOES NOT MAKE ANY REPRESENTATION OR WARRANTY THAT THE
LICENSED INTELLECTUAL PROPERTY, ACTIVE INGREDIENT, OR ANY PRODUCT, OR THE PRACTICE, USE OR MANUFACTURE OF ANY OF THE FOREGOING, WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT OF A THIRD PARTY. 

 

	12.5	LICENSEE Representations and Warranties. LICENSEE represents, warrants, and covenants that LICENSEE has acquired, and will maintain, for its activities
under this Agreement, the necessary permits, insurance, working capital and other financing and that it has made the appropriate trade register, business and other declarations. 

  
 [*]
Confidential treatment requested. 

  
 39 

	12.6	Protective Covenants of LICENSEE. Unless otherwise notified in writing by the LICENSOR, LICENSEE shall: 

 

	(a)	for a period from the Execution Date until the [*] of the Effective Date, not promote or commercialize any product, other than a Product subject to the terms of this
Agreement, for the treatment of any indication in the Field; 

  

	(b)	for a period from the Execution Date until the [*] of the Effective Date, not acquire from any Third Party the right to promote or commercialize any product, other than
a Product subject to the terms of this Agreement, for the treatment of any indication in the Field; 

  

	(c)	for a period from the Execution Date until the [*] of the Effective Date, not enter into any agreement in which any Third Party pursuant to, or in the exercise
of rights under, such agreement may discover, develop, or commercialize any product, other than a Product subject to the terms of this Agreement, for the treatment of any indication in the Field; 

 

	(d)	for a period from the Execution Date until the [*] of the Effective Date, not otherwise enable any Third Party, directly or indirectly, discover, develop, or
commercialize any product, other than a Product subject to the terms of this Agreement, for the treatment of any indication in the Field; 

  

	(e)	not, directly or indirectly, sell, market, promote, advertise, or distribute any Products outside the Territory; 

 

	(f)	restrict its (and its Affiliates’) marketing, promotion, advertisement, sale and distribution of the Products to the Territory; 

 

	(g)	not, directly or indirectly, knowingly sell, market or distribute the Products to any person or entity for resale, marketing or distribution outside the Territory;

  

	(h)	exercise Commercially Reasonable Efforts to ensure its Affiliates, Sublicensees, other Permitted Sellers, and customers do not ship, sell or otherwise distribute the
Products for ultimate use by patients outside the Territory; and 

  

	(i)	not, directly or indirectly, sell via the Internet or mail order Products outside the Territory, and to use all Commercially Reasonable Efforts to impose, as an
essential condition of doing business, upon its Affiliates, distributors, Sublicensees, other Permitted Sellers, and customers a contractual obligation to comply with such obligation. 

LICENSEE shall ensure that all of its Affiliates and Sublicensees comply with all of the requirements and limitations of this Section 12.6.

 It is the intention of the Parties to discuss a possible extension of LICENSEE’s obligations duration under Sections 12.6(a), (b), (c),
and (d). For this purpose, the Parties shall meet at least [*] before the expiration of the relevant [*] term in order to discuss a possible legally-compliant renewal of the limitations of Sections 12.6 (a), (b), (c), and (d) for the aforesaid
duration. 

  
 [*]
Confidential treatment requested. 

  
 40 

	12.7	Protective Covenants of LICENSOR. Unless otherwise notified in writing by the LICENSEE, LICENSOR shall: 

 

	(a)	Termination of ALZA Distribution Agreements. LICENSOR shall ensure that all ALZA Distribution Agreements shall be terminated with respect to Product by
ALZA (or its Affiliates thereof) in all countries of the Territory within [*] after the Effective Date, except in countries where the ALZA Distribution Agreements have Third Parties that hold a Product Registration or Product Registration
Application for the Product, such ALZA Distribution Agreements shall be terminated within [*] after the Regulatory Transfer Date for such countries. 

  

	(b)	Termination of Other ALZA Product Contracts. With respect to any Other ALZA Product Contract, other than those that may be determined, as contemplated by
Schedule 4, to not be terminated or to be assigned to LICENSEE, LICENSOR shall use Commercially Reasonable Efforts to ensure that ALZA and its Affiliates use Transitional Commercially Reasonable Efforts to terminate, or allow to expire,
(i) any Other ALZA Product Contracts determined by the Parties and ALZA to be material to LICENSEE’s rights to manufacture, use, sell, market, develop, distribute or commercialize Product on or before the date [*] after such determination
(or, to the extent any such Other ALZA Product Contract concerns any Group A Market Country, on a country-by-country basis, the later of (I) the date [*] after such determination or (II) the date [*] after the earlier of (x) the applicable
Regulatory Transfer Date or (y) the date [*] following the Effective Date) and (ii) all other Other ALZA Product Contracts material to LICENSEE’S rights to manufacture, use, sell, market, distribute or commercialize Product no later
than the date [*] after the Effective Date. 

  

	(c)	With respect to the Group B Market Countries and Group C Market Countries, LICENSOR shall ensure that ALZA and its Affiliates will not commercialize and sell the
Product in such countries following the Effective Date. 

  

	13	TERM AND TERMINATION 

  

	13.1	Term. Unless sooner terminated as hereinafter provided, this Agreement shall continue in full force and effect until the expiration of the Term. After the
expiration of the Term, LICENSEE shall, on a Product-by-Product and country-by-country basis, have a perpetual, royalty-free, fully paid up, non-exclusive license to continue, at its discretion, to use Licensed Know-How to produce (or have produced)
the Active Ingredient in the Territory, and to make (or have made), promote, market, distribute, offer to sell, sell and import the applicable Product in the applicable country in the Territory, under the Licensed Know-How and any Product
Registrations in the Territory and LICENSEE shall retain all right, title and interest in the Product Trademarks in the Territory it being understood that, if pursuant to any applicable law, a perpetual license is not permitted or may be terminated,
during its term and without reason, by any Party, such license shall be considered to last for a minimum period of 30 (thirty) years after the expiration of this Agreement. 

  
 [*]
Confidential treatment requested. 

  
 41 

	13.2	Termination for Material Breach. Each party to this Agreement shall have the right to terminate this Agreement if the other Party does not fulfil its
obligations according to this Agreement and does not remedy the alleged breach within thirty (30) days from receipt of written notification by the non-breaching Party specifying the occurred material breach, provided however, if cure
cannot be reasonably affected within such 30-day period, to deliver to the non-breaching Party a plan for curing such breach which is reasonably sufficient to effect a cure. Such a plan shall set forth a program for achieving cure as rapidly as
practicable and specify a Commercially Reasonable date for achieving such cure consistent with the foregoing, which shall not, in any event, exceed [*]. Following delivery of such plan, the breaching Party shall use Commercially Reasonable Efforts
to carry out the plan and cure the breach by such date. If the breaching Party fails to cure such breach within the 30-day period (or such later date set forth in the plan provided by the breaching Party in accordance with the foregoing, which shall
not in any event exceed [*] following notice of such breach), or the non-breaching Party reasonably determines that: (a) the proposed corrective plan or the actions being taken to carry it out is/are not commercially practicable by the
specified date; or (b) the specified date for cure in such plan does not represent a commercially reasonable date to achieve such cure as rapidly as practicable through the application of the breaching Party’s commercially reasonable
efforts, the non-breaching Party may, upon written notice, terminate this Agreement in its entirety pursuant, subject to the effects of termination described in Section 13.7 below. Except as otherwise provided in this Agreement, all termination
rights shall be in addition to and not in substitution for any other remedies that may be available to the non-breaching Party. 

  

	13.3	Bankruptcy rights. In the event that this Agreement is terminated or rejected by a Party or its receiver or trustee under any applicable bankruptcy
laws due to such Party’s bankruptcy then all rights and licenses granted under or pursuant to this Agreement by such Party to the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States
bankruptcy code and any similar law or regulation in any other country, licenses of rights to “intellectual property” as defined under Section 101(52) of the United States bankruptcy code. The Parties agree that all intellectual
property rights licensed hereunder, including without limitation, any patents or patent applications of a Party in any country covered by the license grants under this Agreement, are part of the “intellectual property” as defined under
Section 101(52) of the United States bankruptcy code subject to the protections afforded the non-terminating Party under the Section 365(n) of the United States bankruptcy code, and any similar law or regulation in any other country.

  

	13.4	Termination for Diligence. LICENSOR shall have the right to terminate this Agreement, in whole or in part, as set forth in Section 3.2.

  

	13.5	Termination for Patent Challenge. This Agreement may be terminated by LICENSOR upon written notice to LICENSEE, effective upon receipt, in the
event of any Patent Challenge by LICENSEE, any Affiliate thereof, or any Sublicensees or other breach of Section 9.5. 

  

	13.6	 Termination Upon Termination of Lilly Agreement. LICENSOR shall use its best efforts to comply with its obligations under the
Lilly Agreement, subject to LICENSEE’s performance of its corresponding obligations with this Agreement, 

  
 [*]
Confidential treatment requested. 

  
 42 

	 	
provided that, subject to any provisions agreed upon directly between LICENSEE and Lilly, this Agreement shall terminate upon any termination of the Lilly Agreement. LICENSOR shall provide
LICENSEE notice of any such termination of the Lilly Agreement as soon as reasonably possible. 

  

	13.7	Effects of Termination. 

  

	(a)	Termination by LICENSEE under Section 13.2 for Loss of Exclusivity. In case of termination of this Agreement by LICENSEE pursuant to
Section 13.2 as result of an uncured material breach by LICENSOR of Section 2.1 following the Effective Date that would be reasonably likely to enable a Third Party (other than any Permitted Seller) to sell Product in the Field in the
Territory under the Licensed Patents and Licensed Know-How in a manner not authorized by LICENSEE, any Affiliate thereof, or any Sublicensee (such an uncured breach, an “Exclusivity Breach”), and the occurrence of such Exclusivity Breach
is agreed to in writing by LICENSOR or conclusively determined pursuant to Section 16.3, LICENSEE may elect, by written notice to LICENSOR given prior to the effective date of termination and as LICENSEE's sole and exclusive remedy with respect
to such breach, to have LICENSEE’s rights under Section 2.1 continue following such termination in order to permit LICENSEE to produce (or have produced) the Active Ingredient, to make (or have made), promote, market, distribute, offer to
sell, sell and import the Product in the Territory, under Licensed Patents and Licensed Know-How Controlled by LICENSOR at the time of termination and any Product Registrations in the Territory, and to continue the use of the Confidential
Information for such purposes, until the period (including possible extensions) set forth in Section 13.1, and LICENSEE shall, subject to Section 13.7(b), remain the ultimate owner of the Product Trademarks in the Territory. If LICENSEE
exercises its option to have its rights under Section 2.1 survive such termination in accordance with the foregoing, (i) LICENSEE’s rights under Section 2.1, rights and obligations under Section 2.3, and obligations under
Sections 3.1, 3.6, and 8 and Sections 2.8 and 12.6 shall survive such termination (subject to any later termination of LICENSEE’s rights as contemplated below), (ii) Sections 7.3, 7.4, 7.5, 7.6, 7.8, 9.3(d), 9.3(e), 9.3(f), and 9.3(g)
shall remain in effect and applicable between the Parties, (iii) no amounts shall be paid pursuant to Section 7.2 for any milestone events achieved following such termination and the amounts due to LICENSOR under Sections 7.3 and 7.4,
respectively, with respect to sales-based milestones achieved or Net Sales occurring, respectively, after such termination shall be reduced by [*] percent [(*)]%) from those stated in Sections 7.3 and 7.4, respectively, and (iv) LICENSEE’s
election to have its Product-related rights survive such termination shall be LICENSEE’s sole and exclusive remedy with respect to the uncured breach of LICENSOR enabling such termination. Notwithstanding anything to the contrary,
LICENSEE’s surviving rights under Section 2.1 and 2.3 shall remain subject to termination by LICENSOR pursuant to Section 13.2 (with respect to any pre-termination breaches by LICENSEE or any post-termination breaches by LICENSEE of
its surviving obligations), 13.5, or 13.6 and, in the event of any such termination by LICENSOR, LICENSEE’s rights under Section 2.1 and 2.3 of this Agreement shall terminate and Section 13.7(b) shall apply with respect to such
termination. 

  
 [*]
Confidential treatment requested. 

  
 43 

	(b)	 All Other Terminations. In case of (I) any termination of this Agreement, other than a termination by LICENSEE pursuant to
Section 13.2 for which LICENSEE has exercised its right to have its rights under Section 2.1 continue following termination as contemplated by Section 13.7(a), or (II) any termination by LICENSOR of LICENSEE’s rights under
Sections 2.1 and 2.3 following such an election under Section 13.7(a) by LICENSEE, with any such termination by LICENSOR pursuant to Section 13.2 under clause (I) or clause (II) of this Section 13.7(b) requiring, for purposes of
this Section 13.7(b), that the occurrence of such termination is agreed to in writing by LICENSEE or conclusively determined pursuant to Section 16.3, LICENSEE and its Affiliates, at their sole cost, shall, as quickly as reasonably
possible: (a) if and as requested by LICENSOR in writing, shall transfer and assign to LICENSOR all right, title, and interest in (and, with respect to any tangible materials, transfer possession to LICENSOR of) all: (i) Product-related
applications for approval, health registrations, approvals, licenses, and consents with any Regulatory Authority or other governmental agency, which shall include but not be limited to all Product Registrations, Product Registration Applications and
all filings, submissions, correspondence, amendments, and other materials related to any of the foregoing, in each case with respect to the portion of the Territory subject to such termination; (ii) Product-related intellectual property owned
or controlled by LICENSEE or any Affiliate thereof, including but not limited to Patents, Know-How, inventions, data, databases and reports, with respect to such portion of the Territory; (iii) quantities of Active Ingredient and Product, and
any work in process with respect thereto, intended for use or sale in the portion of the Territory subject to such termination; (iv) Product-Related Materials concerning the portion of the Territory subject to such termination; and
(v) Product Trade IP in that portion of the Territory subject to such termination (including Assigned Trademarks), (b) undertake to provide LICENSOR with any and all information in LICENSEE’s or its Affiliates’ possession or
control regarding the Development or Commercialization of the Product in the portion of the Territory subject to such termination, and ensure that all such information is provided to LICENSOR or its designee, and (c) reasonably provide LICENSOR
all relevant and material information requested by LICENSOR concerning any manufacturing, supplier, distributor, research, development, license, or other contracts concerning the Development or Commercialization of Products in the portion of the
Territory subject to such termination entered into by LICENSEE or its Affiliates with Third Parties (“LICENSEE Product-Related Contracts”) and, if and as subsequently requested by LICENSOR, use Commercially Reasonable Efforts to assign
such LICENSEE Product-Related Contracts to LICENSOR or otherwise help facilitate introductions and/or negotiations between LICENSOR and such Third Parties. The “Termination Transition Period” for each country in the Territory shall begin
upon such termination or, if LICENSOR is terminating the Agreement or LICENSEE’s rights under Sections 2.1 and 2.3 pursuant to Section 13.2, when the occurrence of the termination is agreed to in writing by LICENSEE or conclusively
determined pursuant to Section 16.3, and end on the earlier of (I) the date the activities referenced in the preceding sentences of this Section 13.7(b) have been completed to LICENSOR’s reasonable satisfaction for such country
or (II) the date LICENSOR has indicated by written notice to LICENSEE that LICENSOR considers the Termination Transition Period to have expired for such country. During the Termination Transition Period for a particular country, LICENSEE shall
continue to fill any outstanding orders for Product in such country and fulfil any all obligations 

  
 44 

	 	
under the PVG Agreement and any Applicable Laws related to any Product Registrations and clinical trial agreements for the Product in such country. LICENSEE agrees to execute, and cause to be
executed, any documents required by LICENSOR to effect the above-referenced assignments and transfers acting in good faith co-operation with LICENSOR and in a manner which will not cause any delay or interruptions to, or otherwise materially and
adversely affect, the Development or Commercialization of the Product in the Territory and at all times within fifteen (15) days from request therefor by LICENSOR. During the Termination Transition Period in a country, LICENSEE’s license
rights shall convert from an exclusive license to a co-exclusive license (with LICENSOR, its Affiliates, and any licensees or sublicensees of any of LICENSOR or any of its Affiliates). Following expiration of the Termination Transition Period in a
country, this Agreement shall terminate and any and all rights and licenses granted to LICENSEE by LICENSOR pursuant to this Agreement with respect to such country(ies) shall terminate and LICENSEE, its Affiliates, and Sublicensees shall cease all
Development and Commercialization of the Product with respect to such country(ies). 

  

	13.8	Additional Remedies/Reduced Payments. Except as otherwise explicitly set forth in this Agreement, termination of this Agreement under this Article 13 or
any other provision of this Agreement providing any right of termination shall not be exclusive or prejudicial to any legal or equitable rights or remedies each party may have on account of any breach or default of this Agreement or otherwise. The
Parties hereby agree and acknowledge that (i) except as otherwise explicitly set forth in this Agreement, the license grants (or extensions thereof), assignments, and related financial terms, if any, provided in Section 13.7 are in
addition to, and without limitation of, any legal or equitable remedies that may be available with respect to any breach of this Agreement and (ii) the financial terms provided in Section 13.7(a) constitute a reasonable, fair, and
equitable reflection of the relative value of each Party’s contributions and interest in the future value of the opportunity presented under this Agreement in the event of the circumstances under which such economic terms apply, and are not
intended, and shall not be construed, as a form of penalty for any act or omission under this Agreement. 

  

	13.9	Survival. Except as set forth herein, any termination or expiration of this Agreement shall not relieve either Party of any obligation which has accrued
prior to the effective date of such termination or expiration, which obligations shall remain in full force and effect. In addition, the following provisions of this Agreement shall, in addition to any provisions specified elsewhere in this
Agreement as surviving termination hereof in certain circumstances, survive any termination or expiration hereof: Articles 1 (excluding Section 1A), 8, 10, 13 (to the extent set forth therein), 14, 15, 16, and 17 and Sections 2.4, 2.5, 2.7,
3.7(b) (with respect solely to the last two sentences thereof), 5.1, 5.4, 5.5, 7.6, 7.7, 7.9(b), 7.10, 9.1, 9.3(c) (with respect to applicable infringements occurring prior to termination or expiration of this Agreement), 9.3(d) (with respect to
applicable infringements occurring prior to termination or expiration of this Agreement), 9.3(e) (as it relates to the surviving effects of Section 9.3(d) or 9.3(e)), 9.3(f), 11.1, 11.2, 12.2, and 12.4. 

  
 45 

	14	INDEMNIFICATION AND LIMITATION OF DAMAGES 

  

	14.1	 LICENSOR Indemnification. LICENSOR shall defend and indemnify LICENSEE and its Affiliates (“LICENSEE Indemnitees”) and keep
them harmless from and against all suits, claims, proceedings or causes of action brought by any Third Party(ies) (“Claims”), and all associated damages, liabilities, expenses and/or loss, including reasonable legal expenses and reasonable
attorneys’ fees (“Losses”), (V) based on LICENSOR’s or its Affiliates’: (a) breach of this Agreement or failure to comply with any Applicable Laws related to any Product or (b) development, manufacture, use,
sale, distribution, offering for sale, importation, or exportation of Products outside the Territory before and following the Effective Date (which shall include but not be limited to any such liability based on product liability or any personal
injury or death resulting from the administration of any Product to any human subject or patient by or on behalf of LICENSOR or any Affiliate thereof), (W) prior to the Effective Date, directly or indirectly resulting from ALZA’s, its
Affiliates, or ALZA’s or its Affiliates’ licensees’ manufacture, use, sale, offering for sale, marketing, distribution, import, export, development, or commercialization in a particular country in the Territory of Product ,
(X) directly or indirectly resulting from ALZA’s or its Affiliates’ (a) gross negligence or intentional misconduct in connection with the Asset Transfer Agreement, the performance of ALZA’s or its Affiliates’
obligations or exercise of ALZA’s rights thereunder, or ALZA’s, its Affiliates’, or their contractors’ distribution of finished Existing Product in any Group A Market Country on behalf of LICENSOR (and not LICENSEE) during the
period from, on a country-by-country basis, the Effective Date until the Country Transfer Date in a particular country (the “LICENSOR Distribution Period” for a country), (b) the breach of one or more of ALZA’s covenants,
agreements or obligations under the Asset Transfer Agreement, or (c) ALZA’s or any Affiliate’s failure to comply with any Distribution Law related to Existing Product (or the use, development, manufacture, sale, distribution,
promotion, marketing, import, or export thereof), (Y) directly resulting from ALZA’s, its Affiliates’, or any of ALZA’s or its Affiliates’ contractors’ (q) sale or distribution on behalf of LICENSOR (and not
LICENSEE) of any finished Existing Product in any Group A Market Country during the LICENSOR Distribution Period that does not meet the specifications established in the applicable Product Registration(s) for the design, composition, manufacture,
packaging, and/or quality control of such Existing Product as of the Effective Date (as such specifications may be later amended by LICENSOR and ALZA (or an Affiliate thereof) in accordance with Applicable Laws), including the reasonable, documented
costs of any recalls with respect to any such Existing Product, or (r) sale or distribution on behalf of LICENSOR (and not LICENSEE) of any finished Existing Product satisfying the aforementioned specifications in any Group A Market Country
during the LICENSOR Distribution Period, or (Z) violation of the United States’ Foreign Corrupt Practices Act (15 U.S.C. § 78 dd-1 et seq.) (the “FCPA”), or the Organisation for Economic Co-operation and Development’s
Anti-Bribery Convention (including the United Nations Convention against Corruption (resolution 58/4 of October 31, 2003)) collectively “OECD”), by LICENSOR, any Affiliate thereof, or any Third Party selling or distributing
Existing Product on LICENSOR’s behalf in the course of, in each case, such party’s distribution or sale of Existing Product in any Group A Market Country during the LICENSOR Distribution Period, except to the extent (I) such
liabilities, damages, claims, costs 

  
 46 

	 	
or expenses were caused by or arose from (i) LICENSEE’s, its Affiliates’, agents’, employees’, Sublicensees’, or other representatives’ (A) negligence,
wilful or criminal misconduct, breach of this Agreement, or failure to comply with any Applicable Laws or (B) Development, manufacture, use, sale, distribution, offering for sale, importation, exportation, or Commercialization of Products
(which shall include but not be limited to any liability based on product liability or any personal injury or death resulting from the administration of any Product to any human subject or patient) or (ii) any claim related to LICENSEE-Added IP
and other than an Indemnified Third Party IP Claim, by or on behalf of any Third Party that the manufacture, use, sale, offering for sale, import, export, Development, or Commercialization, by or on behalf of LICENSEE, any Affiliate thereof, or any
Sublicensee, of the Active Ingredient or any Product infringes a Third Party’s intellectual property rights or constitutes misappropriation of such Third Party’s trade secrets or (II) with respect to all Losses associated with any and all
Claims resulting from any of the circumstances in clause (Y)(q) above, such Losses exceed USD$[*] in the aggregate (i.e. the maximum total indemnification provided by LICENSOR hereunder with respect to all such Losses and Claims shall not exceed
USD$[*] in the aggregate). 

  

	14.2	LICENSEE Indemnification. LICENSEE shall defend and indemnify and LICENSOR, its Affiliates, directors, officers, employees, agents and other
representatives (“LICENSOR Indemnitees”) and keep them harmless from and against (I) all Claims and Losses based on LICENSEE’s, its Affiliates’, agents’, employees’, Sublicensees’, or other
representatives’: (a) negligence, wilful or criminal misconduct, breach of this Agreement, or failure to comply with any Applicable Laws or (b) Development, manufacture, use, sale, distribution, offering for sale, importation,
exportation, or Commercialization of Products (which shall include but not be limited to any liability based on product liability or any personal injury or death resulting from the administration of any Product to any human subject or patient) or
(c) any claim related to LICENSEE-Added IP (without prejudice to the indemnification by LICENSOR under Section 9.3(d)(i), for an Indemnified Third Party IP Claim) by or on behalf of any Third Party that the manufacture, use, sale, offering
for sale, import, export, Development, or Commercialization, by or on behalf of LICENSEE, any Affiliate thereof, or any Sublicensee, of the Active Ingredient or any Product infringes a Third Party’s intellectual property rights or constitutes
misappropriation of such Third Party’s trade secrets and (II) all Claims, Losses, and other damages, liabilities, expenses, costs and/or losses (including those associated with any recall or withdrawal of Product) directly or indirectly
resulting from ALZA’s, its Affiliates’, or any of ALZA’s or its Affiliates’ contractors’ sale or distribution during the LICENSOR Distribution Period on behalf of LICENSOR (and not LICENSEE) of any finished Existing Products
in any Group A Market Country that do not meet the specifications established in the applicable Product Registration(s) for the design, composition, manufacture, packaging, and/or quality control of such Existing Products as of the Effective Date
(as such specifications may be later amended by LICENSOR and ALZA (or an Affiliate thereof) in accordance with Applicable Laws), to the extent all such Claims, Losses, and other damages, liabilities, expenses, costs and/or losses exceed USD$[*] in
the aggregate; except to the extent, however, that such liabilities, damages, claims, costs or expenses were caused by the recklessness, willful or criminal wrongdoing, negligence, or breach of this Agreement by a LICENSOR Indemnitee.

  
 [*]
Confidential treatment requested. 

  
 47 

	14.3	Conditions of Indemnification. With respect to any indemnification obligations of either party under this Agreement: 

 

	(a)	the indemnified party shall notify the indemnifying party promptly in writing and reasonable detail of the relevant claim, damages, or losses which may give rise to an
obligation on the part of the indemnifying party hereunder; 

  

	(b)	the indemnifying party shall be allowed to timely undertake the sole control of the defence of any third party action and claim subject to indemnification hereunder,
including all negotiations for the settlement, or compromise of such claim or action at its sole expense; and 

  

	(c)	the indemnified party shall, at the expense of the indemnifying party, render reasonable assistance, information, co-operation and authority to permit the indemnifying
party to defend such action. 

 Notwithstanding the foregoing, however, (i) the failure or delay to notify the
indemnifying party shall not relieve the indemnifying party of any obligation or liability that it may have to the indemnified party except to the extent that the indemnifying party demonstrates that its ability to defend or resolve the relevant
Third Party claim is adversely affected thereby, (ii) in no event may the indemnifying party compromise or settle any suit, claim, proceedings or causes of action subject to indemnification hereunder in any manner that (A) admits fault or
wrongdoing on the part of any indemnified party or incur non-indemnified liability on the part of any indemnified party without the prior written consent of the indemnified party or (B) adversely affects the Licensed Patents, Licensed Know-How,
Product Registrations, or Product Registration Applications without the prior written approval of LICENSOR, and (iii) no indemnified party shall enter into any settlement of any claim subject to indemnification under this Section 14
without the prior written consent of the indemnifying party with respect thereto, such consent not to be unreasonably withheld. 

Notwithstanding anything to the contrary, an indemnified party shall have the right to employ separate counsel and to participate in the
defense of any action subject to indemnification hereunder, and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel if: (i) the use of counsel chosen by the indemnifying party to represent the
indemnified party would present such counsel with a conflict of interest, and the indemnifying party does not elect to engage new counsel without such a conflict; (ii) the indemnifying party shall not have employed counsel reasonably
satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of the institution of such action; or (iii) the indemnifying party shall authorize the indemnified party to employ separate counsel
at the indemnifying party’s expense. 
  

	14.4	 Limitation of Damages. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE, FRAUD, WILFUL MISCONDUCT, PATENT INFRINGEMENT BY A PARTY OR ITS
AFFILIATES, OR BREACH OF ARTICLE 10 OR WITH RESPECT TO THE 

  
 48 

	 	
INDEMNIFICATION PROVIDED UNDER SECTION 9.3 AND ARTICLE 14, IN NO EVENT SHALL EITHER PARTY HAVE ANY LIABILITY TOWARDS THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY OR
CONSEQUENTIAL DAMAGES CLAIMED BY THE OTHER PARTY, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, INCLUDING, BUT NOT LIMITED TO THE LOSS OF OPPORTUNITY, LOSS OF USE, OR LOSS OF REVENUE OR
PROFIT, IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT. 

  

	15	COMPLIANCE WITH LAWS AND GOOD BUSINESS PRACTICE 

 (a) LICENSEE will comply with all Applicable Laws and with good business practice with respect to the Development and Commercialization of Products under this Agreement and its exercise of the rights
granted hereunder. Should any of the provisions in this Agreement be contrary to Applicable Law in any jurisdiction, LICENSEE will promptly inform LICENSOR of any discrepancies between the stipulations in this Agreement and the relevant mandatory
provisions in such Applicable Law. Upon such notification, the parties shall negotiate on the revision of the provision(s) to conform to said Applicable Law. Notwithstanding the foregoing, any invalidity, illegality or limitation of the
enforceability with respect to any one or more of the provisions of this Agreement, or any part thereof, shall in no way affect or impair the validity, legality or enforceability of any other provisions of this Agreement. 

(b) Each Party represents and warrants to the other Party that all activities performed, directly and indirectly, under this Agreement
shall be conducted in accordance with all Applicable Laws in force from time to time without exclusions and/or exceptions. 

Either Party, in performing this Agreement, represents and warrants that it will fully and absolutely comply with the provisions of any
applicable legislation on crimes prevention (e.g. OECD and FCPA), as are in force from time to time (hereinafter referred to as the “LAWS”), commits itself to adopt all necessary measures to prevent violation to the LAWS and, more in
general, crimes commission. 
 Without limiting the foregoing, either Party agrees that it will not, in the conduct of its
performance under this Agreement, offer, pay, give, or promise to pay or give, directly or indirectly, any payment or gift of any money or thing of value to (i) any government official to influence any acts or decisions of such official or to
induce such official to use his influence with any government to effect or influence the decision of such government in order to assist the Party in its performance of its obligations under this Agreement or to benefit either of the Parties;
(ii) any political party or candidate for public office for such purpose; or (iii) any person if either Party knows or has reason to know that such money or thing of value will be offered, promised, paid, or given, directly or indirectly,
to any official, political party, or candidate for such purpose. 
 A defaulting Party shall hold harmless and indemnify the
other Party from any and all claim, expense, fine, sanction, prejudice, obligations, consequences or adverse implications that may arise resulting from the conduct of the defaulting Party violating the LAWS. 

  
 49 

 A violation or a threatened violation of the LAWS carried out by individuals in top
positions, de jure or de facto, within the company organization of the defaulting Party or by its employees, consultants, representatives, proxys, agents and/or by those who act, for any reason, in the interest or for the advantage of the
defaulting Party shall constitute a material breach under this Agreement and, therefore, the non defaulting Party shall have the right to terminate this Agreement with immediate effect by simple written notice to the defaulting Party and without
prejudice to any other remedy the non defaulting Party may be entitled to. 
  

	16	DISPUTE RESOLUTION 

  

	16.1	Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during the term of this Agreement which relate to
either party’s rights and/or obligations hereunder. It is the objective of the parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort
to litigation. To accomplish this objective, the parties agree to follow the procedures set forth in this Article 16 if and when a dispute arises under this Agreement. Any and all disputes, controversies or claims of any sort arising from this
Agreement shall first be discussed by the parties hereto, who shall try to settle the dispute among themselves. Should the parties fail to resolve such matter within thirty (30) days of notice from either party initiating such discussions, the
matter in dispute shall be submitted, by written notice from either party, to the CEO of LICENSEE and a designee of LICENSOR, who shall try to resolve the matter within fifteen (15) business days of such notice. In case such executives are
unable to resolve such matter within such fifteen (15) business day period, the dispute shall be finally resolved under Section 16.3. The foregoing procedure shall be applicable also in case of disputes between the Parties not able to
determine the termination of this Agreement on one party’s request. 

  

	16.2	Governing Law. This Agreement shall be deemed to be a contract made under and shall be governed by and construed in accordance with the laws of the
England, without regard to its conflict of laws provisions. It is specifically agreed that the United Nations Convention on Contracts for the International Sale of Goods is not applicable to this Agreement. 

 

	16.3	 Arbitration. All disputes arising under or in connection with this Agreement, and not resolved in accordance with Section 16.1,
shall be finally settled by binding arbitration, initiated by either party on ten (10) day’s notice to the other party, under the Rules of Arbitration of the International Chamber of Commerce (“ICC”), applying the laws of
England, without regards to its conflicts of law provisions, before three (3) independent, neutral arbitrators experienced in the international pharmaceutical industry. The place of arbitration shall be New York, New York. LICENSEE and LICENSOR
shall each be entitled to select one (1) such arbitrator, with the two (2) such arbitrators so selected selecting the third such arbitrator. 

  
 50 

	 	
In the event either party fails to select its arbitrator within such ten (10) day period, the arbitrator selected by the other party within such ten (10) day period shall be entitled to
select such arbitrator. The arbitration shall be conducted in English. The decision of the arbitrators will be final and binding on the parties, and any decision of the arbitrators may be enforced in any court of competent jurisdiction.
Notwithstanding the foregoing, either party may seek injunctive, equitable, or similar relief from a court of competent jurisdiction as necessary to enforce its rights hereunder without the requirement of arbitration. 

 

	17	MISCELLANEOUS 

  

	17.1	Entire Agreements and Amendments. This Agreement, together with all Schedules hereto and the Pharmacovigilance Agreement, represents the full and
complete understanding and agreement of the parties pertaining to the subject matter hereof and prevails over all statements, clauses or conditions which may be contained in any other form or document. There are no covenants, promises, agreements,
warranties, representations, conditions or understandings, either oral or written, between the parties other than as are set forth herein and therein. No modifications and amendments to this Agreement shall be valid unless made in writing and signed
by duly authorised representatives of both parties. 

 In case of discrepancies between this Agreement and any
Schedule, the provisions of this Agreement shall prevail. 
  

	17.2	Force Majeure. In the event of a “force majeure”, i.e., in the event that further performance of this Agreement or any part hereof by
either party shall be materially impeded or rendered impossible, in whole or in part, either directly or indirectly, by or as a consequence of any force majeure event – provided that such event is beyond the reasonable control of the effected
party—such as fire, flood, accident, explosion, other natural disaster or act of God, general labour dispute, delay in commercial carriers or transportation facilities, shortage of labour, failure to obtain normal sources of raw materials, or
shortage of fuel or power, general strike, lockout, boycott, civil disturbance, war (either declared or undeclared), riot, sabotage, or as a result of any law, regulation, order, rule, direction, priority, seizure, allocation, requisition, or any
further or other official action by any governmental, local or national department, bureau, board, administration, or other instrumentality or agency, or any government or political subdivisions thereof having jurisdiction over such party, or any
other similar supervening or unforeseeable event or cause beyond the reasonable control of such party, such party shall not be considered in default hereunder by reason of any failure to perform occasioned thereby provided that the party so affected
by force majeure has forthwith, and in any event at the latest on the fourteenth (14th) day as of the commencement of the relevant force majeure circumstance, informed the other party in writing of such force majeure. Such party shall, however,
use reasonable efforts to overcome such force majeure to the extent such may be reasonably possible. 

  

	17.3	Non-Waiver. Either party’s failure to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver of any such right
or operate to bar the exercise of performance thereof at any time or times thereafter; nor shall its waiver of any right hereunder at any given time, including rights to any payment, be deemed a waiver thereof for any other time.

  
 51 

	17.4	Notices. Notices provided hereunder to be given by either party to the other shall be in writing and shall be sent by facsimile or e-mail (with
transmission confirmed), or delivered by recognised overnight delivery service or sent by government mail service (certified or registered air mail) to the following respective addresses or to such other addresses as the parties may hereafter
communicate to each other in writing: 

 If to LICENSOR: 

GENUPRO, Inc. 

c/o Furiex Pharmaceuticals, Inc. 
 3900 Paramount Parkway 
 Suite 150 

Morrisville, NC 27560 
 Attn: President 
 Fax: 919-456-7850 

If to LICENSEE: 

BERLIN CHEMIE AG 

(MENARINI GROUP) 

Glienicker Weg 125, 
 12489 Berlin Germany 
 Fax: +49 30 6707 3443 

Attn: CFO 
 The
notices shall be deemed to have been received as follows: 
 (a) facsimiles and e-mails, on the day following transmission;

 (b) registered air-mail, on the fifth (5th) days after mailing; 
 (c) notices delivered in any other form, on the day when delivered at the address of the recipient. 
 Nothing contained herein shall justify or excuse failure to give oral notice for the purpose of informing the other party hereto when prompt notification is required, but, it is understood that such oral
notice shall in no way satisfy the requirement of a written notice. 
  

	17.5	No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against either party. 

 

	17.6	 Assignment of Agreement. Without prejudice to the other provisions otherwise in this Agreement, this Agreement may not be assigned by
either party without the other party’s express written consent, provided that, notwithstanding the foregoing, (a) each party shall have the right, upon prior written notice to the

  
 52 

	 	
other party, to assign its obligations under this Agreement without the other party’s consent to one of its Affiliates for so long as such Affiliate remains an Affiliate of such party,
provided that the assigning party shall remain, however, responsible towards the other party for the proper fulfilment of any obligation of this Agreement assigned to the Affiliate and (b) LICENSOR may assign this Agreement without
LICENSEE’s consent to an Affiliate of LICENSOR or to a Third Party in connection with the transfer or sale of all or substantially all of LICENSOR’S assets or business (or the portion of such assets or business related to the subject
matter hereof), its merger, consolidation with another company, or other reorganization. This Agreement shall be binding upon the successors and permitted assigns of the parties. Any assignment or attempted assignment by either party in violation of
the terms of this Section 17.6 shall be null and void and of no legal effect. 

  

	17.7	Headings. All section headings in this Agreement are for convenience only and shall not in any way affect the meaning or interpretation of the
Agreement. 

  

	17.8	Further Actions. Each party agrees to execute, acknowledge and deliver such further instruments, and to do all such other reasonable acts, as may
be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

  

	17.9	No Implied Licenses. Except as expressly and specifically provided under this Agreement, the Parties agree that neither party is granted any
implied rights to or under any of the other party’s current or future patents, trade secrets, copyrights, moral rights, trade or service marks, trade dress, or any other intellectual property rights. 

 

	17.10	Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Any counterpart hereof may be delivered via telecopier, with the intent and understanding that any such counterpart shall have the effect of an original counterpart hereof. 

  
 53 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed in duplicate by
their duly authorised representatives. 
  

			
	GENUPRO, INC.
		
	 By:
	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 
		
	 Date:
	 	 

  

			
	 BERLIN CHEMIE AG

		
	 By:
	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 
		
	 Date:
	 	 

 SCHEDULE 1.46-A 

EUT COUNTRIES 
  

	1.	[*] 

  
 [*]
Confidential treatment requested. 

 SCHEDULE 1.46-B 

CIS COUNTRIES 
  

	1.	[*] 

  
 [*]
Confidential treatment requested. 

 SCHEDULE 1.46-C 

ASIA PACIFIC COUNTRIES 
  

	1.	[*] 

  
 [*]
Confidential treatment requested. 

 SCHEDULE 1.46-D 

SCA COUNTRIES 
  

	1.	[*] 

  
 [*]
Confidential treatment requested. 

 SCHEDULE 1.51 
 LICENSED PATENTS 
  

									
	 South Africa
	  	93/0694	  		 	2/1/93	 	Pharmaceutical Treatments
	 Chile
	  		  	 [*]
 5/31/2004
	 		 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Malaysia
	  	125490-A	  	 PI 20003983

8/29/00
	 	8/30/06 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Australia
	  	762934	  	 68911/00

8/22/00
	 	10/30/03 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Bulgaria
	  	BG65677	  	 106.461

8/22/00
	 	8/26/2009 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Brazil
	  		  	[*] 8/22/00	 		 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Brazil
	  		  	 [*]
 8/22/00
	 		 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 China
	  	 ZL 00815313.2
 (announcement
no. CN 1222283)
	  	 00815313.2

8/22/00
	 	10/12/2005 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Costa

Rica
	  		  	 [*]
 8/22/00
	 		 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Czech

Rep
	  	299 712	  	 PV2002-784

8/22/00
	 	9/18/08 [*]	 	Use of Dapoxetine for Management of Sexual Dysfunction by Administering on an As-Needed Basis
	 Armenia

Azerbaijan

Belarus

Kazakhstan

Kyrgyzstan

Moldova

Russia

Tajikistan

Turkmenistan
	  	004101	  	 200200324

8/22/00
	 	12/25/03 [*]	 	Use of a Rapid-Onset Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Estonia
	  	05315	  	 P200200107

8/22/00
	 	9/7/10 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 EPO

Albania

Austria

Belgium

Switzerland

Cyprus

Germany

Denmark

Spain

Finland

France

Greece

Ireland

Italy

Lithuania

Luxembourg

Latvia

Monaco

Macedonia

Netherlands

Portugal

Romania

Sweden

Slovenia

UK
	  	 1225881
 German Patent No.
60026146.8-08
	  	 00957264.5

8/22/00
	 	2/22/06 [*]	 	The Use of Dapoxetine, a Rapid-Onset Selective Serotonin Reuptake Inhibitor, for Treating Sexual Dysfunction

  
 [*]
Confidential treatment requested. 

  

									
	 EPO divisional
	  		  	06002333.0
 8/22/00
	 		 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Hong Kong
	  	HK1047545	  	02109124.8
 8/22/00
	 	9/22/06 [*]	 	The Use of Dapoxetine, A Rapid-Onset Selective Serotonin Reuptake Inhibitor, For Treating Sexual Dysfunction
	 Hong Kong
	  		  	[*]
 8/22/00
	 		 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Hong Kong
	  		  	[*]
 8/22/00
	 		 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Philippines
	  	1-2000-002326	  	1-2000-002326
 10/17/01
	 	8/6/07 [*]	 	The Use of Dapoxetine, a Rapid-Onset Selective Serotonin Reuptake Inhibitor, for Treating Sexual Dysfunction
	 Hungary
	  		  	[*]
 8/22/00
	 		 	Methods of Using Rapid-Onset Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Indonesia
	  	ID 0 018 894	  	W—  00 2002
00522 8/22/00
	 	2/27/07 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Israel
	  	148159	  	148159
 8/22/00
	 	2/19/2010 [*]	 	Use of dapoxetine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or management of sexual dysfunction
	 S. Korea
	  	719977	  	10-2002-7002870
 8/22/00
	 	5/14/07 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Mexico
	  	236520	  	PA/A/
2002/001811 8/22/00
	 	5/4/06 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Norway
	  	330562	  	20021035
 8/22/00
	 	5/16/2011 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 New Zealand
	  	517038	  	517038
 8/22/00
	 	8/7/03 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Poland
	  		  	[*]
 8/22/00
	 		 	Methods of Using Rapid-Onset Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Singapore
	  	87218	  	200200910-8
 8/22/00
	 	5/31/05 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction

  
 [*]
Confidential treatment requested. 

  

									
	 Ukraine
	  	75580	  	2002031755
 8/22/00
	 	5/15/06 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 South Africa
	  	2002/1407	  	8/22/00	 	7/30/03 [*]	 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Taiwan
	  	I312678	  	089117155
 8/25/00
	 	8/1/2009 [*]	 	Pharmaceutical Composition Comprising Dapoxetine for Treating Sexual Dysfunction
	 Taiwan
	  		  	[*]	 	8/25/2000	 	Pharmaceutical Composition Comprising Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
	 Venezuela
	  		  	[*]
 8/29/00
	 		 	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction

  
 [*]
Confidential treatment requested. 

  

 SCHEDULE 1.52 
 LICENSED TRADE IP 
 Domain Names: 

 

															
	 Domain Name
	  	 registry
	  	 Domain

Translation
	  	 Registrant
	  	Registration
Date	 	  	Renewal Date	 
	 aboutpe.co.nz
	  	New Zealand	  	About Premature Ejaculation	  	Johnson & Johnson	  	 
  
	June 19,
 2009
	  
   
	  	 
  
	June 19,
 2012
	  
   

	 aboutpe.com.au
	  	Australia	  	about premature ejaculation	  	Johnson & Johnson Pacific Pty. Ltd	  	 
  
	April 16,
 2009
	  
   
	  	 
  
	April 16,
 2013
	  
   

	 aboutpe.com.my
	  	Malaysia	  	about premature ejaculation	  	Johnson & Johnson SDN BHD	  	 
  
	July 8,
 2009
	  
   
	  	 
  
	July 8,
 2012
	  
   

	 aboutpriligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 accademiaep.it
	  	Italy	  	pe -> premature eiaculation accedemy	  	Johnson & Johnson SPA	  	 
  
	August 5,
 2009
	  
   
	  	 
  
	August 5,
 2012
	  
   

	 aitopriligy.com
	  	Global	  	genuine priligy	  	Johnson & Johnson	  	 
  
	January 29,
 2009
	  
   
	  	 
  
	January 29,
 2013
	  
   

	 aitopriligy.fi
	  	Finland	  	genuine priligy	  	Janssen-Cilag Oy	  	 
  
	February 3,
 2009
	  
   
	  	 
  
	February 3,
 2013
	  
   

	 aktapriligy.com
	  	Global	  	genuine priligy	  	Johnson & Johnson	  	 
  
	January 29,
 2009
	  
   
	  	 
  
	January 29,
 2013
	  
   

	 äktapriligy.com
	  	Global	  	Genuine Priligy	  	Johnson & Johnson	  	 
 	February 12,
2009	  
  	  	 
 	February 12,
2013	  
  
	 aktapriligy.se
	  	Sweden	  	genuine priligy	  	Johnson & Johnson	  	 
  
	January 31,
 2009
	  
   
	  	 
  
	February 1,
 2013
	  
   

	 äktapriligy.se
	  	Sweden	  	genuinepriligy	  	Johnson & Johnson	  	 
 	February 12,
2009	  
  	  	 
 	February 12,
2013	  
  
	 beatpe.com.my
	  	Malaysia	  	beat Premature Ejaculation	  	Johnson & Johnson SDN BHD	  	 
  
	April 2,
 2010
	  
   
	  	 
  
	April 8,
 2012
	  
   

	 beatpe.net
	  	Global	  	beat Premature Ejaculation	  	Johnson & Johnson	  	 
  
	March 24,
 2010
	  
   
	  	 
  
	March 24,
 2012
	  
   

	 buydapoxetinepriligy.com
	  	Global	  	buy dapoxetine priligy	  	Johnson & Johnson	  	 
  
	August 28,
 2010
	  
   
	  	 
  
	August 28,
 2012
	  
   

	 buypriligy.com
	  	Global	  	buy priligy	  	Johnson & Johnson	  	 
  
	March 10,
 2009
	  
   
	  	 
  
	March 10,
 2012
	  
   

	 buy-priligy.com
	  	Global	  	buy priligy	  	Johnson & Johnson	  	 
 	February 10,
2009	  
  	  	 
 	February 10,
2013	  
  
	 buypriligy.info
	  	Global	  	buy priligy	  	Johnson & Johnson	  	 
  
	July 1,
 2009
	  
   
	  	 
  
	July 1,
 2013
	  
   

	 buy-priligy.net
	  	Global	  	buy priligy	  	Johnson & Johnson	  	 
  
	March 2,
 2010
	  
   
	  	 
  
	March 2,
 2013
	  
   

	 buy-priligy-dapoxetine.com
	  	Global	  	buy priligy dapoxetine	  	Johnson & Johnson	  	 
  
	May 19,
 2010
	  
   
	  	 
  
	May 19,
 2012
	  
   

	 buypriligyonline.com
	  	Global	  	buy priligy online	  	Johnson & Johnson	  	 
  
	February 3,
 2009
	  
   
	  	 
  
	February 3,
 2013
	  
   

	 buy-priligy-online.com
	  	Global	  	buy priligy online	  	Johnson & Johnson	  	 
  
	February 3,
 2009
	  
   
	  	 
  
	February 3,
 2013
	  
   

	 cheappriligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 checkpriligy.co.kr
	  	Korea	  	n/a	  	Johnson & Johnson Korea Ltd.	  	 
 	November 11,
2009	  
  	  	 
 	November 11,
2013	  
  
	 comprarpriligy.com
	  	Global	  	compare priligy	  	Johnson & Johnson	  	 
  
	July 8,
 2009
	  
   
	  	 
  
	July 8,
 2012
	  
   

	 comprar-priligy.com
	  	Global	  	compare priligy	  	Johnson & Johnson	  	 
  
	August 16,
 2010
	  
   
	  	 
  
	August 16,
 2012
	  
   

	 comprarpriligy.es
	  	Spain	  	compare Priligy	  	Johnson & Johnson	  	 
  
	March 16,
 2010
	  
   
	  	 
  
	March 16,
 2013
	  
   

	 comprarpriligy.org
	  	Global	  	compare Priligy	  	Johnson & Johnson	  	 
  
	August 3,
 2010
	  
   
	  	 
  
	August 3,
 2013
	  
   

	 contralaeyaculacionprecoz.com
	  	Global	  	againstprematureeyaculation	  	Johnson & Johnson	  	 
  
	June 2,
 2009
	  
   
	  	 
  
	June 2,
 2012
	  
   

	 controlatueyaculacion.com
	  	Global	  	control your eyaculation	  	Johnson & Johnson	  	 
 	February 24,
2009	  
  	  	 
 	February 24,
2013	  
  
	 controlep.com.ar
	  	Argentina	  	premature eyaculation control	  	Johnson & Johnson de Argentina SACel	  	 
 	November 19,
2009	  
  	  	 
 	November 19,
2012	  
  
	 controleyaculacion.cl
	  	Chile	  	ejaculation control	  	Johnson & Johnson	  	 
 	December 17,
2009	  
  	  	 
 	December 17,
2013	  
  
	 controlpe.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  

															
	 controlpe.com.my
	  	Malaysia	  	 control premat
 ure
ejaculation
	  	Johnson & Johnson
SDN BHD	  	 
  
	April 19,
 2010
	 
   
	  	 
  
	April 29,
 2012
	 
   

	 controlpe.com.sg
	  	Singapore	  	control premature ejaculation	  	Johnson & Johnson
PTE. LTD.	  	 
  
	July 7,
 2010
	  
   
	  	 
  
	July 7,
 2012
	  
   

	 controlpe.my
	  	Malaysia	  	control premature ejaculation	  	Johnson & Johnson
SDN BHD	  	 
  
	April 19,
 2010
	  
   
	  	 
  
	May 7,
 2012
	  
   

	 dapaxatine.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 28,
 2005
	  
   
	  	 
 	September
25, 2012	  
  
	 dapaxatine.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapaxatine.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapaxatine.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapaxatine.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapoxeteen.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 28,
 2005
	  
   
	  	 
 	September 25,
2012	  
  
	 dapoxeteen.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapoxeteen.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapoxeteen.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapoxeteen.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapoxetin.at
	  	Austria	  	None	  	Johnson & Johnson	  	 
  
	August 26,
 2005
	  
   
	  	 
 	August 25,
2012	  
  
	 dapoxetina.cl
	  	Chile	  	dapoxetine	  	Johnson & Johnson	  	 
  
	August 20,
 2009
	  
   
	  	 
 	August 21,
2013	  
  
	 dapoxetina.com.bo
	  	Bolivia	  	dapoxetine	  	Johnson & Johnson	  	 
  
	August 25,
 2009
	  
   
	  	 
 	August 25,
2012	  
  
	 dapoxetina.com.br
	  	Brazil	  	n/a	  	Janssen-Cilag
Farmacêutica Ltda	  	 
  
	April 11,
 2008
	  
   
	  	 
 	April 11,
2012	  
  
	 dapoxetina.com.ec
	  	Ecuador	  	dapoxetine	  	Johnson & Johnson	  	 
  
	August 28,
 2009
	  
   
	  	 
 	August 28,
2012	  
  
	 dapoxetina.com.pe
	  	Peru	  	dapoxetine	  	Johnson & Johnson	  	 
  
	August 19,
 2009
	  
   
	  	 
 	August 19,
2012	  
  
	 dapoxetina.com.py
	  	Paraguay	  	dapoxetine	  	Johnson & Johnson	  	 
  
	August 24,
 2009
	  
   
	  	 
 	August 24,
2012	  
  
	 dapoxetina.com.uy
	  	Uruguay	  	dapoxetine	  	Johnson & Johnson	  	 
  
	September 15,
 2009
	  
   
	  	 
 	September 16,
2012	  
  
	 dapoxetina.com.ve
	  	Venezuela	  	dapoxetina	  	Johnson & Johnson	  	 
  
	September 9,
 2009
	  
   
	  	 
 	September 9,
2012	  
  
	 dapoxetina.es
	  	Spain	  	None	  	Johnson & Johnson	  	 
  
	November 11,
 2005
	  
   
	  	 
 	November 11,
2012	  
  
	 dapoxetinapriligy.com
	  	Global	  	dapoxetine priligy	  	Johnson & Johnson	  	 
  
	December 20,
 2010
	  
   
	  	 
 	December 20,
2013	  
  
	 dapoxetine.at
	  	Austria	  	dapoxetine	  	Johnson & Johnson	  	 
  
	September 26,
 2008
	  
   
	  	 
 	September 25,
2012	  
  
	 dapoxetine.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
 	September 25,
2012	  
  
	 dapoxetine.ca
	  	Canada	  	dapoxetine	  	Johnson & Johnson	  	 
  
	September 26,
 2008
	 
   
	  	 
 	September 26,
2012	  
  
	 dapoxetine.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	July 9,
 2002
	  
   
	  	 	July 9, 2012	  
	 dapoxetine.com.au
	  	Australia	  	dapoxetine	  	Johnson & Johnson
Pacific Pty. Ltd	  	 
 	September 29,
2008	  
  	  	 
 	September 29,
2012	  
  
	 dapoxetine.com.tw
	  	Taiwan	  	n/a	  	Johnson & Johnson
Taiwan Ltd.	  	 
 	January 20,
2009	  
  	  	 
 	January 23,
2020	  
  
	 dapoxetine.dk
	  	Denmark	  	None	  	Johnson & Johnson	  	 
 	March 31,
2006	  
  	  	 
 	March 31,
2012	  
  
	 dapoxetine.es
	  	Spain	  	dapoxetine	  	Johnson & Johnson	  	 
 	September 26,
2008	  
  	  	 
 	September 26,
2012	  
  
	 dapoxetine.eu
	  	European Union	  	None	  	Janssen Pharmaceutica
N.V.	  	 
  
	April 7,
 2006
	  
   
	  	 
 	April 30,
2012	  
  
	 dapoxetine.fi
	  	Finland	  	dapoxetine.fi	  	Janssen-Cilag Oy	  	 
 	January 10,
2009	  
  	  	 
 	January 10,
2013	  
  
	 dapoxetine.fr
	  	France	  	dapoxetine	  	Johnson & Johnson
Consumer France SAS	  	 
 	September 26,
2008	  
  	  	 
 	December 21,
2012	  
  
	 dapoxetine.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapoxetine.md
	  	Moldova	  	None	  	Johnson & Johnson	  	 
  
	May 10,
 2004
	  
   
	  	 	May 10, 2012	  
	 dapoxetine.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapoxetine.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dapoxetine.se
	  	Sweden	  	dapoxetine	  	Johnson & Johnson	  	 
 	September 26,
2008	  
  	  	 
 	September 26,
2012	  
  

															
	 dapoxetinekills.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
  
	October 13,
 2012
	  
   

	 dapoxetinekills.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetinekills.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetinekills.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetinekills.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 21,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetine-priligy.com
	  	Global	  	priligy dapoxetine	  	Johnson & Johnson	  	 
  
	March 25,
 2010
	  
   
	  	 
  
	March 25,
 2012
	  
   

	 dapoxetine-priligy.info
	  	Global	  	priligy dapoxetine	  	Johnson & Johnson	  	 
 	November 29,
2009	  
  	  	 
 	November 29,
2012	  
  
	 dapoxetinesucks.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
  
	October 13,
 2012
	  
   

	 dapoxetinesucks.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetinesucks.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetinesucks.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetinesucks.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetinetruth.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
  
	October 13,
 2012
	  
   

	 dapoxetinetruth.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetinetruth.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
  
	October 15,
 2012
	  
   

	 dapoxetinetruth.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 dapoxetinetruth.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 21,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 depoxetine.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
 	September 25,
2012	  
  
	 depoxetine.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 depoxetine.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 depoxetine.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 depoxetine.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 discountpriligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 dupoxetine.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 28,
 2005
	  
   
	  	 
 	September 25,
2012	  
  
	 dupoxetine.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dupoxetine.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dupoxetine.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 dupoxetine.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	September 26,
2012	  
  
	 early-male-climax.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
  
	October 13,
 2012
	  
   

	 early-male-climax.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 early-male-climax.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 early-male-climax.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 edorpe.com
	  	Global	  	Erectile Dysfunction or Premature Ejaculation	  	Johnson & Johnson	  	 
  
	March 9,
 2005
	  
   
	  	 
  
	March 9,
 2012
	  
   

	 ejaculacaoprecoce.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	February 8,
 2005
	  
   
	  	 
  
	February 8,
 2013
	  
   

	 ejaculacao-precoce.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
 	December 23,
2012	  
  
	 ejaculacaoprecoce.com.pt
	  	Portugal	  	precoce ejaculation	  	Johnson & Johnson	  	 
  
	May 1,
 2009
	  
   
	  	 
  
	May 1,
 2012
	  
   

	 ejaculacaoprecoce.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
 	December 23,
2012	  
  
	 ejaculacaoprecoce.mobi
	  	Global	  	portuguese	  	Johnson & Johnson	  	 
  
	August 14,
 2009
	  
   
	  	 
  
	August 15,
 2013
	  
   

	 ejaculacaoprecoceonline.com.br
	  	Brazil	  	premature ejaculation online	  	Janssen-Cilag Farmacêutica Ltda	  	 
  
	August 15,
 2009
	  
   
	  	 
  
	August 15,
 2012
	  
   

	 ejaculacaoprematura.com.pt
	  	Portugal	  	premature ejaculation	  	Johnson & Johnson	  	 
  
	May 1,
 2009
	  
   
	  	 
  
	May 1,
 2012
	  
   

	 ejaculacaorapidaonline.com.br
	  	Brazil	  	rapid ejaculation online	  	Janssen-Cilag Farmacêutica Ltda	  	 
  
	August 15,
 2009
	  
   
	  	 
  
	August 15,
 2012
	  
   

	 ejacularapido.com.br
	  	Brazil	  	rapid ejaculation	  	Janssen-Cilag Farmacêutica Ltda	  	 
  
	August 15,
 2009
	  
   
	  	 
  
	August 15,
 2012
	  
   

															
	 ejaculationprematurée.com
	  	Global	  	Premature Ejaculation	  	Johnson & Johnson	  	 
  
	December 2,
 2009
	 
   
	  	 
  
	December 2,
 2012
	 
   

	 ejaculationprematuree.fr
	  	France	  	Premature Ejaculation	  	Johnson & Johnson Consumer France SAS	  	 
  
	October 26,
 2009
	  
   
	  	 
  
	December 20,
 2012
	 
   

	 ejaculatiopracox.de
	  	Germany	  	None	  	Johnson & Johnson	  	 
  
	August 29,
 2011
	  
   
	  	 
  
	August 29,
 2012
	  
   

	 ejaculatiopracox.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	December 8,
 2005
	 
   
	  	 
  
	December 8,
 2012
	 
   

	 ejaculatiopraecox.at
	  	Austria	  	None	  	Johnson & Johnson	  	 	August 26, 2005	  	  	 
  
	August 25,
 2012
	  
   

	 ejaculatio-praecox.at
	  	Austria	  	None	  	Johnson & Johnson	  	 
  
	August 26,
 2005
	  
   
	  	 
  
	August 25,
 2012
	  
   

	 ejaculorapidinho.com.br
	  	Brazil	  	portuguese	  	Janssen-Cilag Farmacêutica Ltda	  	 
  
	August 15,
 2009
	  
   
	  	 
  
	August 15,
 2012
	  
   

	 ejakulatioskontroll.se
	  	Sweden	  	ejaculation control	  	Johnson & Johnson	  	 
  
	March 14,
 2009
	  
   
	  	 
  
	March 15,
 2013
	  
   

	 ejeculacaoprecoce.com.pt
	  	Portugal	  	precoce ejaculation	  	Johnson & Johnson	  	 	April 22, 2009	  	  	 
  
	April 22,
 2012
	  
   

	 ejeculacaoprematura.com.pt
	  	Portugal	  	premature ejaculation	  	Johnson & Johnson	  	 
  
	April 22,
 2009
	  
   
	  	 
  
	April 22,
 2012
	  
   

	 ellosyalohanhecho.com
	  	Global	  	theyhavealreadydoneit	  	Johnson & Johnson	  	 
  
	September 29,
 2009
	 
   
	  	 
 	September 29,
2012	  
  
	 ellosyalohanhecho.es
	  	Spain	  	theyhavealreadydoneit	  	Johnson & Johnson	  	 
  
	October 6,
 2009
	  
   
	  	 
  
	October 6,
 2012
	  
   

	 ennenaikainensiemensyoksy.fi
	  	Finland	  	premature ejaculation . fi	  	Janssen-Cilag Oy	  	 
  
	March 5,
 2009
	  
   
	  	 
  
	March 5,
 2013
	  
   

	 ennenaikainensiemensyöksy.fi
	  	Finland	  	premature-ejaculation.fi	  	Janssen-Cilag Oy	  	 
  
	March 6,
 2009
	  
   
	  	 
  
	March 6,
 2013
	  
   

	 everymaleclimax.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
  
	October 13,
 2012
	  
   

	 everymaleclimax.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 everymaleclimax.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 27,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 everymaleclimax.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 everymaleclimax.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 20,
 2005
	  
   
	  	 
  
	October 14,
 2012
	  
   

	 exyaculacionprecoz.com
	  	Global	  	exprematureeyaculation.com	  	Johnson & Johnson	  	 
  
	June 2,
 2009
	  
   
	  	 
  
	June 2,
 2012
	  
   

	 eyaculacion-precoz.com.mx
	  	Mexico	  	None	  	Johnson & Johnson	  	 
  
	August 31,
 2005
	  
   
	  	 
  
	August 30,
 2013
	  
   

	 eyaculacionprecoz.com.ve
	  	Venezuela	  	Premature Ejaculation	  	Johnson & Johnson	  	 
 	September 9,
2009	  
  	  	 
 	September 9,
2012	  
  
	 eyaculacionycontrol.com.ar
	  	Australia	  	eyaculation and control	  	Johnson & Johnson de Argentina SACel	  	 
 	November 19,
2009	  
  	  	 
 	November 19,
2012	  
  
	 fakedapoxetine.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 fakepriligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 foldingthelaundry.com
	  	Global	  	Dapoxetine	  	Johnson & Johnson	  	 	June 8, 2005	  	  	 
  
	June 8,
 2012
	  
   

	 foldingthelaundry.net
	  	Global	  	Dapoxetine	  	Johnson & Johnson	  	 	June 8, 2005	  	  	 
  
	June 8,
 2012
	  
   

	 foldingthelaundry.org
	  	Global	  	Dapoxetine	  	Johnson & Johnson	  	 	June 8, 2005	  	  	 
  
	June 8,
 2013
	  
   

	 fortidigutlosning.se
	  	Sweden	  	premature ejaculation	  	Johnson & Johnson	  	 
 	February 27,
2009	  
  	  	 
  
	March 3,
 2013
	  
   

	 freepriligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	September 29,
 2005
	 
   
	  	 
 	September 29,
2012	  
  
	 fruehersamenerguss.de
	  	Germany	  	rapid ejaculatio	  	Johnson & Johnson	  	 
  
	August 29,
 2011
	  
   
	  	 
  
	August 29,
 2012
	  
   

	 frueher-samenerguss.de
	  	Germany	  	zu schneller samenerguss - too quick ejaculation	  	Johnson & Johnson	  	 
  
	August 29,
 2011
	  
   
	  	 
  
	August 29,
 2012
	  
   

	 fruehzeitiger-samenerguss.at
	  	Austria	  	fruehzeitiger samenerguss - too quick ejaculation	  	Johnson & Johnson	  	 
  
	August 26,
 2005
	  
   
	  	 
  
	August 26,
 2012
	  
   

	 garforfort.se
	  	Sweden	  	goes too fast	  	Johnson & Johnson	  	 
  
	March 14,
 2009
	  
   
	  	 
  
	March 15,
 2013
	  
   

	 garforsnabbt.se
	  	Sweden	  	goes too soon	  	Johnson & Johnson	  	 
  
	February 27,
 2009
	 
   
	  	 
  
	March 3,
 2013
	  
   

	 garfortidigt.se
	  	Sweden	  	goes too soon	  	Johnson & Johnson	  	 
 	February 27,
2009	  
  	  	 
  
	March 4,
 2013
	  
   

	 genericpriligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 genericpriligy.info
	  	Global	  	generic priligy	  	Johnson & Johnson	  	 
  
	July 1,
 2009
	  
   
	  	 
  
	July 1,
 2013
	  
   

	 genericpriligy.org
	  	Global	  	generic priligy	  	Johnson & Johnson	  	 
  
	April 27,
 2010
	  
   
	  	 
  
	April 27,
 2013
	  
   

	 generic-priligy.org
	  	Global	  	generic priligy	  	Johnson & Johnson	  	 
  
	November 13,
 2010
	 
   
	  	 
 	November 13,
2013	  
  
	 genuinepriligy.ca
	  	Canada	  	genuine priligy	  	Johnson & Johnson	  	 
  
	April 17,
 2009
	  
   
	  	 
  
	April 17,
 2013
	  
   

															
	 genuinepriligy.cn
	  	China	  	Genuine PRILIGY	  	Johnson & Johnson HK Ltd.	  	 
  
	December 2,
 2010
	 
   
	  	 
  
	December 2,
 2012
	 
   

	 genuinepriligy.co.nz
	  	New Zealand	  	n/a	  	Johnson & Johnson	  	 
  
	October 2,
 2009
	  
   
	  	 
  
	October 2,
 2012
	  
   

	 genuinepriligy.com
	  	Global	  	genuine priligy	  	Johnson & Johnson	  	 
  
	January 29,
 2009
	  
   
	  	 
  
	January 29,
 2013
	  
   

	 genuinepriligy.com.au
	  	Australia	  	genuine priligy	  	Johnson & Johnson	  	 
  
	February 2,
 2009
	  
   
	  	 
  
	February 2,
 2013
	  
   

	 genuinepriligy.com.cn
	  	China	  	Genuine PRILIGY	  	Johnson & Johnson HK Ltd.	  	 
  
	December 2,
 2010
	  
   
	  	 
  
	December 2,
 2012
	  
   

	 genuinepriligy.com.hk
	  	Hong Kong	  	genuine priligy	  	Johnson & Johnson (HK) Ltd	  	 
  
	May 19,
 2009
	  
   
	  	 
  
	May 20,
 2012
	  
   

	 genuinepriligy.com.my
	  	Malaysia	  	n/a	  	Johnson & Johnson SDN BHD	  	 
  
	October 7,
 2009
	  
   
	  	 
  
	October 7,
 2012
	  
   

	 genuinepriligy.com.ph
	  	Philippines	  	n/a	  	Johnson & Johnson	  	 
  
	October 5,
 2009
	  
   
	  	 
  
	October 5,
 2013
	  
   

	 genuinepriligy.com.sg
	  	Singapore	  	n/a	  	Johnson & Johnson	  	 
  
	September 24,
 2009
	 
   
	  	 
  
	September 24,
 2012
	 
   

	 genuinepriligy.eu
	  	European Union	  	genuine priligy	  	Janssen Pharmaceutica N.V.	  	 
 	January 30,
2009	  
  	  	 
 	January 31,
2013	  
  
	 genuinepriligy.hk
	  	Hong Kong	  	genuine priligy	  	Johnson & Johnson (HK) Ltd	  	 
  
	May 19,
 2009
	  
   
	  	 	May 19, 2012	  
	 gercekpriligy.com
	  	Global	  	real(genuine) priligy	  	Johnson & Johnson	  	 
 	February 17,
2010	  
  	  	 
 	February 17,
2013	  
  
	 gercekpriligy.info
	  	Global	  	real(genuine) priligy	  	Johnson & Johnson	  	 
 	February 17,
2010	  
  	  	 
 	February 17,
2013	  
  
	 getpriligy.com
	  	Global	  	get priligy	  	Johnson & Johnson	  	 	May 20, 2009	  	  	 	May 20, 2012	  
	 ilmoittaudu-priligy.fi
	  	Finland	  	register-priligy	  	Janssen-Cilag Oy	  	 	March 5, 2009	  	  	 	March 5, 2013	  
	 kommaforfort.se
	  	Sweden	  	comes too fast	  	Johnson & Johnson	  	 
 	March 14,
2009	  
  	  	 
 	March 15,
2013	  
  
	 kommaforsnabbt.se
	  	Sweden	  	comes too fast	  	Johnson & Johnson	  	 
 	March 14,
2009	  
  	  	 
 	March 15,
2013	  
  
	 kontrolli.info
	  	Global	  	control.info in finnish	  	Johnson & Johnson	  	 
 	February 24,
2009	  
  	  	 
 	February 24,
2013	  
  
	 laengergeniessen.de
	  	Germany	  	Enjoy longer	  	Johnson & Johnson	  	 
 	August 29,
2011	  
  	  	 
 	August 29,
2012	  
  
	 laenger-geniessen.de
	  	Germany	  	enjoy longer	  	Johnson & Johnson	  	 
 	August 29,
2011	  
  	  	 
 	August 29,
2012	  
  
	 laeyaculacionprecoz.bo
	  	Bolivia	  	premature eyaculation	  	Johnson & Johnson	  	 
 	November 19,
2009	  
  	  	 
 	November 19,
2012	  
  
	 laeyaculacionprecoz.com.py
	  	Paraguay	  	premature eyaculation	  	Johnson & Johnson	  	 
 	January 22,
2010	  
  	  	 
 	January 22,
2013	  
  
	 laeyaculacionprecoz.com.uy
	  	Uruguay	  	premature eyaculation	  	Johnson & Johnson	  	 
 	November 16,
2009	  
  	  	 
 	November 16,
2012	  
  
	 laeyaculacionprecoz.ec
	  	Ecuador	  	premature eyaculation	  	Johnson & Johnson	  	 
 	November 13,
2009	  
  	  	 
 	November 17,
2012	  
  
	 laeyaculacionprecoz.es
	  	Spain	  	theprematureeyaluculation.es	  	Johnson & Johnson	  	 	June 4, 2009	  	  	 	June 4, 2012	  
	 laeyaculacionprecoz.info
	  	Global	  	theprematureeyaculation.com / info	  	Johnson & Johnson	  	 	June 1, 2009	  	  	 	June 1, 2013	  
	 laeyaculacionprecoz.pe
	  	Peru	  	premature eyaculation	  	Johnson & Johnson	  	 
 	November 13,
2009	  
  	  	 
 	November 16,
2012	  
  
	 maleclimax.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 13,
2012	  
  
	 maleclimax.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 14,
2012	  
  
	 maleclimax.info
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 14,
2012	  
  
	 maleclimax.net
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 14,
2012	  
  
	 maleclimax.org
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 14,
2012	  
  
	 managepe.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 mannkannlänger.at
	  	Austria	  	man is able longer	  	Johnson & Johnson	  	 	April 5, 2010	  	  	 	April 5, 2012	  
	 mascontrol-mastiempo.com
	  	Global	  	morecontrol-moretime	  	Johnson & Johnson	  	 
 	October 9,
2009	  
  	  	 
 	October 9,
2012	  
  
	 mascontrolmastiempo.com.mx
	  	Mexico	  	morecontrolmoretime	  	Johnson & Johnson	  	 
 	October 12,
2009	  
  	  	 
 	October 11,
2013	  
  
	 mascontrol-mastiempo.com.mx
	  	Mexico	  	morecontrol-moretime	  	Johnson & Johnson	  	 
 	October 12,
2009	  
  	  	 
 	October 11,
2013	  
  
	 mascontrolmastiempo.mx
	  	Mexico	  	morecontrolmoretime	  	Johnson & Johnson	  	 
 	October 23,
2009	  
  	  	 
 	October 22,
2013	  
  
	 mascontrol-mastiempo.mx
	  	Mexico	  	morecontrol-moretime	  	Johnson & Johnson	  	 
 	October 23,
2009	  
  	  	 
 	October 22,
2013	  
  
	 mehrzeitzuzweit.de
	  	Germany	  	more time twosome	  	Johnson & Johnson	  	 
 	August 29,
2011	  
  	  	 
 	August 29,
2012	  
  

															
	 mehr-zeit-zu-zweit.de
	  	Germany	  	more time twosome	  	Johnson & Johnson	  	 
  
	August 29,
 2011
	 
   
	  	 
  
	August 29,
 2012
	 
   

	 mejorcontrol.com
	  	Global	  	bettercontrol	  	Johnson & Johnson	  	 
  
	April 5,
 2010
	  
   
	  	 
 	April 5,
2012	  
  
	 onlinepriligy.com
	  	Global	  	priligy online	  	Johnson & Johnson	  	 
  
	February 3,
 2009
	  
   
	  	 
 	February 3,
2013	  
  
	 pe.co.at
	  	Austria	  	None	  	Johnson & Johnson	  	 
 	September 7,
2005	  
  	  	 
 	September
6, 2012	  
  
	 pedebate.com
	  	Global	  	Premature Ejaculation Debates	  	Johnson & Johnson	  	 
  
	March 1,
 2010
	  
   
	  	 
 	March 1,
2013	  
  
	 pedebate.info
	  	Global	  	Premature Ejaculation Debates	  	Johnson & Johnson	  	 
  
	March 1,
 2010
	  
   
	  	 
 	March 1,
2013	  
  
	 pedebates.com
	  	Global	  	Premature Ejaculation Debates	  	Johnson & Johnson	  	 
  
	March 1,
 2010
	  
   
	  	 
 	March 1,
2013	  
  
	 pedebates.info
	  	Global	  	Premature Ejaculation Debates	  	Johnson & Johnson	  	 
  
	March 1,
 2010
	  
   
	  	 
 	March 1,
2013	  
  
	 pediscussion.com
	  	Global	  	Premature Ejaculation discussion	  	Johnson & Johnson	  	 
  
	March 10,
 2010
	  
   
	  	 
 	March 10,
2012	  
  
	 pediscussion.info
	  	Global	  	Premature Ejaculation discussion	  	Johnson & Johnson	  	 
  
	March 10,
 2010
	  
   
	  	 
 	March 10,
2013	  
  
	 pediscussions.com
	  	Global	  	Premature Ejaculation discussions	  	Johnson & Johnson	  	 
  
	March 10,
 2010
	  
   
	  	 
 	March 10,
2012	  
  
	 pediscussions.info
	  	Global	  	Premature Ejaculation discussions	  	Johnson & Johnson	  	 
  
	March 10,
 2010
	  
   
	  	 
 	March 10,
2013	  
  
	 pefacts.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	January 27,
 2005
	 
   
	  	 
 	January 27,
2013	  
  
	 pe-kontrolle.at
	  	Austria	  	None	  	Johnson & Johnson	  	 
  
	August 30,
 2005
	  
   
	  	 
 	August 29,
2012	  
  
	 pemedia.biz
	  	Global	  	pe = Pre-ejaculation	  	Johnson & Johnson	  	 
  
	November 4,
 2004
	 
   
	  	 
 	November
3, 2012	  
  
	 pemedia.info
	  	Global	  	pe = Pre-ejaculation	  	Johnson & Johnson	  	 
 	November 4,
2004	  
  	  	 
 	November
4, 2012	  
  
	 pemedia.org
	  	Global	  	pe = Pre-ejaculation	  	Johnson & Johnson	  	 
 	November 4,
2004	  
  	  	 
 	November
4, 2012	  
  
	 pemedication.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September
29, 2005	  
  	  	 
 	September
29, 2012	  
  
	 peored.com
	  	Global	  	Premature Ejaculation or Erectile Dysfunction	  	Johnson & Johnson	  	 
 	March 9,
2005	  
  	  	 
 	March 9,
2012	  
  
	 pesupportcompany.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September
29, 2005	  
  	  	 
 	September
29, 2012	  
  
	 pirligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September
29, 2005	  
  	  	 
 	September
29, 2012	  
  
	 prematureejaculation.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	March 23,
2005	  
  	  	 
 	July 1,
2012	  
  
	 prematureejaculation.com.my
	  	Malaysia	  	premature ejaculation	  	Johnson & Johnson SDN BHD	  	 
 	June 23,
2009	  
  	  	 
 	June 23,
2013	  
  
	 prematureejaculation.com.sg
	  	Singapore	  	n/a	  	Johnson & Johnson PTE. LTD.	  	 
 	June 25,
2010	  
  	  	 
 	June 25,
2012	  
  
	 premature-ejaculation.gr
	  	Greece	  	n/a	  	Johnson & Johnson	  	 
 	February 1,
2009	  
  	  	 
 	January 31,
2013	  
  
	 prematureejaculation.md
	  	Moldova	  	None	  	Johnson & Johnson	  	 
 	May 10,
2004	  
  	  	 
 	May 10,
2012	  
  
	 premature-ejaculation.md
	  	Moldova	  	None	  	Johnson & Johnson	  	 
 	May 10,
2004	  
  	  	 
 	May 10,
2012	  
  
	 prematureejaculation.my
	  	Malaysia	  	premature ejaculation	  	Johnson & Johnson SDN BHD	  	 
 	June 23,
2009	  
  	  	 
 	June 23,
2012	  
  
	 prematureejaculationfacts.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	January 27,
2005	  
  	  	 
 	January 27,
2013	  
  
	 prematureejaculationtruth.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	January 27,
2005	  
  	  	 
 	January 27,
2013	  
  
	 prematurejaculation.se
	  	Sweden	  	premature ejaculation	  	Johnson & Johnson	  	 
 	February 27,
2009	  
  	  	 
 	March 4,
2013	  
  
	 prematurejakulasyon.com
	  	Global	  	Premature Ejaculation	  	Johnson & Johnson	  	 
 	October 30,
2009	  
  	  	 
 	October
30, 2012	  
  
	 preventpe.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September
29, 2005	  
  	  	 
 	September
29, 2012	  
  
	 prilagy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September
29, 2005	  
  	  	 
 	September
29, 2012	  
  
	 prilegy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September
29, 2005	  
  	  	 
 	September
29, 2012	  
  
	 prilgiy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September
29, 2005	  
  	  	 
 	September
29, 2012	  
  

															
	 priligi.de
	  	Germany	  	n/a	  	Johnson & Johnson	  	 
  
	August 29,
 2011
	 
   
	  	 
  
	August 29,
 2012
	 
   

	 priligy.at
	  	Austria	  	priligy	  	Johnson & Johnson	  	 
  
	October 1,
 2008
	  
   
	  	 
 	September 30,
2012	  
  
	 priligy.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 9,
 2004
	  
   
	  	 
  
	June 8,
 2012
	  
   

	 priligy.ca
	  	Canada	  	priligy	  	Johnson & Johnson	  	 
  
	October 1,
 2008
	  
   
	  	 
  
	October 1,
 2012
	  
   

	 priligy.cl
	  	Chile	  	priligy	  	Johnson & Johnson	  	 
  
	August 20,
 2009
	  
   
	  	 
  
	August 21,
 2013
	  
   

	 priligy.co.nz
	  	New Zealand	  	PRILIGY	  	Johnson & Johnson	  	 
  
	June 19,
 2009
	  
   
	  	 
  
	June 19,
 2012
	  
   

	 priligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 	June 9, 2004	  	  	 
  
	June 9,
 2012
	  
   

	 priligy.com.au
	  	Australia	  	priligy	  	JOHNSON JOHNSON PACIFIC PTY LIMITED	  	 
  
	October 2,
 2008
	  
   
	  	 
  
	October 1,
 2012
	  
   

	 priligy.com.bo
	  	Bolivia	  	priligy	  	Johnson & Johnson	  	 
  
	August 24,
 2009
	  
   
	  	 
  
	August 24,
 2012
	  
   

	 priligy.com.br
	  	Brazil	  	Priligy	  	Janssen-Cilag Farmacêutica Ltda	  	 
  
	August 15,
 2009
	  
   
	  	 
  
	August 15,
 2012
	  
   

	 priligy.com.ec
	  	Ecuador	  	priligy	  	Johnson & Johnson	  	 
  
	August 28,
 2009
	  
   
	  	 
  
	August 28,
 2012
	  
   

	 priligy.com.hk
	  	Hong Kong	  	priligy	  	Johnson & Johnson (HK) Ltd	  	 
  
	May 19,
 2009
	  
   
	  	 
  
	May 20,
 2012
	  
   

	 priligy.com.mx
	  	Mexico	  	None	  	Johnson & Johnson	  	 
  
	September 6,
 2005
	  
   
	  	 
  
	September 5,
 2013
	  
   

	 priligy.com.my
	  	Malaysia	  	about premature ejaculation - product site	  	Johnson & Johnson SDN BHD	  	 
  
	November 30,
 2007
	  
   
	  	 
  
	November 30,
 2013
	 
   

	 priligy.com.pe
	  	Peru	  	priligy	  	Johnson & Johnson	  	 
  
	August 19,
 2009
	  
   
	  	 
 	August 19,
2012	  
  
	 priligy.com.py
	  	Paraguay	  	priligy	  	Johnson & Johnson	  	 
  
	January 8,
 2010
	  
   
	  	 
 	January 8,
2013	  
  
	 priligy.com.tr
	  	Turkey	  	Priligy	  	Johnson & Johnson	  	 
  
	December 2,
 2010
	  
   
	  	 
 	December 2,
2012	  
  
	 priligy.com.tw
	  	Taiwan	  	n/a	  	Johnson & Johnson Taiwan Ltd.	  	 
  
	January 20,
 2009
	  
   
	  	 
 	January 23,
2020	  
  
	 priligy.com.uy
	  	Uruguay	  	priligy	  	Johnson & Johnson	  	 
  
	September 15,
 2009
	  
   
	  	 
 	September 16,
2012	  
  
	 priligy.com.ve
	  	Venezuela	  	Priligy	  	Johnson & Johnson	  	 
  
	September 9,
 2009
	  
   
	  	 
 	September 9,
2012	  
  
	 priligy.de
	  	Germany	  	priligy	  	Johnson & Johnson	  	 
  
	August 29,
 2011
	  
   
	  	 
 	August 29,
2012	  
  
	 priligy.dk
	  	Denmark	  	priligy	  	Johnson & Johnson	  	 
  
	October 1,
 2008
	  
   
	  	 
 	October 31,
2012	  
  
	 priligy.es
	  	Spain	  	None	  	Janssen Pharmaceutica N.V.	  	 
  
	September 30,
 2005
	 
   
	  	 
 	October 4,
2012	  
  
	 priligy.eu
	  	European Union	  	priligy	  	Janssen Pharmaceutica N.V.	  	 
 	September 26,
2008	  
  	  	 
 	September 30,
2012	  
  
	 priligy.fi
	  	Finland	  	priligy.fi	  	Janssen-Cilag Oy	  	 
 	January 10,
2009	  
  	  	 
 	January 10,
2013	  
  
	 priligy.fr
	  	France	  	priligy	  	Johnson & Johnson Consumer France SAS	  	 
 	October 1,
2008	  
  	  	 
 	December 21,
2012	  
  
	 priligy.gr
	  	Greece	  	n/a	  	Johnson & Johnson	  	 
 	January 26,
2009	  
  	  	 
 	January 25,
2013	  
  
	 priligy.hk
	  	Hong Kong	  	priligy	  	Johnson & Johnson (HK) Ltd	  	 
  
	May 19,
 2009
	  
   
	  	 	May 19, 2012	  
	 priligy.info
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 9,
 2004
	  
   
	  	 	June 9, 2013	  
	 priligy.it
	  	Italy	  	priligy	  	Johnson & Johnson SPA	  	 
 	October 3,
2008	  
  	  	 
 	October 3,
2012	  
  
	 priligy.mobi
	  	Global	  	priligy mobile apps?	  	Johnson & Johnson	  	 
 	February 3,
2009	  
  	  	 
 	February 3,
2013	  
  
	 priligy.my
	  	Malaysia	  	about premature ejaculation - product site	  	Johnson & Johnson SDN BHD	  	 
  
	June 23,
 2009
	  
   
	  	 	June 23, 2012	  
	 priligy.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 9,
 2004
	  
   
	  	 	June 9, 2012	  
	 priligy.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	June 9,
 2004
	  
   
	  	 	June 9, 2013	  
	 priligy.pt
	  	Portugal	  	priligy	  	Janssen Pharmaceutica N.V.	  	 
 	October 15,
2008	  
  	  	 
 	October 15,
2012	  
  
	 priligy.se
	  	Sweden	  	priligy	  	Johnson & Johnson	  	 
 	October 1,
2008	  
  	  	 
 	October 1,
2012	  
  
	 priligy.us
	  	US	  	None	  	Johnson & Johnson	  	 	June 14, 2004	  	  	 	June 13, 2013	  
	 priligyautentico.com
	  	Global	  	genuine priligy	  	Johnson & Johnson	  	 
 	January 29,
2009	  
  	  	 
 	January 29,
2013	  
  
	 priligyautentico.com.pt
	  	Portugal	  	authentic prigliy	  	Johnson & Johnson	  	 
 	March 20,
2009	  
  	  	 
 	March 19,
2013	  
  
	 priligyautentico.es
	  	Spain	  	authentic prigliy	  	Johnson & Johnson	  	 
 	March 20,
2009	  
  	  	 
 	March 20,
2013	  
  
	 priligyauthentique.ca
	  	Canada	  	authentic prigliy	  	Johnson & Johnson	  	 
 	March 20,
2009	  
  	  	 
 	March 20,
2013	  
  

															
	 priligyauthentique.com
	  	Global	  	authentic prigliy	  	Johnson & Johnson	  	 
  
	March 20,
 2009
	 
   
	  	 
  
	March 20,
 2012
	  
   

	 priligyauthentique.fr
	  	France	  	authentic prigliy	  	Johnson & Johnson Consumer France SAS	  	 
  
	April 1,
 2009
	  
   
	  	 
  
	December 20,
 2012
	  
   

	 priligybuy.com
	  	Global	  	priligy buy	  	Johnson & Johnson	  	 
  
	February 3,
 2009
	 
   
	  	 
  
	February 3,
 2013
	  
   

	 priligy-buy.com
	  	Global	  	priligy buy	  	Johnson & Johnson	  	 
  
	March 25,
 2010
	  
   
	  	 
  
	March 25,
 2012
	  
   

	 priligy-canada.com
	  	Global	  	canada priligy	  	Johnson & Johnson	  	 
  
	June 21,
 2010
	  
   
	  	 
  
	June 21,
 2012
	  
   

	 priligyconsult.com
	  	Global	  	consult priligy	  	Johnson & Johnson	  	 
  
	April 28,
 2010
	  
   
	  	 
  
	April 28,
 2012
	  
   

	 priligy-dapoxetina.com
	  	Global	  	priligy dapoxetine	  	Johnson & Johnson	  	 
  
	August 27,
 2010
	  
   
	  	 
  
	August 27,
 2012
	  
   

	 priligydapoxetine.com
	  	Global	  	priligy dapoxetine	  	Johnson & Johnson	  	 
  
	March 31,
 2010
	  
   
	  	 
  
	March 31,
 2012
	  
   

	 priligy-dapoxetine.com
	  	Global	  	priligy dapoxetine	  	Johnson & Johnson	  	 
  
	March 31,
 2010
	  
   
	  	 
  
	March 31,
 2012
	  
   

	 priligydapoxetine.org
	  	Global	  	priligy dapoxetine	  	Johnson & Johnson	  	 
  
	August 8,
 2009
	  
   
	  	 
  
	November 20,
 2012
	  
   

	 priligydapoxetinereview.com
	  	Global	  	review priligy	  	Johnson & Johnson	  	 
  
	May 5,
 2010
	  
   
	  	 
  
	May 5,
 2012
	  
   

	 priligyecht.at
	  	Austria	  	genuine priligy	  	Johnson & Johnson	  	 
  
	February 3,
 2009
	  
   
	  	 
  
	February 1,
 2012
	  
   

	 priligyecht.ch
	  	Switzerland	  	genuine priligy	  	Johnson & Johnson	  	 
  
	February 2,
 2009
	  
   
	  	 
  
	February 28,
 2012
	  
   

	 priligyecht.com
	  	Global	  	genuine priligy	  	Johnson & Johnson	  	 
  
	January 29,
 2009
	  
   
	  	 
  
	January 29,
 2013
	  
   

	 priligyecht.de
	  	Germany	  	genuine priligy	  	Johnson & Johnson	  	 
  
	September 20,
 2010
	 
   
	  	 
 	September 20,
2012	  
  
	 priligyfacts.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 priligyfaq.com
	  	Global	  	priligy frequently asked questions	  	Johnson & Johnson	  	 
 	October 7,
2005	  
  	  	 
  
	October 7,
 2012
	  
   

	 priligyfrance.com
	  	Global	  	priligy France	  	Johnson & Johnson	  	 	May 11, 2010	  	  	 
  
	May 11,
 2012
	  
   

	 priligygenuino.com
	  	Global	  	genuine priligy	  	Johnson & Johnson	  	 
 	January 29,
2009	  
  	  	 
  
	January 29,
 2013
	  
   

	 priligygenuino.com.br
	  	Brazil	  	genuine priligy	  	Janssen-Cilag Farmacêutica Ltda	  	 
 	November 17,
2009	  
  	  	 
  
	November 17,
 2012
	  
   

	 priligygenuino.es
	  	Spain	  	genuine priligy	  	Johnson & Johnson	  	 
 	January 31,
2009	  
  	  	 
  
	January 31,
 2013
	  
   

	 priligyinfo.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 priligykills.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 priligymexico.com
	  	Global	  	priligy Mexico	  	Johnson & Johnson	  	 
  
	June 21,
 2010
	  
   
	  	 
  
	June 21,
 2012
	  
   

	 priligynews.com
	  	Global	  	priligy news	  	Johnson & Johnson	  	 
 	September 16,
2005	  
  	  	 
 	September 16,
2013	  
  
	 priligynotes.com
	  	Global	  	priligy notes	  	Johnson & Johnson	  	 
  
	April 28,
 2010
	  
   
	  	 
  
	April 28,
 2012
	  
   

	 priligynow.com
	  	Global	  	priligy now	  	Johnson & Johnson	  	 
 	February 3,
2009	  
  	  	 
  
	February 3,
 2013
	  
   

	 priligyny.com
	  	Global	  	priligy ny (new york?)	  	Johnson & Johnson	  	 
  
	April 28,
 2010
	  
   
	  	 
  
	April 28,
 2012
	  
   

	 priligynyc.com
	  	Global	  	priligy nyc (new york city?)	  	Johnson & Johnson	  	 	April 28, 2010	  	  	 
  
	April 28,
 2012
	  
   

	 priligy-online.net
	  	Global	  	online priligy	  	Johnson & Johnson	  	 
 	November 18,
2010	  
  	  	 
  
	November 18,
 2012
	  
   

	 priligy-online.org
	  	Global	  	online priligy	  	Johnson & Johnson	  	 
 	November 13,
2010	  
  	  	 
  
	November 13,
 2013
	 
   

	 priligyoriginal.at
	  	Austria	  	original priligy	  	Johnson & Johnson	  	 
 	February 10,
2009	  
  	  	 
 	February 11,
2012	  
  
	 priligyoriginal.com
	  	Global	  	original priligy	  	Johnson & Johnson	  	 
 	February 6,
2009	  
  	  	 
 	February 6,
2013	  
  
	 priligyoriginal.de
	  	Germany	  	original priligy	  	Johnson & Johnson	  	 
 	August 29,
2011	  
  	  	 
 	August 29,
2012	  
  
	 priligyoriginale.com
	  	Global	  	original priligy	  	Johnson & Johnson	  	 
 	January 29,
2009	  
  	  	 
 	January 29,
2013	  
  
	 priligyoriginale.it
	  	Italy	  	original priligy	  	Johnson & Johnson SPA	  	 
 	February 5,
2009	  
  	  	 
 	February 5,
2012	  
  
	 priligypublicationtoolkit.com
	  	Global	  	n/a	  	Johnson & Johnson	  	 
 	October 15,
2008	  
  	  	 
 	October 15,
2012	  
  
	 priligyresource.com
	  	Global	  	priligy resource	  	Johnson & Johnson	  	 	April 28, 2010	  	  	 	April 28, 2012	  
	 priligyreview.com
	  	Global	  	priligy review	  	Johnson & Johnson	  	 
 	February 17,
2009	  
  	  	 
 	February 17,
2013	  
  
	 priligysmart.com
	  	Global	  	priligy smart	  	Johnson & Johnson	  	 	April 28, 2010	  	  	 
  
	April 28,
 2012
	  
   

	 priligysucks.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  

															
	 prillagy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	September 29,
 2005
	 
   
	  	 
  
	September 29,
 2012
	 
   

	 prillegy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 prilligi.de
	  	Germany	  	n/a	  	Johnson & Johnson	  	 
 	August 29,
2011	  
  	  	 
 	August 29,
2012	  
  
	 prilligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 prilligy.de
	  	Germany	  	n/a	  	Johnson & Johnson	  	 
 	August 29,
2011	  
  	  	 
 	August 29,
2012	  
  
	 prillogy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 prligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 rapidejaculation.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 13,
2012	  
  
	 rapid-ejaculation.biz
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 13,
2012	  
  
	 rapidejaculation.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 14,
2012	  
  
	 rapidejaculation.info
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 14,
2012	  
  
	 rapid-ejaculation.info
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 14,
2012	  
  
	 rapidejaculation.md
	  	Moldova	  	None	  	Johnson & Johnson	  	 
  
	May 10,
 2004
	  
   
	  	 
  
	May 10,
 2012
	  
   

	 rapid-ejaculation.md
	  	Moldova	  	None	  	Johnson & Johnson	  	 
  
	May 10,
 2004
	  
   
	  	 
  
	May 10,
 2012
	  
   

	 rapidejaculation.net
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 14,
2012	  
  
	 rapid-ejaculation.net
	  	Global	  	None	  	Johnson & Johnson	  	 
 	October 14,
2003	  
  	  	 
 	October 14,
2012	  
  
	 rechtzeitigstattvorzeitig.de
	  	Germany	  	timely-instead of-premature	  	Johnson & Johnson	  	 
 	August 29,
2011	  
  	  	 
 	August 29,
2012	  
  
	 rechtzeitig-statt-vorzeitig.de
	  	Germany	  	timely-instead of-premature	  	Johnson & Johnson	  	 
 	August 29,
2011	  
  	  	 
 	August 29,
2012	  
  
	 registera-priligy.se
	  	Sweden	  	register priligy	  	Johnson & Johnson	  	 
 	March 14,
2009	  
  	  	 
 	March 15,
2013	  
  
	 talkaboutpe.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	September 29,
2005	  
  	  	 
 	September 29,
2012	  
  
	 talkingaboutpe.asia
	  	Asia	  	Talking About Premature Ejaculation	  	Johnson & Johnson PTE.LTD.	  	 
 	September 7,
2010	  
  	  	 
 	September 7,
2012	  
  
	 talkingaboutpe.cn
	  	China	  	Talking About Premature Ejaculation	  	Johnson & Johnson HK Ltd.	  	 
 	December 2,
2010	  
  	  	 
 	December 2,
2012	  
  
	 talkingaboutpe.co.id
	  	Indonesia	  	Talking About Premature Ejaculation	  	Johnson & Johnson Indonesia	  	 
 	September 15,
2010	  
  	  	 
 	September 17,
2012	  
  
	 talkingaboutpe.co.in
	  	India	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
 	September 7,
2010	  
  	  	 
 	September 7,
2012	  
  
	 talkingaboutpe.co.kr
	  	Korea	  	Talking About Premature Ejaculation	  	Johnson & Johnson Korea Ltd.	  	 
 	September 15,
2010	  
  	  	 
 	September 15,
2012	  
  
	 talkingaboutpe.co.nz
	  	New Zealand	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
 	September 8,
2010	  
  	  	 
 	September 8,
2012	  
  
	 talkingaboutpe.com
	  	Global	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
 	August 27,
2010	  
  	  	 
 	August 27,
2012	  
  
	 talkingaboutpe.com.au
	  	Australia	  	Talking About Premature Ejaculation	  	Johnson & Johnson Pty Ltd.	  	 
 	September 8,
2010	  
  	  	 
 	September 7,
2012	  
  
	 talkingaboutpe.com.cn
	  	cina	  	Talking About Premature Ejaculation	  	Johnson & Johnson HK Ltd.	  	 
 	December 2,
2010	  
  	  	 
 	December 2,
2012	  
  
	 talkingaboutpe.com.hk
	  	Hong Kong	  	Talking About Premature Ejaculation	  	Johnson & Johnson HK Ltd.	  	 
 	September 8,
2010	  
  	  	 
 	September 9,
2012	  
  
	 talkingaboutpe.com.my
	  	Malaysia	  	Talking About Premature Ejaculation	  	Johnson & Johnson SDN BHD	  	 
 	September 7,
2010	  
  	  	 
 	September 7,
2012	  
  
	 talkingaboutpe.com.ph
	  	Philippines	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
 	September 3,
2010	  
  	  	 
 	September 7,
2013	  
  
	 talkingaboutpe.com.sg
	  	Singapore	  	Talking About Premature Ejaculation	  	Johnson & Johnson PTE. LTD.	  	 
 	September 8,
2010	  
  	  	 
 	September 8,
2012	  
  

															
	 talkingaboutpe.com.tw
	  	Taiwan	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
  
	September 8,
 2010
	 
   
	  	 
  
	September 8,
 2012
	 
   

	 talkingaboutpe.com.vn
	  	Vietnam	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
  
	September 8,
 2010
	  
   
	  	 
  
	September 8,
 2012
	  
   

	 talkingaboutpe.hk
	  	Hong Kong	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
  
	September 8,
 2010
	  
   
	  	 
  
	September 9,
 2012
	  
   

	 talkingaboutpe.in
	  	India	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
  
	September 7,
 2010
	  
   
	  	 
  
	September 7,
 2012
	  
   

	 talkingaboutpe.jp
	  	Japan	  	Talking About Premature Ejaculation	  	Johnson & Johnson K.K.	  	 
  
	September 8,
 2010
	  
   
	  	 
  
	September 30,
 2012
	  
   

	 talkingaboutpe.kr
	  	Korea	  	Talking About Premature Ejaculation	  	Johnson & Johnson Korea Ltd.	  	 
  
	September 15,
 2010
	  
   
	  	 
  
	September 15,
 2012
	  
   

	 talkingaboutpe.mobi
	  	Global	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
  
	September 2,
 2010
	  
   
	  	 
  
	September 2,
 2013
	  
   

	 talkingaboutpe.my
	  	Malaysia	  	Talking About Premature Ejaculation	  	Johnson & Johnson SDN BHD	  	 
  
	September 7,
 2010
	  
   
	  	 
  
	September 3,
 2012
	  
   

	 talkingaboutpe.ph
	  	Philippines	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
  
	September 9,
 2010
	  
   
	  	 
  
	September 9,
 2012
	  
   

	 talkingaboutpe.sg
	  	Singapore	  	Talking About Premature Ejaculation	  	Johnson & Johnson PTE. LTD	  	 
  
	September 8,
 2010
	  
   
	  	 
  
	September 8,
 2012
	  
   

	 talkingaboutpe.tw
	  	Taiwan	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
  
	September 8,
 2010
	  
   
	  	 
  
	September 8,
 2012
	  
   

	 talkingaboutpe.vn
	  	Vietnam	  	Talking About Premature Ejaculation	  	Johnson & Johnson	  	 
  
	September 8,
 2010
	  
   
	  	 
  
	September 8,
 2012
	  
   

	 thetruthaboutpe.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	January 27,
 2005
	  
   
	  	 
  
	January 27,
 2013
	  
   

	 thetruthaboutprematureejaculation.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	January 27,
 2005
	  
   
	  	 
  
	January 27,
 2013
	  
   

	 tidigutlosning.se
	  	Sweden	  	premature ejaculation .se	  	Johnson & Johnson	  	 
  
	March 4,
 2009
	  
   
	  	 
  
	March 3,
 2013
	  
   

	 treatpe.co.nz
	  	New Zealand	  	Treat Premature Ejaculation	  	Johnson & Johnson	  	 
  
	June 19,
 2009
	  
   
	  	 
  
	June 19,
 2012
	  
   

	 treatpe.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	September 29,
 2005
	  
   
	  	 
  
	September 29,
 2012
	  
   

	 treatpe.com.au
	  	Australia	  	Treat Premature Ejaculation	  	Johnson & Johnson	  	 
  
	September 25,
 2009
	  
   
	  	 
  
	February 25,
 2013
	  
   

	 truthaboutpe.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	January 27,
 2005
	  
   
	  	 
  
	January 27,
 2013
	  
   

	 truthaboutpe.net
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	February 28,
 2005
	  
   
	  	 
  
	February 28,
 2013
	  
   

	 truthaboutpe.org
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	February 28,
 2005
	  
   
	  	 
  
	February 28,
 2013
	  
   

	 truthaboutprematureejaculation.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	January 27,
 2005
	  
   
	  	 
  
	January 27,
 2013
	  
   

	 truthaboutpriligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	September 29,
 2005
	  
   
	  	 
  
	September 29,
 2012
	  
   

	 trypriligy.com
	  	Global	  	None	  	Johnson & Johnson	  	 
  
	September 29,
 2005
	 
   
	  	 
  
	September 29,
 2012
	 
   

	 understandingpe.ca
	  	Canada	  	Understanding PE	  	Johnson & Johnson	  	 
  
	June 29,
 2009
	  
   
	  	 
  
	June 30,
 2013
	  
   

	 understandingpe.com
	  	Global	  	None	  	Johnson & Johnson	  	 
 	December 15,
2004	  
  	  	 
 	December 15,
2012	  
  
	 understandingprematureejaculations.ca
	  	Canada	  	Understanding Premature Ejaculations	  	Johnson & Johnson	  	 
  
	June 29,
 2009
	  
   
	  	 
  
	June 30,
 2013
	  
   

	 understandingprematureejaculations.com
	  	Global	  	Understanding Premature Ejaculations	  	Johnson & Johnson	  	 
  
	June 29,
 2009
	  
   
	  	 
  
	June 29,
 2012
	  
   

	 uzunsursun.com
	  	Global	  	Last longer	  	Johnson & Johnson	  	 
 	August 31,
2009	  
  	  	 
 	August 31,
2012	  
  
	 validarpriligy.com
	  	Global	  	validate priligy	  	Johnson & Johnson	  	 
 	January 29,
2009	  
  	  	 
 	January 29,
2013	  
  
	 vorzeitigkommen.de
	  	Germany	  	vorzeitig kommen - prematurely coming	  	Johnson & Johnson	  	 
 	August 30,
2011	  
  	  	 
 	August 30,
2012	  
  
	 vorzeitig-kommen.de
	  	Germany	  	vorzeitig kommen - prematurely coming	  	Johnson & Johnson	  	 
 	August 30,
2011	  
  	  	 
  
	August 30,
 2012
	  
   

															
	 whatispe.ca
	  	Canada	  	What is PE	  	Johnson & Johnson	  	 
  
	June 29,
 2009
	 
   
	  	 
  
	June 30,
 2013
	  
   

	 whatispe.com
	  	Global	  	What is PE	  	Johnson & Johnson	  	 
  
	June 29,
 2009
	  
   
	  	 
  
	June 29,
 2012
	  
   

	 zufruehkommen.de
	  	Germany	  	zu frueh kommen - coming too quickly	  	Johnson & Johnson	  	 
  
	August 30,
 2011
	 
   
	  	 
  
	August 30,
 2012
	  
   

	 zu-frueh-kommen.de
	  	Germany	  	zu frueh kommen - coming too quickly	  	Johnson & Johnson	  	 
 	August 30,
2011	  
  	  	 
  
	August 30,
 2012
	 
   

	 zuschnellersamenerguss.de
	  	Germany	  	zu schneller samenerguss - too quick ejaculation	  	Johnson & Johnson	  	 
 	August 30,
2011	  
  	  	 
 	August 30,
2012	  
  
	 zu-schneller-samenerguss.de
	  	Germany	  	zu schneller samenerguss - too quick ejaculation	  	Johnson & Johnson	  	 
 	August 30,
2011	  
  	  	 
 	August 30,
2012	  
  

 SCHEDULE 1.56 
 [*] 
 Attached hereto 

  
 [*]
Confidential treatment requested. 

  

 SCHEDULE 1.67 
 PRODUCT REGISTRATIONS 
  

					
	 Authorization Country
	  	 Registration Number
	  	 Product Name

	 Argentina
	  	55.412	  	Priligy 30 + 60 mg Tablets
	 Aruba
	  	Registration No. 15.12.02.306	  	Priligy 30 mg Tablets
	 Aruba
	  	Registration No. 15.12.02.305	  	Priligy 60 mg Tablets
	 Australia
	  	ARTG No. AUST R 147946	  	Priligy 30 mg Tablets
	 Austria
	  	Zul Nr. 1-28010	  	Priligy 30 mg Tablets
	 Austria
	  	Zul Nr. 1-28011	  	Priligy 60 mg Tablets
	 Bolivia
	  	II-41872/2010	  	Priligy 30mg Tablets
	 Bolivia
	  	II-41879/2010	  	Priligy 60mg Tablets
	 Brazil
	  	1.1236.3397	  	Priligy 30 mg + 60 mg Tablets
	 Chile
	  	Registro I.S.P. No. F-18,266/10	  	Priligy 30 mg Tablets
	 Chile
	  	Registro I.S.P. No. F-18,267/10	  	Priligy 60 mg Tablets
	 PRC
	  	H20100806	  	Priligy 30 mg Tablets
	 PRC
	  	H20100807	  	Priligy 60 mg Tablets
	 Colombia
	  	2010M-0011743	  	Priligy 30 mg Tablets
	 Colombia
	  	2010M-0011709	  	Priligy 60 mg Tablets
	 Curacao
	  	10.10.017	  	Priligy 30 mg Tablets
	 Curacao
	  	10.10.018	  	Priligy 60 mg Tablets
	 El Salvador
	  	No. F039917082011	  	Priligy 30 mg Tablets
	 El Salvador
	  	No. F041224082011	  	Priligy 60 mg Tablets
	 Finland
	  	24353	  	Priligy 30 mg Tablets
	 Finland
	  	24354	  	Priligy 60 mg Tablets
	 Germany
	  	71669.00.00	  	Priligy 30 mg Tablets
	 Germany
	  	71670.00.00	  	Priligy 60 mg Tablets
	 Ghana
	  	FDB/SD.113-2072	  	Priligy 30 mg Tablets
	 Ghana
	  	FDB/SD.111-5268	  	Priligy 60 mg Tablets
	 Guatemala
	  	PF-4599-2011	  	Priligy 30 mg Tablets
	 Guatemala
	  	PF-45600-2011	  	Priligy 60 mg Tablets
	 Honduras
	  	M-17828	  	Priligy 30 mg Tablets
	 Honduras
	  	M-17828	  	Priligy 60 mg Tablets
	 Hong Kong
	  	Permit No. HK-60174	  	Priligy 30 mg Tablets
	 Hong Kong
	  	Permit No. HK-60175	  	Priligy 60 mg Tablets
	 Italy
	  	039041052/M	  	Priligy 30 mg Tablets, 1 tablet pack
	 Italy
	  	039041076/M	  	Priligy 60 mg Tablets, 1 tablet pack
	 Italy
	  	039041064/M	  	Priligy 30 mg Tablets, 2 tablet pack
	 Italy
	  	039041088/M	  	Priligy 60 mg Tablets, 2 tablet pack
	 Italy
	  	039041037/M	  	Priligy 60 mg Tablets, 3 tablet pack
	 Italy
	  	039041025/M	  	Priligy 30 mg Tablets, 6 tablet pack
	 Italy
	  	039041049/M	  	Priligy 60 mg Tablets, 6 tablet pack
	 Republic of Korea
	  	4945-92	  	Priligy 30 mg Tablets
	 Republic of Korea
	  	4945-91	  	Priligy 60 mg Tablets
	 Lebanon
	  	Reg No. 10/218715	  	Priligy 30 mg Tablets
	 Lebanon
	  	Reg No. 10/218716	  	Priligy 60 mg Tablets
	 Macau
	  	AIC039041013/M (import permit)	  	Priligy 30 mg Tablets
	 Macau
	  	AIC039041037/M (import permit)	  	Priligy 60 mg Tablets
	 Malaysia
	  	Reg No. MAL20102027AR	  	Priligy 30 mg Tablets
	 Malaysia
	  	Reg No. MAL20102028AR	  	Priligy 60 mg Tablets
	 Mexico
	  	Reg San No. 132M2009 SSA	  	Priligy 30 mg + 60 mg Tablets
	 New Zealand
	  	TT50-8048	  	Priligy 30 mg
	 New Zealand
	  	TT50-8048a	  	Priligy 60 mg Tablets
	 Peru
	  	Reg No. E22537	  	Priligy 30 mg Tablets

					
	 Philippines
	  	BFAD Reg No. DR-XY37906	  	Priligy 30 mg Tablets
	 Philippines
	  	BFAD Reg No. DR-XY37907	  	Priligy 60 mg Tablets
	 Portugal
	  	5178215	  	Priligy 30 mg Tablets, 3 tablet pack
	 Portugal
	  	5178231	  	Priligy 60 mg Tablets, 3 tablet pack
	 Portugal
	  	5178223	  	Priligy 30 mg Tablets, 6 tablet pack
	 Portugal
	  	5178249	  	Priligy 60 mg Tablets, 6 tablet pack
	 Singapore
	  	Product License No. SIN13880P	  	Priligy 30 mg Tablets
	 Singapore
	  	Product License No. SIN13881P	  	Priligy 60 mg Tablets
	 Spain
	  	70.874	  	Priligy 30 mg Tablets
	 Spain
	  	70.875	  	Priligy 60 mg Tablets
	 Sweden
	  	MTnr 26319	  	Priligy 30 mg Tablets
	 Sweden
	  	MTnr 26320	  	Priligy 60 mg Tablets
	 Taiwan
	  	 025417
 DHA00202541701
	  	Priligy 30 mg Tablets
	 Turkey
	  	 Registration Certificate No :
 14.07.2011- 131/76
	  	Priligy 30 mg tablets
	 Uruguay
	  	Reg. No. 42800	  	Priligy 30 mg Tablets
	 Uruguay
	  	Reg. No. 42801	  	Priligy 60 mg Tablets

 PRICING APPROVALS 
 Canada 

 SCHEDULE 1.68 
 PRODUCT REGISTRATION APPLICATIONS 
  

					
	 Applicant Country
	  	 Filing Date
	  	 Application Number

	 Canada
	  	6 JUN 08	  	NDS 120605/File 9427-J0921-101
	 South Africa
	  	3 SEP 08	  	 30 mg: 430692
 60 mg: 430693

	 Venezuela
	  	27 Jan 11	  	 30 mg: 110033
 60 mg: 110034

	 Israel
	  	27 Apr 09	  	 MOH rejected application
 30 AUG 11 – application closed

	 Thailand
	  	26 JUN 09	  	Due to the flooding in Thailand, no one is working at the local office, and all records were moved from the ground floor to higher floors or were moved
offsite. Retrieval remains ongoing.
	 Indonesia
	  	05 AUG 10	  	210242030 (30mg and 60mg)
	 Panama
	  	30 DEC 09	  	 30mg: 20091243411
 60mg: 20091243412

	 Costa Rica
	  	18 JAN 10	  	application withdrawn due to no commercial interest
	 Paraguay
	  	18 FEB 10	  	60 mg: 4407 30 mg: 4409
	 Nicaragua
	  	N/A	  	never officially submitted, commercial team may not be interested in product
	 Dominican Republic
	  	25 MAY 10	  	Priligy 30 mg - solicitud 0201-03593-2010
Priligy 60 mg - solicitud 0201-03601-2010
	 Russia
	  	15 APR 10	  	 30 mg,60 mg:
 414954, 23/05/2011

	 Jamaica
	  	28 JUN 10	  	Application was rejected by HA (26Jan11)
	 Vietnam
	  	31 AUG 10	  	 NN-11136, NN-11136
 (30mg and 60mg)

	 Switzerland
	  	6 SEP 10	  	No application number
	 Jordan
	  	14 JUN 11	  	Dapoxetine

 SCHEDULE 2.1(a) 

ALZA DISTRIBUTOR LICENSEES 
 Countries Priligy Currently Marketed (Group A Countries) 
  

					
	 Country
	  	 Third Party Contractor
	  	 MAH

			
	 [*]
	  	[*]	  	
	 [*]
	  	[*]	  	
	 [*]
	  	[*]	  	
	 [*]
	  	[*]	  	
	
	 Countries Priligy Currently Approved But Not Launched (Group B
Countries)

			
	 [*]
	  	[*]	  	
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	
	 [*]
	  	[*]	  	
	 [*]
	  	[*]	  	
	 [*]
	  	[*]	  	
	
	 Currently Filed but Not Approved (Group C Markets)

			
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	

  
 [*]
Confidential treatment requested. 

  

 SCHEDULE 4 
 TECHNOLOGY TRANSFER AND TRANSITION PERIOD 
  

	1.	Definitions. For purposes of this Schedule 4, the following definitions shall apply. All other defined terms in this Schedule 4 shall have the meaning established in
Section 1 of the Agreement. 

  

	1.1	“Control” means possession of the right to grant a license or sublicense or other rights as provided for herein by the applicable Party, ALZA, or any
Affiliate of any of the foregoing, whether through ownership or license from any Affiliate or Third Party, without violating the terms of any agreement with any Third Party. 

 

	1.2	“Country Transfer Date” means, on a country-by-country basis, the date on which all of the Product Assets (other than any Regulatory Submissions and Product
Registrations that cannot be transferred by such date, as contemplated by Section 2.4 of this Schedule 4) in a country are to be transferred, assigned, and delivered to LICENSEE in accordance with the terms of Section 2 of this Schedule 4
pursuant to the Regulatory Transition Plan set forth in Section 3.1.7. 

  

	1.3	“Development Records” means all regulatory filings, records, and other documents (whether in hardcopy or electronic form) in the Control of ALZA, directly or
through its Affiliates thereof pertaining to the development of any Existing Product, including any Existing Product Registrations, Regulatory Submissions, or Manufacturing Records anywhere in the Territory, including such portions of any documents
bearing Licensed Know-How relating to Dapoxetine or any Existing Product and any such Product Registrations or Regulatory Submissions for any Existing Product and all material written communications with Regulatory Authorities with respect thereto.
For the avoidance of doubt, Development Records include such records used to obtain and maintain Product Registrations or Regulatory Submissions, and records needed to support clinical development. 

 

	1.4	“Existing Product Registration” means all Product Registrations approved by any Regulatory Authority as of the Effective Date. 

 

	1.5	“Final Transfer Date” means, for a particular country, the later of the Regulatory Transfer Date or Country Transfer Date. 

 

	1.6	“Manufacturing Records” means all filings, records, and other documents (whether in hardcopy or electronic form) Controlled by ALZA (directly or through its
Affiliates) pertaining to the manufacture of Dapoxetine or any Existing Product, including the portions of any such documents bearing Know-How relating to the manufacture of Dapoxetine or any Existing Product, the chemistry, manufacturing and
controls portion of all Regulatory Submissions and Existing Product Registrations for Dapoxetine or any Existing Product, all drug master files for Dapoxetine or any Existing Product, together with all amendments and supplements, in support thereof,
records used to obtain and maintain Existing Product Registrations or Regulatory Submissions, and records needed to support clinical development of Dapoxetine or any Existing Product. 

	1.7	“MA Delegate” means an entity to which ALZA (directly or through its Affiliates thereof) delegates authority under a Delegation of Authority to distribute
Existing Product in a country under the Existing Product Registration in such country. 

  

	1.8	“Maintain”, in reference to an Existing Product Registration and/or any other existing Product Registrations or existing Regulatory Submissions obtained by or
on behalf of ALZA or any of its Affiliates for Existing Product approved as of the Effective Date in a particular country, or Regulatory Submissions made by or on behalf of ALZA or any of its Affiliates for Existing Product in a particular country
following receipt of Product Registration therein, means to use Transitional Commercially Reasonable Efforts to undertake the following, as may be applicable, during the Regulatory Transfer Transition Period: (a) making safety-related labeling
changes required by a Regulatory Authority; (b) sending Dear Doctor letters required by a Regulatory Authority; (c) filing development safety update reports (DSUR) until transfer of pharmacovigilance responsibilities to LICENSEE;
(d) collecting adverse event reports and filing such reports, and periodic development safety update reports (PSUR) until transfer of pharmacovigilance responsibilities to LICENSEE; (e) making renewals of an Existing Product Registration
and/or any other existing Product Registrations or Regulatory Submissions upon reasonable written request from LICENSEE; (f) responding to Regulatory Authority requests for information; and (g) taking any other actions with respect to any
Marketing Authorisations in such country as may be required by Applicable Laws. The Parties acknowledge that in order for LICENSEE to receive Product Registration in Brazil according to the Applicable Laws of that country, LICENSOR shall have ALZA
or its Affiliate withdraw its Existing Product Registration and LICENSEE shall concurrently file a Product Registration Application on a date that will be agreed to by LICENSOR and LICENSEE (“Brazil MA Date”), and LICENSOR’s
obligation to Maintain the Existing Product Registration in Brazil shall cease on the Brazil MA Date, which date shall be deemed the Regulatory Transfer Date in Brazil. “Maintain”, in reference to a Product Registration Application filed
by or on behalf of ALZA or any of its Affiliates for Product pending as of the Effective Date in a particular country, means to use Transitional Commercially Reasonable Efforts during the Regulatory Transfer Transition Period to seek approval of
such Product Registration Application by (a) timely responding to any Regulatory Authority’s inquiries regarding such Product Registration Application or (b) making such filings or submissions with Regulatory Authorities, or taking
such other actions, as may be reasonably required to obtain such Product Registration, provided that actions shall not, in any event, include the conducting of any clinical trials or other in vivo or in vitro research or development
activities. 

  

	1.9	“Product Assets” means all rights, title and interest in and to the Product Registrations Controlled by ALZA, Regulatory Submissions, Development Records, and
Manufacturing Records, (which shall, except as otherwise provided in this Agreement, revert to LICENSOR upon termination thereof and be licensed to LICENSEE as contemplated by this Agreement). 

 

	1.10	 “Regulatory Submissions” means, with respect to the Territory and to the extent Controlled by ALZA, all applications, filings, dossiers and
other documents submitted to a Regulatory Authority for the purpose of seeking or obtaining 

	 	
Product Registration (or engaging in clinical trials with respect to any human pharmaceutical) or pricing and reimbursement approval from that Regulatory Authority, including, without limitation,
CTAs and Product Registration Applications, and any equivalents of any of the foregoing. 

  

	1.11	“Regulatory Transfer Date” means the date on which the assignment and transfer to LICENSEE of all Regulatory Submissions and Product Registrations Controlled
by ALZA in a given country are effective. 

  

	1.12	“Regulatory Transfer Transition Period” means [*] from the Effective Date. 

 

	1.13	“Transitional Commercially Reasonable Efforts” means the carrying out by a LICENSOR, ALZA, or any Affiliate thereof obligations or activities as specified
herein and exerting overall a level of effort no less than consistent with the level of effort that such Party, or if an obligation or activity is performed by ALZA, or ALZA customarily devotes to corresponding activities, with respect to a
pharmaceutical product or products of similar market potential, profit potential or strategic value, based on conditions then prevailing. Without limiting the foregoing, Transitional Commercially Reasonable Efforts requires that a Party:
(i) timely assign responsibility for such activities to specific employees, contractors, agents or Affiliates, as applicable, who are held accountable for progress with respect to such activities, (ii) monitor such progress on an on-going
basis, (iii) set and seek to achieve objectives and timelines for carrying out such activities, and (iv) allocate resources reasonably designed to advance progress with respect to such objectives and timelines. 

2.0 Transition Process. The Parties acknowledge that, in certain countries of the Territory, based upon information provided by ALZA to identify
countries and designate them in the Regulatory Transition Plan (defined below) in the applicable group as of the Effective Date, the Existing Product has, as of the Effective Date: (a) effective Product Registrations and is being sold in the
“Group A Market Countries”, which are listed in Exhibit 4-A to this Schedule 4; (b) effective Product Registrations but is not being sold in the “Group B Market Countries”, which are listed in Exhibit 4-B to this Schedule 4;
or (c) a pending Product Registration Application in the “Group C Market Countries”, which are listed in Exhibit 4-C to this Schedule 4. LICENSEE requires a transfer of Know-How or other information concerning the Product necessary
and reasonably requested by LICENSEE to enable LICENSEE to Develop and Commercialize the Product in the Territory (“Product Material”). For that purpose, LICENSOR hereby agrees to fulfil its obligations under this Schedule 4 by using
Transitional Commercially Reasonable Efforts to undertake the activities set forth in this Schedule 4 alone or through LICENSOR’S designee, ALZA. 
 2.1 Transition Team. 
 2.1.1 LICENSEE and LICENSOR will establish
a joint committee (the “Transition Team”), to facilitate and oversee the planning and implementation of strategic and tactical plans to effect the transfer and delivery of Product Asset in each applicable country in the Territory in
accordance with the terms of this Schedule 4 and to make decisions pursuant to Section 2.1.2 of this Schedule 4, and to discuss transitional issues and to facilitate communications between the Parties with respect to such matters. The
Transition Team shall also serve as a 

  
 [*]
Confidential treatment requested. 

  

 
forum to address supply chain and inventory management matters during all Transition Periods and to discuss transitional issues and to facilitate communications between the Parties and ALZA with
respect to such matters. Each Party shall appoint reasonably appropriate representatives to the Transition Team, which may include personnel involved with clinical development, regulatory, manufacturing, packaging, distribution, marketing and/or
sales of Product. The Transition Team shall meet (whether by teleconference, in person or by video-conference) (i) at least weekly until specific, written strategic and tactical plans are in place, with detailed timelines for specific actions,
to transfer and deliver Product Assets from ALZA to LICENSOR and/or LICENSEE, and (ii) at least monthly until the transfer of all Product Assets has occurred hereunder (i.e., until the Final Transfer Date has occurred for all countries in the
Territory), provided that the Transition Team may elect to meet with less or more frequency during the period described in (ii) based on the obligations of each Party, and the progress of the Parties’ and ALZA’s efforts, to implement
such transfers. The specific times and places of all meetings shall be determined by the Transition Managers in a manner consistent with the foregoing obligations and reasonably acceptable to the Parties. The Transition Team may also establish
sub-teams or working groups to address specific areas or topics related to the process for transferring the Product Assets in the Territory. 
 2.1.2 The Transition Team may make decisions expressly within its authority under this Schedule 4, and LICENSOR shall use Transitional Commercially Reasonable Efforts to bind ALZA to such decisions and
cause ALZA to act in accordance therewith, provided that such decisions by the Transition Team hereunder shall be required to be unanimous with the representatives for each Party collectively casting one vote, and the Transition Team shall document
such decisions in a writing signed by authorized team representatives of both Parties. For the avoidance of doubt, the Transition Team shall have no authority to modify any term in the body of this Agreement or this Schedule 4. If the Transition
Team is unable to reach consensus regarding any matter within its decision-making authority before it (including any matter that was unable to be resolved by any sub-team), the matter shall be presented to the President of LICENSOR and CFO of
LICENSEE (the “Applicable Senior Officers”) for decision. Once a matter has been presented to the Applicable Senior Officers, they shall have fifteen (15) days to make a decision on the matter. In the event that the Applicable Senior
Officers are unable to reach a mutual decision within such fifteen (15) day period, then the matter shall be resolved under Section 16.3 of the Agreement. 

2.1.3 Each Party shall appoint a senior representative (each, a “Transition Manager”) who possesses a basic
understanding of the relevant operational, regulatory and commercial issues to manage the transfer obligations to LICENSEE envisioned under this Agreement (the “Transition”). The initial Transition Manager for each Party is set forth in
Exhibit 4-D of this Schedule 4, and either Party may later replace such Transition Manager by providing written notice thereof to the other Party (which notice shall identify the new Transition Manager and provide contact information
therefor), provided that any replacement Transition Manager shall possess reasonably sufficient expertise to reasonably satisfy the intended role of the Transition Manager under this Agreement and

 
leadership responsibilities within the relevant Party that are substantially similar to or more senior than those of the preceding Transition Manager. Each Party’s Transition Manager shall
be the primary contact with the other Party in connection with the on-going implementation, communication and voting on matters within the Transition Team’s authority concerning the Transition and shall lead his/her Party’s Transition Team
hereunder. 
 2.2 Completion of Transfer of Product Assets. Except as expressly provided for in this Agreement, the Transition
Team shall decide in writing upon a mutually acceptable date for each applicable country in the Territory that will be the Parties’ desired target Country Transfer Date for the completion of the assignment and transfer of all Product Assets to
LICENSEE in such country, and LICENSOR shall use Transitional Commercially Reasonable Efforts to obtain agreement with ALZA to such target Country Transfer Date. LICENSOR shall use Transitional Commercially Reasonable Efforts to obtain the transfer
or delivery of the Product Assets to LICENSEE on a country-by-country basis in the Territory in accordance with the terms and conditions of this Agreement and, except as otherwise provided in Sections 2.3 or 2.4 of this Schedule 4, the transfer and
delivery of the Product Assets in a country shall be completed and made effective as of the Country Transfer Date. On and after the Effective Date, the Parties shall use good faith Transitional Commercially Reasonable Efforts to expedite the
transfer and delivery of Product Assets in each of the countries of the Territory. For purposes of clarification but not limitation, LICENSEE may request in writing that any portion of the Product Assets be directly assigned, transferred, and
delivered to LICENSEE from ALZA, and LICENSOR shall use Transitional Commercially Reasonable Efforts to comply with such request. 
 2.3 Rights and Obligations of the Parties Based on Country Designation. 
 2.3.1
Group A Market. 
 2.3.1.1 LICENSEE will, subject to any legal obligations ALZA or its Affiliates may have as
holder of Product Registrations or Product Registration Applications prior to the Regulatory Transfer Date, ALZA’s obligations with regard to the Priligy On-Going Clinical Trials or contractual obligations ALZA or its Affiliates may have to
LICENSEE, LICENSOR, or any Affiliate of either of the foregoing, assume full responsibility and control over all aspects of the distribution and commercialization of the Product in the Group A Market countries pursuant to the terms of this
Agreement, and the development and manufacture of Product anywhere for such purposes in each Group A Market Country, except for the manufacture of Product by ALZA (directly or through its Affiliates) for Group A Market countries pursuant to the
Manufacturing Agreement. 
 2.3.1.2 The Parties will coordinate through the Transition Team (directly or through
their Affiliates or designees) to make the necessary inquiries and use Commercially Reasonable Efforts to cause the necessary documents to be filed with the Regulatory Authority in each Group A Market Country in accordance with Applicable Laws of
each such country to transfer ownership and pharmacovigilance responsibility LICENSOR shall, through ALZA, use Transitional Commercially Reasonable Efforts to file and obtain approval of any variations of any Product Registrations or Regulatory
Submissions, needed to effect such transfer, of any Product Registrations and Regulatory Submissions to LICENSEE on or before the date in that country as determined by the Transition Team. 

 2.3.1.3 LICENSOR’s only obligations in each Group A Market country will
be: 
  

	 	(a)	as of the Effective Date, to use Transitional Commercially Reasonable Efforts to ensure that ALZA or its Affiliate (i) make inquiries and file such documents as
set forth in Section 2.3.1.2, and (ii) Maintain the Existing Product Registrations and any other existing Product Registrations and Regulatory Submissions, which obligations shall cease on the Regulatory Transfer Date in all Group A Market
Countries; 

  

	 	(b)	as of the Effective Date, if requested in writing by LICENSEE, to use Commercially Reasonable Efforts to ensure that ALZA or its Affiliates shall appoint LICENSEE as
its MA Delegate in each Group A Market Country under a Delegation of Authority Agreement, which shall expire on a country-by-country basis on the Regulatory Transfer Date in each country, to allow LICENSEE to distribute and commercialize Existing
Product prior to the Regulatory Transfer Date; 

  

	 	(c)	as of the Effective Date, to use Commercially Reasonable Efforts to cause ALZA or its Affiliates to transfer any other Product Assets in each Group A Market Country;

  

	 	(d)	to use Transitional Commercially Reasonable Efforts ensure that ALZA or its Affiliates fulfill any legal obligations they may have as holders of Product Registrations
or Product Registration Applications prior to the Regulatory Transfer Date; and 

  

	 	(e)	LICENSOR’s obligations as set forth in the PVG Agreement. 

 2.3.2 Group B Market. 
 2.3.2.1 LICENSEE will, subject to any
legal obligations ALZA or its Affiliates may have as holder of Product Registrations or Product Registration Applications prior to the Regulatory Transfer Date, ALZA’s obligations with regard to the Priligy On-Going Clinical Trials or
contractual obligations ALZA or its Affiliates may have to LICENSEE, LICENSOR, or any Affiliate of either of the foregoing, assume full responsibility and control over all aspects of the distribution and commercialization of the Product as of the
Effective Date in each Group B Market Country, and the development and manufacture of Product anywhere for such purposes in each Group B Market Country, except for the manufacture of Product by ALZA or its Affiliates pursuant to the Manufacturing
Agreement. 
 2.3.2.2 The Parties will coordinate through the Transition Team (directly or through their
Affiliates or designees) to make the necessary inquiries and use Commercially Reasonable Efforts to cause the filing of the necessary documents with the Regulatory Authority in each Group B Market Country in accordance with Applicable Laws of each
such country to transfer ownership and pharmacovigilance following the transfer of the global safety database for Priligy to LICENSEE. LICENSOR shall, through its designee ALZA, use Transitional

 
Commercially Reasonable Efforts to file and obtain approvals of any variations needed of any Product Registrations or Regulatory Submissions, to effect such transfer, of the Existing Market
Authorization and any other Product Registrations and Regulatory Submissions to LICENSEE and/or its Affiliates on or before the date in that country as determined by the Transition Team. 

2.3.2.3 LICENSOR’s only obligations in each Group B Market country will be: 

 

	 	(a)	as of the Effective Date, to use Transitional Commercially Reasonable Efforts to ensure that ALZA or its Affiliates (i) make inquiries and file such documents as
set forth in Section 2.3.2.2 of Schedule 4 and (ii) Maintain the Existing Product Registrations and any other existing Product Registrations and Regulatory Submissions; 

 

	 	(b)	as of the Effective Date, if requested in writing by LICENSEE, to use Commercially Reasonable Efforts to ensure that ALZA or its Affiliates appoint LICENSEE as its MA
Delegate in each requested Group B Market Country under a Delegation of Authority Agreement, which shall expire on a country-by-country basis on the Regulatory Transfer Date in each country, to allow LICENSEE or its designated Affiliate to
distribute and commercialize Existing Product prior to the Regulatory Transfer Date; 

  

	 	(c)	as of the Effective Date, to use Commercially Reasonable Efforts to cause ALZA or its Affiliates to transfer any other Product Assets in each Group B Market Country;

  

	 	(d)	to use Transitional Commercially Reasonable Efforts to ensure that ALZA or its Affiliates fulfil any legal obligations they may have as holders of Product Registrations
or Product Registration Applications prior to the Regulatory Transfer Date; and 

  

	 	(e)	LICENSOR’s obligations as set forth in the PVG Agreement. 

 The obligations in clauses (a), (b), (c), and (d) of this Section 2.3.2.3 shall cease on the Regulatory Transfer Date in all Group B Market Countries. 

2.3.3 Group C Market. 
 2.3.3.1 LICENSEE will, subject to any legal obligations ALZA or its Affiliates may have as holder of Product Registrations or Regulatory Submissions prior to the Regulatory Transfer Date, ALZA’s
obligations with regard to the Priligy On-Going Clinical Trials or contractual obligations ALZA or its Affiliates may have to LICENSEE, LICENSOR, or any Affiliate of either of the foregoing, assume full responsibility and control over all aspects of
the distribution and commercialization of the Product as of the Effective Date in each Group C Market Country, and the development and manufacture of Existing Product anywhere for such purposes in each Group C Market Country, except for the
manufacture of Existing Product by ALZA or its Affiliates pursuant to the Manufacturing Agreement. 
 2.3.3.2
LICENSOR shall use Commercially Reasonable Efforts to ensure that ALZA or its Affiliates (i) Maintain the Product Registration Applications in each Group C Market Country and (ii) use Transitional Commercially Reasonable

 
Efforts to obtain approval of such Marketing Applications in each Group C Market Country. Upon receipt of Product Registration in a Group C Market Country, the Parties will coordinate through the
Transition Team (directly or through their Affiliates or designees) to make the necessary inquiries and use Commercially Reasonable Efforts to cause the necessary documents to be filed with the Regulatory Authority in each Group C Market Country in
accordance with Applicable Laws of each such country to transfer ownership and pharmacovigilance following the transfer of the global safety database for Priligy to LICENSEE. LICENSOR shall, through its designee ALZA, use Transitional Commercially
Reasonable Efforts to obtain approval of any variations of any Regulatory Submissions or resulting Product Registrations needed to effect such transfer, of the Regulatory Approval and any other Product Registrations and Regulatory Submissions to
LICENSEE as soon as reasonably possible following receipt of Product Registration in such country. 
 2.3.3.3
LICENSOR’s only obligations in each Group C Market country will be: 
  

	 	(a)	to use Commercially Reasonable Efforts to (i) ensure that ALZA or its Affiliates Maintain the Product Registration Application and (ii) use Transitional
Commercially Reasonable Efforts to obtain Regulatory Approval in each Group C Market country. 

  

	 	(b)	to use Commercially Reasonable Efforts to ensure that ALZA or its Affiliates (i) make the inquiries and file such documents as set forth in Section 2.3.3.2 of
this Schedule 4 and (ii) Maintain the Product Registration Application, any resulting Regulatory Approvals, and any other Product Registrations and Regulatory Submissions, which obligations shall cease on the Regulatory Transfer Date in each
Group C Market Country; 

  

	 	(c)	as of the Effective Date, to use Commercially Reasonable Efforts to cause ALZA or its Affiliates to transfer any other Product Assets in each Group C Market Country;
and 

  

	 	(d)	LICENSOR’s obligations as set forth in the PVG Agreement. 

 The obligations in clauses (a), (b), and (c) of this Section 2.3.3.3 shall cease on the Regulatory Transfer Date in each Group C Market Country. 

2.3.4 No Further LICENSOR Obligations in Other Countries. As of the Effective Date, LICENSOR or its designee will have no
further obligation with respect to, any country of the Territory other than LICENSOR’s obligations in the Group A Market Countries, Group B Market Countries, and Group C Market Countries as set forth in this Schedule 4 and the PVG Agreement.

 2.3.5 Transition Periods. 
 2.3.5.1 Country Transfer Transition Period. For each Group A Market Country, Group B Market Country, and Group C Market Country, the Country Transfer Date shall occur no later than the expiration of the
period ending [*] from the Effective Date (“Country Transfer Transition Period”). 

  
 [*]
Confidential treatment requested. 

  

 2.3.5.2 Regulatory Transfer Transition Period. The Regulatory Transfer Date
shall occur no later than the expiration of the period ending [*] from the Effective Date (“Regulatory Transfer Transition Period”). For avoidance of doubt, when the term “Regulatory Transfer Transition Period” is used herein in
reference to a particular country, the Regulatory Transfer Transition Period in such country shall end on the Regulatory Transfer Date in that country. The Parties expect that all transfers of Product Registrations and Regulatory Submissions
envisioned under this Agreement will be approved by the relevant Regulatory Authorities no later than expiry of the Regulatory Transfer Transition Period. For avoidance of doubt, LICENSOR shall have no obligation to Maintain, transfer, or assist
LICENSEE to maintain or transfer Product Registrations and Regulatory Submissions after the expiry of the Regulatory Transfer Transition Period. Notwithstanding the foregoing, the Regulatory Transfer Transition Period shall be extended in the event
of Governmental Transfer Delay as defined in Section 2.4 of this Schedule 4 and shall continue until such time that the transfer of Product Registrations and Regulatory Submissions in the Territory are complete. 

2.3.6 Transfer of Regulatory Responsibility. LICENSOR shall use Transitional Commercially Reasonable Efforts to ensure
that ALZA or its Affiliates shall be responsible for regulatory matters in each Group A Market Country, Group B Market Country, and Group C Market Country during the Regulatory Transfer Transition Period in that country, and LICENSEE shall assume
regulatory responsibility on the Regulatory Transfer Date in each country. In the event that exceptional action or inaction by a Regulatory Authority in a country prevents completion of such transfer prior to expiry of the Regulatory Transfer
Transition Period, LICENSEE agrees to allow LICENSOR to, and LICENSOR shall, negotiate with ALZA in good faith an extension of the Regulatory Transfer Transition Period for that country to effectuate such regulatory transfer, including reasonable
compensation for ALZA, the cost of which will be paid by LICENSEE, and any such extension agreed to by ALZA and LICENSOR shall be effective for purposes of this Schedule 4. Notwithstanding the foregoing, in the event ALZA has performed substantially
all activities necessary to effect such regulatory transfer such that only minimal activity is needed by ALZA, LICENSOR shall use Commercially Reasonable Efforts to ensure that ALZA shall complete the transfer at no cost to LICENSEE, provided that
the foregoing shall not be construed to require LICENSOR to incur any costs or expenses or payment obligations to ALZA or any Affiliate thereof. 
 2.3.7 Regulatory Support. LICENSOR shall use Commercially Reasonable Efforts to ensure that ALZA will provide regulatory support as follows: 

(a) for a period ending [*] from the Regulatory Transfer Date in each country in the Group A Market Countries, Group B Market Countries,
and Group C Market Countries, upon reasonable request by LICENSEE, ALZA will assist with the development of regulatory documents, including the drafting and submission of documents to Regulatory Authorities; and 

(b) for a period beginning [*] from the Regulatory Transfer Date in each country in the Group A Market Countries, Group B Market
Countries, and Group C Market Countries and ending [*] from such Regulatory Transfer Date, ALZA will provide consulting services at no cost regarding regulatory matters. 

  
 [*]
Confidential treatment requested. 

 
Such consulting services shall be limited to responding to reasonable requests for information concerning specific regulatory matters, but shall not include the development of regulatory
documents, including the drafting and submission of responses to Regulatory Authorities. 
 2.4 Delays in Transfer of Product
Registrations, Regulatory Submissions, and Product Assets. The Parties acknowledge that there will be some countries in which the transfer of ownership and control of Product Registrations or Regulatory Submissions (and possibly certain other
Product Assets) to LICENSEE cannot be completed on or before the Country Transfer Date as a result of (a) processes or conditions imposed by Regulatory Authorities or other governmental authorities and that are outside the reasonable control of
the Parties or ALZA or (b) the requirements or limitations of any Applicable Laws in such country(all such circumstances referred to in clause (a) or (b), “Governmental Transfer Delay”). It is the intention of the Parties that,
to the fullest extent possible under Applicable Laws, such delays in transferring Product Registrations or Regulatory Submissions (and/or other Product Assets, if any) in a country should not result in a delay in the transfer of those Product Assets
that can be transferred on or before the Country Transfer Date, so that LICENSEE can assume, to the greatest extent possible pursuant to Applicable Laws, full control and responsibility for the Product (and become entitled to the benefit of all
sales of and other activities with respect to, Product) in such country as of the Country Transfer Date. Accordingly, the Parties agree that in the event of any Governmental Transfer Delay: 

2.4.1 LICENSOR shall, subject to LICENSEE’s provision of any assistance or cooperation reasonably requested by
LICENSOR, use Commercially Reasonable Efforts to ensure that ALZA or its Affiliates will undertake to complete the transfer and delivery of all of the Product Assets that are not the subject of such Governmental Transfer Delay on or before the
Country Transfer Date; and 
 2.4.2 LICENSEE agrees that ALZA or its Affiliates may continue to hold and
maintain the Product Registrations and Regulatory Submissions (and such other Product Assets, if any, that cannot be transferred on or before the Country Transfer Date) for the Product on behalf of and for the sole benefit of LICENSEE and its
designated Affiliates only until such time as the transfer of Product Registrations and Regulatory Submissions(and any other affected Product Assets) to LICENSEE or its designated Affiliates can be completed in such country. For the avoidance of
doubt, nothing herein shall be construed as obligating LICENSOR to, or LICENSOR to cause ALZA or its Affiliates, to undertake or perform any advertising, marketing or promotional services for or on behalf of LICENSEE or its designated Affiliates
and/or any sublicensees with respect to the Product in a country in the Territory on or after the Effective Date. 
 2.4.3 Distribution of Product. LICENSEE (directly or through its Affiliates) shall assume full responsibility (at its own expense) for the distribution and sale of Product in each Group A Market country
as set forth in the Agreement. 
 2.4.3.1 Responsibility for distribution activities for Product (x) in
those countries in the Group B Market Countries, or Group C Market Countries where the transfer of Product Registrations, Regulatory Submissions, or other Product Assets to LICENSEE or its designated Affiliates cannot be completed on or

 
before the Country Transfer Date due to a Governmental Transfer Delay or (y) as of the Effective Date in the Group A Market Countries will be allocated between the Parties as follows:

 (a) LICENSOR shall use Commercially Reasonable Efforts to ensure that, to the extent legally permitted under Applicable Law,
ALZA or its Affiliates will appoint LICENSEE to act on its behalf as an MA Delegate of Existing Product in each such country, such appointment to be made effective as of the Effective Date for the Group A Market Countries and as of the Country
Transfer Date for all other such countries, as further set forth in the Delegation of Authority Agreements, in which case LICENSEE will assume full responsibility for all distribution activities for Product in such country as of the effective date
of such appointment. The Transition Team (or a sub-team thereof) will work with ALZA to use good faith efforts to identify and determine those countries in the Territory where it will be necessary and legally permissible for ALZA or its Affiliates
to appoint LICENSEE (or its designated Affiliate) to distribute Product as contemplated by this Section 2.5.3.1; and 
 (b)
To the extent, on country-by-country basis, that LICENSEE is not appointed as an MA Delegate in any such country (as contemplated by Section 2.5.3.1(a) above) and not transferred responsibility for distribution activities to LICENSEE as set
forth above, LICENSEE agrees that ALZA or its Affiliates may continue to distribute Existing Product on behalf of LICENSOR until the Regulatory Transfer Date for such country. 
 2.5 Reporting During Transition Period. Until the end of the Transition Period in each country, LICENSOR shall use Commercially Reasonable Efforts to ensure that ALZA or its Affiliates shall keep LICENSEE
reasonably informed regarding the ongoing activities by ALZA (directly or through its Affiliates) for the Existing Product in the country. For ALZA distribution activities, ALZA shall (subject to compliance with FCPA and OECD) (i) involve
LICENSOR (who will, to the extent reasonably possible, provide LICENSEE a reasonable opportunity to provide input and guide LICENSOR’s involvement) with regard to any proposed changes in trade activities related to the Existing Product and
(ii) LICENSOR shall use Commercially Reasonable Efforts to ensure that, except as necessary to comply with FCPA and OECD, ALZA or its Affiliates shall not materially change any of its practices with respect to any such activities, or take any
action with respect to its manufacture, supply, distribution, or sale of Existing Product that would materially adversely affect, or would reasonably be anticipated to materially and adversely affect, the manufacture, supply, distribution,
marketing, or sale of Existing Product in such country without LICENSEE’s prior written consent, such consent not to be unreasonably withheld. 

 2.6 Data Collection. The Parties acknowledge that, as of the Effective Date, ALZA (directly
or through its Affiliates) is supporting, conducting or otherwise responsible for the medical affairs activities, the responsibility for which in the Territory shall be transferred to LICENSEE effective when the Final Transfer Date has occurred for
all countries in the world. 
 2.7 Assignment of Other ALZA Product Contracts. Any member of the Transition Team shall have the
right, in its discretion and promptly following its reasonable written request with respect thereto, to review any Other ALZA Product Contract(s) during the Transition Period, subject to the applicable confidentiality and consent provisions of such
Other ALZA Product Contract(s) that any member of the Transition Team desires to review. If the Transition Team decides, by unanimous decision that an Other ALZA Product Contract is material to LICENSEE’S rights to manufacture, use, sell,
market, develop, distribute or commercialize Product (“Material Product Contract”), LICENSOR shall use Transitional Commercially Reasonable Efforts to cause ALZA to terminate with respect to Product, or allow to expire, such
Material Product Contract, such termination subject to ALZA’s pre-existing obligations and other terms of such Material Product Contract and subject to ALZA’s obligations under the License and Asset Transfer Agreement and any Ancillary
Agreement, on or before [*] after the decision date documented in writing by the Transition Team, except in the Group A Market countries, where Transitional Commercially Reasonable Efforts shall be used to terminate with respect to Product,
or allow to expire, such Material Product Contract on a country-by-country basis no later than the later of: (i) [*] after the decision date, (ii) [*] after the Effective Date or (iii) [*] after the Regulatory Transfer Date for each
such country. If, after review of Material Product Contracts, LICENSEE identifies in writing to LICENSOR a Material Product Contract that LICENSEE reasonably requests to have assigned to it, or indicates whether or not LICENSEE wishes such Material
Product Contract to be terminated, allowed to expire, or to remain in effect, LICENSOR shall use Transitional Commercially Reasonable Efforts to cause ALZA to assign such Material Product Contract to LICENSEE, subject to the assignment provision of
such Material Product Contract or comply with LICENSEE’s reasonable request with respect to termination, expiration, or survival thereof. 
  

	3.0	Diligence and Coordination of Efforts 

 3.1 Diligence and Cooperation. On and after the Effective Date, LICENSEE and LICENSOR shall cooperate diligently in coordinated efforts with each other, and LICENSOR shall use Commercially Reasonable
Efforts to cause ALZA to cooperate diligently in coordinated efforts with LICENSOR and LICENSEE, to timely complete the various transfers and delivery of Product Assets provided for in Section 2 of this Schedule 4. Each of LICENSEE and LICENSOR
shall undertake, and shall ensure that their respective Affiliates, as applicable, undertake any actions reasonably necessary to timely complete the various transfers and delivery of Product Assets to LICENSEE and/or its designated Affiliates as
provided in Section 2 of Schedule 4 of this Agreement, including LICENSOR using Commercially Reasonable Efforts to cause ALZA or its Affiliates to execute any documents necessary to transfer and/or assign the Regulatory Submissions and Product
Registrations to LICENSEE or its designated Affiliates in the Territory as contemplated above. 

  
 [*]
Confidential treatment requested. 

 3.1.1 Disposition of Development Records. In connection with the transfer
and delivery of Product Assets to LICENSEE or its designated Affiliates, LICENSOR shall use Commercially Reasonable Efforts to ensure that during the Transition Period for each country in the Territory, ALZA or its Affiliates shall transfer and
deliver to LICENSEE all material Development Records concerning the Product reasonably requested by LICENSEE that are necessary to enable LICENSEE to Develop and Commercialize the Product in such country and in ALZA’s or its Affiliates’
possession or control. LICENSOR shall use Commercially Reasonable Efforts to ensure that ALZA or its Affiliates will coordinate the timing and prioritization of Development Records to be transferred and delivered to LICENSEE or its designated
Affiliates pursuant to this Section 3.1.1 of this Schedule 4. LICENSEE shall work in good faith with LICENSOR and ALZA or its Affiliates and use Transitional Commercially Reasonable Efforts to complete the transfer and delivery of Development
Records as soon as reasonably possible following the Effective Date. 
 3.1.2 Development Records in Electronic
Form. For the avoidance of doubt, to the extent that data and information included within the Development Records to be transferred and delivered to LICENSEE are maintained by ALZA or its Affiliates in electronic form, the obligation of LICENSOR to
cause ALZA or its Affiliates transfer and deliver such Development Records to LICENSEE or its designated Affiliates shall be limited to using Commercially Reasonable Efforts to cause ALZA or its Affiliates to provide LICENSEE or its designated
Affiliates with such electronic data in a mutually agreed format that is reasonably acceptable to both LICENSEE and ALZA. Nothing herein shall be construed as obligating LICENSOR to cause ALZA or its Affiliates to transfer to LICENSEE or to
otherwise provide LICENSEE with access to or rights to use any proprietary software (including Third Party or licensed software and/or software that is owned by ALZA or its Affiliates) that may be utilized by ALZA or its Affiliates from time to time
in connection with such electronic data and information included within Development Records. 
 3.1.3 ALZA
Quality Assurance Records. Notwithstanding anything to the contrary herein, documentation related to quality assurance (QA) audit activities related to Product (including with respect to clinical trials thereof) conducted by or on behalf of ALZA or
its Affiliates will not be transferred to LICENSEE, except to the extent contained or referenced in, or supporting, any Regulatory Submissions or Product Registrations Controlled by ALZA prior to the Effective Date, previously made public, required
to be provided to any Regulatory Authority, or required by Applicable Law to be disclosed. At LICENSEE’s prior written request, LICENSOR shall use Commercially Reasonable Efforts to cause ALZA to permit individuals employed by LICENSEE’s
quality assurance department to review, by appointment during normal business hours, at a facility identified by ALZA, the quality assurance audit reports for the Priligy On-Going Clinical Trials, however, no copies in full or in part will be
provided except as set forth herein above. In addition, LICENSEE agrees that, except to the extent contained or referenced in, or supporting, any Regulatory Submissions or Product Registrations existing as of the Effective Date, previously made
public, required to be provided to any Regulatory Authority, or required by Applicable Law to be disclosed, these quality assurance audits will not be referenced within any filing with any Regulatory Authority and will be held in strict confidence.

 3.1.4 Retained Rights to Development Records. LICENSEE acknowledges and
agrees that ALZA and its Affiliates shall be entitled to retain copies of Development Records being transferred and delivered to LICENSEE to the extent necessary, and for the limited purposes of: (i) complying with all Applicable Laws with
respect thereto (including without limitation compliance with GMP, generally accepted accounting principles, external financial reporting obligations, and Sarbanes-Oxley); (ii) compliance with internal corporate policies and standard operating
procedures regarding the creation and retention of books and records; and (iii) performing ALZA’s and its Affiliates’ Product-related contractual obligations to LICENSEE or LICENSOR; and maintaining an archival copy for legal
purposes. 
 3.1.5 Additional Information. In addition to the foregoing, LICENSOR shall convey to ALZA any
written request by LICENSEE to LICENSOR to provide additional data or information material to the development, packaging, marketing, promotion, distribution or sale of Existing Product in one or more countries in the Territory. Except as otherwise
provided in Section 3.1.6 of this Schedule 4, all such requests shall be copied and coordinated through the Transition Team. LICENSOR shall use Commercially Reasonable Efforts to (x) ensure that ALZA or its Affiliates will use Transitional
Commercially Reasonable Efforts to promptly satisfy any such requests by LICENSEE for additional data or information and (y) notify LICENSEE in writing of any such material information of which LICENSOR becomes aware at any time after the
Effective Date and provide LICENSEE such information; provided, however, nothing herein shall be construed as obligating LICENSOR or ALZA or its Affiliates to: (i) generate or procure any data or information that is not in its or their
possession or control, (ii) provide LICENSEE with data or information to the extent that it is owned or controlled by a Third Party and was made available to ALZA, LICENSOR, or their Affiliates under terms and conditions that do not permit its
disclosure or transfer to others, (iii) provide LICENSEE with any data or information related to any products other than Existing Product, or (iv) provide LICENSEE with any data or information to the extent precluded by Applicable Laws
(including without limitation, antitrust or competition law). 
 3.1.6 Communication with ALZA Affiliates.
Promptly after the Effective Date, the Transition Team shall exchange relevant contact information and permit direct communications between their respective global regulatory personnel, and upon Transition Team agreement the Transition Team shall
exchange relevant contact information and permit direct communications between their respective regional and local regulatory personnel with copy of all such communications to the relevant global regulatory personnel, as each Party may designate in
those regions and/or countries in the Territory in order to facilitate planning and implementation of certain aspects of the Regulatory Transition Plan, and LICENSOR shall use Commercially Reasonable Efforts to integrate those efforts with the
corresponding efforts with respect to the ALZA Transition Team under the Asset Transfer Agreement. The Transition Team will also agree in writing upon the specific subject matter for such direct interactions, and LICENSOR shall reflect

 
such agreement in its corresponding activities with respect to the ALZA Transition Team. As of the Effective Date, LICENSEE agrees that no direct interactions with those Affiliates to be
identified by ALZA (“Local Affiliates”) have been authorized and LICENSEE shall not, and shall use Transitional Commercially Reasonable Efforts to ensure that its Affiliates and/or Sublicensees do not, communicate requests for data,
information or materials directly to any of ALZA’s Local Affiliates in any country in the Territory unless and solely to the extent (i) expressly authorized in advance by ALZA in writing or (ii) required by Applicable Law, provided
that LICENSEE shall provide ALZA and LICENSOR with prompt notice of such Applicable Law. Any request or proposal for direct interactions between LICENSEE and any of ALZA’s Local Affiliates not permitted by clause (i) or (ii) above
shall be communicated through the Transition Team, and LICENSOR shall use Commercially Reasonable Efforts to cause ALZA to reasonably consider any such requests; provided, however, that nothing herein shall be construed as obligating ALZA to agree
to any such request or proposal, provided, however, that LICENSOR shall use Commercially Reasonable Efforts to cause ALZA, notwithstanding anything to the contrary herein, to provide any information or documentation in ALZA’s or any of its
Affiliates’ possession or control to the extent requested (directly or through any of its Affiliates, LICENSEE, or any independent contractors of any of the foregoing) by any Regulatory Authority or as necessary to comply with any Applicable
Law or enable the transfer of Product Assets to LICENSEE in a timely fashion. If ALZA does agree to permit its Local Affiliates in one or more regions or countries in the Territory to engage in direct interactions with LICENSEE, LICENSEE shall
negotiate in good faith and agree with ALZA in advance and in writing on the specific subject matter and scope of those permitted interactions, shall communicate that information to their respective Affiliates, as applicable, and shall exchange
relevant contact information identifying their respective representatives who will participate in those interactions. 
 3.1.7 Regulatory Transition Plan. LICENSOR shall use Commercially Reasonable Efforts to ensure that ALZA or its Affiliates use Transitional Commercially Reasonable Efforts to complete the activities by
the various dates set forth in a regulatory transition plan (“Regulatory Transition Plan”). LICENSEE shall promptly notify LICENSOR and ALZA in the event that LICENSEE determines that the activities and/or timelines set forth in the
Regulatory Transition Plan require modification. LICENSOR shall use Commercially Reasonable Efforts to (a) ensure that ALZA or its Affiliates notify LICENSEE in the event that ALZA determines that the activities and/or timelines set forth in
the Regulatory Transition Plan require modification and (b) notify LICENSEE in the event that LICENSOR determines that the activities and/or timelines set forth in the Regulatory Transition Plan require modification. The Transition Team shall
be responsible for periodically reviewing and approving any changes to the Regulatory Transition Plan that are proposed by LICENSOR, LICENSEE or ALZA and/or that are necessary to address any requests or requirements that may be imposed by Regulatory
Authorities in the Territory with respect to the transfer to LICENSEE of any Product Registrations or Regulatory Submissions. In such event, the Transition Team shall use good faith efforts to agree upon a mutually acceptable means to address the
relevant issues. Notwithstanding anything to the contrary, the Regulatory Transition Plan shall be amended as agreed upon in writing by LICENSEE, LICENSOR, and ALZA. 

 3.1.8 Cooperation by the Parties. At all times prior to the Final Transfer
Date in a particular country in the Territory, LICENSOR shall use Commercially Reasonable Efforts to ensure that ALZA and its applicable Affiliates, reasonably cooperate with LICENSEE to facilitate communications or other interactions with
Regulatory Authorities in the Territory that are reasonably necessary in connection with ALZA’s performance of the obligations described under Section 2.3 of this Schedule 4 or LICENSEE’s and/or its Affiliates’ planning and
preparations for the transfer of Product Registrations or Regulatory Submissions, including, without limitation, by providing LICENSEE with copies of any material communications with or from Regulatory Authorities (including meeting minutes).
LICENSOR shall use Commercially Reasonable Efforts to cause ALZA to consider and grant any reasonable requests by LICENSEE for any consent or authorizations necessary to enable LICENSEE to engage in direct communications with Regulatory Authorities
in connection with the maintenance, filing, seeking, or transfer of Regulatory Submissions and Product Registrations. LICENSEE shall not, and shall ensure that its Affiliates and/or Sublicensees do not, knowingly and intentionally take any actions
in the course of any such direct communications with any Regulatory Authorities in connection with any such transfer which (i) may reasonably be expected to materially damage or impair the goodwill or reputation of ALZA or its Affiliates and/or
(ii) would, without the prior written consent of ALZA, impose any new obligations or commitments (financial or otherwise) upon ALZA or its Affiliates related to or in connection with the development, registration or commercialization of Product
in such country. Prior to the Final Transfer Date for a particular country in the Territory, LICENSOR shall use Commercially Reasonable Efforts to (a) ensure that ALZA keeps LICENSOR and LICENSEE reasonably informed, provides LICENSOR and/or
LICENSEE a reasonable opportunity to comment, as to any of ALZA’s or its Affiliates’ communications with Regulatory Authorities, filing or amendment of any Product Registration Applications, pursuit of Regulatory Approvals, and/or other
developments related to the transition of Product Registrations, Regulatory Submissions, or any other Product Assets, including but not limited to those actions contemplated by Section 2.3 of this Schedule 4, and in particular promptly notifies
LICENSOR and/or LICENSEE with respect to any new developments related to such activities, including but not limited to those that may materially and adversely affect (x) the development, manufacture, or commercialization of Existing Product in
a country by LICENSEE and/or (y) the rights and responsibilities of LICENSOR or ALZA with respect to, and/or the timing of, the transfer and delivery of the Product Assets in a country to LICENSEE and/or its Affiliates, (b) promptly share
any information received from ALZA in the course of the foregoing with LICENSEE (to the extent not provided directly to LICENSEE by ALZA or any Affiliate thereof), and (c) follow LICENSEE’s reasonable direction with respect to
LICENSOR’s exercise of such Commercially Reasonable Efforts under clause (a) in this sentence. LICENSOR shall use Commercially Reasonable Efforts to ensure that, prior to the Final Transfer Date in a particular country in the Territory,
ALZA shall provide reasonable advance to LICENSOR and/or LICENSEE notice of any scheduled meeting or conference call between ALZA or its Affiliate and any Regulatory Authority relating to any Product Registrations or Regulatory

 
Submissions, and LICENSEE shall have a right to have up to two (2) representatives of LICENSEE attend, and, if and as reasonably requested by LICENSEE, participate in, any such meeting.
Prior to the Final Transfer Date in a particular country in the Territory, LICENSEE shall keep ALZA reasonably informed as to any of LICENSEE’s communications with Regulatory Authorities and/or other developments related to the transition of
Product Registrations, Regulatory Submissions, or any other Product Assets in the Territory, and in particular shall promptly notify ALZA with respect to any new developments related to such activities in the Territory that may materially and
adversely affect (x) the sale of Existing Product in a country in the Territory by ALZA and/or its Affiliates during any Transition Period and/or (y) the rights and responsibilities of LICENSOR, LICENSEE and ALZA with respect to, and/or
the timing of, the transfer and delivery of the Product Assets in a country in the Territory to LICENSEE. 
 3.2
Pharmacovigilance Responsibilities and Product Inquiries. The responsibilities of LICENSOR, LICENSEE and ALZA for pharmacovigilance activities respecting Product and the transfer of such responsibilities from ALZA to LICENSEE, and LICENSOR’s
reporting responsibilities to LICENSEE, shall be set forth in commercially reasonable and customary form of pharmacovigilance agreements to be executed by LICENSEE, ALZA or Affiliates thereof, and LICENSOR on the Effective Date. 

3.3 Other External Communications Related to Product. As soon as practicable after the Effective Date, the Transition Team shall develop
in writing, and from time to time thereafter during the applicable Transition Period in each country in the Territory update as necessary, one or more external communications plans related to the transfer of Product Assets with respect thereto to be
proposed to LICENSEE, and work with ALZA in the finalization thereof, and, upon agreement by ALZA with respect to such plan(s), LICENSEE agrees to implement and comply with such plan(s). Until the Final Transfer Date for a particular country in the
Territory, LICENSEE agrees that the Transition Managers from LICENSOR and ALZA will coordinate review, with the Transition Team, of any proposed press releases, public statements or similar communications with Third Parties with respect to the
transfer of the Product Assets in such country, the contents of which shall be limited to publicly available information unless approved in advance by both LICENSOR and ALZA, such approval not to be unreasonably withheld, or required by any
Applicable Law or rule of any securities exchange, and LICENSOR agrees to use Commercially Reasonable Efforts to (a) provide LICENSEE a reasonable opportunity to provide its input with respect thereto and (b) follow LICENSEE’s
reasonable direction with respect to any of the foregoing to the extent solely concerning the Territory. To the extent reasonably practicable, LICENSEE agrees that it will provide ALZA and LICENSOR a reasonable opportunity to review and comment on
any such planned communication concerning a country in the Territory prior to such country’s Final Transfer Date, at least five (5) business days prior to its planned release or implementation and use good faith efforts to address any
comments or concerns raised by ALZA or LICENSOR with respect to the timing and/or content of the planned communication. LICENSEE agrees that it shall not have the right to use the names, logos or trademarks of ALZA or LICENSOR (or any of such other
Affiliates thereof), respectively, in any such communications in a particular country in the Territory prior to such country’s Final Transfer Date without the prior written consent of ALZA or LICENSOR, except to the extent required by
Applicable Law. For the avoidance of doubt, LICENSEE will have the right to use the Assigned Trademarks and Domain Names in any communications in the Territory issued pursuant to this Section 3.3. 

 EXHIBIT 4A 
 Group A Market Countries 
 [*] 

  
 [*]
Confidential treatment requested. 

  

 EXHIBIT 4B 
 Group B Market Countries 
 [*] 

  
 [*]
Confidential treatment requested. 

  

 EXHIBIT 4C 
 Group C Market Countries 
 [*] 

  
 [*]
Confidential treatment requested. 

  

 EXHIBIT 4D 
 Transition Team Managers 
 LICENSOR – [*] 

LICENSEE – [*] 

  
 [*]
Confidential treatment requested. 

  

 SCHEDULE 6.1 
 ON-GOING CLINICAL TRIALS 
 R096769-PRE-1005—A Randomized, Double-Blind, Placebo-Controlled,
Crossover Study Assessing the Pharmacodynamic Effects of Dapoxetine Concomitantly Administered in Subjects Taking Terazosin 

R096769PRE3008—A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of
Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor; COUPLE: Concomitant Use of Priligy in Men Treated for Erectile Dysfunction 

R096769-PRE-4001—A Prospective, Observational Study of Men with Premature Ejaculation Who Are Treated With PRILIGYTM or Alternate Care; The
PAUSE Study (Premature Ejaculation—Actual Use Safety and Effectiveness Study) 
 R096769PRE4005—PRILIGY Usage Patterns in Selected
Populations 

 SCHEDULE 10.4 
 PRESS RELEASE 
  

			
	

	  	

 Furiex Pharmaceuticals and Menarini Announce License Agreement for Priligy® 
 MORRISVILLE, N.C. and FLORENCE, ITALY (May XX, 2012) – Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) and Menarini Group today announced that they have entered into a license agreement by which
Furiex will license to Menarini rights to commercialize Priligy® in Europe, most of Asia, Africa, Latin America
and the Middle East. Furiex will retain full development and commercialization rights in the United States, Japan and Canada. Currently, Priligy® is marketed for on-demand treatment of premature ejaculation in 15 countries in Europe, Asia and Latin America, while it is approved for that indication in 43
countries worldwide. 
 Under the terms of the agreement, Furiex will be eligible to receive a $15 million payment upon closing, up to $20
million in regulatory and launch milestones and up to $40 million in sales-based milestones, plus tiered royalties on product sales ranging from mid-teens to mid-twenties in percentage terms. Menarini will assume responsibility for commercialization
activities in the licensed territories and will fund ongoing clinical trials. 
 June Almenoff, M.D., Ph.D.,
president and chief medical officer of Furiex, stated, “We are extremely pleased to partner with Menarini and are confident that our experience and skills, coupled with the global presence and pharmaceutical experience of Menarini, should
expand the development and commercialization of Priligy®.” 

Commenting on the transaction, Dott. Alberto Giovanni Aleotti, Member of the Board of Menarini Group stated, “Priligy® is an innovative drug and the only product that has received regulatory approval specifically for the treatment of
premature ejaculation. Premature Ejaculation is an underdiagnosed medical condition with only 9 % of sufferers seeking medical advice due to the social stigma associated with the condition. Menarini is committed to enhance the medical and
scientific information available on the condition, in order to contribute in improving the quality of life of millions of people.” 
 As previously disclosed, Furiex recently entered into an agreement with ALZA and Janssen whereby ALZA and Janssen would transfer to Furiex worldwide
Priligy® product rights. 
 The asset transfer agreement between Furiex, ALZA and Janssen and this license agreement are subject to various closing conditions, including negotiation and execution of additional agreements with
Janssen designed to ensure a smooth transition of all production and marketing capability for the product. 

 About Premature Ejaculation 
 Premature ejaculation (PE) is a distressing sexual dysfunction that can be present from the first sexual encounter or can develop later in life. It is the most common male sexual dysfunction, affecting
about 30 percent of male adult population at some point during their lives. The condition consists of three major components: a short time to ejaculation, lack of ejaculatory control, and negative personal impact, including distress related to rapid
ejaculation. A combination of physiological and psychological factors is believed to influence the mechanism of ejaculation. Research suggests serotonin plays a central role in the timing of ejaculation. 

About
Priligy® 
 Priligy® (dapoxetine) the first oral medication approved for
“on-demand” treatment of PE. Priligy® is a unique, short-acting, selective serotonin reuptake
inhibitor (SSRI) designed to be taken only when needed—one to three hours before sexual intercourse is anticipated—rather than every day. The drug is specifically developed for the on-demand treatment of PE and was evaluated in five
randomized, placebo-controlled Phase III clinical trials involving more than 6,000 men with PE and their partners. This is the largest and most comprehensive clinical trial program to date for a drug therapy to treat PE. 

Priligy®
 is approved for on-demand treatment of PE in 43 countries. On January 20, 2012, the European Commission issued a decision confirming the positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) recommending
the approval of Priligy® in the remaining 20 European Union countries, Norway and Iceland where the drug was not
yet approved. Pending national regulatory steps, marketing authorizations can be granted in these 22 European countries. 
 About Furiex

 Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and
increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Our drug development programs are designed and driven by a core team with extensive drug development
experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including two Phase III-ready assets, one compound in Phase III
development with a partner and two products on the market. The company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies
for patients. For more information, visit www.furiex.com. 
 About Menarini 

Menarini is an international pharmaceutical company with over 13,000 employees worldwide and a presence in more than 100 countries in Europe, Asia, Latin
America, Africa and the Middle East. The company was established 125 years ago and currently markets products in the cardiovascular, gastroenterology, metabolic, infectious disease and anti-inflammatory/analgesic therapeutic areas. With a three
billion Euro turnover the Menarini Group is one of the world’s largest private pharmaceutical companies. 
 For further details, visit
www.menarini.com 
 Except for historical information, all of the statements, expectations and assumptions contained in this news
release are forward-looking statements that involve a number of risks and uncertainties. Although Furiex attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions
on which such statements are based. In addition, other important factors which could cause actual results to differ materially include the following: the risks that the closing conditions will not be met and the asset transfer and out-license
agreements will not close; the demand for our potential products, if and when approved; the inability of our licensee to commercialize our products; increased commercialization challenges arising from general industry conditions and competition;
domestic and foreign health care reforms and governmental laws and regulations; changes in the safety and efficacy profile of our product as it progresses through market use; progress of our product in

 
the marketplace as it relates to receiving future royalty and milestone payments; time required to gain regulatory approvals; continuing losses and our potential need for additional financing;
the costs of defending or prosecuting any patent opposition or litigation necessary to protect our proprietary technologies; and the other risk factors set forth from time to time in the SEC filings for Furiex, copies of which can be found on our
website. 
 Contact for Furiex 
 Media/Analysts/Investors: 
 Sailash Patel 
 919.456.7814 
 sailash.patel@furiex.com 

Contact for Menarini 
 Menarini Press
Office 
 pressoffice@menarini.com 

 SCHEDULE 11.3 
 PVG AGREEMENT 
 CONFIDENTIAL 

PHARMACOVIGILANCE AGREEMENT 
 BY AND BETWEEN 
 ALZA CORPORATION AND JANSSEN PHARMACEUTICA, NV

 AND 
 FURIEX PHARMACEUTICALS, INC., AND GENUPRO, INC. 
 (A WHOLLY-OWNED
SUBSIDIARY OF FURIEX PHARMACEUTICALS, INC.) 
 AND 

BERLIN-CHEMIE AG 
 (MENARINI GROUP) 

  
 1 

 Pharmacovigilance Agreement 
 THIS AGREEMENT is made this July     of 2012 (the “Effective Date”) between: 
  

	(1)	ALZA CORPORATION, a company incorporated in the State of Delaware and having its principal place of business at 700 Eubanks Drive, Vacaville, CA 95688 and
JANSSEN PHARMACEUTICA NV, a corporation organised under the laws of the Kingdom of Belgium and having its principal place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (“JANSSEN”) (collectively
“ALZA”); 

  

	(2)	FURIEX PHARMACEUTICALS, INC., a company incorporated in the State of Delaware and having its registered office at 3900 Paramount Parkway, Suite 150, Morrisville,
NC 27560 (“FURIEX”) and GENUPRO, INC. (“GENUPRO”), a wholly-owned subsidiary of FURIEX organized under the laws of the State of North Carolina and having its registered office at 3900 Paramount Parkway, Suite
150, Morrisville, NC 27560 (collectively “FURIEX”); and 

  

	(3)	BERLIN-CHEMIE AG (MENARINI GROUP) Glienicker Weg 125 , 12489 Berlin (Germany) (“MENARINI”) 

ALZA, MENARINI and FURIEX may be referred to herein individually as a “Party” and collectively as the “Parties”.

 Recital 
  

	(A)	ALZA and FURIEX entered into a License and Asset Transfer Agreement, executed on May 14, 2012 (as amended from time to time, hereinafter referred to as the
“Primary Agreement”) whereby ALZA transfers to FURIEX certain rights relating to Agreement Product (defined below) in accordance with the terms and conditions set forth in the Primary Agreement. 

 

	(B)	FURIEX and Berlin Chemie AG (Menarini Group) entered into the Priligy License Agreement, executed on May 14, 2012 (hereinafter referred to as the “Menarini
Priligy Sublicensing Agreement”). 

  

	(C)	The Parties acknowledge that the Regulatory Submissions and Governmental Permits will be transferred from ALZA to FURIEX or its designated Affiliate or to MENARINI as
FURIEX’s Sub licensee, and it is anticipated that the approvals or effectiveness of such transfers by the applicable Regulatory Authorities (“MA Transfer Approvals”) will occur on a country-by-country basis. The date of such
transfer shall be the MA Transfer Approvals Date for such country. After MA Transfer Approvals Date, ALZA shall transfer safety activities relating to Agreement Product to FURIEX or MENARINI, on a country-by-country basis.

  
 2 

	(D)	ALZA and FURIEX acknowledge that MENARINI belongs to the Menarini Group and have a centralised management of safety data through an electronic database , the [*] of the
Menarini Group, under the responsibility of the European Qualified Person for Pharmacovigilance and the Central Drug Safety Unit Manager (CDSUM). 

  

	(E)	This Agreement defines the responsibilities of the Parties regarding the management and the exchange of safety data related to the Agreement Product. It describes the
roles and responsibilities of the Parties in relation to management and exchange of safety data concerning the Agreement Product in compliance with Legal Requirements. 

 IT IS AGREED as follows: 
  

	1	Definitions 

 Capitalized
terms defined in this Agreement shall be equally applicable to both the singular and plural forms of the terms defined. The terms used in this Agreement are intended to be consistent with the corresponding terms used in the ICH guidelines (E2A, E2C
and E2D) relating to the collection, maintenance, analysis and reporting of an adverse event or experience (“AE”)”, adverse drug reaction (“ADR”) and serious adverse event or experience or serious adverse drug
reaction (“SAE/ SADR”). For the purpose of this Agreement, AE shall include AE and ADR and SAE shall include SAE and SADR. 
  

	1.1	“AE Reports” means any safety information relating to the Agreement Product, including pregnancy (maternal or paternal exposure), lactation, overdose,
abuse, misuse, medication errors, lack of efficacy, reports from falsified product, reports of any suspected transmission of an infectious agent via the Agreement Product and AEs associated with Agreement Product quality complaints. For the purpose
of signal detection, AE Reports shall also include reports that do not contain the minimum criteria (i.e. reporter, patient, adverse event and suspect drug) but at a minimum a suspect drug and an adverse event. 

 

	1.2	“Affiliates” means a person or entity that directly or indirectly through one or more intermediates, controls, is controlled by, or is under common
control with the person or entity specified. For the purpose of this definition, “control” shall mean with respect to an entity, (a) the direct or indirect ownership of: (x) at least fifty percent (50%) or more of the
capital stock or share capital entitled to vote for the election of directors of the entity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction); or (y) at least fifty
percent (50%) of equity or voting interest of the entity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) or (b) the power to direct or cause the direction of the
management and policies of the corporation or other entity. 

  
 [*]
Confidential Treatment Requested. 

  
 3 

	1.3	“Aggregate Report” means a report that summarizes and analyzes aggregate safety data that is prepared to be submitted to Regulatory Authorities
according to Legal Requirements. 

  

	1.4	“Agreement Product” means a drug product in its final dosage form(s) containing Dapoxetine described in any ALZA Regulatory Submissions made by or on
behalf of ALZA or any Affiliate thereof prior to the Effective Date or in ALZA Marketing Authorizations of ALZA or any Affiliate thereof. Agreement Product is listed in Schedule 1. 

 

	1.5	“ALZA Marketing Authorizations” means all health registrations, marketing authorizations, centralized registrations, labelling approvals, Regulatory
Approvals, any other technical, medical and scientific licenses, authorizations or approvals in the Territory for any Agreement Product (together with any amendments or supplements to any of the foregoing) filed with or granted by any Regulatory
Authority, that, in each case, are Controlled by ALZA or any Affiliate thereof (and which shall include those held or controlled by a Third Party MAH on behalf of ALZA or an Affiliate thereof pursuant to a Distribution Agreement), as of the
Effective Date, or come under the Control of ALZA or any Affiliate thereof (or any Third Party MAH) prior to the end of the Transition Completion Date. 

  

	1.6	“Business Day” means any day which is considered as an official working day of the week, typically NOT a Saturday, a Sunday, a company or a public
holiday, but may vary by country. 

  

	1.7	“Calendar Day” means any day including a Saturday, a Sunday, a company or a public holiday in the relevant country. 

 

	1.8	“Commercially Reasonable Efforts” means the carrying out by a Party of obligations or activities as specified herein exerting overall a level of effort
no less than consistent with the level of effort that such Party customarily devotes to corresponding activities, with respect to a pharmaceutical product or products of similar market potential, profit potential or strategic value, based on
conditions then prevailing. Without limiting the foregoing, Commercially Reasonable Efforts requires that a Party: (i) timely assign responsibility for such activities to specific employees, contractors, agents, Affiliates or sublicensees, as
applicable, who are held accountable for progress with respect to such activities, (ii) monitor such progress on an on-going basis, (iii) set and seek to achieve objectives and timelines for carrying out such activities, and
(iv) allocate resources reasonably designed to advance progress with respect to such objectives and timelines. 

  

	1.9	“Control” means possession of the right to grant a license or sublicense or other rights as provided for herein by the applicable Party, whether
through ownership or license from any Affiliate or Third Party, without violating the terms of any agreement with any Third Party. 

  
 4 

	1.10	“Dapoxetine” means (a) (+/-)-N,N-dimethyl-l -phenyl-3-(1-naphthalenyloxy)-propanamine,
(b) (S)-(+)-N,N-dimethyl-l-phenyl-3-(1-naphthalenyloxy)-propanamine, (c) (R)-(-)-N,N-dimethyl-l-phenyl-3-(1-naphthalenyloxy)-propanamine, (d) (+/-)-N,N-dimethyl-a-[2-(1-naphthalenyloxy)
ethyl-benzenemethanamine, (e) (S)-(+)-N,N-dimethyl-a-[2-(1-naphthalenyloxy) ethyl-benzenemethanamine,
(f) (R)-(-)-N,N-dimethyl-a-[2-(1-naphthalenyloxy) ethyl-benzenemethanamine, (g) any pharmaceutically acceptable salt of any of the foregoing, or (h) any active metabolite of any of the
foregoing, including without limitation mono-desmethyl dapoxetine and di-desmethyl dapoxetine. 

  

	1.11	“Date of First Receipt” means the date of receipt or coming into possession or control of a report of AE or pregnancy information by any Party or by
any of its Affiliates or designees, which contains minimum information as defined by the Legal Requirements (i.e., an identifiable subject, identifiable reporter, suspect medicinal product, and adverse event). [*] shall be considered as [*] or [*]
for regulatory reporting and safety data exchange purposes. 

  

	1.12	“Distribution Agreements” means all agreements between ALZA (and/or its Affiliates) and any Third Party, including Third Party MAHs, granting such
Third Party rights to market, promote, distribute and commercialize Agreement Product. 

  

	1.13	“Global Safety Database” means the database containing, but shall not be limited to containing, ALL AE, pregnancy reports (including maternal
and paternal exposure), overdose, or misuse or abuse reports for the Agreement Product that will support regulatory reporting and responses to safety queries from Regulatory Authorities. 

 

	1.14	“Governmental Permits” means (i) the ALZA Marketing Authorizations and (ii) any and all pricing or pricing reimbursement approvals for any
Agreement Product granted, in either case, by any Regulatory Authorities anywhere in the Territory. 

  

	1.15	“Legal Requirements” means any applicable federal, state, local or foreign constitution, law, statute, rule or regulation, including, as applicable,
GCP, GLP, and GMP. 

  

	1.16	“Marketing Applications” means all applications for Regulatory Approval. 

 

	1.17	“Reference Safety Information” means safety information by which the Party responsible for the Global Safety Database as set forth in this Agreement
assess expectedness and according to which events are assessed for regulatory safety reporting to Regulatory Authorities. (e.g. Investigator Brochure (IB), Company Core Data Sheet (CCDS), local label). 

  
 [*]
Confidential Treatment Requested. 

  
 5 

	1.18	“Regulatory Approval” means, for any Agreement Product, all permissions, approvals, licenses, registrations, authorizations, or clearances of any
Regulatory Authority that are necessary for the sale of such Agreement Product as a human pharmaceutical in any country in the Territory (excluding pricing and reimbursement approvals). 

 

	1.19	“Regulatory Authority” means any regulatory agency, ministry, department, commission, council or other governmental body having authority in any
country to authorize or control development, manufacture, marketing and sale of human pharmaceutical products, and including among others the Food and Drug Administration (or any successor agency) and the European Medical Agency (or any successor
agency). 

  

	1.20	“Regulatory Submissions” means, with respect to the Territory, all applications, filings, dossiers and other documents submitted to a Regulatory
Authority for the purpose of seeking or obtaining Regulatory Approval (or engaging in clinical trials with respect to any human pharmaceutical) for Agreement Product or pricing and reimbursement approval from that Regulatory Authority for Agreement
Product, including, without limitation, Clinical Trial Applications (including INDs), and Marketing Applications (including ANDAs, NDAs, and sNDAs), and any equivalents of any of the foregoing. 

 

	1.21	“Regulatory Transfer Date” means the date on which the assignment and transfer to GENUPRO or its designated Affiliates or Sublicensees of all ALZA
Regulatory Submissions and Governmental Permits in a given country are effective, except with respect to any Governmental Permits or ALZA Regulatory Submissions that cannot be transferred and assigned due to limitations imposed by Legal
Requirements, in which event the Regulatory Transfer Date in such country shall be the date on which a substitute action taken by ALZA (directly or through its Affiliates), or caused by ALZA to be taken by a Third Party MAH becomes effective.

  

	1.22	“Regulatory Transfer Transition Period” means the period during which ALZA or its Affiliates shall transfer the Governmental Permits and ALZA
Regulatory Submissions for each country in which ALZA, its Affiliates, or a Third Party MAH holds an ALZA Marketing Authorization, during which the Parties shall take Commercially Reasonable Efforts to cause the Regulatory Transfer Date to occur no
later than the expiration of the period ending [*] from the Effective Date. 

  

	1.23	“Risk Management Plan” means a risk management plan required by a Regulatory Authority that covers MAH activities to identify, characterise or minimize
risks associated with the Agreement Product. 

  

	1.24	“Territory” means all the countries of the world. 

  
 [*]
Confidential Treatment Requested. 

  
 6 

	1.25	“Third Party” means mean any individual, corporation or entity, or any government, or any agency or political subdivisions thereof, other than ALZA,
MENARINI, GENUPRO or their respective Affiliates. 

  

	1.26	“Third Party MAH” means those Third Parties identified on Schedule 1.26 are under contractual obligations, as set forth in the Distribution
Agreements therewith, to ALZA or its Affiliates with respect to the distribution, sale, and promotion of Agreement Product in the corresponding countries noted on Schedule 1.26, and have filed or maintained, respectively, Marketing
Applications or ALZA Marketing Authorizations, respectively, on behalf of ALZA or its Affiliates in such countries. 

  

	2	Overall Governance 

  

	2.1	The Parties agree to transfer and exchange safety information for the Agreement Product between FURIEX, MENARINI and ALZA as set forth in this Agreement in order to
ensure compliance with good pharmacovigilance practices and maintain compliance with the worldwide reporting requirements of the relevant Regulatory Authorities, and all Legal Requirements, for the Agreement Product (hereinafter “Management
of Safety Information”). 

  

	2.2	ALZA, MENARINI and FURIEX each acknowledge that when it (or any Affiliate or licensee of it or its Affiliates) is the holder of Marketing Authorizations
(“MAH”) and/ or Clinical Trial Applications (“Sponsor”) it remains legally responsible for the performance of pharmacovigilance obligations in respect of the Agreement Product in its respective Territory, and in any
new Territory where it (or any Affiliate or licensee of it or its Affiliates) may become MAH and/ or Sponsor regardless of any delegation and sub-contracting of such obligations to any such affiliate or designee. 

 

	2.3	ALZA, FURIEX and MENARINI may delegate the performance of certain of their obligations under this Agreement to its designee or its designated Affiliates and in such
event shall enter into a written arrangement to ensure compliance with this Agreement. 

  

	2.4	Each Party will make provision to nominate a contact person having responsibility for such Party’s pharmacovigilance and ensuring compliance with Legal
Requirements (“Responsible Person”). The contact information of such Responsible Person is listed in Schedule 2. 

  

	2.5	Further, MENARINI and ALZA shall ensure that MENARINI European Economic Area Qualified Person for Pharmacovigilance (“MENARINI EEA QPPV”) and
ALZA’s European Economic Area Qualified Person for Pharmacovigilance (“ALZA EEA QPPV”) are kept informed of the status of and progress towards obtaining MA Transfer Approvals (including but not limited to the EEA), and will
cooperate and work together in good faith to ensure that transfer of QPPV responsibilities occurs effectively. 

  
 7 

	3	Global Safety Database 

  

	3.1	On [*], ALZA shall transfer the Global Safety Database to MENARINI (“Global Safety Database Transfer Date”). ALZA will provide FURIEX and/or MENARINI
with html files of all Agreement Product AE Reports in the Global Safety Database. 

  

	3.2	Before the Global Safety Database Transfer Date, ALZA will hold and maintain the Global Safety Database of all the safety reports of the Agreement Product collected
worldwide and exchanged through this Agreement. ALZA shall provide MENARINI and FURIEX with safety information relevant to the Agreement Product contained in the Global Safety Database as MENARINI and FURIEX may request and which is necessary for
MENARINI and FURIEX to comply with Legal Requirements. 

  

	3.3	After Global Safety Database Transfer Date, MENARINI will hold and maintain the Global Safety Database of all the safety reports of the Agreement Product collected
worldwide and exchanged through this Agreement. MENARINI shall provide ALZA and FURIEX with safety information relevant to the Agreement Product contained in the Global Safety Database as ALZA and FURIEX may request and which is necessary for ALZA
and FURIEX to comply with Legal Requirements. 

  

	4	Procedures for Exchanging AEs 

 From Effective Date to Global Safety Database Transfer Date 
  

	4.1	For AE Reports (with the exception of reports of pregnancy (maternal or paternal exposure), lactation, overdose, abuse, misuse, medication errors, lack of efficacy and
reports from falsified product without an AE) received by MENARINI in countries where MENARINI (or any Affiliate or licensee of MENARINI or its Affiliates) is the MAH or Sponsor, MENARINI shall process the AE Report in its local safety database and
shall forward to ALZA and FURIEX in the completed CIOMS I form or E2B electronic files, together with a local reference number, as soon as possible but no later than: 

 

	 	4.1.1	[*] of the Date of First Receipt for Death/Life threatening SADRs from interventional clinical studies that meet the 7 day reporting requirement;

  

	 	4.1.2	[*] of the Date of First Receipt for all other SAEs; and 

  

	 	4.1.3	[*] of the Date of First Receipt for all NSAEs. 

  

	4.2	For AE Reports containing pregnancy (maternal or paternal exposure), lactation, overdose, abuse, misuse, medication errors, lack of efficacy and reports from falsified
product without an AE, received by MENARINI in countries where MENARINI (or any Affiliate or licensee of MENARINI or its Affiliates) is the MAH or Sponsor, MENARINI shall provide ALZA with source documents that it receives, translated into English,
as 

  
 [*]
Confidential Treatment Requested. 

  
 8 

	 	
necessary, regardless of source, together with MENARINI’s Date of First Receipt with a local reference number by agreed means within [*] or [*], whichever is shorter, after MENARINI’s
Date of First Receipt. In the event that it is not possible for MENARINI to translate entire source documents within these timelines, MENARINI will translate and forward to ALZA the Four (4) minimum criteria (i.e. an identifiable
patient; a suspect medicinal product; an identifiable reporting source and the non-AE term (e.g., medication error-no AE) within [*] or [*], whichever is shorter, after MENARINI’s Date of First Receipt. MENARINI shall translate the remainder of
medically relevant source documents of within [*] after MENARINI’s Date of First Receipt. 

  

	4.3	For AE Reports received by FURIEX, FURIEX shall report as follows: 

  

	 	4.3.1	In the event an AE Report is from an interventional clinical study, FURIEX shall process and forward to MENARINI and ALZA in the form of completed CIOMS I form or E2B
electronic files, together with a local reference number, within [*] of the Date of First Receipt for Death/Life threatening SADRs from the interventional clinical study that meet the 7 day reporting requirement and all other SAEs within [*] of the
Date of First Receipt. 

  

	 	4.3.2	In the event an AE Report is from all other sources in countries where FURIEX (or any Affiliate or licensee of FURIEX or its Affiliates) is the MAH or Sponsor, FURIEX
shall provide ALZA with source documents that it receives, translated into English, as necessary, regardless of source, together with FURIEX’s Date of First Receipt with a local reference number by agreed means within [*] or [*], whichever is
shorter, after FURIEX’s Date of First Receipt. 

  

	4.4	For AE Reports a) received by ALZA in countries where ALZA is the MAH or Sponsor; b) provided by MENARINI pursuant to Section 4.2; and c) provided by FURIEX
pursuant to Section 4.3, ALZA shall process and forward to MENARINI and FURIEX in the form of completed CIOMS I form or E2B electronic files, together with a local reference number, within 

 

	 	4.4.1	[*] of the Date of First Receipt for Death/Life threatening SADRs from interventional clinical studies that meet the 7 day reporting requirement;

  

	 	4.4.2	[*] of the Date of First Receipt for all other SAEs; and 

  

	 	4.4.3	[*] of the Date of First Receipt for all NSAEs 

  

	4.5	Notwithstanding the Sections 4.1, 4.2 and 4.4 above, during [*], MENARINI and FURIEX shall forward to ALZA all NSAEs within [*] of ALZA’s notification of the data
lock date. 

  
 [*]
Confidential Treatment Requested. 

  
 9 

 After Global Safety Database Transfer Date 

 

	4.6	For AE Reports received by ALZA in countries where ALZA (or any Affiliate or licensee of it or its Affiliates) is the MAH or Sponsor, ALZA shall forward to MENARINI and
FURIEX, in the form of E2B files/completed CIOMS I form, together with a local reference number, within 

  

	 	4.6.1	[*] of the Date of First Receipt for Death/Life threatening SADRs from interventional clinical studies that meet the 7 day reporting requirement;

  

	 	4.6.2	[*] of the Date of First Receipt for all other SAEs; and 

  

	 	4.6.3	[*] of the Date of First Receipt for all NSAEs. 

  

	4.7	For AE Reports received by FURIEX, FURIEX shall report as follows: 

  

	 	4.7.1	In the event an AE Report is from an interventional clinical study, FURIEX shall process and forward to MENARINI in the form of completed CIOMS I form or E2B electronic
files, together with a local reference number, within [*] of the Date of First Receipt for Death/Life threatening SADRs from the interventional clinical study that meet the 7 day reporting requirement and all other SAEs within [*] of the Date of
First Receipt. 

  

	 	4.7.2	In the event an AE Report is from all other sources in countries where FURIEX (or any Affiliate or licensee of FURIEX or its Affiliates) is the MAH or Sponsor, FURIEX
shall provide MENARINI with source documents that it receives, translated into English, as necessary, regardless of source, together with FURIEX’s Date of First Receipt with a local reference number by agreed means within [*] or [*], whichever
is shorter, after FURIEX’s Date of First Receipt. 

  

	4.8	For AE Reports a) received by MENARINI in countries where MENARINI is the MAH or Sponsor; and b) provided by FURIEX pursuant to Section 4.7, MENARINI will process
the AE Report and shall forward to ALZA and FURIEX in the form of completed CIOMS forms or E2B electronic files, together with a local reference number, within 

 

	 	4.8.1	[*] of the Date of First Receipt for Death/Life threatening SADRs from interventional clinical studies that meet the 7 day reporting requirement;

  

	 	4.8.2	[*] of the Date of First Receipt for all other SAEs; and 

  

	 	4.8.3	[*] of the Date of First Receipt for all NSAEs. 

  

	4.9	For AE Reports received by ALZA in countries where MENARINI or FURIEX (or any Affiliate or licensee of MENARINI or FURIEX or their Affiliates) is the MAH or Sponsor,
ALZA shall forward to MENARINI, source documents for all safety information it receives within [*] of the Date of First Receipt. 

  
 [*]
Confidential Treatment Requested. 

  
 10 

	4.10	Notwithstanding the Sections 4.6, 4.7 and 4.8 above, during [*], ALZA and FURIEX shall forward to MENARINI all NSAEs within [*] of MENARINI’s notification of the
data-lock date. 

 AE’s Exchanged within SAE Timelines 

 

	4.11	The Parties acknowledge that from time to time they shall agree upon lists of AEs which are exchanged within SAE timelines, including but not limited to:

  

	 	4.11.1	List of AEs classified as [*]; and 

  

	 	4.11.2	List of AEs that [*] 

  

	4.12	Parties shall forward all AEs in the agreed lists according to the timelines for reporting SAEs in this Agreement. The list may be amended from time to time by
mutual agreement. 

 Follow-up 

 

	4.13	Each Party shall be responsible for conducting follow-up activities for AE Reports according to its standard operating procedures in countries where the Party (or any
Affiliate or licensee of it or its Affiliates) is the MAH or Sponsor and forward follow-up information according to the same timelines and mechanism as initial information noted in this Section 4 and will include the Date of First Receipt for
the follow-up information. 

 Literature Review 

 

	4.14	Before Global Safety Database Transfer Date, ALZA shall be responsible for reviewing, on a [*] basis, the global literature for potentially reportable causally related
AEs (i.e. ADRs) according to its standard operating procedures. ALZA, for any case report identified, will provide the other Parties with the report as CIOMS I form within the timelines specified in this Section 4. 

 

	4.15	After the Global Safety Database Transfer Date, MENARINI shall be responsible for reviewing, on a [*] basis, the global literature for potentially reportable causally
related AEs (i.e. ADRs) according to its standard operating procedures. MENARINI, for any case report identified, will provide the other Parties with the report as CIOMS I form within the timelines specified in this Section 4.

  

	4.16	The Party (or any Affiliate or licensee of it or its Affiliates) that is MAH in a country shall be responsible for reviewing local published scientific literature and
unpublished scientific literature in accordance with the Legal Requirements in that country that it becomes aware of according to its standard operating procedures and exchange the AE Report according to the timelines specified in this
Section 4. 

  
 [*]
Confidential Treatment Requested. 

  
 11 

 Transmission 

 

	4.17	Each Party shall transmit to the other Party the information in this Section 4 by secure e-mail or other agreed electronic means. 

Single Case Reconciliation Process 
  

	4.18	Each Party will send an acknowledgement to the sending Party confirming receipt of information referred to under this Section 4 within [*] of receipt. If
confirmation is not received within [*], the sending Party must contact the receiving Party promptly to confirm acknowledgment of receipt and request that a written acknowledgement be resent according to the means described in this Section 4.

  

	4.19	In case of discrepancy, each Party will provide any comment by email no later than [*] from the receipt from the other Parties. The Parties agree to co-operate in good
faith and in accordance with good pharmacovigilance practices to manage any discrepancies relating to seriousness, causality and coding (“Main Items”) to reach a common alignment as far as possible before the submission. If due to the time
constraint a consolidated version regarding the Main Items is not agreed in time to respect the regulatory deadline, the originating Party will proceed with the submission of the original version. The Parties will then further discuss and agree a
common position. If necessary a follow up CIOM version of the AE Report will be issued, which will fully coincide on such items with the version that will be inserted in the Global Safety Database. 

 

	4.20	Once [*] on the [*], each Party will send to the other Parties a reconciliation listing of all reports it received in the [*] (e.g., [*]). The database
reconciliation will consist of a completeness of case identification numbers. In case of discrepancies, the Parties will collaborate to identify and complete any missing database information. 

 

	5	Procedures for Coordination of Safety Information 

 Signal Detection 
  

	5.1	Before the Global Safety Database Transfer Date, ALZA will be responsible for the conduct of surveillance and safety signal detection activity and ad-hoc reports
according to its standard operating procedure and will notify FURIEX and MENARINI in a timely manner of safety signals that do, or may, affect the Agreement Product labelling, taking into consideration the urgency of the matter and Legal
Requirements. ALZA shall provide to FURIEX and MENARINI a copy of ALZA’s process for signal detection and the relevant output. 

  
 [*]
Confidential Treatment Requested. 

  
 12 

	5.2	After the Global Safety Database Transfer Date, MENARINI will be responsible for the conduct of surveillance and safety signal detection activity and ad-hoc reports
according to its standard operating procedure and will notify FURIEX and ALZA in a timely manner of safety signals that do, or may, affect the Agreement Product labelling, taking into consideration the urgency of the matter and Legal Requirements.
MENARINI shall provide to FURIEX and ALZA a copy of MENARINI’s process for signal detection and the relevant output. 

 Risk Management Plans 
  

	5.3	Each Party shall be responsible for the maintenance and implementation of Risk Management Plans (e.g. Genuine Priligy Program) in countries where the Party (or any
Affiliate or licensee of it or its Affiliates) is the MAH according to Legal Requirement. 

 Reference Safety
Information (“RSI”) 
  

	5.4	Before Global Safety Database Transfer Date, ALZA shall maintain the CCDS and IB and shall provide updates and supporting documentation to FURIEX and MENARINI according
to its standard operating procedures. After Global Safety Database Transfer, MENARINI shall maintain the CCDS and IB and shall provide updates and supporting documentation to FURIEX and ALZA according to its standard operating procedures.

  

	5.5	Each Party (or any Affiliate or licensee of it or its Affiliates) will own and shall be responsible for implementing any updates to the local labels for the Agreement
Product in the country where it is MAH, in accordance with the CCDS. Any deviations from the CCDS or changes to the local label mandated by Legal Requirements or Regulatory Authorities that may have a potential impact on the CCDS must be
communicated to the other Parties in a timely manner. 

 Preparation of Aggregate Reports 

 

	5.6	Before Global Safety Database Transfer Date, ALZA shall be responsible for the production, compilation and finalization of Aggregate Reports for the Agreement Product,
and will provide required safety data from the Global Safety Database to FURIEX and MENARINI to prepare local Aggregate Reports. Concerning Global PSUR and DSUR, ALZA will notify MENARINI and FURIEX [*] in advance of the data-lock date for the
Aggregate Reports, requesting information required to complete such reports. MENARINI and FURIEX will provide ALZA with all information required to complete the report up to and including the data-lock date (e.g. relevant sales and/or exposure/usage

  
 [*]
Confidential Treatment Requested. 

  
 13 

	 	
figures from countries where MENARINI or FURIEX (or any Affiliate or licensee of MENARINI or FURIEX or their Affiliates) is the MAH or Sponsor, comprehensive lists of all ongoing studies, etc.)
no later than [*] after the data-lock date. ALZA shall provide FURIEX and MENARINI with the draft Aggregate Reports within [*] of the data lock date for FURIEX's and MENARINI’s review and comment which must be provided within [*] of the
data-lock date. ALZA shall, to the extent practicable, incorporate any reasonable comments. The final version for submission will be delivered no later than [*] of the data-lock date. 

 

	5.7	After Global Safety Database Transfer, MENARINI shall be responsible for the production, compilation and finalization of Aggregate Reports for the Agreement Product,
and will provide required safety data from the Global Safety Database to FURIEX and ALZA to prepare local Aggregate Reports. Concerning Global PSUR and DSUR, MENARINI will notify ALZA and FURIEX [*] in advance of the data-lock date for the Aggregate
Reports, requesting information required to complete such reports. ALZA and FURIEX will provide MENARINI with all information required to complete the report up to and including the data-lock date (e.g. relevant sales and/or exposure/usage figures
from countries where ALZA or FURIEX (or any Affiliate or licensee of ALZA or FURIEX or their Affiliates) is the MAH or Sponsor, comprehensive lists of all ongoing studies, etc.) no later than [*] after the data-lock date. MENARINI shall provide
FURIEX and ALZA with the draft Aggregate Reports within [*] of the Data Lock-Point for review and comment which must be provided within [*] of the data-lock date. MENARINI shall, to the extent practicable, incorporate any reasonable comments. The
final version for submission will be delivered no later than [*] on the data-lock date. 

  

	5.8	The Parties shall provide each other copies of the any Aggregate Reports upon completion of the reports, including reports required for countries where FURIEX or ALZA
(or any Affiliate or licensee of FURIEX or ALZA or their Affiliates) is the MAH or Sponsor. 

Communication of safety information 
  

	5.9	The Parties shall inform each other, of all safety information relating to the Agreement Product, including but not limited to: 

 

	 	5.9.1	Medically relevant safety issues that each Party becomes aware of through media allegations, Party’s sponsored websites, incidental reports, sales discontinuation,
product recalls; 

  

	 	5.9.2	Signal detection and benefit risk assessments; and 

  
 [*]
Confidential Treatment Requested. 

  
 14 

	 	5.9.3	Reference Safety Information and safety information communications for the Agreement Product (e.g. direct Healthcare Professional communications or similar
communications) 

 The Parties shall consult and cooperate with each other in the preparation of all such
communications promptly taking into consideration the urgency of the matter and Legal Requirements. 
  

	5.10	Each Party (or any Affiliate or licensee of it or its Affiliates) shall be responsible for leading the process for the preparation of safety communications in countries
where it is MAH and shall coordinate and communicate with the other Parties clear timelines for the different steps in the process as necessary depending on the urgency of the matter and Legal Requirements. 

 

	6	Regulatory Reporting 

  

	6.1	Each Party (or any Affiliate or licensee of it or its Affiliates) shall be responsible for all regulatory submissions (including single case AE reports and Aggregate
Reports) to Regulatory Authorities where it is MAH or Sponsor according to local Legal Requirements. 

 Regulatory Query

  

	6.2	The Parties shall cooperate in responding to all safety-related regulatory queries from Regulatory Authorities, investigators and ethics committees related to the
Agreement Product, including without limitation: 

  

	 	6.2.1	Informing the other Parties of any safety-related regulatory query (excluding administrative request e.g. single case report) involving the Agreement Product within [*]
taking into consideration the urgency of the matter and Legal Requirements; 

  

	 	6.2.2	Providing to the other Parties all correspondence and documents received from and sent to Regulatory Authorities relating to AEs or safety within [*] (with the
exception of specific case information requests) taking into consideration the urgency of the matter and Legal Requirements; and; 

  

	 	6.2.3	Drafting of any response to such queries and providing the other Parties the right to review and comment on any response prior to submission to the appropriate
Regulatory Authority. 

  
 [*]
Confidential Treatment Requested. 

  
 15 

 Regulatory Action 

 

	6.3	Each Party will notify the other Parties [*] and in any case not later than [*] of any regulatory action (including Regulatory Authority inquiries related to the safety
of the Agreement Product) or pending actions that might result in a change in labelling or market restriction due to signals, including but not limited to the following. 

 

	 	•	 	 Marketing authorization withdrawal or suspension; 

  

	 	•	 	 Failure to obtain a marketing authorization renewal; 

  

	 	•	 	 Restrictions on distribution (for example, Agreement Product recalls); 

 

	 	•	 	 Clinical trial suspension; 

  

	 	•	 	 Dosage modification for safety reasons; 

  

	 	•	 	 Changes in target population or indications for safety reasons; and 

 

	 	•	 	 Formulation changes for safety reasons. 

 Regulatory Authority Pharmacovigilance Inspections 
  

	6.4	Each Party undertakes to notify the other Parties [*] of any pharmacovigilance inspection pertaining to the Agreement Product by any Regulatory Authority and agrees to
cooperate in the event of inspections by Regulatory Authorities. 

  

	6.5	Each Party will provide [*] response to requests for assistance and/or information that are made during, in anticipation of, or in response to such inspections. Summary
of results of Regulatory Authority inspections relating to the Agreement Product will be exchanged between the Parties in a timely manner. 

  

	6.6	Notwithstanding the foregoing, for site specific inspections, ALZA shall provide MENARINI and FURIEX 

 

	 	6.6.1	regulatory support for a period beginning on the Regulatory Transfer Date and ending [*] after the Regulatory Transfer Date in each country; and

  

	 	6.6.2	consulting service for a period beginning on the Regulatory Transfer Date and ending [*] after such Regulatory Transfer Date in each country. 

 

	7	Training and Record Keeping 

  

	7.1	Each Party will ensure that its personnel involved in this Agreement are trained, within a reasonable period following execution of this Agreement, as necessary to
ensure compliance with this Agreement and the Legal Requirements. 

  
 [*]
Confidential Treatment Requested. 

  
 16 

	7.2	Each Party (or any Affiliate or licensee of it or its Affiliates) will retain and maintain all safety records according its standard operating procedures and Legal
Requirements in countries where it is MAH. After MA Transfer Approvals Date, on a country by country basis, ALZA will provide FURIEX or MENARINI, whichever is the MA transferee, a copy of the legacy documentation. 

 

	8	Verification of Compliance 

  

	8.1	Each Party or its designee will have the right to audit the other Parties to verify compliance with this Agreement and to the Legal Requirements, provided that the
Party that wishes to carry out the audit provides the other Party or Parties with at least [*] prior written notice. Such audits will be performed according to an audit plan that may be jointly developed by the Parties and a written audit plan will
be submitted [*] prior to audit. 

  

	8.2	Notwithstanding the conditions set forth in Sections 8.1, if a Party reasonably believes a for cause audit is needed, the auditing Party shall notify the Party to be
audited in writing [*] in advance, such notice will provide information concerning the basis for the for cause audit. 

  

	8.3	Each Party will allow such access to its facilities, systems, personnel and records, in whatever form and in any location (including locations owned or operated by a
third party) as may reasonably be necessary to enable the auditing Party or its designee to evaluate and ensure compliance with this Agreement and the Legal Requirements and audit findings will be communicated in a written audit report in a timely
manner. The Parties undertake to cooperate with each other to diligently investigate and resolve any such audit findings. 

  

	9	Representations and Warranties 

 Mutual Representations and Warranties 
  

	9.1	Each Party hereby represents, warrants and undertakes to the other that: 

  

	 	9.1.1	it has the requisite power and authority to execute, deliver and perform its obligations under this Agreement, and the execution, delivery and performance by each Party
to this Agreement have been duly and validly authorized by all necessary corporate action on the part of such Party, when executed and delivered will constitute, a valid and binding obligation of each Party, enforceable against each Party in
accordance with its terms, except that enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization or other similar laws affecting creditors’ rights, generally and by principles of equity regarding the
availability of remedies; 

  
 [*]
Confidential Treatment Requested. 

  
 17 

	 	9.1.2	the execution, delivery and performance by it of its obligations under this Agreement will not result in a breach of, or constitute a default under, any instrument or
agreement to which it is a party or by which it is bound or result in a violation of any law or regulation in any jurisdiction or of any order, judgement or decree of any court or governmental agency by which it is bound, except as would not,
individually or in the aggregate, materially adversely affect the ability of either Party to perform its obligations hereunder; and 

  

	 	9.1.3	it is duly organized, validly existing and in good standing under the laws of the state or country of its organization. 

Compliance with Legal Requirements 
  

	9.2	Each Party hereby represents, warrants and undertakes to the other Parties that, when it (or any Affiliate or licensee of it or its Affiliates) is the MAH and/or
Sponsor, it (or any Affiliate or licensee of it or its Affiliates): 

  

	 	9.2.1	are at all times, in compliance with all Legal Requirements in particular with regards to the safety management of the Agreement Product; 

 

	 	9.2.2	have and maintain the Governmental Permits and Regulatory Submissions in compliance with Legal Requirements; and 

 

	 	9.2.3	have all authorizations of Regulatory Authorities necessary to conduct its and their business. 

 

	10	Indemnity and Limitation of Liability 

  

	10.1	Each Party shall defend, indemnify, and hold harmless the other Parties and their Affiliates, and their respective directors, officers, employees and agents from and
against all liabilities, losses, Damages, settlements, claims, penalties, fines, defense costs or expenses (including reasonable lawyers' fees), judgments and other expenses arising out of or in connection with any action, claim or threat by a Third
Party, including a Regulatory Authority (any of the foregoing, a “Loss”), arising out of or resulting from: 

  

	 	10.1.1	negligence, recklessness or intentional acts or omissions of the indemnifying Party and its Affiliates and their respective directors, officers, employees and agents
with respect to the indemnifying Party’s Management of Safety Information as contemplated under this Agreement; and 

  

	 	10.1.2	 any breach of a representation, warranty, covenant or agreement of the indemnifying Party hereunder; but only to the extent that with respect to each
of 

  
 18 

	 	
the foregoing clauses, such Loss did not arise out of or resulted from (i) any other Party’s or its Affiliates’, or their respective directors’, officers’,
employees’ or agents’, breach of this Agreement (including any representation, warranty or covenant of such Party contained herein), failure to comply with any Legal Requirement, negligence, or intentional acts or omissions; or
(ii) any matter subject to indemnification by any other Party under this Agreement. 

  

	10.2	Procedures. Each Party shall promptly give the other Parties written notice of any claim for which indemnification may be sought under this Agreement. However,
failure of a Party with a right to be indemnified hereunder (an “Indemnified Party”) to provide notice of a claim to the allegedly indemnifying Party shall only affect the Indemnified Party’s right to indemnification if and to the
extent that such failure has a material adverse effect on the ability of the indemnifying Party (the “Indemnifying Party”) to defend the claim and/or the nature or amount of such claim The Indemnifying Party shall have the right to assume
control of the defense of the suit or claim, and the Indemnified Party shall cooperate as reasonably requested by the Indemnifying Party (at the expense of the Indemnifying Party) in the defense of any claim subject to indemnification hereunder;
provided, however, that if, in the reasonable judgment of the Indemnified Party, such suit or claim involves an issue or matter which could have a materially adverse effect on the business operations or assets of the Indemnified Party, the
Indemnified Party may, by written notice to the Indemnifying Party, waive its rights to indemnity under this Agreement and control the defense or settlement thereof, but in no event shall any such waiver be construed as a waiver of any rights which
such Party may have at law or in equity. If the Indemnifying Party controls the defense of the suit or claim, the Indemnified Party may fully participate in (but not control) the defense thereof and be represented by counsel at its sole cost and
expense. 

  

	10.3	Settlements. Notwithstanding the foregoing, no Party may settle a claim or action that is subject to the terms of this Section 10 without the prior written
consent of another Party if such settlement would (i) impose any non-indemnified monetary obligation on such other Party, (ii) admit fault or wrongdoing on the part of such other Party, (iii) require such other Party to submit to an
injunction, (iv) limit the other Party’s rights under the Primary Agreement, the Menarini Priligy Sublicensing Agreement, or any Ancillary Agreement, or surviving rights under the License Agreement, or (v) limit or otherwise adversely
affect the other Party’s (or its Affiliates’ or Sub licensees’) rights or ability to make, have made, use, sell, offer for sale, import, export, market, distribute, develop, or commercialize Agreement Product or any other Licensed
Product (if any) to the extent it retains or otherwise has such rights hereunder or under the Product Rights. Any payment required pursuant to any settlement agreement entered into in violation of this Section 10.3 shall be at the settling
Party’s own cost and expense. 

  
 19 

	10.4	Except in relation to the indemnity in Section 10.1 above, the liability of either party arising in any way out of the subject-matter of this Agreement, will not
extend to any loss of profits, lost savings, loss of revenue, business interruption and/or other similar costs nor to any special, indirect, incidental or consequential damages or losses whatsoever. 

 

	10.5	Nothing in this Agreement shall operate or be construed as to exclude or restrict the liability of a party for death or personal injury caused
by the negligence of that party or for fraud. 

  

	11	Term and Termination 

  

	11.1	The term of this Agreement will commence upon the Effective Date and will continue until after the end of the Regulatory Transfer Transition Period (the
“Term”). Notwithstanding the preceding sentence, this Agreement shall terminate on [*] if at that date the both the Primary Agreement and the Menarini Priligy Sublicensing Agreement. have not become effective. 

 

	11.2	After the Term of this Agreement, all of ALZA’s obligations shall terminate and ALZA shall no longer be receiving any AE Reports. FURIEX and MENARINI shall enter
into a separate pharmacovigilance agreement. 

  

	11.3	Notwithstanding the above, ALZA agrees that it will promptly forward to FURIEX any information it receives relating to an AE associated with the Agreement Product in
accordance with ALZA’s standard operating procedures for notifying AEs related to other manufacturer’s companies’ product. 

  

	12	Miscellaneous 

  

	12.1	The Parties shall use English to communicate and transmit written information to one another pursuant to this Agreement. 

 

	12.2	The Parties will report to each other, promptly and in any event within [*], any change in the Legal Requirements of which they become aware that might alter their
obligations under this Agreement. 

 Conflict 

 

	12.3	In the event of any conflict between the terms of this Agreement and the terms of the Primary Agreement or the Priligy License Agreement, as applicable, on matters
relating to the Parties’ respective responsibilities for pharmacovigilance and sharing of Agreement Product AE information, the terms of this Agreement shall govern and control. 

  
 [*]
Confidential Treatment Requested. 

  
 20 

	 	
In the event of any conflict between the terms of this Agreement and either the terms of the Primary Agreement or the Priligy License Agreement, relating to any other matters, the Primary
Agreement shall govern and control as to matters between FURIEX and ALZA, and the Priligy License Agreement will govern and control, as to matters between FURIEX and MENARINI. 

 

	12.4	Dispute Resolution 

 (a) The Parties
recognize that a bona fide dispute as to certain matters arising out of this Agreement or relating to the interpretation of this Agreement or performance hereunder, including any such controversy or claim involving a Party (a “Dispute”)
may from time to time arise. In the event of the occurrence of any Dispute, including any question regarding the Agreement’s existence, validity or termination, or performance of a Party’s obligations (directly or through any Affiliates),
such Dispute shall be resolved in accordance with this Section 12.4. Either Party may initiate Dispute resolution by written notice to the other, in which event such Dispute shall be referred to the Parties’ respective executives
designated below or the executive’s successor, for attempted resolution by good faith negotiations within [*] after such notice is received. The Parties’ designated executives for this purpose are as follows: (a) for GENUPRO: [*],
[*]; (b) for ALZA: [*] or his designee and (c) for MENARINI: [*]. No statements made during executive mediation under this Section 12.4, which shall be held in confidence, shall be admissible in any arbitration under
Section 12.4(b). 
 (b) In the event that the respective executives are unable to resolve a Dispute by executive
mediation within [*] of the disputing Party’s notice (unless the Parties agree in writing to extend that period), the Dispute shall be resolved by binding arbitration in accordance with the Commercial Arbitration Rules of the AAA
(“AAA Rules”; see www.adr.org) and the Federal Arbitration Act, 9 U.S.C. §1 et seq. The arbitration shall be conducted in New York, New York by three (3) independent, neutral arbitrators reasonably experienced in the
pharmaceutical industry appointed as follows: GENUPRO, ALZA and MENARINI shall each be entitled to select one (1) such arbitrator with the two (2) such arbitrators so selected selecting the third (3rd) such arbitrator. In the event either Party fails to select its
arbitrator within [*] of notice from either Party initiating arbitration hereunder, the arbitrator selected by the other Party within such [*] period shall be entitled to select such arbitrator. The arbitration shall be conducted in English. The
decision of the arbitrators will be final and binding on the Parties, and any decision of the arbitrators may be enforced in any court of competent jurisdiction. Each Party shall bear its own expenses and an equal share of the reasonable, documented
expenses of the arbitration panel and any fees required by AAA to submit such matter to arbitration, unless the panel determines that any such fees or expenses are to be paid by the non-prevailing Party. 

  
 [*]
Confidential Treatment Requested. 

  
 21 

 (c) The arbitrators shall follow the ICDR Guidelines for Arbitrators Concerning Exchanges of
Information in managing and ruling on requests for discovery. Each arbitrator, by accepting appointment, undertakes to exert her or his best efforts to conduct the process so as to issue an award as soon as reasonably possible, but in any event
within [*] of her or his appointment, provided that failure to meet that timetable shall not affect the validity of the award. 
 (d) The
arbitrators shall decide the Dispute in accordance with the substantive law of the State of New York, U.S.A., without regard to the choice of law provisions thereof, which law shall govern the interpretation of this Agreement. The arbitrators may
not award punitive or consequential damages, nor may the arbitrators apply any multiplier to any award of actual damages, except as may be required by statute or permitted by this Agreement (i.e. to the extent such damages are not precluded by
Section 12.5). The award of the arbitrators may be entered in any court of competent jurisdiction. The award of arbitration shall be final and binding upon both Parties. The Parties waive all rights to seek review of the award for errors of law
or fact in any court. 
 (e) The Parties hereby irrevocably and unconditionally submit to the jurisdiction of the AAA for the purposes of the
arbitration proceedings, and any counterclaims that relate in any respect to the Agreement. 
 (f) Notwithstanding the foregoing, either Party
may seek injunctive, equitable, or similar relief from a court of competent jurisdiction as necessary to enforce its rights or protect its interests hereunder without the requirement of arbitration. 

No Consequential Damages 
  

	12.5	THE PARTIES EXPRESSLY AGREE THAT IN NO EVENT SHALL EITHER PARTY OR ITS AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE,
EXEMPLARY, LOSS OF PROFITS OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT, PROVIDED THAT, NOTWITHSTANDING ANYTHING TO THE
CONTRARY HEREIN, THE FOREGOING SHALL NOT BE CONSTRUED TO LIMIT: (i) THE INDEMNITY OBLIGATIONS SET FORTH ABOVE OR IN ANY ANCILLARY AGREEMENT; OR (ii) EITHER PARTY’S LIABILITY FOR FRAUD, GROSS NEGLIGENCE, OR PATENT INFRINGEMENT.

 Assignment 
  

	12.6	Neither Party may assign or transfer this Agreement, in whole or in part, nor any rights or obligations hereunder, by merger, operation of law or otherwise, without the
prior written 

  
 [*]
Confidential Treatment Requested. 

  
 22 

	 	
consent of the other Parties, except that (i) a Party may make such an assignment without the other Parties’ consents to any of its Affiliates and (ii) either Party may make such
an assignment without the others’ consents in connection with the transfer or sale of all or substantially all of the assigning Party’s assets or business (or that portion thereof related, in either case, to this Agreement and the Primary
Agreement and/or the Priligy License Agreement, as is relevant between the Party’s of such Agreements), or in the event of a Party’s merger, consolidation, change in control, reorganization, or similar transaction; provided that, in either
case, the assigning Party provides the other Parties with written notice of such assignment and the assignee agrees to be bound to all of the terms and conditions of this Agreement applicable to such assigned or transferred rights and obligations.
Any permitted assignment shall be binding on the successors of the assigning Party. In the event a Party assigns this Agreement to an Affiliate other than a successor to such Party, the assigning Party shall remain liable to the other Parties for
the performance of the assignee Affiliate for so long as such assignee remains an Affiliate of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 12.6 shall be null and void and
of no legal effect. 

 Amendments and Variations 

 

	12.7	The Parties understand and agree that the procedures set out in this Agreement may be amended by either Party at any time, by mutual written agreement, to ensure that
they comply with the Legal Requirements. Upon the written request of ALZA, MENARINI or FURIEX, the Parties shall meet within [*] of such request to renegotiate in good faith all or some of these procedures. These procedures shall not be construed to
restrict either Party’s ability to take action that it deems to be appropriate or required of it under the Legal Requirements. 

  

	12.8	No variation of this Agreement, with the exception of the Schedules attached, shall be valid unless it is in writing and signed by or on behalf of each of the Parties.
Any variation of the Schedules shall not require this Agreement to be re-issued and signed off, but shall require the written acknowledgement of both Parties. 

 Entire Agreement 
  

	12.9	This Agreement constitutes the entire agreement and understanding of the Parties and supersedes any previous agreement between the Parties relating to the subject
matter of this Agreement. 

  
 [*]
Confidential Treatment Requested. 

  
 23 

 Headings 

 

	12.10	The headings contained in this Agreement have been added for convenience only and shall not affect the construction, meaning or interpretation of this Agreement or any
of its terms and conditions. 

 Severability 

 

	12.11	If any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining
provisions of this Agreement shall not in any way be affected or impaired thereby. 

 No waiver of rights

  

	12.12	The failure of any Party hereto to insist upon strict performance of any provision of this Agreement or to exercise any right hereunder will not constitute a waiver of
that provision or right. 

  

	13	Governing Law 

 This Agreement shall be
interpreted and construed in accordance with the governing law as set forth in Section 12.4 of this Agreement. 
 [This
space intentionally left blank] 

  
 24 

 IN WITNESS WHEREOF, this Agreement has been executed by the duly authorized representatives of the
Parties. 
 SIGNED for and on behalf of ALZA CORPORATION: 

 

			
	  

	Name:	 	Luis Toca
		
	Title:	 	Treasurer
	Date:	 	

 SIGNED for and on behalf of JANSSEN PHARMACEUTICA NV: 

 

	
	  

	Name:
	
	Title:
	Date:

 SIGNED for and on behalf of FURIEX PHARMACEUTICALS, INC.: 

 

			
	  

	Name:	 	June Almenoff, M.D., Ph.D.
		
	Title:	 	President and Chief Medical Officer
	Date:	 	

 SIGNED for and on behalf of GENUPRO, INC.: 

 

			
	  

	Name:	 	June Almenoff, M.D., Ph.D.
		
	Title:	 	President and Chief Medical Officer
	Date:	 	

 SIGNED for and on behalf of BERLIN-CHEMIE AG (“MENARINI”): 

 

			
	  

	Name:	 	Francesco Sarlo
		
	Title:	 	EU QPPV
	Date:	 	

  

			
	Name:	 	Elio Serrotti
		
	Title:	 	CDSUM and Deputy EU QPPV
	Date:	 	

  
 25 

 SCHEDULE 1: AGREEMENT PRODUCT 

Priligy 30 mg film-coated tablets 

Priligy 60 mg film-coated tablets 

  
 26 

 SCHEDULE 1.26: THIRD PARTY MAH 

 

					
	[*]	  	[*]	  	[*]
			
	[*]	  	[*]	  	[*]
			
	[*]	  	[*]	  	[*]
			
	[*]	  	[*]	  	[*]
			
	[*]	  	[*]	  	[*]

  
 [*]
Confidential treatment requested. 

  
 27 

 SCHEDULE 2: CONTACT LIST 

ALZA CORPORATION 
  

			
	Activity	  	[*]
		  	[*]
	 Responsible Person
 (Single
Point of Contact for Alliance)
	  	
		  	[*]
		
	 AE Reports (Incoming)
  

Single Case AE/SAE Reports
	  	
		
		  	[*]
		
	 AE Reports (Outgoing)
  

Single Case
 CIOMS/MedWatch/E2B
Distribution
	  	
		
		  	[*]
		
	 Individual Case Queries
  

confirmation of receipt; single case queries and follow-up queries
	  	
		  	[*]
	Health Agency Queries and Related Aggregate Data Review (e.g. Benefit Risk Assessment, CCDS)	  	
		  	[*]
	Requests for Database Searches	  	
		
		  	[*]
	 Aggregate Report Preparation (including Periodic Safety Update Reports (PSURs)

 
 Call For Information
	  	
		
		  	[*]
	Development Safety Update Reports (DSURs)/SUSAR LL Reports	  	

  
 [*]
Confidential Treatment Requested. 

  
 28 

			
	Activity	  	[*]
		  	[*]
		
	 Aggregate Report Final Distribution
  

Responsibility of J&J
	  	
		
	 Compliance Contact
 for regular
scheduled compliance outputs
	  	[*]
		
		  	[*]
		
	 Regulatory Matters

(submissions to authorities/final clinical reports/communications from agencies/labeling changes/registration status)

 
 Updates to Investigator Brochure
	  	
		
	EEA Qualified Person For Pharmacovigilance	  	[*]
		
	 Pharmacovigilance Agreement

(matters pertaining to this agreement including PVA compliance, contact updates, revisions, notification of PV audits)
	  	[*]

  
 [*]
Confidential Treatment Requested. 

  
 29 

 MENARINI 

 

			
	Activity	  	[*]
		  	[*]
		
	All data exchange	  	
		
		  	[*]
	Aggregate Report	  	
		
	 EEA Qualified Person for
 for
Pharmacovigilance (EEA QPPV)
	  	[*]
		
	EEA QPPV Deputy and CDSU Manager	  	[*]
	 Pharmacovigilance Agreement

(matters pertaining to this agreement including general issues, contact updates, revisions)
	  	[*]

  
 [*]
Confidential Treatment Requested. 

  
 30 

 FURIEX PHARMACEUTICALS, INC. 

 

			
	 Activity
	  	 Individual / Department Responsible

	  	  	 [*]

	 AE Reports (Outgoing)
  

Single Case AE/SAE
 Reports to
GMS
	  	
		
		  	[*]
	 AE Reports (Incoming)
  

Receipt of CIOMS I
 /MedWatch/E2B
	  	
		  	[*]
	 AE Reports
 (Single Case
Queries)
	  	
		
	 Single Case Medical Assessment and Review
 (including AE Coding/Labeling)
	  	[*]
		
		  	[*]
	 General Safety Queries and issues on Product, CCDS, benefit-risk assessment (including Risk Management Plan)

 
 Database Searches
	  	

  
 [*]
Confidential Treatment Requested. 

  
 31 

 SCHEDULE 12.3(a) 

THIRD PARTY CONSENT 
 [*]

  
 [*]
Confidential treatment requested.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]